Cancer-associated IDH1 mutations produce 2-hydroxyg

Nature

462, 739-744

DOI: 10.1038/nature08617

Citation Report

#	Article	IF	Citations
3	Keeping A Breast of Recent Developments in Cancer Metabolism. Current Drug Targets, 2010, 11, 1112-1120.	1.0	11
4	Intrathecal Nucleic Acid Injections to Treat Neuropathic Pain. Neurosurgery, 2010, 66, N18-N18.	0.6	0
5	CT Alone May Be Inadequate for Detecting Occult Spinal Injuries. Neurosurgery, 2010, 66, N23-N24.	0.6	0
6	Key Factors Contributing to the Success of Clinician Investigators. Neurosurgery, 2010, 66, N14-N15.	0.6	2
7	Thoughts on Consciousness. Neurosurgery, 2010, 66, N22-N23.	0.6	0
8	A T Cell-Orchestrated Immune Response in the Adult Dorsal Spinal Cord as a Cause of Neuropathic Pain-Like Hypersensitivity After Peripheral Nerve Damage. Neurosurgery, 2010, 66, N24-N25.	0.6	4
9	Riding the Waves. Neurosurgery, 2010, 66, N15-N16.	0.6	1
10	IDH1 and IDH2 Mutations in Gliomas and the Associated Induction of Hypoxia-Inducible Factor and Production of 2-hydroxyglutarate. Neurosurgery, 2010, 66, N20-N21.	0.6	10
11	Regeneration of Neuromuscular Synapses. Neurosurgery, 2010, 66, N19-N20.	0.6	7
12	Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers. Oncology Letters, 2010, 1, 883-884.	0.8	7
13	IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody. Haematologica, 2010, 95, 1797-1798.	1.7	13
14	Immunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers?. Blood, 2010, 115, 1490-1499.	0.6	56
15	IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood, 2010, 116, 5486-5496.	0.6	175
16	The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood, 2010, 116, 2779-2782.	0.6	121
17	Forcing Tumor Stem Cells to an End. Neurosurgery, 2010, 66, N17-N18.	0.6	0
18	Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers. FEBS Letters, 2010, 584, 3800-3811.	1.3	206
19	The role of mitochondria in pulmonary vascular remodeling. Journal of Molecular Medicine, 2010, 88, 1003-1010.	1.7	94
20	The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathologica, 2010, 119, 487-494.	3.9	262

#	Article	IF	Citations
21	Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathologica, 2010, 119, 501-507.	3.9	108
22	Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. Acta Neuropathologica, 2010, 120, 261-267.	3.9	47
23	Molecular diagnostics of gliomas: state of the art. Acta Neuropathologica, 2010, 120, 567-584.	3.9	243
24	Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathologica, 2010, 120, 707-718.	3.9	719
25	Strain-dependent expression of metabolic proteins in the mouse hippocampus. Amino Acids, 2010, 39, 1451-1462.	1.2	4
26	Novel findings in intermediary metabolism regulation. Science Bulletin, 2010, 55, 3231-3234.	1.7	0
27	Molecular markers in gliomas: impact for the clinician. Targeted Oncology, 2010, 5, 201-210.	1.7	21
29	Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurology, The, 2010, 9, 717-726.	4.9	251
30	Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma. Ca-A Cancer Journal for Clinicians, 2010, 60, 166-193.	157.7	1,182
31	Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer, 2010, 10, 401.	1.1	140
32	Cancer as a metabolic disease. Nutrition and Metabolism, 2010, 7, 7.	1.3	494
33	Exploiting the balance between life and death: Targeted cancer therapy and â€œoncogenic shockâ€• Biochemical Pharmacology, 2010, 80, 666-673.	2.0	53
34	IDH1 Mutations in Gliomas: When an Enzyme Loses Its Grip. Cancer Cell, 2010, 17, 7-9.	7.7	63
35	The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting Î±-Ketoglutarate to 2-Hydroxyglutarate. Cancer Cell, 2010, 17, 225-234.	7.7	1,754
36	IDH1 and IDH2: Not Your Typical Oncogenes. Cancer Cell, 2010, 17, 215-216.	7.7	65
37	Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma. Cancer Cell, 2010, 17, 510-522.	7.7	2,078
38	Leukemic IDH1 and IDH2 Mutations Result inÂa Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell, 2010, 18, 553-567.	7.7	2,328
39	From Standard Treatment to Personalized Medicine: Role of IDH1 Mutations in Low-Grade Glioma Evolution and Treatment. World Neurosurgery, 2010, 73, 234-236.	0.7	3

#	Article	IF	Citations
40	Increased levels of 2â€hydroxyglutarate in AML patients with IDH1â€R132H and IDH2â€R140Q mutations. European Journal of Haematology, 2010, 85, 457-459.	1.1	39
41	The mitochondrial bioenergetic capacity of carcinomas. IUBMB Life, 2010, 62, 554-60.	1.5	43
42	The Glycerophospho Metabolome and Its Influence on Amino Acid Homeostasis Revealed by Brain Metabolomics of GDE1(â^'/â^') Mice. Chemistry and Biology, 2010, 17, 831-840.	6.2	34
43	Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene, 2010, 29, 6409-6417.	2.6	259
44	IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia, 2010, 24, 1302-1309.	3.3	300
45	Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia, 2010, 24, 1128-1138.	3.3	499
46	IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia, 2010, 24, 1146-1151.	3.3	180
47	Genomics boosts brain-cancer work. Nature, 2010, 463, 278-278.	13.7	12
48	Big science: The cancer genome challenge. Nature, 2010, 464, 972-974.	13.7	89
49	Oncology's energetic pipeline. Nature Biotechnology, 2010, 28, 888-891.	9.4	18
51	Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nature Reviews Cancer, 2010, 10, 319-331.	12.8	660
52	Activity-based protein profiling for biochemical pathway discovery in cancer. Nature Reviews Cancer, 2010, 10, 630-638.	12.8	289
53	Targeting tumour metabolism. Nature Reviews Drug Discovery, 2010, 9, 503-504.	21.5	12
54	New cancer targets emerging from studies of the Von Hippelâ€Lindau tumor suppressor protein. Annals of the New York Academy of Sciences, 2010, 1210, 1-7.	1.8	11
55	Les mutations du rÃ©sidu arginine 132 dâ€™IDH1 dans les tumeurs gliales lui confÃ¨rent une nouvelle fonction enzymatique. Bulletin Du Cancer, 2010, 97, 289-290.	0.6	0
58	Metabolism, Gliomas, andIDH1. New England Journal of Medicine, 2010, 362, 1144-1145.	13.9	14
59	Molecular mechanisms of â€œoff-on switchâ€•of activities of human IDH1 by tumor-associated mutation R132H. Cell Research, 2010, 20, 1188-1200.	5.7	103
60	Prognostic markers in gliomas. Future Oncology, 2010, 6, 733-739.	1.1	17

#	Article	IF	Citations
61	Balancing biosynthesis and bioenergetics: metabolic programs in oncogenesis. Endocrine-Related Cancer, 2010, 17, R287-R304.	1.6	62
62	IDH2 Mutations in Patients with <scp>d</scp> -2-Hydroxyglutaric Aciduria. Science, 2010, 330, 336-336.	6.0	177
63	Separating the wheat from the chaff. Neurology, 2010, 74, 1848-1849.	1.5	1
64	On Getting There from Here. Science, 2010, 330, 1338-1339.	6.0	104
65	Computational Tools for the Interactive Exploration of Proteomic and Structural Data. Molecular and Cellular Proteomics, 2010, 9, 1703-1715.	2.5	9
66	IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2010, 28, 2348-2355.	0.8	699
67	Update on molecular findings, management and outcome in low-grade gliomas. Nature Reviews Neurology, 2010, 6, 695-701.	4.9	128
68	Redefining disease. Clinical Medicine, 2010, 10, 584-594.	0.8	13
69	IDH1 Gene Mutations: A New Paradigm in Glioma Prognosis and Therapy?. Oncologist, 2010, 15, 196-199.	1.9	48
70	Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. Journal of Experimental Medicine, 2010, 207, 339-344.	4.2	657
71	Metabolism and the leukemic stem cell. Journal of Experimental Medicine, 2010, 207, 677-680.	4.2	70
72	Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. European Journal of Endocrinology, 2010, 163, 747-755.	1.9	74
73	Creation and Validation of a New Animal Model of Intracranial Aneurysms. Neurosurgery, 2010, 66, N16-N17.	0.6	0
75	Metabolic Syndromes and Malignant Transformation: Where the Twain Shall Meet. Science Translational Medicine, 2010, 2, 54ps50.	5.8	2
76	Mutations of the Metabolic GenesIDH1,IDH2, andSDHAF2Are Not Major Determinants of the Pseudohypoxic Phenotype of Sporadic Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1469-1472.	1.8	25
77	Oxygen Sensing: A Common Crossroad in Cancer and Neurodegeneration. Current Topics in Microbiology and Immunology, 2010, 345, 71-103.	0.7	21
79	TET2 gene is not deleted in chronic myelomonocytic leukemia: a FISH retrospective study. Haematologica, 2010, 95, 1798-1800.	1.7	9
80	IDH1 and IDH2 mutations in myeloid neoplasms - Novel paradigms and clinical implications. Haematologica, 2010, 95, 1623-1627.	1.7	23

#	Article	IF	Citations
81	Nontargeted Elucidation of Metabolic Pathways Using Stable-Isotope Tracers and Mass Spectrometry. Analytical Chemistry, 2010, 82, 6621-6628.	3.2	111
82	Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?. Future Oncology, 2010, 6, 1407-1414.	1.1	23
83	Detection of IDH1 and IDH2 Mutations by Fluorescence Melting Curve Analysis as a Diagnostic Tool for Brain Biopsies. Journal of Molecular Diagnostics, 2010, 12, 487-492.	1.2	72
84	The Mitochondrial Proteome and Human Disease. Annual Review of Genomics and Human Genetics, 2010, 11, 25-44.	2.5	497
85	IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication. Journal of Clinical Oncology, 2010, 28, 3636-3643.	0.8	728
86	Prognostic Value of IDH1 Mutations Identified with PCR-RFLP Assay in Glioblastoma Patients. Molecular Diagnosis and Therapy, 2010, 14, 163-169.	1.6	27
87	Exploring Disease through Metabolomics. ACS Chemical Biology, 2010, 5, 91-103.	1.6	193
88	Hypoxia-Inducible Factors and the Response to Hypoxic Stress. Molecular Cell, 2010, 40, 294-309.	4.5	1,930
89	IDH mutations in glioma and acute myeloid leukemia. Trends in Molecular Medicine, 2010, 16, 387-397.	3.5	322
90	Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree?. Current Opinion in Genetics and Development, 2010, 20, 324-329.	1.5	111
91	Glioma-derived mutations in IDH: From mechanism to potential therapy. Biochemical and Biophysical Research Communications, 2010, 397, 127-130.	1.0	42
92	IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochemical and Biophysical Research Communications, 2010, 402, 378-383.	1.0	38
93	Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1. Cancer Research, 2010, 70, 8981-8987.	0.4	439
94	Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 2010, 28, 3717-3723.	0.8	189
95	All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology, 2010, 74, 1886-1890.	1.5	240
96	IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research, 2010, 16, 1597-1604.	3.2	364
97	Where metabolism meets oncogenesis: another false lead?. Lancet Oncology, The, 2010, 11, 309-310.	5.1	1
98	Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism. Journal of the National Cancer Institute, 2010, 102, 932-941.	3.0	448

#	Article	IF	Citations
99	Metabolic Modulation of Glioblastoma with Dichloroacetate. Science Translational Medicine, 2010, 2, 31ra34.	5.8	606
101	Identification of the 2-Hydroxyglutarate and Isovaleryl-CoA Dehydrogenases as Alternative Electron Donors Linking Lysine Catabolism to the Electron Transport Chain of Arabidopsis Mitochondria Â. Plant Cell, 2010, 22, 1549-1563.	3.1	296
102	Cancer genomics identifies determinants of tumor biology. Genome Biology, 2010, 11, 211.	13.9	17
103	2-hydroxyglutarate accumulation caused byIDHmutation is involved in the formation of malignant gliomas. Expert Review of Neurotherapeutics, 2010, 10, 487-489.	1.4	10
104	Metabolomics annotates ABHD3 as a physiologic regulator of medium-chain phospholipids. Nature Chemical Biology, 2011, 7, 763-765.	3.9	59
105	Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro-Oncology, 2011, 13, 566-579.	0.6	121
106	Dynamic Metabolic Transformation in Tumor Invasion and Metastasis in Mice with LM-8 Osteosarcoma Cell Transplantation. Journal of Proteome Research, 2011, 10, 3513-3521.	1.8	33
107	Diagnostic Testing for IDH1 and IDH2 Variants in Acute Myeloid Leukemia. Journal of Molecular Diagnostics, 2011, 13, 678-686.	1.2	46
108	Metabolism of glioma and IDH1/IDH2 mutations. Revue Neurologique, 2011, 167, 699-703.	0.6	12
109	Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes. Journal of Clinical Oncology, 2011, 29, 504-515.	0.8	288
110	Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes and Development, 2011, 25, 2436-2452.	2.7	565
111	Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research. Neoplasia, 2011, 13, 81-97.	2.3	623
112	A Tale of Two Subunits: How the Neomorphic R132H IDH1 Mutation Enhances Production of Î±HG. Biochemistry, 2011, 50, 4804-4812.	1.2	94
113	p53, Aerobic Metabolism, and Cancer. Antioxidants and Redox Signaling, 2011, 15, 1739-1748.	2.5	46
114	Clinical Implications of Novel Mutations in Epigenetic Modifiers in AML. Hematology/Oncology Clinics of North America, 2011, 25, 1119-1133.	0.9	40
115	Hypothesis: Environmental regulation of 5-hydroxymethylcytosine by oxidative stress. Epigenetics, 2011, 6, 853-856.	1.3	145
116	Metabolomics in Drug Target Discovery. Cold Spring Harbor Symposia on Quantitative Biology, 2011, 76, 235-246.	2.0	75
117	Targeting cancer metabolism: a therapeutic window opens. Nature Reviews Drug Discovery, 2011, 10, 671-684.	21.5	1,227

#	Article	IF	Citations
118	Oncogene addiction in gliomas: Implications for molecular targeted therapy. Journal of Experimental and Clinical Cancer Research, 2011, 30, 58.	3.5	33
119	Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nature Genetics, 2011, 43, 1262-1265.	9.4	368
120	Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nature Genetics, 2011, 43, 1256-1261.	9.4	488
121	Inhibition of 2-oxoglutarate dependent oxygenases. Chemical Society Reviews, 2011, 40, 4364.	18.7	336
122	Substrate Specificity of 2-Hydroxyglutaryl-CoA Dehydratase fromClostridium symbiosum: Toward a Bio-Based Production of Adipic Acid. Biochemistry, 2011, 50, 3540-3550.	1.2	40
123	Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation. American Journal of Pathology, 2011, 178, 1395-1402.	1.9	122
124	Survival of the fittest: metabolic adaptations in cancer. Current Opinion in Genetics and Development, 2011, 21, 59-66.	1.5	23
125	Enzymatic characterization of isocitrate dehydrogenase from an emerging zoonotic pathogen Streptococcus suis. Biochimie, 2011, 93, 1470-1475.	1.3	14
126	Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. European Journal of Cancer, 2011, 47, 802-808.	1.3	39
127	A lymphoblast model for IDH2 gain-of-function activity in d-2-hydroxyglutaric aciduria type II: Novel avenues for biochemical and therapeutic studies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 1380-1384.	1.8	14
128	Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Biochemical and Biophysical Research Communications, 2011, 406, 608-613.	1.0	46
129	Glioma-derived mutations in isocitrate dehydrogenase 2 beneficial to traditional chemotherapy. Biochemical and Biophysical Research Communications, 2011, 410, 218-223.	1.0	16
130	Back to the Future: Molecular Biology Meets Metabolism. Cold Spring Harbor Symposia on Quantitative Biology, 2011, 76, 403-411.	2.0	7
131	Cancer Cell Metabolism. Cold Spring Harbor Symposia on Quantitative Biology, 2011, 76, 299-311.	2.0	136
132	5-Hydroxymethylcytosine Is Strongly Depleted in Human Cancers but Its Levels Do Not Correlate with IDH1 Mutations. Cancer Research, 2011, 71, 7360-7365.	0.4	400
133	ABPP Methodology: Introduction and Overview. Topics in Current Chemistry, 2011, 324, 1-41.	4.0	29
134	Functional Analysis of Protein Targets by Metabolomic Approaches. Topics in Current Chemistry, 2011, 324, 137-162.	4.0	0
135	Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients. Medical Hypotheses, 2011, 76, 602-603.	0.8	20

#	Article	IF	Citations
136	Molecular targeting of glioblastoma: Drug discovery and therapies. Trends in Molecular Medicine, 2011, 17, 301-312.	3.5	114
137	Revisiting the TCA cycle: signaling to tumor formation. Trends in Molecular Medicine, 2011, 17, 641-649.	3.5	216
138	Anticancer Drugs Targeting the Mitochondrial Electron Transport Chain. Antioxidants and Redox Signaling, 2011, 15, 2951-2974.	2.5	79
139	TET Family Proteins and Their Role in Stem Cell Differentiation and Transformation. Cell Stem Cell, 2011, 9, 193-204.	5.2	209
140	Protein degradation â€“ an alternative respiratory substrate for stressed plants. Trends in Plant Science, 2011, 16, 489-498.	4.3	367
141	Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?. Lancet Oncology, The, 2011, 12, 83-91.	5.1	188
142	Role of Glutamine in Cancer: Therapeutic and Imaging Implications: FIGURE 1.. Journal of Nuclear Medicine, 2011, 52, 1005-1008.	2.8	105
143	Cancer and Altered Metabolism: Potential Importance of Hypoxia-Inducible Factor and 2-Oxoglutarate-Dependent Dioxygenases. Cold Spring Harbor Symposia on Quantitative Biology, 2011, 76, 335-345.	2.0	143
144	The Role of IDH1 and IDH2 Mutations in Malignant Gliomas. , 2011, , 47-52.		0
145	PHGDH amplification and altered glucose metabolism in human melanoma. Pigment Cell and Melanoma Research, 2011, 24, 1112-1115.	1.5	114
146	Myelodysplastic/myeloproliferative neoplasms. Seminars in Diagnostic Pathology, 2011, 28, 283-297.	1.0	20
147	Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, 623-630.	0.4	203
148	Mitochondria in cancer: at the crossroads of life and death. Chinese Journal of Cancer, 2011, 30, 526-539.	4.9	116
149	Implication of IDH1 and IDH2 gene mutations in acute myeloid leukemia. Hematologie, 2011, 17, 132-144.	0.0	0
150	Genetic Alterations and Their Clinical Implications in Acute Myeloid Leukemia. , 2011, , .		1
151	The Role of Isocitrate Dehydrogenase Mutations in Glioma Brain Tumors. , 0, , .		2
152	Metabolic alterations in cancer cells and therapeutic implications. Chinese Journal of Cancer, 2011, 30, 508-525.	4.9	82
153	2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations. PLoS ONE, 2011, 6, e16812.	1.1	100

#	Article	IF	Citations
154	Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma. PLoS ONE, 2011, 6, e19868.	1.1	71
155	Genetics of the myeloproliferative neoplasms. Current Opinion in Hematology, 2011, 18, 117-123.	1.2	44
156	Isocitrate dehydrogenase mutations in gliomas. Current Opinion in Neurology, 2011, 24, 648-652.	1.8	75
157	Neuronal-Astrocyte Metabolic Interactions: Understanding the Transition Into Abnormal Astrocytoma Metabolism. Journal of Neuropathology and Experimental Neurology, 2011, 70, 167-176.	0.9	100
158	Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of theIDH1-R132HMutation in Diffuse Glioma Biopsy Specimens. Journal of Neuropathology and Experimental Neurology, 2011, 70, 715-723.	0.9	98
159	The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood, 2011, 118, 409-412.	0.6	233
160	Identification of Metabolites in the Normal Ovary and Their Transformation in Primary and Metastatic Ovarian Cancer. PLoS ONE, 2011, 6, e19963.	1.1	128
161	IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas. Oncology Reports, 2011, 26, 1479-85.	1.2	28
162	Mutational analysis of D2HGDH and L2HGDH in brain tumours without IDH1 or IDH2 mutations. Neuropathology and Applied Neurobiology, 2011, 37, 330-332.	1.8	10
163	Scientific correspondence. Neuropathology and Applied Neurobiology, 2011, 37, 428-430.	1.8	54
164	Evaluation of mutations in the isocitrate dehydrogenase genes in therapyâ€related and secondary acute myeloid leukaemia identifies a patient with clonal evolution to IDH2 R172K homozygosity due to uniparental disomy. British Journal of Haematology, 2011, 152, 669-672.	1.2	10
165	Enzymatic features of the glucose metabolism in tumor cells. FEBS Journal, 2011, 278, 2436-2459.	2.2	56
166	Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nature Genetics, 2011, 43, 309-315.	9.4	706
167	Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Nature Medicine, 2011, 17, 304-312.	15.2	94
168	A close look at cancer. Nature Medicine, 2011, 17, 262-265.	15.2	11
170	Metabolism unhinged: IDH mutations in cancer. Nature Medicine, 2011, 17, 291-293.	15.2	144
172	Regulation of cancer cell metabolism. Nature Reviews Cancer, 2011, 11, 85-95.	12.8	4,100
173	Otto Warburg's contributions to current concepts of cancer metabolism. Nature Reviews Cancer, 2011, 11, 325-337.	12.8	2,566

#	Article	IF	Citations
174	The oncometabolite 2â€hydroxyglutarate inhibits histone lysine demethylases. EMBO Reports, 2011, 12, 463-469.	2.0	851
175	A fresh look at cancer metabolism in a historical setting. EMBO Reports, 2011, 12, 289-291.	2.0	0
176	IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. Leukemia, 2011, 25, 178-181.	3.3	27
177	A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders. Leukemia, 2011, 25, 184-186.	3.3	17
178	The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia, 2011, 25, 246-253.	3.3	150
179	Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation. Histopathology, 2011, 58, 1167-1172.	1.6	13
180	The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations. Brain Pathology, 2011, 21, 74-87.	2.1	150
181	Glioblastoma, Cancer Stem Cells and Hypoxia. Brain Pathology, 2011, 21, 119-129.	2.1	98
182	Isocitrate Dehydrogenase 1 Analysis Differentiates Gangliogliomas from Infiltrative Gliomas. Brain Pathology, 2011, 21, 564-574.	2.1	55
183	Unraveling the Glioma Epigenomeâ€"From Molecular Mechanisms to Novel Biomarkers and Therapeutic Targets. Brain Pathology, 2011, 21, 619-632.	2.1	38
184	Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme. Neurobiology of Disease, 2011, 44, 84-91.	2.1	98
185	Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients. Leukemia Research, 2011, 35, 1301-1306.	0.4	19
186	IDH1 mutations in gliomas: First series from a tertiary care centre in India with comprehensive review of literature. Experimental and Molecular Pathology, 2011, 91, 385-393.	0.9	34
187	Oxidative phosphorylation in cancer cells. Biochimica Et Biophysica Acta - Bioenergetics, 2011, 1807, 534-542.	0.5	183
188	Cell metabolism: An essential link between cell growth and apoptosis. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 645-654.	1.9	133
189	Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of Î±-Ketoglutarate-Dependent Dioxygenases. Cancer Cell, 2011, 19, 17-30.	7.7	2,340
190	Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation. Cancer Cell, 2011, 20, 11-24.	7.7	1,105
191	Predictive and prognostic factors for gliomas. Expert Review of Anticancer Therapy, 2011, 11, 781-789.	1.1	54

#	Article	IF	Citations
192	Molecular Pathogenesis of Malignant Glial Tumors. Toxicologic Pathology, 2011, 39, 158-166.	0.9	19
193	Anticancer Targets in the Glycolytic Metabolism of Tumors: A Comprehensive Review. Frontiers in Pharmacology, 2011, 2, 49.	1.6	367
194	Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nature Genetics, 2011, 43, 869-874.	9.4	945
195	Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood, 2011, 118, 3932-3941.	0.6	290
196	CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood, 2011, 117, e198-e206.	0.6	143
197	Aerobic Glycolysis: Meeting the Metabolic Requirements of Cell Proliferation. Annual Review of Cell and Developmental Biology, 2011, 27, 441-464.	4.0	2,333
198	Insights into the Pathogenesis and Treatment of Cancer from Inborn Errors of Metabolism. American Journal of Human Genetics, 2011, 88, 402-421.	2.6	58
199	Mitochondrial Metabolism Inhibitors for Cancer Therapy. Pharmaceutical Research, 2011, 28, 2731-2744.	1.7	45
200	Whole-genomic survey of oligodendroglial tumors: correlation between allelic imbalances and gene expression profiles. Journal of Neuro-Oncology, 2011, 103, 71-85.	1.4	7
201	Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. Journal of Neuro-Oncology, 2011, 104, 339-349.	1.4	45
202	IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. Journal of Neuro-Oncology, 2011, 105, 345-357.	1.4	86
203	IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. Journal of Neuro-Oncology, 2011, 105, 591-600.	1.4	59
204	IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Childrenâ€™s Oncology Group. Child's Nervous System, 2011, 27, 87-94.	0.6	152
205	Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathologica, 2011, 121, 241-252.	3.9	124
206	R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1Î± upregulation in adult glioma. Acta Neuropathologica, 2011, 121, 279-281.	3.9	67
207	High frequency of IDH-1 mutation links glioneuronal tumors with neuropil-like islands to diffuse astrocytomas. Acta Neuropathologica, 2011, 122, 367-369.	3.9	16
208	Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathology, 2011, 28, 115-123.	1.1	96
209	New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status. Brain Tumor Pathology, 2011, 28, 203-208.	1.1	7

#	Article	IF	Citations
211	Inborn and acquired metabolic defects in cancer. Journal of Molecular Medicine, 2011, 89, 213-220.	1.7	132
212	Therapeutic targeting of cancer cell metabolism. Journal of Molecular Medicine, 2011, 89, 205-212.	1.7	151
213	Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. Clinical Epigenetics, 2011, 2, 197-212.	1.8	36
214	Papillary thyroid carcinoma shows elevated levels of 2-hydroxyglutarate. Tumor Biology, 2011, 32, 325-333.	0.8	25
215	Genomic Profiles of Glioma. Current Neurology and Neuroscience Reports, 2011, 11, 291-297.	2.0	39
216	Structure of a highly NADP⁺-specific isocitrate dehydrogenase. Acta Crystallographica Section D: Biological Crystallography, 2011, 67, 856-869.	2.5	9
217	IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. Journal of Pathology, 2011, 224, 334-343.	2.1	834
218	Aberrant succination of proteins in fumarate hydrataseâ€deficient mice and HLRCC patients is a robust biomarker of mutation status. Journal of Pathology, 2011, 225, 4-11.	2.1	225
219	Isocitrate dehydrogenase 1/2 mutational analyses and 2â€hydroxyglutarate measurements in Wilms tumors. Pediatric Blood and Cancer, 2011, 56, 379-383.	0.8	28
220	Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenaseâ€1. Proteomics, 2011, 11, 4139-4154.	1.3	12
221	Separation strategies for untargeted metabolomics. Journal of Separation Science, 2011, 34, 3460-3469.	1.3	109
222	Detection of tumor glutamate metabolism in vivo using ¹³C magnetic resonance spectroscopy and hyperpolarized [1â€¹³C]glutamate. Magnetic Resonance in Medicine, 2011, 66, 18-23.	1.9	55
223	Wholeâ€exome sequencing detects somatic mutations of IDH1 in metaphyseal chondromatosis with <scp>D</scp>â€2â€hydroxyglutaric aciduria (MCâ€HGA). American Journal of Medical Genetics, Part A, 2011, 155, 2609-2616.	0.7	47
224	Isocitrate dehydrogenase mutations: A challenge to traditional views on the genesis and malignant progression of gliomas. Glia, 2011, 59, 1200-1204.	2.5	44
225	Molecular subclassification of diffuse gliomas: Seeing order in the chaos. Glia, 2011, 59, 1190-1199.	2.5	201
226	Novel germline SDHD deletion associated with an unusual sympathetic head and neck paraganglioma. Head and Neck, 2011, 33, 1233-1240.	0.9	3
227	Using metabolomic analysis to understand inflammatory bowel diseases. Inflammatory Bowel Diseases, 2011, 17, 1021-1029.	0.9	56
228	Molecular signatures classify astrocytic gliomas by IDH1 mutation status. International Journal of Cancer, 2011, 128, 1095-1103.	2.3	75

#	Article	IF	Citations
229	Proteins with neomorphic moonlighting functions in disease. IUBMB Life, 2011, 63, 489-494.	1.5	62
231	5â€Hydroxymethylcytosine, the Sixth Base of the Genome. Angewandte Chemie - International Edition, 2011, 50, 6460-6468.	7.2	221
232	Mitochondrial Subversion in Cancer. Cancer Prevention Research, 2011, 4, 638-654.	0.7	160
233	Genomic alterations and the pathogenesis of glioblastoma. Cell Cycle, 2011, 10, 1174-1175.	1.3	4
234	2010: Signaling Breakthroughs of the Year. Science Signaling, 2011, 4, eg1.	1.6	2
235	Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AMLâ€“BFM and DCOG study groups. Leukemia, 2011, 25, 1704-1710.	3.3	73
236	The Redox Basis of Epigenetic Modifications: From Mechanisms to Functional Consequences. Antioxidants and Redox Signaling, 2011, 15, 551-589.	2.5	242
237	DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma. Journal of the National Cancer Institute, 2011, 103, 143-153.	3.0	224
238	Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of Î±-ketoglutarate to citrate to support cell growth and viability. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19611-19616.	3.3	851
239	Genomics of Acute Myeloid Leukemia. Cancer Journal (Sudbury, Mass), 2011, 17, 487-491.	1.0	20
240	Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. Journal of Experimental Medicine, 2011, 208, 313-326.	4.2	639
241	Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications. Journal of Clinical Pathology, 2011, 64, 835-844.	1.0	43
242	Understanding the Enemy. Science Translational Medicine, 2011, 3, 98ps37.	5.8	4
243	Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3270-3275.	3.3	390
244	IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia, 2011, 25, 1570-1577.	3.3	80
245	Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. Clinical Medicine Insights: Oncology, 2011, 5, CMO.S7685.	0.6	34
246	Differential Activity of NADPH-Producing Dehydrogenases Renders Rodents Unsuitable Models to Study IDH1^{R132} Mutation Effects in Human Glioblastoma. Journal of Histochemistry and Cytochemistry, 2011, 59, 489-503.	1.3	29
247	Neurooncology. Toxicologic Pathology, 2011, 39, 124-128.	0.9	1

#	Article	IF	Citations
248	TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations: Figure 1. Journal of Clinical Pathology, 2011, 64, 850-852.	1.0	65
249	Stem Cells in Brain Tumor Development. Current Topics in Developmental Biology, 2011, 94, 15-44.	1.0	14
250	Targeting ErbB Receptors in High-Grade Glioma. Current Pharmaceutical Design, 2011, 17, 2468-2487.	0.9	36
251	Cancer-stromal interactions. Cancer Biology and Therapy, 2011, 11, 150-156.	1.5	57
252	Plant d-2-Hydroxyglutarate Dehydrogenase Participates in the Catabolism of Lysine Especially during Senescence. Journal of Biological Chemistry, 2011, 286, 11382-11390.	1.6	63
253	Novel ways to target brain tumour metabolism. Expert Opinion on Therapeutic Targets, 2011, 15, 1227-1239.	1.5	13
254	Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Research, 2011, 39, e118-e118.	6.5	1,622
255	Acute Myeloid Leukemia With IDH1 or IDH2 Mutation. American Journal of Clinical Pathology, 2011, 135, 35-45.	0.4	145
256	Autophagy, Stress, and Cancer Metabolism: What Doesn't Kill You Makes You Stronger. Cold Spring Harbor Symposia on Quantitative Biology, 2011, 76, 389-396.	2.0	101
257	Genetic Alterations in Glioma. Cancers, 2011, 3, 1129-1140.	1.7	24
258	Pharmacometabonomic Profiling as a Predictor of Toxicity in Patients with Inoperable Colorectal Cancer Treated with Capecitabine. Clinical Cancer Research, 2011, 17, 3019-3028.	3.2	102
259	Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: an evolutionary alternative to the Warburg shift?. Neuro-Oncology, 2011, 13, 1262-1264.	0.6	6
260	Role of isocitrate dehydrogenase in glioma. Expert Review of Neurotherapeutics, 2011, 11, 1399-1409.	1.4	15
261	A Switching Mechanism in Doxorubicin Bioactivation Can Be Exploited to Control Doxorubicin Toxicity. PLoS Computational Biology, 2011, 7, e1002151.	1.5	38
262	Mutations to metabolic enzymes in cancer herald a need to unify genetics and biochemistry. Cell Cycle, 2011, 10, 2819-2820.	1.3	1
263	Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients. Leukemia, 2012, 26, 101-105.	3.3	129
264	TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State. International Journal of Cell Biology, 2012, 2012, 1-9.	1.0	133
265	Cancer cell growth and survival as a system-level property sustained by enhanced glycolysis and mitochondrial metabolic remodeling. Frontiers in Physiology, 2012, 3, 362.	1.3	24

#	Article	IF	Citations
266	Interactions between epigenetics and metabolism in cancers. Frontiers in Oncology, 2012, 2, 163.	1.3	67
267	A heterozygous IDH1^{R132H/WT} mutation induces genome-wide alterations in DNA methylation. Genome Research, 2012, 22, 2339-2355.	2.4	157
268	Cancer-Associated Isocitrate Dehydrogenase Mutations. Oncologist, 2012, 17, 5-8.	1.9	18
269	Isocitrate Dehydrogenase (IDH) Mutations Promote a Reversible ZEB1/MicroRNA (miR)-200-dependent Epithelial-Mesenchymal Transition (EMT). Journal of Biological Chemistry, 2012, 287, 42180-42194.	1.6	86
270	Magnetic Resonance of 2-Hydroxyglutarate in IDH1 -Mutated Low-Grade Gliomas. Science Translational Medicine, 2012, 4, 116ra5.	5.8	161
271	Frontiers in metabolic reconstruction and modeling of plant genomes. Journal of Experimental Botany, 2012, 63, 2247-2258.	2.4	79
272	The Metabolomic Signature of Malignant Glioma Reflects Accelerated Anabolic Metabolism. Cancer Research, 2012, 72, 5878-5888.	0.4	147
273	Metabolomics of Human Cerebrospinal Fluid Identifies Signatures of Malignant Glioma. Molecular and Cellular Proteomics, 2012, 11, M111.014688.	2.5	89
274	Conceptual Framework for Cutting the Pancreatic Cancer Fuel Supply. Clinical Cancer Research, 2012, 18, 4285-4290.	3.2	52
275	Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. Neuro-Oncology, 2012, 14, 1465-1472.	0.6	35
276	Expanding the Reach of Cancer Metabolomics. Cancer Prevention Research, 2012, 5, 1337-1340.	0.7	19
277	IDHmutations: new genetic signatures in cholangiocarcinoma and therapeutic implications. Expert Review of Anticancer Therapy, 2012, 12, 543-546.	1.1	23
278	Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro-Oncology, 2012, 14, iv100-iv108.	0.6	154
279	A biocatalyst inspired by cancer. Nature Chemical Biology, 2012, 8, 874-875.	3.9	1
280	An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro-Oncology, 2012, 14, 184-191.	0.6	145
281	LOW GRADE GLIOMAS. Neuro-Oncology, 2012, 14, i69-i81.	0.6	5
282	IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia, 2012, 26, 475-480.	3.3	146
283	2HG on the brain (tumor). Science-Business EXchange, 2012, 5, 117-117.	0.0	0

#	Article	IF	Citations
284	Identification of Isocitrate Dehydrogenase 1 as a Potential Diagnostic and Prognostic Biomarker for Non-small Cell Lung Cancer by Proteomic Analysis. Molecular and Cellular Proteomics, 2012, 11, M111.008821.	2.5	52
285	Passenger mutations take the wheel. Science-Business EXchange, 2012, 5, 915-915.	0.0	0
286	Magnetic Resonance Metabolic Imaging of Glioma. Science Translational Medicine, 2012, 4, 116ps1.	5.8	5
287	SIRT3 Protein Deacetylates Isocitrate Dehydrogenase 2 (IDH2) and Regulates Mitochondrial Redox Status. Journal of Biological Chemistry, 2012, 287, 14078-14086.	1.6	361
288	Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping. Oncologist, 2012, 17, 72-79.	1.9	629
289	Promoter Methylation Analysis of IDH Genes in Human Gliomas. Frontiers in Oncology, 2012, 2, 193.	1.3	5
290	The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells. International Journal of Cell Biology, 2012, 2012, 1-12.	1.0	89
291	The Keap1â€“Nrf2 system in cancers: stress response and anabolic metabolism. Frontiers in Oncology, 2012, 2, 200.	1.3	305
292	Detection of 2-Hydroxyglutarate in IDH -Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy. Science Translational Medicine, 2012, 4, 116ra4.	5.8	367
293	IDH1 mutation of gliomas with long-term survival analysis. Oncology Reports, 2012, 28, 1639-1644.	1.2	38
294	Metabolic Profiling, a Noninvasive Approach for the Detection of Experimental Colorectal Neoplasia. Cancer Prevention Research, 2012, 5, 1358-1367.	0.7	46
295	The diagnosis of spinal tumors: established and emerging methods. Expert Opinion on Medical Diagnostics, 2012, 6, 95-108.	1.6	2
296	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field ofClinical Practice. Clinical Practice (London, England), 2012, 9, 241-246.	0.1	0
298	Ten-Eleven Translocation-2 gene mutations: A potential new molecular marker in malignant gliomas (Review). Oncology Letters, 2012, 3, 7-10.	0.8	2
299	Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2. Current Opinion in Oncology, 2012, 24, 83-89.	1.1	52
300	Cerebral Neoplasms in L-2 Hydroxyglutaric Aciduria: 3 New Cases and Meta-Analysis of Literature Data. American Journal of Neuroradiology, 2012, 33, 940-943.	1.2	56
301	IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy. International Journal of Oncology, 2012, 41, 1325-1336.	1.4	67
302	Metabolic sensors and their interplay with cell signalling and transcription. Biochemical Society Transactions, 2012, 40, 311-323.	1.6	18

#	Article	IF	Citations
303	IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood, 2012, 119, 1901-1903.	0.6	435
304	Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. International Journal of Oncology, 2012, 40, 2058-62.	1.4	23
305	Primary brain tumours in adults. Lancet, The, 2012, 379, 1984-1996.	6.3	723
306	How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature, 2012, 491, 364-373.	13.7	800
307	IDH Mutation Detection in Formalinâ€Fixed Paraffinâ€Embedded Gliomas Using Multiplex PCR and Singleâ€Base Extension. Brain Pathology, 2012, 22, 619-624.	2.1	21
308	Global Profiling Strategies for Mapping Dysregulated Metabolic Pathways in Cancer. Cell Metabolism, 2012, 16, 565-577.	7.2	103
309	Genetically-defined metabolic reprogramming in cancer. Trends in Endocrinology and Metabolism, 2012, 23, 552-559.	3.1	72
310	Enzymatic assay for quantitative analysis of (d)-2-hydroxyglutarate. Acta Neuropathologica, 2012, 124, 883-891.	3.9	58
311	Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood, 2012, 120, 4649-4652.	0.6	116
312	Loss of the respiratory enzyme citrate synthase directly links the Warburg effect to tumor malignancy. Scientific Reports, 2012, 2, 785.	1.6	108
313	Identification of Retinol Binding Protein 1 Promoter Hypermethylation in Isocitrate Dehydrogenase 1 and 2 Mutant Gliomas. Journal of the National Cancer Institute, 2012, 104, 1458-1469.	3.0	56
314	Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nature Medicine, 2012, 18, 1835-1840.	15.2	647
315	D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes and Development, 2012, 26, 2038-2049.	2.7	257
316	IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives. Clinical Cancer Research, 2012, 18, 5562-5571.	3.2	341
317	Nuclear Exclusion of TET1 Is Associated with Loss of 5-Hydroxymethylcytosine in IDH1 Wild-Type Gliomas. American Journal of Pathology, 2012, 181, 675-683.	1.9	98
318	Cancer-associated Isocitrate Dehydrogenase Mutations Inactivate NADPH-dependent Reductive Carboxylation. Journal of Biological Chemistry, 2012, 287, 14615-14620.	1.6	140
319	IDH1 mutation, a genetic alteration associated with adult gliomatosis cerebri. Neuropathology, 2012, 32, 30-37.	0.7	18
320	Expanding the concepts and tools of metabolic engineering to elucidate cancer metabolism. Biotechnology Progress, 2012, 28, 1409-1418.	1.3	18

#	Article	IF	Citations
321	Detection of â€œoncometaboliteâ€•2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. Journal of Molecular Medicine, 2012, 90, 1161-1171.	1.7	77
322	Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma. Brain Tumor Pathology, 2012, 29, 201-206.	1.1	83
323	IDH1 mutations inhibit multiple Î±-ketoglutarate-dependent dioxygenase activities in astroglioma. Journal of Neuro-Oncology, 2012, 109, 253-260.	1.4	27
324	Tailor-Made Renal Cell Carcinoma Vaccines. Cancer Cell, 2012, 22, 287-289.	7.7	3
325	IDH1 Mutations Disrupt Blood, Brain, and Barriers. Cancer Cell, 2012, 22, 285-287.	7.7	11
326	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell, 2012, 22, 425-437.	7.7	1,551
327	Terapie molecolari mirate e antiangiogeniche nel trattamento dei glioblastomi. EMC - Neurologia, 2012, 12, 1-14.	0.0	0
328	Something Old and Something New About Molecular Diagnostics in Gliomas. Surgical Pathology Clinics, 2012, 5, 919-939.	0.7	12
329	Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. Genome Medicine, 2012, 4, 37.	3.6	88
330	Impaired TCA cycle flux in mitochondria in skeletal muscle from type 2 diabetic subjects: Marker or maker of the diabetic phenotype?. Archives of Physiology and Biochemistry, 2012, 118, 156-189.	1.0	51
331	IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure: the Journal of the British Epilepsy Association, 2012, 21, 194-197.	0.9	123
332	Alterations of metabolic genes and metabolites in cancer. Seminars in Cell and Developmental Biology, 2012, 23, 370-380.	2.3	100
333	New aspects of the Warburg effect in cancer cell biology. Seminars in Cell and Developmental Biology, 2012, 23, 352-361.	2.3	262
334	IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma. Clinical Cancer Research, 2012, 18, 2490-2501.	3.2	127
335	Metabolome 2.0: quantitative genetics and network biology of metabolic phenotypes. Molecular BioSystems, 2012, 8, 2494.	2.9	55
336	Phosphofructokinase 1 Glycosylation Regulates Cell Growth and Metabolism. Science, 2012, 337, 975-980.	6.0	527
337	Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo. ACS Medicinal Chemistry Letters, 2012, 3, 850-855.	1.3	175
338	Therapeutic targets in cancer cell metabolism and autophagy. Nature Biotechnology, 2012, 30, 671-678.	9.4	310

#	Article	IF	Citations
339	Model-based Confirmation of Alternative Substrates of Mitochondrial Electron Transport Chain. Journal of Biological Chemistry, 2012, 287, 11122-11131.	1.6	19
340	The role of mutations in epigenetic regulators in myeloid malignancies. Nature Reviews Cancer, 2012, 12, 599-612.	12.8	614
341	Why Proteins in Mammalian Cells?. Methods in Molecular Biology, 2012, 801, 1-12.	0.4	9
342	Cancer Cell Metabolism: One Hallmark, Many Faces. Cancer Discovery, 2012, 2, 881-898.	7.7	773
343	Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. Annals of Diagnostic Pathology, 2012, 16, 161-170.	0.6	22
344	Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1Î± and Î²-catenin signaling: Possible impact on glioma cell metastasis and chemo-resistance. International Journal of Biochemistry and Cell Biology, 2012, 44, 770-775.	1.2	48
345	Glycine Decarboxylase Activity Drives Non-Small Cell Lung Cancer Tumor-Initiating Cells and Tumorigenesis. Cell, 2012, 148, 259-272.	13.5	593
346	Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us?. Cell, 2012, 148, 1132-1144.	13.5	684
347	Functional Repurposing Revealed by Comparing S.Âpombe and S.Âcerevisiae Genetic Interactions. Cell, 2012, 149, 1339-1352.	13.5	154
348	Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells. Cell Metabolism, 2012, 15, 110-121.	7.2	923
349	Metabolic Regulation of Epigenetics. Cell Metabolism, 2012, 16, 9-17.	7.2	568
350	Opening Pandora's Boxâ€"the new biology of driver mutations and clonal evolution in cancer as revealed by next generation sequencing. Current Opinion in Genetics and Development, 2012, 22, 3-9.	1.5	34
351	Lactate Activates HIF-1 in Oxidative but Not in Warburg-Phenotype Human Tumor Cells. PLoS ONE, 2012, 7, e46571.	1.1	204
352	Metabolic reprogramming in cancer: Unraveling the role of glutamine in tumorigenesis. Seminars in Cell and Developmental Biology, 2012, 23, 362-369.	2.3	310
353	Gatekeepers of chromatin: Small metabolites elicit big changes in gene expression. Trends in Biochemical Sciences, 2012, 37, 477-483.	3.7	40
354	A framework to identify gene expression profiles in a model of inflammation induced by lipopolysaccharide after treatment with thalidomide. BMC Research Notes, 2012, 5, 292.	0.6	1
355	Genotype-Phenotype Interactions in the Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America, 2012, 26, 993-1015.	0.9	7
356	Magnetic Resonance Spectroscopy of Cancer Metabolism and Response to Therapy. Radiation Research, 2012, 177, 398-435.	0.7	16

#	Article	IF	Citations
357	Enzyme redesign guided by cancer-derived IDH1 mutations. Nature Chemical Biology, 2012, 8, 887-889.	3.9	22
358	Epigenetic Alterations in Glioblastoma Multiforme. , 2012, , 71-90.		1
359	Landscape of TET2 mutations in acute myeloid leukemia. Leukemia, 2012, 26, 934-942.	3.3	210
360	Glutamineâ€fueled mitochondrial metabolism is decoupled from glycolysis in melanoma. Pigment Cell and Melanoma Research, 2012, 25, 732-739.	1.5	93
361	Mitochondria and cancer. Nature Reviews Cancer, 2012, 12, 685-698.	12.8	1,829
362	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 2012, 482, 226-231.	13.7	2,129
363	IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature, 2012, 488, 656-659.	13.7	474
364	2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nature Medicine, 2012, 18, 624-629.	15.2	711
365	Identification of additional IDH mutations associated with oncometabolite R(â^')-2-hydroxyglutarate production. Oncogene, 2012, 31, 2491-2498.	2.6	172
368	In Vivo Detection of Brain Krebs Cycle Intermediate by Hyperpolarized Magnetic Resonance. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 2108-2113.	2.4	72
369	A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 423-433.	3.3	79
370	The Role of DNA Methylation in Aging, Rejuvenation, and Age-Related Disease. Rejuvenation Research, 2012, 15, 483-494.	0.9	307
371	Stopping a chromatin enzyme. Nature Chemical Biology, 2012, 8, 875-876.	3.9	7
372	Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature, 2012, 483, 484-488.	13.7	630
373	Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Human Pathology, 2012, 43, 1552-1558.	1.1	211
374	IDH mutations in acute myeloid leukemia. Human Pathology, 2012, 43, 1541-1551.	1.1	103
375	Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma. Annals of Diagnostic Pathology, 2012, 16, 255-259.	0.6	17
376	Maximizing the value of metabolomic data. Bioanalysis, 2012, 4, 2199-2201.	0.6	11

#	Article	IF	Citations
377	LCâ€MS Data Processing with MAVEN: A Metabolomic Analysis and Visualization Engine. Current Protocols in Bioinformatics, 2012, 37, Unit14.11.	25.8	406
378	IDH1 Mutations in Diffusely Infiltrating Astrocytomas. American Journal of Clinical Pathology, 2012, 138, 177-184.	0.4	31
379	Cancer metabolism: current perspectives and future directions. Cell Death and Disease, 2012, 3, e248-e248.	2.7	327
380	Epigenetic alterations in hematopoietic malignancies. International Journal of Hematology, 2012, 96, 413-427.	0.7	48
381	Induced Fit and the Catalytic Mechanism of Isocitrate Dehydrogenase. Biochemistry, 2012, 51, 7098-7115.	1.2	32
384	Low-Grade Gliomas. Hematology/Oncology Clinics of North America, 2012, 26, 797-809.	0.9	6
385	Kinetic Analysis of Iron-Dependent Histone Demethylases: Î±-Ketoglutarate Substrate Inhibition and Potential Relevance to the Regulation of Histone Demethylation in Cancer Cells. Biochemistry, 2012, 51, 8699-8701.	1.2	47
386	Systems Metabolic Engineering. , 2012, , .		11
387	Untuning the tumor metabolic machine: HIF-Î±: pro- and antitumorigenic?. Nature Medicine, 2012, 18, 1024-1025.	15.2	29
388	Clonal Analysis in Recurrent Astrocytic, Oligoastrocytic and Oligodendroglial Tumors Implicates IDH1- Mutation as Common Tumor Initiating Event. PLoS ONE, 2012, 7, e41298.	1.1	43
389	Activating Mutations and Targeted Therapy in Cancer. , 0, , .		3
390	Targeting the Human Kinome for Cancer Therapy: Current Perspectives. Critical Reviews in Oncogenesis, 2012, 17, 233-246.	0.2	26
391	Molecular biomarkers of glioblastoma: current targets and clinical implications. Current Biomarker Findings, 0, , 63.	0.4	4
392	Breathless cancer cells get fat on glutamine. Cell Research, 2012, 22, 443-446.	5.7	56
393	Links between metabolism and cancer. Genes and Development, 2012, 26, 877-890.	2.7	846
394	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature, 2012, 483, 479-483.	13.7	1,668
395	The mechanisms of IDH mutations in tumorigenesis. Cell Research, 2012, 22, 1102-1104.	5.7	32
396	IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature, 2012, 483, 474-478.	13.7	1,693

#	Article	IF	Citations
397	Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. Journal of Hematology and Oncology, 2012, 5, 5.	6.9	83
398	Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission. Leukemia, 2012, 26, 527-529.	3.3	21
399	Systems-Level Analysis of Cancer Metabolism. , 2012, , 349-381.		1
400	Pharmacoâ€metabolomics: An emerging â€œomicsâ€•tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets. Journal of Cellular Physiology, 2012, 227, 2827-2831.	2.0	68
401	2â€Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. International Journal of Cancer, 2012, 131, 766-768.	2.3	74
402	MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations. International Journal of Cancer, 2012, 131, 1104-1113.	2.3	78
403	Metabolomics: the apogee of the omics trilogy. Nature Reviews Molecular Cell Biology, 2012, 13, 263-269.	16.1	1,931
404	Inhibition of Î±-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes and Development, 2012, 26, 1326-1338.	2.7	855
405	Meta-analysis of untargeted metabolomic data from multiple profiling experiments. Nature Protocols, 2012, 7, 508-516.	5.5	154
406	Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with highâ€dose cytarabine and idarubicin. Cancer, 2012, 118, 2665-2673.	2.0	47
407	The secrets of the bone marrow niche: Metabolic priming for AML. Nature Medicine, 2012, 18, 865-867.	15.2	15
408	Mutations in Epigenetic Modifiers in Myeloid Malignancies and the Prospect of Novel Epigenetic-Targeted Therapy. Advances in Hematology, 2012, 2012, 1-12.	0.6	73
409	Signaling in Control of Cell Growth and Metabolism. Cold Spring Harbor Perspectives in Biology, 2012, 4, a006783-a006783.	2.3	237
410	Experimental results using 3-bromopyruvate in mesothelioma: in vitro and in vivo studies. Journal of Bioenergetics and Biomembranes, 2012, 44, 81-90.	1.0	13
411	Recent advances in the molecular understanding of glioblastoma. Journal of Neuro-Oncology, 2012, 108, 11-27.	1.4	358
412	1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth. Journal of Neuro-Oncology, 2012, 108, 69-75.	1.4	46
413	Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. Journal of Neuro-Oncology, 2012, 108, 361-373.	1.4	45
414	Clinical Implications of Molecular Neuropathology and Biomarkers for Malignant Glioma. Current Neurology and Neuroscience Reports, 2012, 12, 302-307.	2.0	21

#	Article	IF	Citations
415	Progress in understanding 2â€hydroxyglutaric acidurias. Journal of Inherited Metabolic Disease, 2012, 35, 571-587.	1.7	226
416	Detection of 2â€Hydroxyglutarate in Formalinâ€Fixed Paraffinâ€Embedded Glioma Specimens by Gas Chromatography/Mass Spectrometry. Brain Pathology, 2012, 22, 26-31.	2.1	49
417	Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate. Cancer Cell, 2012, 21, 297-308.	7.7	2,617
418	How Chemoproteomics Can Enable Drug Discovery and Development. Chemistry and Biology, 2012, 19, 11-22.	6.2	137
419	Identifying malignant transformations in recurrent low grade gliomas using high resolution magic angle spinning spectroscopy. Artificial Intelligence in Medicine, 2012, 55, 61-70.	3.8	15
420	Targeting cancer metabolism â€“ aiming at a tumour's sweet-spot. Drug Discovery Today, 2012, 17, 232-241.	3.2	145
421	Understanding the central role of citrate in the metabolism of cancer cells. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1825, 111-116.	3.3	102
422	From cancer metabolism to new biomarkers and drug targets. Biotechnology Advances, 2012, 30, 30-51.	6.0	62
423	Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: Novel Pathogenetic Lesions. Seminars in Oncology, 2012, 39, 67-73.	0.8	41
424	Mutational Determinants of Epigenetic Instablity in Myeloid Malignancies. Seminars in Oncology, 2012, 39, 80-96.	0.8	4
425	IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia and associated with NPM1 mutations and FABâ€M2 subtype. International Journal of Laboratory Hematology, 2012, 34, 502-509.	0.7	10
426	Metabolomics as a Key Integrator for â€œOmicâ€•Advancement of Personalized Medicine and Future Therapies. Clinical and Translational Science, 2012, 5, 285-288.	1.5	46
427	Adverse impact of IDH1 and IDH2 mutations in primary AML: Experience of the Spanish CETLAM group. Leukemia Research, 2012, 36, 990-997.	0.4	41
428	Direct mutation analysis by high-throughput sequencing: From germline to low-abundant, somatic variants. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2012, 729, 1-15.	0.4	75
429	Stable isotope-resolved metabolomics and applications for drug development. , 2012, 133, 366-391.		186
430	Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Science, 2012, 103, 587-592.	1.7	87
431	Epigenetics and blood disorders. British Journal of Haematology, 2012, 158, 307-322.	1.2	11
432	Molecular pathology in adult highâ€grade gliomas: from molecular diagnostics to target therapies. Neuropathology and Applied Neurobiology, 2012, 38, 271-291.	1.8	97

#	Article	IF	Citations
433	The hypermethylation of the O⁶â€methylguanineâ€DNA methyltransferase gene promoter in gliomasâ€"correlation with array comparative genome hybridization results and IDH1 mutation. Genes Chromosomes and Cancer, 2012, 51, 20-29.	1.5	13
434	IDH1 mutations in grade II astrocytomas are associated with unfavorable progressionâ€free survival and prolonged postrecurrence survival. Cancer, 2012, 118, 452-460.	2.0	77
435	Metabolism of [Uâ€¹³C]glucose in human brain tumors in vivo. NMR in Biomedicine, 2012, 25, 1234-1244.	1.6	282
436	Disordered Epigenetic Regulation in the Pathophysiology of Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports, 2012, 7, 34-42.	1.2	7
437	Transformation of a Chronic Myeloproliferative Neoplasm to Acute Myelogenous Leukemia: Does Anything Work?. Current Hematologic Malignancy Reports, 2012, 7, 78-86.	1.2	31
438	Role of TET2 Mutations in Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports, 2012, 7, 57-64.	1.2	32
439	Mutations in epigenetic regulators in myelodysplastic syndromes. International Journal of Hematology, 2012, 95, 8-16.	0.7	30
440	IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Annals of Hematology, 2012, 91, 519-525.	0.8	96
441	Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. Journal of Neuro-Oncology, 2012, 107, 1-12.	1.4	47
442	Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. Journal of Neuro-Oncology, 2012, 107, 197-205.	1.4	280
443	Metabolic symbiosis in cancer: Refocusing the Warburg lens. Molecular Carcinogenesis, 2013, 52, 329-337.	1.3	131
444	Novel SNP development and analysis at a NADP⁺â€specific IDH enzyme gene in a four species mixed oak forest. Plant Biology, 2013, 15, 126-137.	1.8	9
445	Biochemical characterization of NADP+-dependent isocitrate dehydrogenase from Microcystis aeruginosa PCC7806. Molecular Biology Reports, 2013, 40, 2995-3002.	1.0	11
446	Expression and characterization of a novel isocitrate dehydrogenase from Streptomyces diastaticus No. 7 strain M1033. Molecular Biology Reports, 2013, 40, 1615-1623.	1.0	7
447	Metabolomics of colorectal cancer: past and current analytical platforms. Analytical and Bioanalytical Chemistry, 2013, 405, 5013-5030.	1.9	50
448	GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients. Journal of Neuro-Oncology, 2013, 113, 65-74.	1.4	87
449	Interlaboratory comparison of IDH mutation detection. Journal of Neuro-Oncology, 2013, 112, 173-178.	1.4	59
450	Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1. Journal of Neuro-Oncology, 2013, 111, 245-255.	1.4	89

#	Article	IF	Citations
451	New Advances on Disease Biomarkers and Molecular Targets in Biomedicine. , 2013, , .		0
452	Advances in Understanding the Coupling of DNA Base Modifying Enzymes to Processes Involving Base Excision Repair. Advances in Cancer Research, 2013, 119, 63-106.	1.9	11
453	Progress on molecular biomarkers and classification of malignant gliomas. Frontiers of Medicine, 2013, 7, 150-156.	1.5	21
454	Contribution of Molecular Biology to the Classification of Low-Grade Diffuse Glioma. , 2013, , 61-72.		0
455	Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and Î±-KG. Acta Neuropathologica Communications, 2013, 1, 18.	2.4	54
456	Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. International Journal of Hematology, 2013, 98, 648-657.	0.7	101
459	Metabolismâ€“epigenome crosstalk in physiology and diseases. Journal of Human Genetics, 2013, 58, 410-415.	1.1	34
460	2-Hydroxyglutarate as a Magnetic Resonance Biomarker for Glioma Subtyping. Translational Oncology, 2013, 6, 92-98.	1.7	27
461	Isotopically nonstationary 13C flux analysis of Myc-induced metabolic reprogramming in B-cells. Metabolic Engineering, 2013, 15, 206-217.	3.6	81
462	Methylglyoxal-induced modification of arginine residues decreases the activity of NADPH-generating enzymes. Free Radical Biology and Medicine, 2013, 61, 229-242.	1.3	12
463	A Role for Cytosolic Fumarate Hydratase in Urea Cycle Metabolism and Renal Neoplasia. Cell Reports, 2013, 3, 1440-1448.	2.9	78
464	An Untargeted Metabolomic Workflow to Improve Structural Characterization of Metabolites. Analytical Chemistry, 2013, 85, 7713-7719.	3.2	67
465	Understanding the Tumor Microenvironment and Radioresistance by Combining Functional Imaging With Global Gene Expression. Seminars in Radiation Oncology, 2013, 23, 296-305.	1.0	16
466	Metabolic targets for cancer therapy. Nature Reviews Drug Discovery, 2013, 12, 829-846.	21.5	592
467	The nexus of chromatin regulation and intermediary metabolism. Nature, 2013, 502, 489-498.	13.7	341
468	The CpG Island Methylator Phenotype: What's in a Name?. Cancer Research, 2013, 73, 5858-5868.	0.4	154
470	Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood, 2013, 121, 4917-4924.	0.6	175
471	Systems biological approaches to measure and understand vaccine immunity in humans. Seminars in Immunology, 2013, 25, 209-218.	2.7	58

#	Article	IF	Citations
472	Glioblastoma Multiforme Therapy and Mechanisms of Resistance. Pharmaceuticals, 2013, 6, 1475-1506.	1.7	229
473	Cancer Development, Progression, and Therapy: An Epigenetic Overview. International Journal of Molecular Sciences, 2013, 14, 21087-21113.	1.8	257
474	Targeting Cancer Metabolisms. , 2013, , 159-174.		0
475	Exome sequencing identifies distinct mutational patterns in liver flukeâ€"related and non-infection-related bile duct cancers. Nature Genetics, 2013, 45, 1474-1478.	9.4	426
476	Liquid Chromatography Coupled to Mass Spectrometry-Based Metabolomics and the Concept of Biomarker. Advances in Botanical Research, 2013, 67, 159-218.	0.5	6
477	Modulation of oxidative stress as an anticancer strategy. Nature Reviews Drug Discovery, 2013, 12, 931-947.	21.5	2,735
478	IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. Future Oncology, 2013, 9, 1923-1935.	1.1	53
479	Epigenetic Alterations in Oncogenesis. Advances in Experimental Medicine and Biology, 2013, 754, v-vii.	0.8	10
480	Metabolic Mechanisms of Epigenetic Regulation. ACS Chemical Biology, 2013, 8, 2607-2621.	1.6	63
481	IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. Neuro-Oncology, 2013, 15, 1114-1126.	0.6	100
482	Update on Targets and Novel Treatment Options for High-Grade Osteosarcoma and Chondrosarcoma. Hematology/Oncology Clinics of North America, 2013, 27, 1021-1048.	0.9	65
483	The biology and clinical impact of genetic lesions in myeloid malignancies. Blood, 2013, 122, 3741-3748.	0.6	47
484	Targeting IDH: the next big thing in AML. Blood, 2013, 122, 2770-2771.	0.6	22
485	Fueling Immunity: Insights into Metabolism and Lymphocyte Function. Science, 2013, 342, 1242454.	6.0	1,070
486	Tumor biology as a basis for molecular targeting in cancer. Clinical and Translational Imaging, 2013, 1, 397-406.	1.1	2
487	Emerging patterns of somatic mutations in cancer. Nature Reviews Genetics, 2013, 14, 703-718.	7.7	442
488	Deficiency in SLC25A1, Encoding the Mitochondrial Citrate Carrier, Causes Combined D-2- and L-2-Hydroxyglutaric Aciduria. American Journal of Human Genetics, 2013, 92, 627-631.	2.6	122
489	Non-invasive in vivo assessment of IDH1 mutational status in glioma. Nature Communications, 2013, 4, 2429.	5.8	118

#	Article	IF	Citations
490	Therapeutic strategies impacting cancer cell glutamine metabolism. Future Medicinal Chemistry, 2013, 5, 1685-1700.	1.1	110
491	Biology â€“ cancer metabolic phenotype. , 2013, , 15-138.		2
492	Metabolite proofreading, a neglected aspect of intermediary metabolism. Journal of Inherited Metabolic Disease, 2013, 36, 427-434.	1.7	69
493	Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multiâ€specific monoclonal antibody MsMabâ€1. Cancer Medicine, 2013, 2, 803-814.	1.3	46
494	Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms. Journal of Cellular and Molecular Medicine, 2013, 17, 1218-1235.	1.6	49
495	Multi-Specific Monoclonal Antibody MsMab-2 Recognizes IDH1-R132L and IDH2-R172M Mutations. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2013, 32, 377-381.	0.8	20
496	Novel Monoclonal Antibodies GMab-r1 and LMab-1 Specifically Recognize IDH1-R132G and IDH1-R132L Mutations. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2013, 32, 224-228.	0.8	12
497	Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood, 2013, 121, 3563-3572.	0.6	218
498	Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nature Genetics, 2013, 45, 18-24.	9.4	359
499	Objective assessment of cancer genes for drug discovery. Nature Reviews Drug Discovery, 2013, 12, 35-50.	21.5	111
500	Genetic profiling in acute myeloid leukaemia â”€ where are we and what is its role in patient management. British Journal of Haematology, 2013, 160, 303-320.	1.2	47
501	The Cancer Biology of Molecular Imaging. , 2013, , 3-19.		0
502	The Definition of Primary and Secondary Glioblastoma. Clinical Cancer Research, 2013, 19, 764-772.	3.2	819
503	Expanding the spectrum of IDH1 mutations in gliomas. Modern Pathology, 2013, 26, 619-625.	2.9	37
504	Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas. Cancer Research, 2013, 73, 496-501.	0.4	108
505	Glioblastoma, a Brief Review of History, Molecular Genetics, Animal Models and Novel Therapeutic Strategies. Archivum Immunologiae Et Therapiae Experimentalis, 2013, 61, 25-41.	1.0	191
506	Metabolic changes in cancer: beyond the Warburg effect. Acta Biochimica Et Biophysica Sinica, 2013, 45, 18-26.	0.9	127
507	Mitoplasticity: Adaptation Biology of the Mitochondrion to the Cellular Redox State in Physiology and Carcinogenesis. Antioxidants and Redox Signaling, 2013, 18, 808-849.	2.5	40

#	Article	IF	Citations
508	(R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible. Science, 2013, 339, 1621-1625.	6.0	624
509	Metabolite damage and its repair or pre-emption. Nature Chemical Biology, 2013, 9, 72-80.	3.9	248
510	The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization. Journal of Biological Chemistry, 2013, 288, 3804-3815.	1.6	141
511	IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro-Oncology, 2013, 15, 469-479.	0.6	158
512	NADP+-dependent IDH1R132 mutation and its relevance for glioma patient survival. Medical Hypotheses, 2013, 80, 728-731.	0.8	29
513	Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations. Biochemical and Biophysical Research Communications, 2013, 432, 40-45.	1.0	25
514	Unraveling the mystery of cancer metabolism in the genesis of tumor-initiating cells and development of cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2013, 1836, 49-59.	3.3	18
515	A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation. Biochemical and Biophysical Research Communications, 2013, 432, 564-567.	1.0	16
516	The long and winding road to the mitochondrial pyruvate carrier. Cancer & Metabolism, 2013, 1, 6.	2.4	61
517	Profiling metabolic networks to study cancer metabolism. Current Opinion in Biotechnology, 2013, 24, 60-68.	3.3	99
518	Chromatin Remodeling Defects in Pediatric and Young Adult Glioblastoma: A Tale of a Variant <scp>H</scp>istone 3 Tail. Brain Pathology, 2013, 23, 210-216.	2.1	74
519	R-2-Hydroxyglutarate as the Key Effector of IDH Mutations Promoting Oncogenesis. Cancer Cell, 2013, 23, 274-276.	7.7	77
520	Altered energy metabolism in cancer. Cancer Biology and Therapy, 2013, 14, 81-89.	1.5	113
521	Chemical approaches to study metabolic networks. Pflugers Archiv European Journal of Physiology, 2013, 465, 427-440.	1.3	13
522	Anaplastic Oligodendroglioma: Advances and Treatment Options. Current Treatment Options in Neurology, 2013, 15, 289-301.	0.7	10
523	Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro-Oncology, 2013, 15, 57-68.	0.6	128
524	Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody. Proteomics, 2013, 13, 866-877.	1.3	21
525	Epigenetic methylations and their connections with metabolism. Cellular and Molecular Life Sciences, 2013, 70, 1495-1508.	2.4	30

#	Article	IF	Citations
526	Ten Eleven Translocation Enzymes and 5-Hydroxymethylation in Mammalian Development and Cancer. Advances in Experimental Medicine and Biology, 2013, 754, 57-79.	0.8	56
527	Breathingâ€in epigenetic change with vitamin C. EMBO Reports, 2013, 14, 337-346.	2.0	118
528	Genetic and epigenetic alterations of myeloproliferative disorders. International Journal of Hematology, 2013, 97, 183-197.	0.7	60
529	NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nature Chemical Biology, 2013, 9, 300-306.	3.9	335
530	Current concepts in organic acidurias: understanding intraâ€•and extracerebral disease manifestation. Journal of Inherited Metabolic Disease, 2013, 36, 635-644.	1.7	52
531	How Molecular Testing Can Help (and Hurt) in the Workup of Gliomas. American Journal of Clinical Pathology, 2013, 139, 275-288.	0.4	6
532	From Systems to Structure: Bridging Networks and Mechanism. Molecular Cell, 2013, 49, 222-231.	4.5	46
533	Influence of Metabolism on Epigenetics and Disease. Cell, 2013, 153, 56-69.	13.5	729
534	Lessons from the Cancer Genome. Cell, 2013, 153, 17-37.	13.5	1,133
535	The same, but better. Nature, 2013, 496, 40-41.	13.7	0
536	A metabolic metamorphosis. Nature, 2013, 496, 38-40.	13.7	11
537	Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells. Protein and Cell, 2013, 4, 186-196.	4.8	34
538	Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. Future Medicinal Chemistry, 2013, 5, 553-572.	1.1	116
539	Gene mutations of acute myeloid leukemia in the genome era. International Journal of Hematology, 2013, 97, 165-174.	0.7	56
540	Targeting apoptosis pathways in glioblastoma. Cancer Letters, 2013, 332, 335-345.	3.2	60
541	<scp>IDH1</scp> Mutations in Oligodendroglial Tumors: Comparative Analysis of Direct Sequencing, Pyrosequencing, Immunohistochemistry, Nested <scp>PCR</scp> and <scp>PNA</scp>â€Mediated Clamping <scp>PCR</scp>. Brain Pathology, 2013, 23, 285-293.	2.1	28
542	Cancer mistunes methylation. Nature Chemical Biology, 2013, 9, 293-294.	3.9	26
543	A comparative study of shortâ€•and longâ€TE ¹H MRS at 3 T for in vivo detection of 2â€hydroxyglutarate in brain tumors. NMR in Biomedicine, 2013, 26, 1242-1250.	1.6	73

#	Article	IF	Citations
544	What do we know about IDH1/2 mutations so far, and how do we use it?. Acta Neuropathologica, 2013, 125, 621-636.	3.9	133
545	IDH1 and IDH2 Mutations in Gliomas. Current Neurology and Neuroscience Reports, 2013, 13, 345.	2.0	469
546	Anaplastic Astrocytoma. Current Treatment Options in Neurology, 2013, 15, 302-315.	0.7	8
547	Understanding Metabolic Regulation and Its Influence on Cell Physiology. Molecular Cell, 2013, 49, 388-398.	4.5	253
548	Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nature Biotechnology, 2013, 31, 522-529.	9.4	381
549	Prognostic impact of the isocitrate dehydrogenase 1 singleâ€nucleotide polymorphism rs11554137 in malignant gliomas. Cancer, 2013, 119, 806-813.	2.0	26
550	Differential sensitivities of glioblastoma cell lines towards metabolic and signaling pathway inhibitions. Cancer Letters, 2013, 336, 299-306.	3.2	29
551	Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase. ACS Medicinal Chemistry Letters, 2013, 4, 542-546.	1.3	70
552	Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation. Science, 2013, 340, 622-626.	6.0	721
553	Cancer metabolism: Key players in metabolic reprogramming. Cancer Science, 2013, 104, 275-281.	1.7	210
554	Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathologica, 2013, 125, 659-669.	3.9	250
555	Nutrient Sensing, Metabolism, and Cell Growth Control. Molecular Cell, 2013, 49, 379-387.	4.5	285
557	The mutational landscape of adenoid cystic carcinoma. Nature Genetics, 2013, 45, 791-798.	9.4	394
558	Diagnostic and prognostic markers in gliomas â€“ an update. British Journal of Neurosurgery, 2013, 27, 311-315.	0.4	12
559	Molecular subtypes of glioma identified by genomeâ€wide methylation profiling. Genes Chromosomes and Cancer, 2013, 52, 665-674.	1.5	27
560	5-hydroxymethylcytosine and its potential roles in development and cancer. Epigenetics and Chromatin, 2013, 6, 10.	1.8	157
561	Mutant IDH1 Enhances the Production of 2-Hydroxyglutarate Due to Its Kinetic Mechanism. Biochemistry, 2013, 52, 4563-4577.	1.2	69
562	Metabolism in physiological cell proliferation and differentiation. Trends in Cell Biology, 2013, 23, 484-492.	3.6	195

#	Article	IF	Citations
563	Epigenetic alterations and microRNAs. Epigenetics, 2013, 8, 561-570.	1.3	30
564	BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nature Medicine, 2013, 19, 901-908.	15.2	388
565	Serine, glycine and one-carbon units: cancer metabolism in full circle. Nature Reviews Cancer, 2013, 13, 572-583.	12.8	1,221
566	Expression of R132H Mutational IDH1 in Human U87 Glioblastoma Cells Affects the SREBP1a Pathway and Induces Cellular Proliferation. Journal of Molecular Neuroscience, 2013, 50, 165-171.	1.1	16
568	A mechanistic overview of TET-mediated 5-methylcytosine oxidation. Biochemical and Biophysical Research Communications, 2013, 436, 115-120.	1.0	50
569	Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation. Cancer Letters, 2013, 328, 297-306.	3.2	21
570	Emerging novel functions of the oxygen-sensing prolyl hydroxylase domain enzymes. Trends in Biochemical Sciences, 2013, 38, 3-11.	3.7	123
571	Genomics-Driven Oncology: Framework for an Emerging Paradigm. Journal of Clinical Oncology, 2013, 31, 1806-1814.	0.8	315
572	Metabolic alteration in tumorigenesis. Science China Life Sciences, 2013, 56, 1067-1075.	2.3	19
573	Structural, Kinetic and Chemical Mechanism of Isocitrate Dehydrogenase-1 from Mycobacterium tuberculosis. Biochemistry, 2013, 52, 1765-1775.	1.2	28
574	Proteomics analysis of tumor microenvironment: Implications of metabolic and oxidative stresses in tumorigenesis. Mass Spectrometry Reviews, 2013, 32, 267-311.	2.8	15
575	Screening forIDHmutations in chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2013, 54, 406-407.	0.6	4
576	TET proteins: on the frenetic hunt for new cytosine modifications. Briefings in Functional Genomics, 2013, 12, 191-204.	1.3	40
577	Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia. Annals of Hematology, 2013, 92, 1319-1323.	0.8	8
578	Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 1416-1425.	2.2	62
579	A Highly Facile and Specific Assay for Cancer-Causing Isocitrate Dehydrogenase Mutant Using ¹³C₄-Labeled Î±-Ketoglutarate and Heteronuclear NMR. Analytical Chemistry, 2013, 85, 11987-11992.	3.2	3
580	Exploring metabolic pathways that contribute to the stem cell phenotype. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 2361-2369.	1.1	42
581	Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene, 2013, 32, 3091-3100.	2.6	324

#	Article	IF	Citations
582	Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene, 2013, 32, 663-669.	2.6	499
583	Molecular genetics of low-grade gliomas: genomic alterations guiding diagnosis and therapeutic intervention. 11th Annual Frye-Halloran Brain Tumor Symposium. Neurosurgical Focus, 2013, 34, E9.	1.0	10
584	Personalized Medicine for Glioblastoma: Current Challenges and Future Opportunities. Current Molecular Medicine, 2013, 13, 358-367.	0.6	0
585	Focus on the epigenome in the myeloproliferative neoplasms. Hematology American Society of Hematology Education Program, 2013, 2013, 538-544.	0.9	11
586	5-hydroxymethylcytosine profiling as an indicator of cellular state. Epigenomics, 2013, 5, 655-669.	1.0	52
587	Isocitrate dehydrogenase 1: what it means to the neurosurgeon. Journal of Neurosurgery, 2013, 118, 1176-1180.	0.9	20
588	Cancer cell metabolism: implications for therapeutic targets. Experimental and Molecular Medicine, 2013, 45, e45-e45.	3.2	295
589	Metabolism and Cancer: Old and New Players. International Journal of Cell Biology, 2013, 2013, 1-2.	1.0	5
590	What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes and Development, 2013, 27, 836-852.	2.7	491
591	Novel cases of D-2-hydroxyglutaric aciduria withIDH1orIDH2mosaic mutations identified by amplicon deep sequencing. Journal of Medical Genetics, 2013, 50, 754-759.	1.5	19
592	Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy. Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013030.	0.5	3
593	Targeting Metabolism to Induce Cell Death in Cancer Cells and Cancer Stem Cells. International Journal of Cell Biology, 2013, 2013, 1-13.	1.0	57
594	How does the metabolism of tumour cells differ from that of normal cells. Bioscience Reports, 2013, 33, .	1.1	59
595	Ionizing Radiation in Glioblastoma Initiating Cells. Frontiers in Oncology, 2013, 3, 74.	1.3	27
596	Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas. Neuro-Oncology, 2013, 15, 682-690.	0.6	26
597	Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology. Frontiers in Oncology, 2013, 3, 38.	1.3	208
598	Brain Tumors and Gliomas. , 2013, , 749-764.		0
599	The molecular landscape of diffuse glioma and prospects for biomarker development. Expert Opinion on Medical Diagnostics, 2013, 7, 573-587.	1.6	9

#	Article	IF	Citations
600	Mutations in the Isocitrate Dehydrogenase Genes IDH1 and IDH2 in Tumors. Advances in Anatomic Pathology, 2013, 20, 32-38.	2.4	73
601	Silencing a Metabolic Oncogene. Science, 2013, 340, 558-559.	6.0	11
602	Induction of sarcomas by mutant IDH2. Genes and Development, 2013, 27, 1986-1998.	2.7	135
603	DNMT1 Is Regulated by ATP-Citrate Lyase and Maintains Methylation Patterns during Adipocyte Differentiation. Molecular and Cellular Biology, 2013, 33, 3864-3878.	1.1	75
604	Molecular prognostic factors in glioblastoma: state of the art and future challenges. CNS Oncology, 2013, 2, 495-510.	1.2	9
605	Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17017-17022.	3.3	125
606	Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations. Clinical Cancer Research, 2013, 19, 5146-5157.	3.2	157
607	Proliferation-Independent Control of Tumor Glycolysis by PDGFR-Mediated AKT Activation. Cancer Research, 2013, 73, 1831-1843.	0.4	39
608	Functional analysis of sucraseâ€“isomaltase mutations from chronic lymphocytic leukemia patients. Human Molecular Genetics, 2013, 22, 2273-2282.	1.4	25
609	The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms. Frontiers in Oncology, 2013, 3, 169.	1.3	44
610	Applications of metabolomics in cancer research. Journal of Carcinogenesis, 2013, 12, 9.	2.5	83
611	2-Hydroxyglutarate inIDHmutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. Leukemia and Lymphoma, 2013, 54, 408-410.	0.6	21
612	Metabolic dysfunction in pulmonary hypertension: the expanding relevance of the <scp>W</scp>arburg effect. European Journal of Clinical Investigation, 2013, 43, 855-865.	1.7	85
613	Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia. Leukemia and Lymphoma, 2013, 54, 1028-1035.	0.6	30
614	2-Hydroxyglutarate is not a metabolite; D-2-hydroxyglutarate and L-2-hydroxyglutarate are!. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4939-E4939.	3.3	37
615	Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities. Cancer Discovery, 2013, 3, 730-741.	7.7	371
616	Assaying 2-HG's function. Science-Business EXchange, 2013, 6, 205-205.	0.0	0
617	Oncometabolite takedown. Science-Business EXchange, 2013, 6, 328-328.	0.0	0

#	Article	IF	Citations
618	Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes and Development, 2013, 27, 1974-1985.	2.7	165
619	BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. Molecular Therapy - Nucleic Acids, 2013, 2, e109.	2.3	284
620	Clinical application of the CpG island methylator phenotype to prognostic diagnosis in neuroblastomas. Journal of Human Genetics, 2013, 58, 428-433.	1.1	20
621	Distinct IDH1/IDH2 mutation profiles in purely insular versus paralimbic WHO Grade II gliomas. Journal of Neurosurgery, 2013, 118, 866-872.	0.9	21
622	Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood, 2013, 122, 2877-2887.	0.6	186
623	Molecular Distinction of Chondrosarcoma From Chondroblastic Osteosarcoma Through IDH1/2 Mutations. American Journal of Surgical Pathology, 2013, 37, 787-795.	2.1	92
624	Neuro-oncologic Applications of Exosomes, Microvesicles, and Other Nano-Sized Extracellular Particles. Neurosurgery, 2013, 72, 501-510.	0.6	35
625	An R132H Mutation in Isocitrate Dehydrogenase 1 Enhances p21 Expression and Inhibits Phosphorylation of Retinoblastoma Protein in Glioma Cells. Neurologia Medico-Chirurgica, 2013, 53, 645-654.	1.0	11
626	Establishment of a Multi-Specific Monoclonal Antibody MsMab-1 Recognizing Both IDH1 and IDH2 Mutations. Tohoku Journal of Experimental Medicine, 2013, 230, 103-109.	0.5	27
627	Mechanisms of Aggressiveness in Glioblastoma: Prognostic and Potential Therapeutic Insights. , 2013, , .		0
628	Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. Journal of Clinical Investigation, 2013, 123, 2907-2920.	3.9	165
629	Prolyl-hydroxylase 3: evolving roles for an ancient signaling protein. Hypoxia (Auckland, N Z), 2013, 2013, 13.	1.9	26
630	Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. Journal of Clinical Investigation, 2013, 123, 3659-3663.	3.9	147
631	Isocitrate Dehydrogenase from Streptococcus mutans: Biochemical Properties and Evaluation of a Putative Phosphorylation Site at Ser102. PLoS ONE, 2013, 8, e58918.	1.1	12
632	A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1. PLoS ONE, 2013, 8, e59773.	1.1	39
633	Systematic Identification of Combinatorial Drivers and Targets in Cancer Cell Lines. PLoS ONE, 2013, 8, e60339.	1.1	6
634	Alterations of 5-Hydroxymethylcytosine in Human Cancers. Cancers, 2013, 5, 786-814.	1.7	46
635	The Significance of IDH1 Mutations in Tumor-Associated Seizure in 60 Chinese Patients with Low-Grade Gliomas. Scientific World Journal, The, 2013, 2013, 1-4.	0.8	19

#	Article	IF	Citations
636	Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. OncoTargets and Therapy, 2013, 6, 1363.	1.0	127
637	The Distribution and Significance of IDH Mutations in Gliomas. , 0, , .		5
638	Chemotherapeutic Agent for Glioma. , 2013, , .		1
639	Insight out: Advances in understanding metabolism achieved by high-throughput mass spectrometry. Biomedical Spectroscopy and Imaging, 2013, 2, 1-8.	1.2	0
640	Genetic Profiling: Searching for Novel Genetic Aberrations in Glioblastoma. , 0, , .		0
641	Gliomas Biology: Angiogenesis and Invasion. , 2013, , .		2
642	Recent Advances in Metabolic Profiling and Imaging of Prostate Cancer. Current Metabolomics, 2014, 2, 53-69.	0.5	28
643	In-Silico Prediction of Key Metabolic Differences between Two Non-Small Cell Lung Cancer Subtypes. PLoS ONE, 2014, 9, e103998.	1.1	25
644	Glioma Cells with the IDH1 Mutation Modulate Metabolic Fractional Flux through Pyruvate Carboxylase. PLoS ONE, 2014, 9, e108289.	1.1	62
645	Prognostic and Predictive Biomarkers in Adult and Pediatric Gliomas: Toward Personalized Treatment. Frontiers in Oncology, 2014, 4, 47.	1.3	36
646	Complex role of HIF in cancer: the known, the unknown, and the unexpected. Hypoxia (Auckland, N Z), 2014, 2, 59.	1.9	11
647	MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. Journal of Clinical Investigation, 2014, 124, 398-412.	3.9	348
648	Large scale integration of drug-target information reveals poly-pharmacological drug action mechanisms in tumor cell line growth inhibition assays. Oncotarget, 2014, 5, 659-666.	0.8	5
649	Brain stem cells as the cell of origin in glioma. World Journal of Stem Cells, 2014, 6, 43.	1.3	70
650	New Molecular Abnormalities and Clonal Architecture in AML: From Reciprocal Translocations to Whole-Genome Sequencing. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e334-e340.	1.8	10
651	5-Hydroxymethylcytosine Plays a Critical Role in Glioblastomagenesis by Recruiting the CHTOP-Methylosome Complex. Cell Reports, 2014, 9, 48-60.	2.9	122
652	Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro-Oncology, 2014, 16, 414-420.	0.6	82
653	Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. Expert Opinion on Pharmacotherapy, 2014, 15, 2047-2061.	0.9	19

#	Article	IF	Citations
654	In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies. Cellular and Molecular Life Sciences, 2014, 71, 4007-4026.	2.4	42
655	Endothelial cell metabolism: parallels and divergences with cancer cell metabolism. Cancer & Metabolism, 2014, 2, 19.	2.4	91
656	Genetic variations in IDH gene as prognosis predictors in TACE-treated hepatocellular carcinoma patients. Medical Oncology, 2014, 31, 278.	1.2	9
657	Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy. Acta Neuropathologica Communications, 2014, 2, 158.	2.4	48
658	IDH1 R132H Mutation Generates a Distinct Phospholipid Metabolite Profile in Glioma. Cancer Research, 2014, 74, 4898-4907.	0.4	78
659	Isocitrate Dehydrogenase 1 (IDH1) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate. Oncologist, 2014, 19, 602-607.	1.9	61
660	Hyperpolarized [1-13C] Glutamate: A Metabolic Imaging Biomarker of IDH1 Mutational Status in Glioma. Cancer Research, 2014, 74, 4247-4257.	0.4	77
661	Metabolic circuits in neural stem cells. Cellular and Molecular Life Sciences, 2014, 71, 4221-4241.	2.4	53
662	Mechanisms underlying the biological changes induced by isocitrate dehydrogenase-1 mutation in glioma cells. Oncology Letters, 2014, 7, 651-657.	0.8	9
663	Genetically Modeled Mice with Mutations in Mitochondrial Metabolic Enzymes for the Study of Cancer. Frontiers in Oncology, 2014, 4, 200.	1.3	19
664	IDH1R132HMutation Increases U87 Glioma Cell Sensitivity to Radiation Therapy in Hypoxia. BioMed Research International, 2014, 2014, 1-5.	0.9	13
665	IDH1/IDH2but NotTP53Mutations Predict Prognosis in Bulgarian Glioblastoma Patients. BioMed Research International, 2014, 2014, 1-9.	0.9	37
666	The evolving genomic landscape of myeloproliferative neoplasms. Hematology American Society of Hematology Education Program, 2014, 2014, 287-296.	0.9	62
667	Genomic landscape of glioblastoma and the potential clinical utility. CNS Oncology, 2014, 3, 169-172.	1.2	0
668	Sequencing IDH1/2 glioma mutation hotspots in gliomas and malignant peripheral nerve sheath tumors. Neuro-Oncology, 2014, 16, 320-322.	0.6	5
669	Molecular and cellular heterogeneity: the hallmark of glioblastoma. Neurosurgical Focus, 2014, 37, E11.	1.0	147
670	IDH mutations in liver cell plasticity and biliary cancer. Cell Cycle, 2014, 13, 3176-3182.	1.3	30
671	Isocitrate dehydrogenase 1R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype. Epigenetics, 2014, 9, 1454-1460.	1.3	20

#	Article	IF	Citations
672	Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nature Communications, 2014, 5, 5694.	5.8	295
673	The Double Life of p85. Cancer Cell, 2014, 26, 445-447.	7.7	14
674	Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma. Neurosurgical Focus, 2014, 37, E13.	1.0	48
675	IDH1 mutation is associated with seizures and protoplasmic subtype in patients with lowâ€grade gliomas. Epilepsia, 2014, 55, 1438-1443.	2.6	66
676	Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors. Acta Neuropathologica, 2014, 128, 615-627.	3.9	49
677	<scp>TET2</scp> as an epigenetic master regulator for normal and malignant hematopoiesis. Cancer Science, 2014, 105, 1093-1099.	1.7	89
678	Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone. Cancer Science, 2014, 105, 744-748.	1.7	37
679	Epigenetics in the hematologic malignancies. Haematologica, 2014, 99, 1772-1783.	1.7	60
680	Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105Câ€‰>â€‰T have a prognostic value in acute myeloid leukemia. Biomarker Research, 2014, 2, 18.	2.8	36
681	Molecular Genetics of Gliomas. Cancer Journal (Sudbury, Mass), 2014, 20, 66-72.	1.0	93
682	Isocitrate dehydrogenase mutations in chondrosarcoma. Current Opinion in Oncology, 2014, 26, 403-407.	1.1	9
683	Isocitrate Dehydrogenase-1 Is Mutated in Inflammatory Bowel Diseaseâ€“associated Intestinal Adenocarcinoma With Low-grade Tubuloglandular Histology but Not in Sporadic Intestinal Adenocarcinoma. American Journal of Surgical Pathology, 2014, 38, 1147-1156.	2.1	32
684	Emerging drugs for biliary cancer. Expert Opinion on Emerging Drugs, 2014, 19, 11-24.	1.0	6
685	Mutant IDH1-Driven Cellular Transformation Increases RAD51-Mediated Homologous Recombination and Temozolomide Resistance. Cancer Research, 2014, 74, 4836-4844.	0.4	65
687	Characterization of acute myeloid leukemia based on levels of global hydroxymethylation. Blood, 2014, 124, 1110-1118.	0.6	80
688	Diagnosis and Characterization of Brain Tumors: MR Spectroscopic Imaging. , 2014, , 39-55.		3
689	Tumor Metabolome Targeting and Drug Development. Cancer Drug Discovery and Development, 2014, , .	0.2	0
690	Citrate â€“ new functions for an old metabolite. Biological Chemistry, 2014, 395, 387-399.	1.2	223

#	Article	IF	Citations
691	IDHMutation in Glioma. JAMA Neurology, 2014, 71, 1319.	4.5	176
692	Transcriptional and Epigenetic Regulation in the Development of Myeloid Cells: Normal and Diseased Myelopoiesis. Epigenetics and Human Health, 2014, , 223-245.	0.2	0
693	Network-level architecture and the evolutionary potential of underground metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11762-11767.	3.3	101
694	The Epigenetic Landscape of Acute Myeloid Leukemia. Advances in Hematology, 2014, 2014, 1-15.	0.6	76
695	Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma. Endocrine-Related Cancer, 2014, 21, R261-R277.	1.6	31
696	Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma. Current Opinion in Gastroenterology, 2014, 30, 295-302.	1.0	42
697	Immunohistochemical Demonstration of Isocitrate Dehydrogenase 1 (IDH1) Mutation in a Small Subset of Prostatic Carcinomas. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 284-287.	0.6	12
698	Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Experimental Hematology, 2014, 42, 247-251.	0.2	125
699	Glioblastoma: From Molecular Pathology to Targeted Treatment. Annual Review of Pathology: Mechanisms of Disease, 2014, 9, 1-25.	9.6	427
700	Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery. Drug Discovery Today, 2014, 19, 171-182.	3.2	140
701	Origins of aberrant DNA methylation in acute myeloid leukemia. Leukemia, 2014, 28, 1-14.	3.3	112
702	Metabolic alterations due to IDH1 mutation in glioma: opening for therapeutic opportunities?. Acta Neuropathologica Communications, 2014, 2, 6.	2.4	19
703	Autophagy and oxidative stress in gliomas with IDH1 mutations. Acta Neuropathologica, 2014, 127, 221-233.	3.9	68
704	Short-term survivors in glioblastomas with oligodendroglioma component: a clinical study of 186 Chinese patients from a single institution. Journal of Neuro-Oncology, 2014, 116, 395-404.	1.4	13
705	Chemical and technical challenges in the analysis of central carbon metabolites by liquid-chromatography mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 966, 21-33.	1.2	49
706	Chromatin modifiers and the promise of epigenetic therapy in acute leukemia. Leukemia, 2014, 28, 1396-1406.	3.3	66
707	Activity-based proteomic and metabolomic approaches for understanding metabolism. Current Opinion in Biotechnology, 2014, 28, 116-126.	3.3	30
708	Glutamate as chemotactic fuel for diffuse glioma cells: Are they glutamate suckers?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 66-74.	3.3	39

#	Article	IF	Citations
709	Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma. Clinical Cancer Research, 2014, 20, 1884-1890.	3.2	110
710	Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation. Tumor Biology, 2014, 35, 5911-5920.	0.8	95
711	Targeting Metabolic Changes in Cancer: Novel Therapeutic Approaches. Annual Review of Medicine, 2014, 65, 157-170.	5.0	54
712	A High-Throughput Fluorimetric Assay for 2-Hydroxyglutarate Identifies Zaprinast as a Glutaminase Inhibitor. Cancer Discovery, 2014, 4, 828-839.	7.7	70
713	Mitochondrial pathology: stress signals from the energy factory. Trends in Molecular Medicine, 2014, 20, 282-292.	3.5	121
714	Mutant IDH1 inhibits PI3K/Akt signaling in human glioma. Cancer, 2014, 120, 2440-2447.	2.0	39
715	Deregulation of cell signaling in cancer. FEBS Letters, 2014, 588, 2558-2570.	1.3	103
716	Epigenetic dysregulation in glioma. Cancer Science, 2014, 105, 363-369.	1.7	58
717	Cysteine Catabolism: A Novel Metabolic Pathway Contributing to Glioblastoma Growth. Cancer Research, 2014, 74, 787-796.	0.4	116
718	A hierarchical statistical modeling approach to analyze proteomic isobaric tag for relative and absolute quantitation data. Bioinformatics, 2014, 30, 549-558.	1.8	34
719	Lactate dehydrogenase A silencing in IDH mutant gliomas. Neuro-Oncology, 2014, 16, 686-695.	0.6	162
720	The role of mitochondrial electron transport in tumorigenesis and metastasis. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 1454-1463.	1.1	47
721	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nature Reviews Cancer, 2014, 14, 92-107.	12.8	469
722	Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China. Journal of Cancer Research and Clinical Oncology, 2014, 140, 45-51.	1.2	57
723	Reversing DNA Methylation: Mechanisms, Genomics, and Biological Functions. Cell, 2014, 156, 45-68.	13.5	914
724	Hypoxia and Metabolism in Cancer. Advances in Experimental Medicine and Biology, 2014, 772, 1-39.	0.8	39
725	Functional Brain Tumor Imaging. , 2014, , .		2
726	Compendium of aberrant DNA methylation and histone modifications in cancer. Biochemical and Biophysical Research Communications, 2014, 455, 3-9.	1.0	58

#	Article	IF	Citations
727	Epigenetic Changes in Gliomas. , 2014, , 23-45.		0
728	The Evolving Role of Molecular Markers in the Diagnosis and Management of Diffuse Glioma. Clinical Cancer Research, 2014, 20, 5601-5611.	3.2	53
729	Combining content and elements of communication into an upperâ€level biochemistry course. Biochemistry and Molecular Biology Education, 2014, 42, 136-141.	0.5	12
730	Molecular pathology of bone tumours: diagnostic implications. Histopathology, 2014, 64, 461-476.	1.6	21
731	Signal Transduction: From the Atomic Age to the Post-Genomic Era. Cold Spring Harbor Perspectives in Biology, 2014, 6, a022913-a022913.	2.3	21
732	Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice. Leukemia, 2014, 28, 1343-1346.	3.3	18
733	Hominoid-specific enzyme GLUD2 promotes growth of IDH1 ^{R132H} glioma. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14217-14222.	3.3	87
734	Hyperpolarized Magnetic Resonance as a Sensitive Detector of Metabolic Function. Biochemistry, 2014, 53, 7333-7357.	1.2	143
735	Simultaneous Steady-state and Dynamic 13C NMR Can Differentiate Alternative Routes of Pyruvate Metabolism in Living Cancer Cells. Journal of Biological Chemistry, 2014, 289, 6212-6224.	1.6	49
736	Serum 2-Hydroxyglutarate Production in IDH1- and IDH2-Mutated De Novo Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 2014, 32, 297-305.	0.8	109
737	Current Approaches and Recent Developments in the Management of Head and Neck Paragangliomas. Endocrine Reviews, 2014, 35, 795-819.	8.9	124
738	Metabolomic strategies to map functions of metabolic pathways. American Journal of Physiology - Endocrinology and Metabolism, 2014, 307, E237-E244.	1.8	8
739	Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases: Synthesis, Structureâ€“Activity Relationship, and Selective Antitumor Activity. Journal of Medicinal Chemistry, 2014, 57, 8307-8318.	2.9	48
740	Section III: Molecular diagnostics in neuro-oncology. Current Problems in Cancer, 2014, 38, 175-179.	1.0	6
741	Tumor cells in search for glutamate: an alternative explanation for increased invasiveness of IDH1 mutant gliomas. Neuro-Oncology, 2014, 16, 1669-1670.	0.6	22
742	PARP and other prospective targets for poisoning cancer cell metabolism. Biochemical Pharmacology, 2014, 92, 164-171.	2.0	24
743	Action at a Distance: Allostery and the Development of Drugs to Target Cancer Cell Metabolism. Chemistry and Biology, 2014, 21, 1143-1161.	6.2	39
744	Development and Quantitative Evaluation of a High-Resolution Metabolomics Technology. Analytical Chemistry, 2014, 86, 2175-2184.	3.2	164

#	Article	IF	Citations
745	Mitochondrial substrates in cancer: Drivers or passengers?. Mitochondrion, 2014, 19, 8-19.	1.6	14
746	Exploring Metabolic Pathways and Regulation through Functional Chemoproteomic and Metabolomic Platforms. Chemistry and Biology, 2014, 21, 1171-1184.	6.2	19
747	Cancer-associated Isocitrate Dehydrogenase 1 (IDH1) R132H Mutation and d-2-Hydroxyglutarate Stimulate Glutamine Metabolism under Hypoxia. Journal of Biological Chemistry, 2014, 289, 23318-23328.	1.6	81
748	Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) Low-grade Glioma Research Workshop. Neuro-Oncology, 2014, 16, 173-178.	0.6	23
749	IDH1 regulates phospholipid metabolism in developing astrocytes. Neuroscience Letters, 2014, 582, 87-92.	1.0	7
750	Isocitrate dehydrogenase 1 and 2 mutations in gliomas. Journal of Neuroscience Research, 2014, 92, 1611-1620.	1.3	18
751	<scp>l</scp>-2-Hydroxyglutarate: An Epigenetic Modifier and Putative Oncometabolite in Renal Cancer. Cancer Discovery, 2014, 4, 1290-1298.	7.7	226
752	Epidemiologic and Molecular Prognostic Review of Glioblastoma. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1985-1996.	1.1	933
753	The metabolic cooperation between cells in solid cancer tumors. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 216-225.	3.3	44
754	Emerging approaches to target tumor metabolism. Current Opinion in Pharmacology, 2014, 17, 22-29.	1.7	18
755	Somatic alterations and dysregulation of epigenetic modifiers in cancers. Biochemical and Biophysical Research Communications, 2014, 455, 24-34.	1.0	29
756	The role of mutation of metabolism-related genes in genomic hypermethylation. Biochemical and Biophysical Research Communications, 2014, 455, 16-23.	1.0	25
757	Oncometabolitesâ€driven tumorigenesis: From genetics to targeted therapy. International Journal of Cancer, 2014, 135, 2237-2248.	2.3	119
758	New Insights in AML Biology From Genomic Analysis. Seminars in Hematology, 2014, 51, 282-297.	1.8	16
759	Stability of the CpG island methylator phenotype during glioma progression and identification of methylated loci in secondary glioblastomas. BMC Cancer, 2014, 14, 506.	1.1	20
760	Defects in mitochondrial metabolism and cancer. Cancer & Metabolism, 2014, 2, 10.	2.4	208
761	A joint analysis of metabolomics and genetics of breast cancer. Breast Cancer Research, 2014, 16, 415.	2.2	161
762	Molecular Neuro-oncology and the Challenge of the Blood-Brain Barrier. Seminars in Oncology, 2014, 41, 438-445.	0.8	12

#	Article	IF	Citations
764	The role of 5-hydroxymethylcytosine in human cancer. Cell and Tissue Research, 2014, 356, 631-641.	1.5	87
765	D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma. Acta Neuropathologica Communications, 2014, 2, 19.	2.4	72
766	Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets. Annals of Surgical Oncology, 2014, 21, 3827-3834.	0.7	123
767	Mechanism and Function of Oxidative Reversal of DNA and RNA Methylation. Annual Review of Biochemistry, 2014, 83, 585-614.	5.0	289
768	IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism. Cancer Research, 2014, 74, 3317-3331.	0.4	224
769	Docosahexaenoic Acid Modulates the Enterocyte Caco-2 Cell Expression of MicroRNAs Involved in Lipid Metabolism. Journal of Nutrition, 2014, 144, 575-585.	1.3	64
770	Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer. Journal of Biomolecular Screening, 2014, 19, 1193-1200.	2.6	27
771	Driver mutations of cancer epigenomes. Protein and Cell, 2014, 5, 265-296.	4.8	139
772	Pancreatic tumor cell metabolism: Focus on glycolysis and its connected metabolic pathways. Archives of Biochemistry and Biophysics, 2014, 545, 69-73.	1.4	42
773	Extracellular vesicles shed by glioma cells: pathogenic role and clinical value. Tumor Biology, 2014, 35, 8425-8438.	0.8	70
774	Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to haveIDH1orIDH2mutations. Leukemia and Lymphoma, 2014, 55, 1431-1434.	0.6	4
775	Can Diffusion Tensor Imaging Noninvasively Detect IDH1 Gene Mutations in Astrogliomas? A Retrospective Study of 112 Cases. American Journal of Neuroradiology, 2014, 35, 920-927.	1.2	58
776	Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11121-11126.	3.3	230
777	Mutant IDH inhibits HNF-4Î± to block hepatocyte differentiation and promote biliary cancer. Nature, 2014, 513, 110-114.	13.7	367
778	The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells. Acta Neuropathologica, 2014, 128, 723-732.	3.9	16
779	Role of somatic cancer mutations in human protein lysine methyltransferases. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 366-379.	3.3	34
780	Dihydropyrimidine Accumulation Is Required for the Epithelial-Mesenchymal Transition. Cell, 2014, 158, 1094-1109.	13.5	186
781	Derivatization of the tricarboxylic acid intermediates with O-benzylhydroxylamine for liquid chromatographyâ€“tandem mass spectrometry detection. Analytical Biochemistry, 2014, 465, 134-147.	1.1	75

#	Article	IF	Citations
782	Biochemical, Cellular, and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1. Journal of Biological Chemistry, 2014, 289, 13717-13725.	1.6	78
783	Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. Neuro-Oncology, 2014, 16, 1478-1483.	0.6	64
784	Mitochondrial 2-hydroxyglutarate metabolism. Mitochondrion, 2014, 19, 275-281.	1.6	38
785	Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance. Cell Stem Cell, 2014, 14, 329-341.	5.2	172
786	The Metabolic Alterations of Cancer Cells. Methods in Enzymology, 2014, 542, 1-23.	0.4	87
787	Expression of Hedgehog ligand and signal transduction components in mutually distinct isocitrate dehydrogenase mutant glioma cells supports a role for paracrine signaling. Journal of Neuro-Oncology, 2014, 119, 243-251.	1.4	6
788	A vaccine targeting mutant IDH1 induces antitumour immunity. Nature, 2014, 512, 324-327.	13.7	613
789	Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance. Molecular Cell, 2014, 54, 716-727.	4.5	771
790	Tracing Compartmentalized NADPH Metabolism in the Cytosol and Mitochondria of Mammalian Cells. Molecular Cell, 2014, 55, 253-263.	4.5	477
791	MGMT testingâ€"the challenges for biomarker-based glioma treatment. Nature Reviews Neurology, 2014, 10, 372-385.	4.9	454
792	DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia, 2014, 28, 1774-1783.	3.3	225
793	Targeting histone lysine demethylases â€" Progress, challenges, and the future. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2014, 1839, 1416-1432.	0.9	170
794	mTORC2 in the center of cancer metabolic reprogramming. Trends in Endocrinology and Metabolism, 2014, 25, 364-373.	3.1	110
795	Krebs cycle intermediates regulate DNA and histone methylation: Epigenetic impact on the aging process. Ageing Research Reviews, 2014, 16, 45-65.	5.0	95
796	Mitochondria: The Anti- cancer Target for the Third Millennium. , 2014, , .		3
797	The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 326-341.	3.3	118
798	Mutation and expression analysis of the IDH1, IDH2, DNMT3A, and MYD88 genes in colorectal cancer. Gene, 2014, 546, 263-270.	1.0	22
799	Oxidation of Alpha-Ketoglutarate Is Required for Reductive Carboxylation in Cancer Cells with Mitochondrial Defects. Cell Reports, 2014, 7, 1679-1690.	2.9	281

#	Article	IF	Citations
800	Characterizing DNA methylation alterations from The Cancer Genome Atlas. Journal of Clinical Investigation, 2014, 124, 17-23.	3.9	162
801	Applying Metabolomics to Understand the Aggressive Phenotype and Identify Novel Therapeutic Targets in Glioblastoma. Metabolites, 2014, 4, 740-750.	1.3	19
802	Genetics and epigenetics of gliomas. Swiss Medical Weekly, 2014, 144, w14018.	0.8	7
803	Oncology applications: Skin cancer. , 2014, , 380-395.		0
804	Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor-Î�ºB activation in a hypoxia-inducible factor 1-Î± dependent manner. Molecular Medicine Reports, 2014, 9, 1799-1805.	1.1	27
805	Recent developments in myelodysplastic syndromes. Blood, 2014, 124, 2793-2803.	0.6	147
806	Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. Cell Reports, 2015, 13, 2353-2361.	2.9	153
807	The mitochondrial proteome and human disease. Pathology, 2015, 47, S28.	0.3	0
808	Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcoma. Journal of Pathology: Clinical Research, 2015, 1, 95-105.	1.3	32
809	IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Scientific Reports, 2015, 5, 16238.	1.6	259
810	Metabolic profiling reveals potential metabolic markers associated with Hypoxia Inducible Factor-mediated signalling in hypoxic cancer cells. Scientific Reports, 2015, 5, 15649.	1.6	30
811	IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood, 2015, 125, 296-303.	0.6	143
813	Modeling cancer metabolism on a genome scale. Molecular Systems Biology, 2015, 11, 817.	3.2	152
814	Functions of idh1 and its mutation in the regulation of developmental hematopoiesis in zebrafish. Blood, 2015, 125, 2974-2984.	0.6	23
815	Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila. Blood, 2015, 125, 336-345.	0.6	25
816	Fish provide ID(H)eas on targeting leukemia. Blood, 2015, 125, 2880-2882.	0.6	1
817	Sensitive Determination of Onco-metabolites of D- and L-2-hydroxyglutarate Enantiomers by Chiral Derivatization Combined with Liquid Chromatography/Mass Spectrometry Analysis. Scientific Reports, 2015, 5, 15217.	1.6	58
818	PO69THE IMPACT OF MGMT METHYLATION AND IDH-1 MUTATION ON LONG TERM OUTCOME FOR GLIOBLASTOMA TREATED WITH CHEMORADIOTHERAPY. Neuro-Oncology, 2015, 17, viii12.5-viii12.	0.6	0

#	Article	IF	Citations
819	Pediatric gliomas as neurodevelopmental disorders. Glia, 2016, 64, 879-895.	2.5	51
820	Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics. British Journal of Haematology, 2015, 170, 305-322.	1.2	36
821	2â€Hydoxyglutarate: D/Riving Pathology in gLiomaS. Brain Pathology, 2015, 25, 760-768.	2.1	11
822	HMMvar-func: a new method for predicting the functional outcome of genetic variants. BMC Bioinformatics, 2015, 16, 351.	1.2	10
823	13C-labeled biochemical probes for the study of cancer metabolism with dynamic nuclear polarization-enhanced magnetic resonance imaging. Cancer & Metabolism, 2015, 3, 9.	2.4	36
824	HOT mutation screening in human glioblastomas. Future Science OA, 2015, 1, .	0.9	1
825	Genetic and epigenetic characterization of lowâ€grade gliomas reveals frequent methylation of the <scp>M</scp>LH3 gene. Genes Chromosomes and Cancer, 2015, 54, 655-667.	1.5	8
826	Magnetic Resonance (MR) Metabolic Imaging in Glioma. Brain Pathology, 2015, 25, 769-780.	2.1	37
827	Predictors of preoperative and early postoperative seizures in patients with intraâ€axial primary and metastatic brain tumors: A retrospective observational single center study. Annals of Neurology, 2015, 78, 917-928.	2.8	60
828	Imaging Genomics in Gliomas. Cancer Journal (Sudbury, Mass), 2015, 21, 225-234.	1.0	22
829	Low-grade Gliomas. CONTINUUM Lifelong Learning in Neurology, 2015, 21, 345-354.	0.4	17
830	Imaging Markers of Isocitrate Dehydrogenase-1 Mutations in Gliomas. Neurosurgery, 2015, 62, 166-170.	0.6	2
831	Imaging Genomics of Glioblastoma. Topics in Magnetic Resonance Imaging, 2015, 24, 155-163.	0.7	14
833	The Biology and Management of Cartilaginous Tumors: A Role For Targeting Isocitrate Dehydrogenase. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e648-e655.	1.8	13
834	IDH1 and IDH2 mutations in different histologic subtypes and WHO grading gliomas in a sample from Northern Brazil. Genetics and Molecular Research, 2015, 14, 6533-6542.	0.3	4
835	DNA Demethylation by TET Proteins: A Potential Therapeutic Target in Cancer. Epigenetic Diagnosis & Therapy, 2015, 1, 49-59.	0.1	0
836	Epigenetic crosstalk a molecular language in human metabolic disorders. Frontiers in Bioscience - Scholar, 2015, 7, 46-57.	0.8	13
837	EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation. Arquivos De Neuro-Psiquiatria, 2015, 73, 561-568.	0.3	17

#	Article	IF	Citations
838	Heavy Metals and Epigenetic Alterations in Brain Tumors. Current Genomics, 2015, 15, 457-463.	0.7	50
839	Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas. Oncotarget, 2015, 6, 20266-20277.	0.8	38
840	Functions of TET Proteins in Hematopoietic Transformation. Molecules and Cells, 2015, 38, 925-935.	1.0	21
841	Cancer Metabolism and Drug Resistance. Metabolites, 2015, 5, 571-600.	1.3	130
842	New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma. International Journal of Medical Sciences, 2015, 12, 201-213.	1.1	83
843	Emerging Role of Linker Histone Variant H1x as a Biomarker with Prognostic Value in Astrocytic Gliomas. A Multivariate Analysis including Trimethylation of H3K9 and H4K20. PLoS ONE, 2015, 10, e0115101.	1.1	30
844	OVCAR-3 Spheroid-Derived Cells Display Distinct Metabolic Profiles. PLoS ONE, 2015, 10, e0118262.	1.1	29
845	Metabolic Reprogramming in Mutant IDH1 Glioma Cells. PLoS ONE, 2015, 10, e0118781.	1.1	67
846	Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing. PLoS ONE, 2015, 10, e0123476.	1.1	12
847	Radiological and Pathological Features Associated with IDH1-R132H Mutation Status and Early Mortality in Newly Diagnosed Anaplastic Astrocytic Tumours. PLoS ONE, 2015, 10, e0123890.	1.1	24
848	Oxygen Concentration Controls Epigenetic Effects in Models of Familial Paraganglioma. PLoS ONE, 2015, 10, e0127471.	1.1	27
849	Non-targeted Tracer Fate Detection. Methods in Enzymology, 2015, 561, 277-302.	0.4	13
850	Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells. PLoS ONE, 2015, 10, e0133813.	1.1	88
851	Cancer Metabolism: A Modeling Perspective. Frontiers in Physiology, 2015, 6, 382.	1.3	58
853	Succinate Dehydrogenase Loss in Familial Paraganglioma: Biochemistry, Genetics, and Epigenetics. International Journal of Endocrinology, 2015, 2015, 1-14.	0.6	28
854	Brain Tumor Metabolism â€" Unraveling Its Role in Finding New Therapeutic Targets. , 0, , .		2
856	Isocitrate dehydrogenase mutations: new opportunities for translational research. BMB Reports, 2015, 48, 266-270.	1.1	9
857	Chronic Lymphocytic Leukemia â€" Microenvironment and B Cells. , 2015, , .		2

#	Article	IF	Citations
858	The Evolving Molecular Genetics of Low-grade Glioma. Advances in Anatomic Pathology, 2015, 22, 94-101.	2.4	89
859	Imaging Tumor Metabolism Using In Vivo Magnetic Resonance Spectroscopy. Cancer Journal (Sudbury,) Tj ETQq1 1 0.784314 rgBT /Ove	1.0	31
860	Mutant IDH is sufficient to initiate enchondromatosis in mice. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2829-2834.	3.3	115
861	Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Science Translational Medicine, 2015, 7, 274ra17.	5.8	257
862	Reciprocal regulation of amino acid import and epigenetic state through Lat1 and <scp>EZH</scp> 2. EMBO Journal, 2015, 34, 1773-1785.	3.5	47
863	Metabolomic Markers of Altered Nucleotide Metabolism in Early Stage Adenocarcinoma. Cancer Prevention Research, 2015, 8, 410-418.	0.7	79
864	Cancer stem cells: a potential target for cancer therapy. Cellular and Molecular Life Sciences, 2015, 72, 3411-3424.	2.4	53
865	Activation of the NRF2 pathway and its impact on the prognosis of anaplastic glioma patients. Neuro-Oncology, 2015, 17, 555-565.	0.6	48
866	Defining the Metabolome: Size, Flux, and Regulation. Molecular Cell, 2015, 58, 699-706.	4.5	234
867	Molecular subtypes, stem cells and heterogeneity: Implications for personalised therapy in glioma. Journal of Clinical Neuroscience, 2015, 22, 1219-1226.	0.8	41
868	Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia. Seminars in Hematology, 2015, 52, 165-171.	1.8	44
869	Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies. Brain Tumor Pathology, 2015, 32, 237-244.	1.1	13
870	Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers. Acta Neuropathologica, 2015, 129, 789-808.	3.9	45
871	CXCR7 and CXCR4 Expressions in Infiltrative Astrocytomas and Their Interactions with HIF1Î± Expression and IDH1 Mutation. Pathology and Oncology Research, 2015, 21, 229-240.	0.9	13
872	IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism. Cancer Research, 2015, 75, 2999-3009.	0.4	106
873	Brain Tumor Stem Cells. Molecular Pathology Library, 2015, , 23-34.	0.1	1
875	TP53: an oncogene in disguise. Cell Death and Differentiation, 2015, 22, 1239-1249.	5.0	227
876	Biomarker-driven diagnosis of diffuse gliomas. Molecular Aspects of Medicine, 2015, 45, 87-96.	2.7	71

#	Article	IF	Citations
877	Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia. Expert Opinion on Therapeutic Targets, 2015, 19, 1187-1202.	1.5	16
878	Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell, 2015, 28, 773-784.	7.7	327
879	Emerging roles of ATRX in cancer. Epigenomics, 2015, 7, 1365-1378.	1.0	54
880	Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. Cancer Research, 2015, 75, 5341-5354.	0.4	130
881	Bevacizumab and other novel therapies for recurrent oligodendroglial tumors. CNS Oncology, 2015, 4, 333-339.	1.2	4
882	Metabolomics: an emerging but powerful tool for precision medicine. Journal of Physical Education and Sports Management, 2015, 1, a000588.	0.5	373
883	Update on recurrent genetic aberrations in acute myeloid leukemia. International Journal of Hematologic Oncology, 2015, 4, 179-190.	0.7	1
884	Short-echo three-dimensional H-1 MR spectroscopic imaging of patients with glioma at 7 tesla for characterization of differences in metabolite levels. Journal of Magnetic Resonance Imaging, 2015, 41, 1332-1341.	1.9	44
885	Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia, 2015, 29, 2134-2142.	3.3	77
886	Evidence that 2-hydroxyglutarate is not readily metabolized in colorectal carcinoma cells. Cancer & Metabolism, 2015, 3, 13.	2.4	10
887	CRL4VprBP E3 Ligase Promotes Monoubiquitylation and Chromatin Binding of TET Dioxygenases. Molecular Cell, 2015, 57, 247-260.	4.5	90
888	Genome-wide transcriptional analyses of Chinese patients reveal cell migration is attenuated in IDH1-mutant glioblastomas. Cancer Letters, 2015, 357, 566-574.	3.2	25
889	Metabolic modulation of cancer: a new frontier with great translational potential. Journal of Molecular Medicine, 2015, 93, 127-142.	1.7	27
891	TET Family Proteins: Oxidation Activity, Interacting Molecules, and Functions in Diseases. Chemical Reviews, 2015, 115, 2225-2239.	23.0	89
892	Mitochondrial dependency in progression of acute myeloid leukemia. Mitochondrion, 2015, 21, 41-48.	1.6	57
893	Digging deep into â€œdirtyâ€•drugs â€“ modulation of the methylation machinery. Drug Metabolism Reviews, 2015, 47, 252-279.	1.5	63
894	Human Phospholipase D Activity Transiently Regulates Pyrimidine Biosynthesis in Malignant Gliomas. ACS Chemical Biology, 2015, 10, 1258-1268.	1.6	20
895	Glioblastoma. , 2015, , 909-917.		6

#	Article	IF	Citations
896	Genomic discoveries in adult astrocytoma. Current Opinion in Genetics and Development, 2015, 30, 17-24.	1.5	17
897	Epithelialâ€“mesenchymal transition in human cancer: Comprehensive reprogramming of metabolism, epigenetics, and differentiation. , 2015, 150, 33-46.		243
898	Chromatin signatures of cancer. Genes and Development, 2015, 29, 238-249.	2.7	171
899	Metabolic signatures of human breast cancer. Molecular and Cellular Oncology, 2015, 2, e992217.	0.3	56
900	A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia. Nature Medicine, 2015, 21, 113-114.	15.2	3
901	Reducing peripheral serotonin turns up the heat in brown fat. Nature Medicine, 2015, 21, 114-116.	15.2	7
903	Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2â€“mutated blastic plasmacytoid dendritic cell neoplasm. Human Pathology, 2015, 46, 322-326.	1.1	8
904	Metabolic Regulation of Histone Post-Translational Modifications. ACS Chemical Biology, 2015, 10, 95-108.	1.6	259
905	¹H NMR spectroscopy of glioblastoma stemâ€like cells identifies alphaâ€aminoadipate as a marker of tumor aggressiveness. NMR in Biomedicine, 2015, 28, 317-326.	1.6	27
906	Metabolomic comparison between cells overâ€expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism. Journal of Neurochemistry, 2015, 132, 183-193.	2.1	16
907	Clinical impact of molecular biomarkers in gliomas. Journal of Clinical Neuroscience, 2015, 22, 437-444.	0.8	57
908	Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nature Medicine, 2015, 21, 178-184.	15.2	459
909	Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders. Blood Cells, Molecules, and Diseases, 2015, 54, 286-291.	0.6	18
910	Extracellular Metabolic Energetics Can Promote Cancer Progression. Cell, 2015, 160, 393-406.	13.5	293
911	Cancer metabolomics in basic science perspective. Archives of Pharmacal Research, 2015, 38, 372-380.	2.7	24
912	Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation. Tumor Biology, 2015, 36, 655-662.	0.8	117
913	Phosphorylation of TET Proteins Is Regulated via O-GlcNAcylation by the O-Linked N-Acetylglucosamine Transferase (OGT). Journal of Biological Chemistry, 2015, 290, 4801-4812.	1.6	102
914	Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Neurosurgical Focus, 2015, 38, E2.	1.0	42

#	Article	IF	Citations
915	The future of high-grade glioma: Where we are and where are we going. , 2015, 6, 9.		29
916	Metabolic dysregulation in monogenic disorders and cancer â€" finding method in madness. Nature Reviews Cancer, 2015, 15, 440-448.	12.8	89
917	Conditions for 13C NMR detection of 2-hydroxyglutarate in tissue extracts from isocitrate dehydrogenase-mutated gliomas. Analytical Biochemistry, 2015, 481, 4-6.	1.1	10
918	Hypoxia-Mediated Increases in l -2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress. Cell Metabolism, 2015, 22, 291-303.	7.2	270
919	Novel Type II and Monomeric NAD+ Specific Isocitrate Dehydrogenases: Phylogenetic Affinity, Enzymatic Characterization and Evolutionary Implication. Scientific Reports, 2015, 5, 9150.	1.6	27
920	Direct comparison of quantitative digital PCR and 2-hydroxyglutarate enantiomeric ratio for IDH mutant allele frequency assessment in myeloid malignancy. Leukemia, 2015, 29, 2421-2423.	3.3	10
921	Clinical Significance of Epigenetic Alterations in Glioblastoma. , 2015, , 339-350.		0
922	Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis. Experimental Hematology, 2015, 43, 609-624.	0.2	47
923	IDH1, lipid metabolism and cancer: Shedding new light on old ideas. Biochimica Et Biophysica Acta - General Subjects, 2015, 1850, 1781-1785.	1.1	33
924	Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Molecular Cell, 2015, 59, 345-358.	4.5	125
925	2-Oxoglutarate-dependent dioxygenases are sensors of energy metabolism, oxygen availability, and iron homeostasis: potential role in the regulation of aging process. Cellular and Molecular Life Sciences, 2015, 72, 3897-3914.	2.4	78
926	Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer. Cancer Prevention Research, 2015, 8, 702-711.	0.7	47
927	2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. Cell Metabolism, 2015, 22, 508-515.	7.2	190
928	The broad spectrum 2-oxoglutarate oxygenase inhibitor N-oxalylglycine is present in rhubarb and spinach leaves. Phytochemistry, 2015, 117, 456-461.	1.4	16
929	Cancer modelling in the NGS era â€" Part I: Emerging technology and initial modelling. Critical Reviews in Oncology/Hematology, 2015, 96, 274-307.	2.0	9
930	Diagnostic Value of Plasma and Urinary 2-Hydroxyglutarate to Identify Patients With Isocitrate Dehydrogenase-Mutated Glioma. Oncologist, 2015, 20, 562-567.	1.9	55
931	Pheochromocytoma: Gasping for Air. Hormones and Cancer, 2015, 6, 191-205.	4.9	26
932	D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2. Nature Communications, 2015, 6, 7768.	5.8	64

#	Article	IF	Citations
933	Applicable advances in the molecular pathology of glioblastoma. Brain Tumor Pathology, 2015, 32, 153-162.	1.1	12
934	Isocitrate Dehydrogenase (IDH) Mutation in Gliomas. , 2015, , 441-458.		0
935	Molecular Heterogeneity in Glioblastoma: Potential Clinical Implications. Frontiers in Oncology, 2015, 5, 55.	1.3	186
936	Organ-Specific Cancer Metabolism and Its Potential for Therapy. Handbook of Experimental Pharmacology, 2015, 233, 321-353.	0.9	86
937	2-Hydroxyglutarate production is necessary for the reaction catalyzed by 3-phosphoglycerate dehydrogenase in Escherichia coli. Review Journal of Chemistry, 2015, 5, 21-29.	1.0	5
938	Distinct serum metabolomics profiles associated with malignant progression in the KrasG12Dmouse model of pancreatic ductal adenocarcinoma. BMC Genomics, 2015, 16, S1.	1.2	35
939	Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathologica Communications, 2015, 3, 4.	2.4	100
940	The deep end of the metabolite pool: influences on epigenetic regulatory mechanisms in cancer. European Journal of Clinical Investigation, 2015, 45, 9-15.	1.7	14
941	The Emerging Molecular Foundations of Pediatric Brain Tumors. Journal of Child Neurology, 2015, 30, 1838-1850.	0.7	17
942	Cytosine modifications in myeloid malignancies. , 2015, 152, 42-53.		13
944	Mathematical analysis predicts imbalanced IDH1/2 expression associates with 2-HG-inactivating Î²-oxygenation pathway in colorectal cancer. International Journal of Oncology, 2015, 46, 1181-1191.	1.4	17
945	Molecular and Genomic Alterations in Glioblastoma Multiforme. American Journal of Pathology, 2015, 185, 1820-1833.	1.9	141
946	Markers for bone sarcomas. , 2015, , 273-285.		2
947	EPMA position paper in cancer: current overview and future perspectives. EPMA Journal, 2015, 6, 9.	3.3	86
948	Metabolic pathways promoting cancer cell survival and growth. Nature Cell Biology, 2015, 17, 351-359.	4.6	1,142
949	Prognostic Factors in Lobar World Health Organization Grade II Astrocytomas. World Neurosurgery, 2015, 84, 154-162.	0.7	12
950	Viral Pseudo-Enzymes Activate RIG-I via Deamidation to Evade Cytokine Production. Molecular Cell, 2015, 58, 134-146.	4.5	66
951	Metabolic consequences of oncogenic IDH mutations. , 2015, 152, 54-62.		125

#	Article	IF	Citations
952	Epigenetic modifiers in normal and malignant hematopoiesis. Epigenomics, 2015, 7, 301-320.	1.0	23
953	Molecular targets in glioblastoma. Future Oncology, 2015, 11, 1407-1420.	1.1	32
954	Rotenone Stereospecifically Increases (S)-2-Hydroxyglutarate in SH-SY5Y Neuronal Cells. Chemical Research in Toxicology, 2015, 28, 948-954.	1.7	11
955	Next Generation Sequencing in Cancer Research, Volume 2. , 2015, , .		4
956	Oncometabolites: tailoring our genes. FEBS Journal, 2015, 282, 2796-2805.	2.2	112
957	Enzyme complexity in intermediary metabolism. Journal of Inherited Metabolic Disease, 2015, 38, 721-727.	1.7	18
958	Novel Therapeutic Targets of Tumor Metabolism. Cancer Journal (Sudbury, Mass), 2015, 21, 62-69.	1.0	36
959	Molecular Pathways in Gliomagenesis and Their Relevance to Neuropathologic Diagnosis. Advances in Anatomic Pathology, 2015, 22, 50-58.	2.4	78
960	Comparison of Next-generation Sequencing Mutation Profiling With BRAF and IDH1 Mutation-specific Immunohistochemistry. American Journal of Surgical Pathology, 2015, 39, 454-461.	2.1	25
961	Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA methylation. , 2015, 151, 121-140.		35
962	A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma. Biochemical and Biophysical Research Communications, 2015, 459, 636-642.	1.0	4
963	Nonantibiotic Effects of Fluoroquinolones in Mammalian Cells. Journal of Biological Chemistry, 2015, 290, 22287-22297.	1.6	72
964	IDH1R132H mutation causes a less aggressive phenotype and radiosensitizes human malignant glioma cells independent of the oxygenation status. Radiotherapy and Oncology, 2015, 116, 381-387.	0.3	33
965	A role of astrocytes in mediating postnatal neurodegeneration in Glutaric acidemiaâ€type 1. FEBS Letters, 2015, 589, 3492-3497.	1.3	12
966	Evaluation of IDH1G105 polymorphism as prognostic marker in intermediate-risk AML. Annals of Hematology, 2015, 94, 1991-2001.	0.8	3
967	New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Nature Chemical Biology, 2015, 11, 878-886.	3.9	151
968	The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate. American Journal of Physiology - Renal Physiology, 2015, 309, F492-F498.	1.3	33
969	CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13982-13987.	3.3	172

#	Article	IF	Citations
970	Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas. BMC Cancer, 2015, 15, 32.	1.1	34
971	Discovery of Î±-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5625-5631.	1.0	16
972	Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4410-7.	3.3	283
973	A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas. Biochemical and Biophysical Research Communications, 2015, 466, 733-739.	1.0	13
974	Dysregulated metabolism contributes to oncogenesis. Seminars in Cancer Biology, 2015, 35, S129-S150.	4.3	225
975	D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH. Cell Death and Disease, 2015, 6, e1704-e1704.	2.7	27
976	IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy. Journal of Neuro-Oncology, 2015, 124, 493-500.	1.4	9
977	Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds. Journal of Medicinal Chemistry, 2015, 58, 6899-6908.	2.9	63
978	Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis?. Carcinogenesis, 2015, 36, S203-S231.	1.3	93
979	Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. Cancer Research, 2015, 75, 4790-4802.	0.4	127
980	The widespread role of non-enzymatic reactions in cellular metabolism. Current Opinion in Biotechnology, 2015, 34, 153-161.	3.3	105
981	Metabolism and Epigenetics. Annual Review of Cell and Developmental Biology, 2015, 31, 473-496.	4.0	147
982	IDH1 mutation-associated long non-coding RNA expression profile changes in glioma. Journal of Neuro-Oncology, 2015, 125, 253-263.	1.4	16
983	Metabolic responses induced by DNA damage and poly (ADP-ribose) polymerase (PARP) inhibition in MCF-7 cells. Metabolomics, 2015, 11, 1779-1791.	1.4	20
984	Metabolomics identifies the intersection of phosphoethanolamine with menaquinone-triggered apoptosis in an in vitro model of leukemia. Molecular BioSystems, 2015, 11, 2406-2416.	2.9	25
985	TET proteins in cancer: Current â€˜state of the artâ€™. Critical Reviews in Oncology/Hematology, 2015, 96, 425-436.	2.0	30
986	Genetically altered cancer epigenome. , 2015, , 265-289.		1
987	Structure, regulation, and function of TET family proteins. , 2015, , 379-395.		4

#	Article	IF	Citations
988	Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. CNS Oncology, 2015, 4, 287-294.	1.2	48
989	NADP+-IDH Mutations Promote Hypersuccinylation that Impairs Mitochondria Respiration and Induces Apoptosis Resistance. Molecular Cell, 2015, 60, 661-675.	4.5	175
990	The Metabolism of Cell Growth and Proliferation. , 2015, , 191-208.e2.		4
992	Selective Inhibition of Mutant Isocitrate Dehydrogenase 1 (IDH1) via Disruption of a Metal Binding Network by an Allosteric Small Molecule. Journal of Biological Chemistry, 2015, 290, 762-774.	1.6	111
993	Genetic analysis of the Warburg effect in yeast. Advances in Biological Regulation, 2015, 57, 185-192.	1.4	14
994	Emerging Interplay of Genetics and Epigenetics in Gliomas: A New Hope for Targeted Therapy. Seminars in Pediatric Neurology, 2015, 22, 14-22.	1.0	12
995	Glioma Biology and Molecular Markers. Cancer Treatment and Research, 2015, 163, 15-30.	0.2	161
996	A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres. Journal of Neuro-Oncology, 2015, 121, 479-487.	1.4	14
997	Imaging Genomics ofÂGlioblastoma. Neuroimaging Clinics of North America, 2015, 25, 141-153.	0.5	37
998	Current Understanding and Treatment of Gliomas. Cancer Treatment and Research, 2015, , .	0.2	11
999	Successive distinct highâ€grade gliomas in Lâ€2â€hydroxyglutaric aciduria. Journal of Inherited Metabolic Disease, 2015, 38, 273-277.	1.7	20
1000	Cancer cell metabolism and the modulating effects of nitric oxide. Free Radical Biology and Medicine, 2015, 79, 324-336.	1.3	86
1001	Mitochondrial dysfunctions in cancer: Genetic defects and oncogenic signaling impinging on TCA cycle activity. Cancer Letters, 2015, 356, 217-223.	3.2	97
1002	NMR Insights into the Inner Workings of Living Cells. Analytical Chemistry, 2015, 87, 119-132.	3.2	41
1003	Mitochondrial energy metabolism and apoptosis regulation in glioblastoma. Brain Research, 2015, 1595, 127-142.	1.1	30
1004	Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. Brain Tumor Pathology, 2015, 32, 3-11.	1.1	62
1005	Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite <scp>d</scp>-2-Hydroxyglutarate. ACS Chemical Biology, 2015, 10, 510-516.	1.6	152
1006	IDH1/2 mutation detection in gliomas. Brain Tumor Pathology, 2015, 32, 79-89.	1.1	44

#	Article	IF	Citations
1007	Biological insights through nontargeted metabolomics. Current Opinion in Biotechnology, 2015, 34, 1-8.	3.3	115
1008	Impact of MYC in regulation of tumor cell metabolism. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2015, 1849, 563-569.	0.9	135
1009	Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. Cancer, 2015, 121, 502-516.	2.0	120
1010	Investigational cancer drugs targeting cell metabolism in clinical development. Expert Opinion on Investigational Drugs, 2015, 24, 79-94.	1.9	58
1011	The Importance of Mutational Drivers in GBM. Critical Reviews in Eukaryotic Gene Expression, 2016, 26, 19-26.	0.4	6
1013	Critical Molecular and Genetic Markers in Primary Brain Tumors with Their Clinical Importance. , 0, , .		1
1014	New genomic landscapes and therapeutic targets for biliary tract cancers. Frontiers in Bioscience - Landmark, 2016, 21, 707-718.	3.0	5
1015	Brain Tumors: Epidemiology and Current Trends in Treatment. Journal of Brain Tumors & Neurooncology, 2016, 01, .	0.1	6
1016	Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis. Frontiers in Oncology, 2016, 6, 211.	1.3	7
1017	Epigenetic Alterations in Endocrine-Dependent Cancers: Implications of Endocrine Dysfunctions. , 2016, , 351-374.		0
1018	Chromatin Dynamics and Epigenetics of Stem Cells and Stem-Like Cancer Cells. , 2016, , 311-327.		0
1019	On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancer. Oncotarget, 2016, 7, 67626-67649.	0.8	42
1020	A Journey in Science: â€œNot Lost in Translationâ€• Molecular Medicine, 2016, 22, 675-679.	1.9	0
1021	Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 75-81.	1.8	17
1022	Downregulation of HSP60 disrupts mitochondrial proteostasis to promote tumorigenesis and progression in clear cell renal cell carcinoma. Oncotarget, 2016, 7, 38822-38834.	0.8	50
1024	In-VivoProton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists. Korean Journal of Radiology, 2016, 17, 620.	1.5	31
1025	Networks and Consortia for Epigenetic Drug Discovery. , 2016, , 143-166.		1
1026	The 2-oxoglutarate analog 3-oxoglutarate decreases normoxic hypoxia-inducible factor-1α in cancer cells, induces cell death, and reduces tumor xenograft growth. Hypoxia (Auckland, N Z), 2016, 4, 15.	1.9	7

#	Article	IF	Citations
1027	Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation. Frontiers in Oncology, 2016, 6, 16.	1.3	60
1028	Quantitative Imaging of D-2-Hydroxyglutarate in Selected Histological Tissue Areas by a Novel Bioluminescence Technique. Frontiers in Oncology, 2016, 6, 46.	1.3	6
1029	Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells. Frontiers in Oncology, 2016, 6, 60.	1.3	29
1030	DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders. Frontiers in Oncology, 2016, 6, 187.	1.3	38
1031	ROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic Strategies. International Journal of Molecular Sciences, 2016, 17, 984.	1.8	104
1032	Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovahâ€™s Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia. Pharmaceuticals, 2016, 9, 12.	1.7	7
1033	Personalized Proteomics: The Future of Precision Medicine. Proteomes, 2016, 4, 29.	1.7	101
1034	Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla. Journal of Translational Medicine, 2016, 14, 274.	1.8	35
1035	IDH1R132H in Neural Stem Cells: Differentiation Impaired by Increased Apoptosis. PLoS ONE, 2016, 11, e0154726.	1.1	18
1036	Precise Detection of IDH1/2 and BRAF Hotspot Mutations in Clinical Glioma Tissues by a Differential Calculus Analysis of High-Resolution Melting Data. PLoS ONE, 2016, 11, e0160489.	1.1	39
1037	Biochemical Characterization and Complete Conversion of Coenzyme Specificity of Isocitrate Dehydrogenase from Bifidobacterium longum. International Journal of Molecular Sciences, 2016, 17, 296.	1.8	8
1038	IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. Journal of Blood Medicine, 2016, Volume 7, 171-180.	0.7	176
1039	IDH1/2 Mutants Inhibit TET-Promoted Oxidation of RNA 5mC to 5hmC. PLoS ONE, 2016, 11, e0161261.	1.1	16
1040	Targeting Histone Methylation. , 2016, , 209-238.		1
1041	Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. Oncotarget, 2016, 7, 79722-79735.	0.8	133
1042	Isocitrate Dehydrogenase Mutation Leads to Alteration in 3-Dimensional DNA Structure and Oncogene Activation in Gliomas. Neurosurgery, 2016, 78, N20-N22.	0.6	1
1043	Clinical ramifications of â€œgenomic stagingâ€•of low-grade gliomas. Journal of Neuro-Oncology, 2016, 129, 195-199.	1.4	11
1044	Comparison of highâ€•resolution melting analysis with direct sequencing for the detection of recurrent mutations in <scp>DNA</scp> methyltransferase 3<scp>A</scp> and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients. European Journal of Haematology, 2016, 96, 181-187.	1.1	14

#	Article	IF	Citations
1045	Hyperpolarization MRI. Topics in Magnetic Resonance Imaging, 2016, 25, 31-37.	0.7	19
1046	Iron-induced epigenetic abnormalities of mouse bone marrow through aberrant activation of aconitase and isocitrate dehydrogenase. International Journal of Hematology, 2016, 104, 491-501.	0.7	10
1047	Metabolic, autophagic, and mitophagic activities in cancer initiation and progression. Biomedical Journal, 2016, 39, 98-106.	1.4	23
1048	Novel therapeutic strategies in myelodysplastic syndromes. Current Opinion in Hematology, 2016, 23, 79-87.	1.2	2
1049	Metabolic rewiring of pancreatic ductal adenocarcinoma: New routes to follow within the maze. International Journal of Cancer, 2016, 138, 787-796.	2.3	20
1050	Distinctly perturbed metabolic networks underlie differential tumor tissue damages induced by immune modulator Î²-glucan in a two-case ex vivo non-small-cell lung cancer study. Journal of Physical Education and Sports Management, 2016, 2, a000893.	0.5	52
1051	MR spectroscopy for in vivo assessment of the oncometabolite 2â€hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T. Journal of Magnetic Resonance Imaging, 2016, 44, 823-833.	1.9	36
1052	2-Hydroxy-Glutarate 3-Dimensional Functional Spectroscopy in the Evaluation of Isocitrate Dehydrogenaseâ€“Mutant Glioma Response to Therapy. Neurosurgery, 2016, 78, N9.	0.6	2
1053	Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutantIDHglioma patients. Neuro-Oncology, 2016, 18, now100.	0.6	30
1055	Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis. Neurologia Medico-Chirurgica, 2016, 56, 170-179.	1.0	18
1056	Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia. Genome Biology, 2016, 17, 140.	3.8	67
1057	Urine 2-Hydroxyglutarate in Glioma. Oncologist, 2016, 21, 1026-1026.	1.9	3
1058	Metaâ€analysis of clinical metabolic profiling studies in cancer: challenges and opportunities. EMBO Molecular Medicine, 2016, 8, 1134-1142.	3.3	83
1059	The hypoxic microenvironment: A determinant of cancer stem cell evolution. BioEssays, 2016, 38, S65-74.	1.2	164
1060	The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 15084-15089.	3.3	96
1061	Nutrient Exploitation within the Tumorâ€“Stroma Metabolic Crosstalk. Trends in Cancer, 2016, 2, 736-746.	3.8	41
1062	IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. Cancer Research, 2016, 76, 7118-7129.	0.4	99
1063	Genetics of glioma. , 0, , 1-23.		1

#	Article	IF	Citations
1064	Beyond the Oncogene Revolution: Four New Ways to Combat Cancer. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 85-92.	2.0	6
1065	Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives. Journal of Hematology and Oncology, 2016, 9, 49.	6.9	124
1066	Detecting isocitrate dehydrogenase gene mutations in oligodendroglial tumors using diffusion tensor imaging metrics and their correlations with proliferation and microvascular density. Journal of Magnetic Resonance Imaging, 2016, 43, 45-54.	1.9	28
1067	Role of mitochondrial dysfunction in cancer progression. Experimental Biology and Medicine, 2016, 241, 1281-1295.	1.1	212
1069	Targeted Metabolomics: The Next Generation of Clinical Chemistry!. Translational Bioinformatics, 2016, , 175-211.	0.0	2
1070	Breaking Cryo-EM Resolution Barriers to Facilitate Drug Discovery. Cell, 2016, 165, 1698-1707.	13.5	458
1071	Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs. European Journal of Medicinal Chemistry, 2016, 119, 218-230.	2.6	13
1072	Oncometabolites: Unconventional triggers of oncogenic signalling cascades. Free Radical Biology and Medicine, 2016, 100, 175-181.	1.3	137
1073	Further understanding of the pathology of glioma: implications for the clinic. Expert Review of Neurotherapeutics, 2016, 16, 1055-1065.	1.4	32
1074	Pathogenesis of Myeloproliferative Disorders. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 101-126.	9.6	38
1075	Investigational new drugs for brain cancer. Expert Opinion on Investigational Drugs, 2016, 25, 937-956.	1.9	16
1076	NADPH production, a growth marker, is stimulated by maslinic acid in gilthead sea bream by increased NADP-IDH and ME expression. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2016, 187, 32-42.	1.3	7
1077	Chiral separation of 2-hydroxyglutaric acid on cinchonan carbamate based weak chiral anion exchangers by high-performance liquid chromatography. Journal of Chromatography A, 2016, 1467, 239-245.	1.8	29
1078	Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1022, 290-297.	1.2	30
1079	Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma. Oncologist, 2016, 21, 214-219.	1.9	33
1080	Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas. Medicine (United States), 2016, 95, e2583.	0.4	99
1081	Interrogating the Druggability of the 2-Oxoglutarate-Dependent Dioxygenase Target Class by Chemical Proteomics. ACS Chemical Biology, 2016, 11, 2002-2010.	1.6	36
1082	Epigenetic regulators and their impact on therapy in acute myeloid leukemia. Haematologica, 2016, 101, 269-278.	1.7	45

#	Article	IF	Citations
1083	Mitochondria and the hallmarks of cancer. FEBS Journal, 2016, 283, 803-814.	2.2	100
1084	A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas. Pituitary, 2016, 19, 407-414.	1.6	12
1085	The Crabtree and Warburg effects: Do metabolite-induced regulations participate in their induction?. Biochimica Et Biophysica Acta - Bioenergetics, 2016, 1857, 1139-1146.	0.5	35
1086	Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate. Leukemia, 2016, 30, 1708-1715.	3.3	38
1087	Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy forIDH1mutant glioma. Neuro-Oncology, 2016, 18, now090.	0.6	56
1088	Metabolic Regulation of Gene Expression by Histone Lysine Î²-Hydroxybutyrylation. Molecular Cell, 2016, 62, 194-206.	4.5	406
1089	Structural analysis of oncogenic mutation of isocitrate dehydrogenase 1. Molecular BioSystems, 2016, 12, 2276-2287.	2.9	92
1090	Advances in mass spectrometry-based clinical biomarker discovery. Clinical Proteomics, 2016, 13, 1.	1.1	218
1093	MicroRNAs and oncogenic transcriptional regulatory networks controlling metabolic reprogramming in cancers. Computational and Structural Biotechnology Journal, 2016, 14, 223-233.	1.9	62
1094	Differential Aspartate Usage Identifies a Subset of Cancer Cells Particularly Dependent on OGDH. Cell Reports, 2016, 17, 876-890.	2.9	54
1095	Interrogating Metabolism in Brain Cancer. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 687-703.	0.6	17
1096	Hyperpolarized 13 C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring. NeuroImage: Clinical, 2016, 12, 180-189.	1.4	57
1097	Ã‰valuation prÃ©opÃ©ratoire comparative de 43Âgliomes de grade II et III par TEP au 18F-FDG et Ã la 18F-DOPAÂ: corrÃ©lation aux donnÃ©es histologiques et molÃ©culaires. Medecine Nucleaire, 2016, 40, 285-296.	0.2	0
1098	Actionable Molecular Biomarkers in Primary Brain Tumors. Trends in Cancer, 2016, 2, 338-349.	3.8	41
1099	Extraordinary Cancer Epigenomics: Thinking Outside the Classical Coding and Promoter Box. Trends in Cancer, 2016, 2, 572-584.	3.8	22
1100	Oncometabolite Accumulation and Epithelial-to-Mesenchymal Transition: The Turn of Fumarate. Cell Metabolism, 2016, 24, 529-530.	7.2	14
1101	Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma. Journal of Clinical Oncology, 2016, 34, 4030-4039.	0.8	157
1102	Expression of Idh1R132H in the Murine Subventricular Zone Stem Cell Niche Recapitulates Features of Early Gliomagenesis. Cancer Cell, 2016, 30, 578-594.	7.7	122

#	Article	IF	Citations
1103	An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas. Science and Technology of Advanced Materials, 2016, 17, 618-625.	2.8	12
1104	Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. Nature Reviews Cancer, 2016, 16, 680-693.	12.8	306
1105	Mutant IDH1 and thrombosis in gliomas. Acta Neuropathologica, 2016, 132, 917-930.	3.9	130
1106	Transcription factors as readers and effectors of DNA methylation. Nature Reviews Genetics, 2016, 17, 551-565.	7.7	482
1107	Astrocytic gliomas WHO grades II and III. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 345-360.	1.0	11
1108	Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma. Surgical Pathology Clinics, 2016, 9, 457-473.	0.7	42
1109	Molecular Pathology. Surgical Pathology Clinics, 2016, 9, 489-521.	0.7	3
1110	Mitochondria and Cancer. Cell, 2016, 166, 555-566.	13.5	1,203
1111	Sterol Regulatory Element Binding Protein Regulates the Expression and Metabolic Functions of Wild-Type and Oncogenic IDH1. Molecular and Cellular Biology, 2016, 36, 2384-2395.	1.1	25
1112	The hypoxic microenvironment: A determinant of cancer stem cell evolution. Inside the Cell, 2016, 1, 96-105.	0.4	7
1113	Mitochondrial metabolic remodeling in response to genetic and environmental perturbations. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2016, 8, 272-285.	6.6	17
1114	The importance of serine metabolism in cancer. Journal of Cell Biology, 2016, 214, 249-257.	2.3	299
1115	Quantitative Analysis of Cancer Metabolism: From pSIRM to MFA. Recent Results in Cancer Research, 2016, 207, 207-220.	1.8	4
1116	Metabolism in Cancer. Recent Results in Cancer Research, 2016, , .	1.8	5
1117	A journey beyond apoptosis: new enigma of controlling metastasis by pro-apoptotic Par-4. Clinical and Experimental Metastasis, 2016, 33, 757-764.	1.7	6
1118	ZEB1 expression is increased in IDH1-mutant lower-grade gliomas. Journal of Neuro-Oncology, 2016, 130, 111-122.	1.4	14
1119	Relationship between IDH1 mutation and preoperative seizure in low-grade gliomas: A meta-analysis. Clinical Neurology and Neurosurgery, 2016, 148, 79-84.	0.6	9
1120	A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a Dâ€2â€hydroxyglutaric aciduria type II mouse model. Journal of Inherited Metabolic Disease, 2016, 39, 807-820.	1.7	11

#	Article	IF	Citations
1121	Discovery of 8-Membered Ring Sulfonamides as Inhibitors of Oncogenic Mutant Isocitrate Dehydrogenase 1. ACS Medicinal Chemistry Letters, 2016, 7, 944-949.	1.3	21
1123	Tissue-Based Metabolomics to Analyze the Breast Cancer Metabolome. Recent Results in Cancer Research, 2016, 207, 157-175.	1.8	25
1124	Structural basis for multi-specific peptide recognition by the anti-IDH1/2 monoclonal antibody, MsMab-1. Biochemical and Biophysical Research Communications, 2016, 478, 1274-1279.	1.0	4
1125	Defining and Detecting Complex Peak Relationships in Mass Spectral Data: The Mz.unity Algorithm. Analytical Chemistry, 2016, 88, 9037-9046.	3.2	65
1126	Clinical significance of T cell metabolic reprogramming in cancer. Clinical and Translational Medicine, 2016, 5, 29.	1.7	69
1127	Establishing a Robust Molecular Taxonomy for Diffuse Gliomas of Adulthood. Surgical Pathology Clinics, 2016, 9, 379-390.	0.7	4
1128	The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy. Acta Neurochirurgica, 2016, 158, 1943-1953.	0.9	37
1129	Suffocation of gene expression. Nature, 2016, 537, 42-43.	13.7	4
1130	Undercover: gene control by metabolites and metabolic enzymes. Genes and Development, 2016, 30, 2345-2369.	2.7	192
1131	Molecular or Metabolic Reprograming: What Triggers Tumor Subtypes?. Cancer Research, 2016, 76, 5195-5200.	0.4	41
1132	Leveraging premalignant biology for immune-based cancer prevention. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10750-10758.	3.3	57
1133	Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis. Molecular Cancer Research, 2016, 14, 976-983.	1.5	84
1134	Cancer metabolism at a glance. Journal of Cell Science, 2016, 129, 3367-3373.	1.2	176
1135	Emerging tale of UPR and cancer: an essentiality for malignancy. Tumor Biology, 2016, 37, 14381-14390.	0.8	37
1136	Metabolic control of epigenetics in cancer. Nature Reviews Cancer, 2016, 16, 694-707.	12.8	317
1137	Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histoneÂdemethylation. Nature Cell Biology, 2016, 18, 1090-1101.	4.6	291
1138	Isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), fumarate hydratase (FH): three players for one phenotype in cancer?. Biochemical Society Transactions, 2016, 44, 1111-1116.	1.6	65
1139	Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation. Epigenomics, 2016, 8, 945-957.	1.0	21

#	Article	IF	Citations
1140	Genomic Landscape of Brain Tumors. , 2016, , 653-663.		0
1141	Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma. Cancer Medicine, 2016, 5, 1783-1790.	1.3	34
1142	Perspectives on investigational drugs and immunotherapies for glioblastoma. Expert Opinion on Investigational Drugs, 2016, 25, 1007-1009.	1.9	2
1143	Non-invasive metabolic imaging of brain tumours in the era of precision medicine. Nature Reviews Clinical Oncology, 2016, 13, 725-739.	12.5	88
1144	Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process. Cancer Research, 2016, 76, 6680-6689.	0.4	55
1145	Acute myeloid leukaemia. Nature Reviews Disease Primers, 2016, 2, 16010.	18.1	277
1146	Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells. Journal of Medicinal Chemistry, 2016, 59, 11120-11137.	2.9	31
1147	The Role of DNA Methylation in Cancer. Advances in Experimental Medicine and Biology, 2016, 945, 151-172.	0.8	76
1148	Oncometabolite D-2-Hydroxyglurate Directly Induces Epithelial-Mesenchymal Transition and is Associated with Distant Metastasis in Colorectal Cancer. Scientific Reports, 2016, 6, 36289.	1.6	87
1149	Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability. Human Molecular Genetics, 2016, 25, 3524-3538.	1.4	8
1150	Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma. Scientific Reports, 2016, 6, 30486.	1.6	11
1151	Fundamentals of cancer metabolism. Science Advances, 2016, 2, e1600200.	4.7	2,039
1152	S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate. Nature, 2016, 540, 236-241.	13.7	306
1153	Mitochondrial Protein Lipoylation and the 2-Oxoglutarate Dehydrogenase Complex Controls HIF1Î± Stability in Aerobic Conditions. Cell Metabolism, 2016, 24, 740-752.	7.2	112
1154	Emerging targeted therapies for glioma. Expert Opinion on Emerging Drugs, 2016, 21, 441-452.	1.0	45
1155	Occurrence, Biological Consequences, and Human Health Relevance of Oxidative Stress-Induced DNA Damage. Chemical Research in Toxicology, 2016, 29, 2008-2039.	1.7	131
1156	The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway. Nature Communications, 2016, 7, 12700.	5.8	134
1157	The Warburg effect: 80 years on. Biochemical Society Transactions, 2016, 44, 1499-1505.	1.6	351

#	Article	IF	Citations
1158	The emergence of intracellular metabolite signaling networks. IUBMB Life, 2016, 68, 871-872.	1.5	0
1159	IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients. Pathology, 2016, 48, 675-683.	0.3	26
1160	The oncometabolite R-2-hydroxyglutarate activates NF-Î¹B-dependent tumor-promoting stromal niche for acute myeloid leukemia cells. Scientific Reports, 2016, 6, 32428.	1.6	68
1161	Metformin targets histone acetylation in cancer-prone epithelial cells. Cell Cycle, 2016, 15, 3355-3361.	1.3	17
1162	Differential expression of alternatively spliced transcripts related to energy metabolism in colorectal cancer. BMC Genomics, 2016, 17, 1011.	1.2	50
1163	Diaphorase Coupling Protocols for Red-Shifting Dehydrogenase Assays. Assay and Drug Development Technologies, 2016, 14, 207-212.	0.6	18
1164	Genomic Characterization of Isocitrate Dehydrogenase-1â€“Mutant Glioma Malignant Progression. Neurosurgery, 2016, 78, N8-N9.	0.6	0
1165	Radiobiology of Glioblastoma. Current Clinical Pathology, 2016, , .	0.0	2
1166	Chromatin Remodeling Factor LSH Drives Cancer Progression by Suppressing the Activity of Fumarate Hydratase. Cancer Research, 2016, 76, 5743-5755.	0.4	85
1167	The expanding scope and impact of epigenetic cytosine modifications. Current Opinion in Chemical Biology, 2016, 33, 67-73.	2.8	24
1168	3D-QSAR and docking studies on 1-hydroxypyridin-2-one compounds as mutant isocitrate dehydrogenase 1 inhibitors. Journal of Molecular Structure, 2016, 1123, 335-343.	1.8	6
1169	Lactate Dehydrogenase C Produces S-2-Hydroxyglutarate in Mouse Testis. ACS Chemical Biology, 2016, 11, 2420-2427.	1.6	37
1170	Anaplastic astrocytoma. CNS Oncology, 2016, 5, 145-157.	1.2	51
1171	Interplay between Metabolism and Epigenetics: A Nuclear Adaptation to Environmental Changes. Molecular Cell, 2016, 62, 695-711.	4.5	363
1172	Translational and clinical implications of the genetic landscape of prostate cancer. Nature Reviews Clinical Oncology, 2016, 13, 597-610.	12.5	63
1173	Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 460-465.	0.2	84
1174	Increased Expression of PHGDH and Prognostic Significance in Colorectal Cancer. Translational Oncology, 2016, 9, 191-196.	1.7	59
1175	A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamental roles in the development and progression of diverse tumors. Clinical and Translational Medicine, 2016, 5, 3.	1.7	65

#	Article	IF	Citations
1176	DNA methylation in adult diffuse gliomas. Briefings in Functional Genomics, 2016, 15, elw019.	1.3	11
1177	Genetic and Epigenetic Determinants in Tumor Initiation and Progression of Glioblastoma. Current Clinical Pathology, 2016, , 177-187.	0.0	0
1178	Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase. Clinical Cancer Research, 2016, 22, 6256-6265.	3.2	43
1179	Mutations of myelodysplastic syndromes (MDS): An update. Mutation Research - Reviews in Mutation Research, 2016, 769, 47-62.	2.4	87
1180	Give it or take it: the flux of oneâ€carbon in cancer cells. FEBS Journal, 2016, 283, 3695-3704.	2.2	34
1181	Lipid and metabolite profiles of human brain tumors by desorption electrospray ionization-MS. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1486-1491.	3.3	183
1182	The Emerging Hallmarks of Cancer Metabolism. Cell Metabolism, 2016, 23, 27-47.	7.2	3,943
1183	Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility. Expert Review of Hematology, 2016, 9, 447-469.	1.0	12
1184	Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy. Expert Review of Hematology, 2016, 9, 351-360.	1.0	15
1185	IDH mutation is associated with higher risk of malignant transformation in low-grade glioma. Journal of Neuro-Oncology, 2016, 127, 363-372.	1.4	48
1186	Metabolic changes associated with tumor metastasis, part 2: Mitochondria, lipid and amino acid metabolism. Cellular and Molecular Life Sciences, 2016, 73, 1349-1363.	2.4	101
1187	Unveiling the Catalytic Mechanism of NADP⁺-Dependent Isocitrate Dehydrogenase with QM/MM Calculations. ACS Catalysis, 2016, 6, 357-368.	5.5	23
1188	Metabolic control of methylation and acetylation. Current Opinion in Chemical Biology, 2016, 30, 52-60.	2.8	241
1189	Gliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 497-521.	9.6	37
1190	Roles of IDH1/2 and TET2 mutations in myeloid disorders. International Journal of Hematology, 2016, 103, 627-633.	0.7	44
1191	Magnetic resonance analysis of malignant transformation in recurrent glioma. Neuro-Oncology, 2016, 18, 1169-1179.	0.6	28
1192	IDH mutations in cancer and progress toward development of targeted therapeutics. Annals of Oncology, 2016, 27, 599-608.	0.6	367
1193	The importance of plasma Dâ€2HG measurement in screening for IDH mutations in acute myeloid leukaemia. British Journal of Haematology, 2016, 173, 323-326.	1.2	11

#	Article	IF	Citations
1195	Applications of NMR spectroscopy to systems biochemistry. Progress in Nuclear Magnetic Resonance Spectroscopy, 2016, 92-93, 18-53.	3.9	164
1196	Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era. Critical Reviews in Oncology/Hematology, 2016, 100, 190-208.	2.0	89
1197	Idh1 mutations contribute to the development of T-cell malignancies in genetically engineered mice. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1387-1392.	3.3	16
1198	Cystine Deprivation Triggers Programmed Necrosis in VHL-Deficient Renal Cell Carcinomas. Cancer Research, 2016, 76, 1892-1903.	0.4	72
1199	Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. Clinical Cancer Research, 2016, 22, 1837-1842.	3.2	165
1200	Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1778-1783.	3.3	239
1201	Notch stimulates growth by direct regulation of genes involved in the control of glycolysis and the tricarboxylic acid cycle. Open Biology, 2016, 6, 150155.	1.5	51
1202	The Simultaneous Determination of Tricarboxylic Acid Cycle Acids and 2-Hydroxyglutarate in Serum from Patients with Nasopharyngeal Carcinoma Via GCâ€“MS. Chromatographia, 2016, 79, 501-508.	0.7	7
1203	Acute myeloid leukemia: advancing clinical trials and promising therapeutics. Expert Review of Hematology, 2016, 9, 433-445.	1.0	9
1204	Mitochondria and Cancer. Molecular Cell, 2016, 61, 667-676.	4.5	800
1206	Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. Journal of Experimental Medicine, 2016, 213, 483-497.	4.2	68
1207	Epigenetics: A primer for clinicians. Blood Reviews, 2016, 30, 285-295.	2.8	42
1208	Biomarkers Applied to Specific Tumor Types. , 2016, , 59-98.		0
1209	Prospective of curcumin, a pleiotropic signalling molecule from Curcuma longa in the treatment of Glioblastoma. European Journal of Medicinal Chemistry, 2016, 109, 23-35.	2.6	59
1210	Acetoacetate Accelerates Muscle Regeneration and Ameliorates Muscular Dystrophy in Mice. Journal of Biological Chemistry, 2016, 291, 2181-2195.	1.6	55
1211	Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro-Oncology, 2016, 18, 283-290.	0.6	161
1212	Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations. Cancer Research, 2016, 76, 43-49.	0.4	108
1213	Photoactivation of Mutant Isocitrate Dehydrogenase 2 Reveals Rapid Cancer-Associated Metabolic and Epigenetic Changes. Journal of the American Chemical Society, 2016, 138, 718-721.	6.6	39

#	Article	IF	Citations
1214	Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes. Journal of Biological Chemistry, 2016, 291, 4256-4265.	1.6	234
1215	Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature, 2016, 529, 110-114.	13.7	1,048
1216	Glutamine at focus: versatile roles in cancer. Tumor Biology, 2016, 37, 1541-1558.	0.8	38
1217	Update on Brain Tumors: New Developments in Neuroâ€oncologic Diagnosis and Treatment, and Impact on Rehabilitation Strategies. PM and R, 2016, 8, 678-689.	0.9	14
1218	Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia. Leukemia, 2016, 30, 782-788.	3.3	23
1219	A three-dimensional engineered tumour for spatial snapshot analysis of cell metabolism andÂphenotype in hypoxic gradients. Nature Materials, 2016, 15, 227-234.	13.3	113
1220	DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 61-70.	2.0	43
1221	Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells. Molecular Oncology, 2016, 10, 73-84.	2.1	129
1222	RHOA mutation may be associated with diffuse-type gastric cancer progression, but is it gain or loss?. Gastric Cancer, 2016, 19, 326-328.	2.7	8
1223	Advances and Technical Standards in Neurosurgery. Advances and Technical Standards in Neurosurgery, 2016, , .	0.2	2
1224	Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas. Advances and Technical Standards in Neurosurgery, 2016, , 91-108.	0.2	37
1225	Cancer-Specific Production of N-Acetylaspartate via NAT8L Overexpression in Nonâ€“Small Cell Lung Cancer and Its Potential as a Circulating Biomarker. Cancer Prevention Research, 2016, 9, 43-52.	0.7	33
1226	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clinical Cancer Research, 2016, 22, 1632-1641.	3.2	127
1227	ccmGDB: a database for cancer cell metabolism genes. Nucleic Acids Research, 2016, 44, D959-D968.	6.5	41
1228	Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions. Neuro-Oncology, 2016, 18, 160-172.	0.6	214
1229	Isocitrate dehydrogenase mutations in gliomas. Neuro-Oncology, 2016, 18, 16-26.	0.6	221
1230	In vivo detection of 2â€hydroxyglutarate in brain tumors by optimized pointâ€resolved spectroscopy (PRESS) at 7T. Magnetic Resonance in Medicine, 2017, 77, 936-944.	1.9	40
1231	Alpha-Ketoglutarate as a Molecule with Pleiotropic Activity: Well-Known and Novel Possibilities of Therapeutic Use. Archivum Immunologiae Et Therapiae Experimentalis, 2017, 65, 21-36.	1.0	140

#	Article	IF	Citations
1232	An IDH1-mutated primary gliosarcoma: case report. Journal of Neurosurgery, 2017, 126, 476-480.	0.9	5
1233	Cancer metabolism: a therapeutic perspective. Nature Reviews Clinical Oncology, 2017, 14, 11-31.	12.5	1,028
1234	Heterogeneity in Cancer Metabolism: New Concepts in an Old Field. Antioxidants and Redox Signaling, 2017, 26, 462-485.	2.5	162
1235	Mitochondrial dysfunction and mitochondrial dynamics-The cancer connection. Biochimica Et Biophysica Acta - Bioenergetics, 2017, 1858, 602-614.	0.5	276
1236	Acetylation Enhances TET2 Function in Protecting against Abnormal DNA Methylation during Oxidative Stress. Molecular Cell, 2017, 65, 323-335.	4.5	120
1237	Quality management in inÂvivo proton MRS. Analytical Biochemistry, 2017, 529, 98-116.	1.1	24
1238	Chiral separation of short chain aliphatic hydroxycarboxylic acids on cinchonan carbamate-based weak chiral anion exchangers and zwitterionic chiral ion exchangers. Journal of Chromatography A, 2017, 1487, 194-200.	1.8	25
1239	Drosophila larvae synthesize the putative oncometabolite L-2-hydroxyglutarate during normal developmental growth. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1353-1358.	3.3	64
1240	Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy. Metabolomics, 2017, 13, 9.	1.4	64
1241	Inference of cancer mechanisms through computational systems analysis. Molecular BioSystems, 2017, 13, 489-497.	2.9	7
1242	Point mutation (R153H or R153C) in Escherichia coli isocitrate dehydrogenase: Biochemical characterization and functional implication. Journal of Basic Microbiology, 2017, 57, 41-49.	1.8	1
1243	Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity. Structure, 2017, 25, 506-513.	1.6	53
1244	The Î² and Î³ subunits play distinct functional roles in the Î±2Î²Î³ heterotetramer of human NAD-dependent isocitrate dehydrogenase. Scientific Reports, 2017, 7, 41882.	1.6	28
1245	Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression. Molecular Cancer Research, 2017, 15, 507-520.	1.5	41
1246	Oncometabolic Tracks in the Heart. Circulation Research, 2017, 120, 267-269.	2.0	14
1247	2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Science Translational Medicine, 2017, 9, .	5.8	420
1248	Targeted Therapy of IDH1-Mutated Tumors. , 2017, , 151-161.		0
1249	A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome. Leukemia, 2017, 31, 2011-2019.	3.3	30

#	Article	IF	Citations
1250	Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma. Modern Pathology, 2017, 30, 650-659.	2.9	94
1251	Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches. Oncogene, 2017, 36, 3359-3374.	2.6	219
1252	Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathologica, 2017, 133, 629-644.	3.9	146
1253	Epimetabolites: discovering metabolism beyond building and burning. Current Opinion in Chemical Biology, 2017, 36, 70-76.	2.8	45
1254	Genetic alterations in Krebs cycle and its impact on cancer pathogenesis. Biochimie, 2017, 135, 164-172.	1.3	80
1255	Overexpression of TET dioxygenases in seminomas associates with low levels of DNA methylation and hydroxymethylation. Molecular Carcinogenesis, 2017, 56, 1837-1850.	1.3	17
1256	Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair. Cancer Research, 2017, 77, 1709-1718.	0.4	159
1257	Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. Molecular Systems Biology, 2017, 13, 914.	3.2	73
1258	Precision medicine driven by cancer systems biology. Cancer and Metastasis Reviews, 2017, 36, 91-108.	2.7	38
1259	New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. Current Neurology and Neuroscience Reports, 2017, 17, 19.	2.0	87
1260	Metabolic Inputs into the Epigenome. Cell Metabolism, 2017, 25, 544-558.	7.2	156
1261	Comparative analyses identify molecular signature of MRI-classified SVZ-associated glioblastoma. Cell Cycle, 2017, 16, 765-775.	1.3	15
1262	Catabolism of GABA, succinic semialdehyde or gamma-hydroxybutyrate through the GABA shunt impair mitochondrial substrate-level phosphorylation. Neurochemistry International, 2017, 109, 41-53.	1.9	35
1263	A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML. Leukemia, 2017, 31, 1466-1470.	3.3	25
1264	Glutaminolysis: A Hallmark of Cancer Metabolism. Annual Review of Biomedical Engineering, 2017, 19, 163-194.	5.7	528
1265	Asperspiropene A, a novel fungal metabolite as an inhibitor of cancer-associated mutant isocitrate dehydrogenase 1. Organic Chemistry Frontiers, 2017, 4, 1137-1144.	2.3	16
1266	TET2 in Normal and Malignant Hematopoiesis. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026518.	2.9	69
1267	SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026468.	2.9	60

#	Article	IF	Citations
1268	Cancer metabolism in space and time: Beyond the Warburg effect. Biochimica Et Biophysica Acta - Bioenergetics, 2017, 1858, 556-572.	0.5	147
1269	Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets. Expert Review of Gastroenterology and Hepatology, 2017, 11, 349-356.	1.4	16
1270	The importance of mitochondrial folate enzymes in human colorectal cancer. Oncology Reports, 2017, 37, 417-425.	1.2	47
1271	Understanding the Intersections between Metabolism and Cancer Biology. Cell, 2017, 168, 657-669.	13.5	1,561
1272	Review of metabolic pathways activated in cancer cells as determined through isotopic labeling and network analysis. Metabolic Engineering, 2017, 43, 113-124.	3.6	52
1273	Molecular mechanism of the allosteric regulation of the Î±Î³ heterodimer of human NAD-dependent isocitrate dehydrogenase. Scientific Reports, 2017, 7, 40921.	1.6	24
1274	Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 381-389.	1.4	31
1275	Response assessment of bevacizumab therapy in GBM with integrated 11C-MET-PET/MRI: a feasibility study. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1285-1295.	3.3	14
1276	L-2-Hydroxyglutarate production arises from noncanonical enzyme function at acidic pH. Nature Chemical Biology, 2017, 13, 494-500.	3.9	190
1277	The Î±-ketoglutarate dehydrogenase complex in cancer metabolic plasticity. Cancer & Metabolism, 2017, 5, 3.	2.4	78
1278	Convenient expression, purification and quantitative liquid chromatography-tandem mass spectrometry-based analysis of TET2 5-methylcytosine demethylase. Protein Expression and Purification, 2017, 132, 143-151.	0.6	4
1279	Metabolomics: A Primer. Trends in Biochemical Sciences, 2017, 42, 274-284.	3.7	273
1280	AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations. Cancer Discovery, 2017, 7, 478-493.	7.7	350
1281	NF-ÎºB controls four genes encoding core enzymes of tricarboxylic acid cycle. Gene, 2017, 621, 12-20.	1.0	12
1282	Therapeutic targeting of isocitrate dehydrogenase mutant AML. Expert Opinion on Investigational Drugs, 2017, 26, 525-530.	1.9	19
1283	IDH1 Mutation Promotes Tumorigenesis by Inhibiting JNK Activation and Apoptosis Induced by Serum Starvation. Cell Reports, 2017, 19, 389-400.	2.9	24
1284	Mutant IDH1 and seizures in patients with glioma. Neurology, 2017, 88, 1805-1813.	1.5	167
1285	Metabolic Pathway Inhibition in Liver Cancer. SLAS Technology, 2017, 22, 237-244.	1.0	19

#	Article	IF	Citations
1286	Applied Cancer Immunogenomics. Cancer Journal (Sudbury, Mass), 2017, 23, 125-130.	1.0	16
1287	Mitochondrial dysfunction in cancer: Potential roles of ATF5 and the mitochondrial UPR. Seminars in Cancer Biology, 2017, 47, 43-49.	4.3	80
1288	Accuracy of 1H magnetic resonance spectroscopy for quantification of 2-hydroxyglutarate using linear combination and J-difference editing at 9.4 T. Zeitschrift Fur Medizinische Physik, 2017, 27, 300-309.	0.6	2
1289	PPARÎ´ promotes tumor progression via activation of Glut1 and SLC1-A5 transcription. Carcinogenesis, 2017, 38, 748-755.	1.3	28
1290	The role of 5-hydroxymethylcytosine in development, aging and age-related diseases. Ageing Research Reviews, 2017, 37, 28-38.	5.0	69
1291	Noninvasive Assessment ofIDHMutational Status in World Health Organization Grade II and III Astrocytomas Using DWI and DSC-PWI Combined with Conventional MR Imaging. American Journal of Neuroradiology, 2017, 38, 1138-1144.	1.2	103
1292	Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models. Cancer Discovery, 2017, 7, 459-461.	7.7	14
1293	Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes and Development, 2017, 31, 774-786.	2.7	313
1294	PII Protein-Derived FRET Sensors for Quantification and Live-Cell Imaging of 2-Oxoglutarate. Scientific Reports, 2017, 7, 1437.	1.6	29
1295	TET family dioxygenases and DNA demethylation in stem cells and cancers. Experimental and Molecular Medicine, 2017, 49, e323-e323.	3.2	126
1296	The interplay between metabolic remodeling and immune regulation in glioblastoma. Neuro-Oncology, 2017, 19, 1308-1315.	0.6	46
1297	Metabolomic signature of brain cancer. Molecular Carcinogenesis, 2017, 56, 2355-2371.	1.3	86
1298	From K-space to Nucleotide. Topics in Magnetic Resonance Imaging, 2017, 26, 33-41.	0.7	2
1299	The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletionâ€“Mediated Cytotoxicity. Cancer Research, 2017, 77, 4102-4115.	0.4	74
1300	The winding path of protein methylation research: milestones and new frontiers. Nature Reviews Molecular Cell Biology, 2017, 18, 517-527.	16.1	154
1302	Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?. European Journal of Cancer, 2017, 81, 161-173.	1.3	27
1303	Current and upcoming mitochondrial targets for cancer therapy. Seminars in Cancer Biology, 2017, 47, 154-167.	4.3	41
1305	Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro-Oncology, 2017, 19, 1460-1468.	0.6	213

#	Article	IF	Citations
1306	High expression of COX5B is associated with poor prognosis in breast cancer. Future Oncology, 2017, 13, 1711-1719.	1.1	12
1307	A Comprehensive Review of Genomics and Noncoding RNA in Gliomas. Topics in Magnetic Resonance Imaging, 2017, 26, 3-14.	0.7	18
1308	2-HG Inhibits Necroptosis by Stimulating DNMT1-Dependent Hypermethylation of the RIP3 Promoter. Cell Reports, 2017, 19, 1846-1857.	2.9	50
1309	Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone. Human Pathology, 2017, 65, 239-246.	1.1	50
1310	Back to the Future: Therapeutic Targeting of Cancer Cell Metabolism. SLAS Discovery, 2017, 22, 333-337.	1.4	2
1311	Precancer Atlas to Drive Precision Prevention Trials. Cancer Research, 2017, 77, 1510-1541.	0.4	116
1312	Looking to the metabolic landscapes for prostate health monitoring. Prostate International, 2017, 5, 85-88.	1.2	7
1313	Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency. Journal of Biological Chemistry, 2017, 292, 7971-7983.	1.6	40
1314	Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma. Scientific Reports, 2017, 7, 44792.	1.6	63
1315	Crosstalk between epigenetics and metabolismâ€"Yin and Yang of histone demethylases and methyltransferases in cancer. Briefings in Functional Genomics, 2017, 16, 320-325.	1.3	26
1316	Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development. Annual Review of Biochemistry, 2017, 86, 305-331.	5.0	161
1317	Targeted rescue of cancer-associated IDH1 mutant activity using an engineered synthetic antibody. Scientific Reports, 2017, 7, 556.	1.6	4
1318	A novel all-in-one intraoperative genotyping system for IDH1-mutant glioma. Brain Tumor Pathology, 2017, 34, 91-97.	1.1	16
1319	The leukaemia epigenome targeted. Nature, 2017, 543, 634-635.	13.7	2
1320	DNA methylation aberrancies as a guide for surveillance and treatment of human cancers. Epigenetics, 2017, 12, 416-432.	1.3	98
1321	Molecular mechanisms and therapeutic targets in pediatric brain tumors. Science Signaling, 2017, 10, .	1.6	53
1322	Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions. , 2017, 177, 123-128.		23
1323	Targeted Differentiation Therapy with Mutant IDH Inhibitors: Early Experiences and Parallels with Other Differentiation Agents. Annual Review of Cancer Biology, 2017, 1, 379-401.	2.3	14

#	Article	IF	Citations
1324	The Effect of Molecular Diagnostics on the Treatment of Glioma. Current Oncology Reports, 2017, 19, 26.	1.8	40
1325	NMR-based Stable Isotope Resolved Metabolomics in systems biochemistry. Archives of Biochemistry and Biophysics, 2017, 628, 123-131.	1.4	43
1326	Cancer metabolism as we know it today. Genes and Diseases, 2017, 4, 4-6.	1.5	6
1327	Oncometabolites <scp>d</scp>- and <scp>l</scp>-2-Hydroxyglutarate Inhibit the AlkB Family DNA Repair Enzymes under Physiological Conditions. Chemical Research in Toxicology, 2017, 30, 1102-1110.	1.7	62
1328	PPARÎ± Promotes Cancer Cell Glut1 Transcription Repression. Journal of Cellular Biochemistry, 2017, 118, 1556-1562.	1.2	21
1329	1D-spectral editing and 2D multispectral inÂvivo 1 H-MRS and 1 H-MRSI - Methods and applications. Analytical Biochemistry, 2017, 529, 48-64.	1.1	45
1330	Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis. Cancer Research, 2017, 77, 960-970.	0.4	78
1331	Targeted full-scan LC-MS metabolomics: simultaneous quantitation of knowns and feature discovery provide the best of both worlds. Bioanalysis, 2017, 9, 5-8.	0.6	4
1332	Nontargeted in vitro metabolomics for high-throughput identification of novel enzymes in Escherichia coli. Nature Methods, 2017, 14, 187-194.	9.0	125
1333	Integrating genomic information and signaling dynamics for efficient cancer therapy. Current Opinion in Systems Biology, 2017, 1, 38-43.	1.3	1
1334	T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. Journal of the National Cancer Institute, 2017, 109, djw248.	3.0	28
1335	Targeted Next-Generation Sequencing in Molecular Subtyping of Lower-Grade Diffuse Gliomas. Journal of Molecular Diagnostics, 2017, 19, 328-337.	1.2	35
1336	Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1. ACS Medicinal Chemistry Letters, 2017, 8, 151-156.	1.3	35
1338	Metabolic synthetic lethality in cancer therapy. Biochimica Et Biophysica Acta - Bioenergetics, 2017, 1858, 723-731.	0.5	50
1339	Fumarate Hydratase Loss Causes Combined Respiratory Chain Defects. Cell Reports, 2017, 21, 1036-1047.	2.9	61
1340	A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit. Scientific Reports, 2017, 7, 13853.	1.6	34
1341	Isocitrate dehydrogenaseâ€mutant glioma: Evolving clinical and therapeutic implications. Cancer, 2017, 123, 4535-4546.	2.0	103
1342	Low-Grade Astrocytoma Mutations in IDH1, P53, and ATRX Cooperate to Block Differentiation of Human Neural Stem Cells via Repression of SOX2. Cell Reports, 2017, 21, 1267-1280.	2.9	95

#	Article	IF	Citations
1343	Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays. Scientific Reports, 2017, 7, 12758.	1.6	59
1344	Taking control of spin currents. Nature, 2017, 549, 464-465.	13.7	1
1345	Targeting Metabolism for Cancer Therapy. Cell Chemical Biology, 2017, 24, 1161-1180.	2.5	677
1346	Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1. Bioorganic and Medicinal Chemistry, 2017, 25, 6379-6387.	1.4	10
1347	Oncometabolites: A New Paradigm for Oncology, Metabolism, and the Clinical Laboratory. Clinical Chemistry, 2017, 63, 1812-1820.	1.5	77
1348	InÂVivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors. Cell Metabolism, 2017, 26, 830-841.e3.	7.2	82
1349	Diffusion tensor image features predict IDH genotype in newly diagnosed WHO grade II/III gliomas. Scientific Reports, 2017, 7, 13396.	1.6	57
1350	Metabolic Reprogramming and Redox Signaling in Pulmonary Hypertension. Advances in Experimental Medicine and Biology, 2017, 967, 241-260.	0.8	13
1351	Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Blood, 2017, 130, 2469-2474.	0.6	110
1352	The impact of cellular metabolism on chromatin dynamics and epigenetics. Nature Cell Biology, 2017, 19, 1298-1306.	4.6	369
1353	Altered metabolic landscape in <scp>IDH</scp> â€mutant gliomasÂaffects phospholipid, energy, and oxidative stress pathways. EMBO Molecular Medicine, 2017, 9, 1681-1695.	3.3	111
1354	Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia. Current Hematologic Malignancy Reports, 2017, 12, 537-546.	1.2	31
1355	State of the Art Update and Next Questions: Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 703-709.	0.2	6
1356	Pharmacometabolomics Informs Quantitative Radiomics for Glioblastoma Diagnostic Innovation. OMICS A Journal of Integrative Biology, 2017, 21, 429-439.	1.0	15
1357	Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy. BioDrugs, 2017, 31, 379-392.	2.2	8
1358	Targeting metabolic pathways for head and neck cancers therapeutics. Cancer and Metastasis Reviews, 2017, 36, 503-514.	2.7	36
1359	Nanomedicine associated with photodynamic therapy for glioblastoma treatment. Biophysical Reviews, 2017, 9, 761-773.	1.5	45
1360	Studies on the Interaction of the Histone Demethylase KDM5B with Tricarboxylic Acid Cycle Intermediates. Journal of Molecular Biology, 2017, 429, 2895-2906.	2.0	29

#	Article	IF	Citations
1361	Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10743-10748.	3.3	109
1362	Mutations in myeloproliferative neoplasms â€“ their significance and clinical use. Expert Review of Hematology, 2017, 10, 961-973.	1.0	19
1363	Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor. ACS Medicinal Chemistry Letters, 2017, 8, 1116-1121.	1.3	84
1364	The Molecular Basis of DNA Demethylation. Cancer Drug Discovery and Development, 2017, , 53-73.	0.2	1
1365	Expression patterns of members of the isocitrate dehydrogenase gene family in murine inner ear. Biotechnic and Histochemistry, 2017, 92, 536-544.	0.7	4
1366	Future Perspective of DNA and Histone Methylation as Cancer Targets. Cancer Drug Discovery and Development, 2017, , 607-622.	0.2	0
1367	TET proteins in natural and induced differentiation. Current Opinion in Genetics and Development, 2017, 46, 202-208.	1.5	27
1368	Colorectal cancer: epigenetic alterations and their clinical implications. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 439-448.	3.3	48
1369	Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administrationâ€“Approved Drugs. Pharmacological Reviews, 2017, 69, 479-496.	7.1	58
1370	A Î± -KA fluorescent probe for discrimination of blood cancer serum. Chinese Chemical Letters, 2017, 28, 1991-1993.	4.8	9
1371	Approaches and techniques to characterize cancer metabolism in vitro and in vivo. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 412-419.	3.3	11
1372	IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes. Acta Haematologica, 2017, 138, 143-151.	0.7	18
1374	Vitamin C regulates stem cells and cancer. Nature, 2017, 549, 462-464.	13.7	11
1375	The Molecular Basis of Histone Demethylation. Cancer Drug Discovery and Development, 2017, , 151-219.	0.2	8
1376	Exploring Metabolism In Vivo Using Endogenous 11 C Metabolic Tracers. Seminars in Nuclear Medicine, 2017, 47, 461-473.	2.5	7
1377	Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancerâ€“Predisposing Mutations in Pheochromocytomas and Paragangliomas. Clinical Cancer Research, 2017, 23, 6315-6324.	3.2	73
1378	Predicting IDH mutation status in grade II gliomas using amide proton transferâ€weighted (APTw) MRI. Magnetic Resonance in Medicine, 2017, 78, 1100-1109.	1.9	126
1379	EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma. Molecular Cancer Research, 2017, 15, 1517-1530.	1.5	39

#	Article	IF	Citations
1380	Letter: A Role for Wild-Type Isocitrate Dehydrogenase 1 in Gliomagenesis. Neurosurgery, 2017, 81, E56-E57.	0.6	0
1381	Measurement of Oncometabolites d-2-Hydroxyglutaric Acid and l-2-Hydroxyglutaric Acid. Methods in Molecular Biology, 2017, 1633, 219-234.	0.4	7
1382	Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling. Trends in Cell Biology, 2017, 27, 738-752.	3.6	99
1383	Deciphering metabolic rewiring in breast cancer subtypes. Translational Research, 2017, 189, 105-122.	2.2	45
1384	Discovery of a novel calcium-sensitive fluorescent probe for Î±-ketoglutarate. Acta Pharmacologica Sinica, 2017, 38, 1683-1690.	2.8	10
1385	Interrogating IDH Mutation in Brain Tumor. Topics in Magnetic Resonance Imaging, 2017, 26, 27-32.	0.7	5
1386	Genetic factors affecting intraoperative 5-aminolevulinic acid-induced fluorescence of diffuse gliomas. Radiology and Oncology, 2017, 51, 142-150.	0.6	21
1387	The Updated World Health Organization Glioma Classification: Cellular and Molecular Origins of Adult Infiltrating Gliomas. Archives of Pathology and Laboratory Medicine, 2017, 141, 1633-1645.	1.2	30
1388	An integrated computational and experimental study uncovers <scp>FUT</scp> 9 as a metabolic driver of colorectal cancer. Molecular Systems Biology, 2017, 13, 956.	3.2	38
1389	Myeloproliferative neoplasms: from origins to outcomes. Blood, 2017, 130, 2475-2483.	0.6	107
1390	Cancer Biology of Molecular Imaging. , 2017, , 3-34.		0
1391	Chemical Similarity Enrichment Analysis (ChemRICH) as alternative to biochemical pathway mapping for metabolomic datasets. Scientific Reports, 2017, 7, 14567.	1.6	257
1392	BCAT1 restricts Î±KG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature, 2017, 551, 384-388.	13.7	261
1393	Application of metabolomics in sarcoma: From biomarkers to therapeutic targets. Critical Reviews in Oncology/Hematology, 2017, 116, 1-10.	2.0	12
1394	Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metabolism, 2017, 26, 94-109.	7.2	374
1395	Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations. Neuro-Oncology, 2017, 19, 1640-1650.	0.6	54
1396	Proton NMR characterization of intact primary and metastatic melanoma cells in 2D & 3D cultures. Biological Research, 2017, 50, 12.	1.5	7
1397	The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nature Reviews Cancer, 2017, 17, 5-19.	12.8	542

#	Article	IF	Citations
1398	Structure of the Open Reading Frame 49 Protein Encoded by Kaposi's Sarcoma-Associated Herpesvirus. Journal of Virology, 2017, 91, .	1.5	3
1399	Quantitative metabolic flux analysis reveals an unconventional pathway of fatty acid synthesis in cancer cells deficient for the mitochondrial citrate transport protein. Metabolic Engineering, 2017, 43, 198-207.	3.6	80
1400	Neomorphic mutations create therapeutic challenges in cancer. Oncogene, 2017, 36, 1607-1618.	2.6	24
1401	Cancer Genomics. , 2017, , 43-63.		0
1402	Glutamate and Î±-ketoglutarate: key players in glioma metabolism. Amino Acids, 2017, 49, 21-32.	1.2	89
1403	Detection of 2â€hydroxyglutarate in brain tumors by tripleâ€refocusing MR spectroscopy at 3T in vivo. Magnetic Resonance in Medicine, 2017, 78, 40-48.	1.9	28
1404	IDH1 Associated with Neuronal Apoptosis in Adult Rats Brain Following Intracerebral Hemorrhage. Cellular and Molecular Neurobiology, 2017, 37, 831-841.	1.7	8
1405	Analyzing Tumor Metabolism In Vivo. Annual Review of Cancer Biology, 2017, 1, 99-117.	2.3	33
1406	Molecular pathology of paediatric central nervous system tumours. Journal of Pathology, 2017, 241, 159-172.	2.1	51
1407	Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses. Molecular Neurobiology, 2017, 54, 5996-6005.	1.9	41
1408	Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia, 2017, 31, 272-281.	3.3	278
1409	Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling. Oncogene, 2017, 36, 4235-4242.	2.6	59
1410	Metabolic interactions with cancer epigenetics. Molecular Aspects of Medicine, 2017, 54, 50-57.	2.7	40
1411	One-Carbon Metabolism in Health and Disease. Cell Metabolism, 2017, 25, 27-42.	7.2	1,275
1412	ãƒ“ã‚¿ãƒŸãƒ³CãŒå¹¹ç´°èƒžã•ãŒã‚‰ã‚“ã‚’è¿ç¯€ã™ã‚‹. Nature Digest, 2017, 14, 36-37.	0.0	0
1413	IDH1 mutation diminishes aggressive phenotype in glioma stem cells. International Journal of Oncology, 2018, 52, 270-278.	1.4	16
1414	EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients. Journal of Molecular Cell Biology, 2017, 9, 477-488.	1.5	48
1415	Dysregulated metabolic enzymes and metabolicÃ¯Â¿Â½reprogramming in cancer cells (Review). Biomedical Reports, 2018, 8, 3-10.	0.9	54

#	Article	IF	Citations
1416	Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1. Oncotarget, 2017, 8, 44255-44265.	0.8	25
1417	ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming. Journal of Clinical Investigation, 2017, 128, 323-340.	3.9	63
1418	Spatial distribution of disease-associated variants in three-dimensional structures of protein complexes. Oncogenesis, 2017, 6, e380-e380.	2.1	20
1419	LC-MS-based metabolomics revealed SLC25A22 as an essential regulator of aspartate-derived amino acids and polyamines in KRAS-mutant colorectal cancer. Oncotarget, 2017, 8, 101333-101344.	0.8	15
1420	Epigenetic dysregulation in brain tumors and neurodevelopment. , 2017, , 261-276.		0
1421	Myeloproliferative neoplasms: from origins to outcomes. Hematology American Society of Hematology Education Program, 2017, 2017, 470-479.	0.9	29
1422	Cancer Biology and the Principles of Targeted Cancer Drug Discovery. , 2017, , 1-38.		1
1423	MicroRNA Regulation of Glycolytic Metabolism in Glioblastoma. BioMed Research International, 2017, 2017, 1-13.	0.9	24
1424	The potential of cryo-electron microscopy for structure-based drug design. Essays in Biochemistry, 2017, 61, 543-560.	2.1	34
1425	Collateral Damage Intendedâ€"Cancer-Associated Fibroblasts and Vasculature Are Potential Targets in Cancer Therapy. International Journal of Molecular Sciences, 2017, 18, 2355.	1.8	30
1426	Mitochondrial Deficiencies in the Predisposition to Paraganglioma. Metabolites, 2017, 7, 17.	1.3	21
1427	Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas. Metabolites, 2017, 7, 29.	1.3	48
1428	Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges. Contrast Media and Molecular Imaging, 2017, 2017, 1-27.	0.4	78
1429	The Enzymology of 2-Hydroxyglutarate, 2-Hydroxyglutaramate and 2-Hydroxysuccinamate and Their Relationship to Oncometabolites. Biology, 2017, 6, 24.	1.3	13
1430	Molecular Markers of Gliomas. Molecular Genetics, Microbiology and Virology, 2017, 32, 180-190.	0.0	2
1431	Cofactors As Metabolic Sensors Driving Cell Adaptation in Physiology and Disease. Frontiers in Endocrinology, 2017, 8, 304.	1.5	19
1432	Targeting the Metabolic Reprogramming That Controls Epithelial-to-Mesenchymal Transition in Aggressive Tumors. Frontiers in Oncology, 2017, 7, 40.	1.3	101
1433	Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma. Frontiers in Oncology, 2017, 7, 45.	1.3	45

#	Article	IF	Citations
1434	Cancer: Linking Powerhouses to Suicidal Bags. Frontiers in Oncology, 2017, 7, 204.	1.3	15
1435	Metabolic Alterations at the Crossroad of Aging and Oncogenesis. International Review of Cell and Molecular Biology, 2017, 332, 1-42.	1.6	16
1436	Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives. BioMed Research International, 2017, 2017, 1-13.	0.9	239
1437	Update on hypoxia-inducible factors and hydroxylases in oxygen regulatory pathways: from physiology to therapeutics. Hypoxia (Auckland, N Z), 2017, Volume 5, 11-20.	1.9	26
1438	IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced. PLoS ONE, 2017, 12, e0169038.	1.1	34
1439	Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight. Cell and Bioscience, 2017, 7, 37.	2.1	69
1440	Tumor-Specific Mutations in Gliomas and Their Implications for Immunotherapy. , 2017, , 83-107.		0
1441	Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. Journal of Clinical Investigation, 2017, 127, 1425-1437.	3.9	334
1442	The Process and Regulatory Components of Inflammation in Brain Oncogenesis. Biomolecules, 2017, 7, 34.	1.8	84
1443	Molecular Testing of Brain Tumor. Journal of Pathology and Translational Medicine, 2017, 51, 205-223.	0.4	56
1444	Brain Tumor Imaging. Journal of Clinical Oncology, 2017, 35, 2432-2438.	0.8	53
1446	Mutations in DNA Methyltransferases and Demethylases. , 2017, , 528-528.		0
1447	Interaction Between Cellular Metabolic States and Chromatin Dynamics. , 2017, , 373-398.		1
1448	Mutant Isocitrate Dehydrogenase 1 Disrupts PKM2â€“Î²-Cateninâ€“BRG1 Transcriptional Network-Driven CD47 Expression. Molecular and Cellular Biology, 2018, 38, .	1.1	33
1449	The crucial role of multiomic approach in cancer research and clinically relevant outcomes. EPMA Journal, 2018, 9, 77-102.	3.3	184
1450	Emerging molecular target antagonists for the treatment of biliary tract cancer. Expert Opinion on Emerging Drugs, 2018, 23, 63-75.	1.0	14
1451	Metabo-Devo: A metabolic perspective of development. Mechanisms of Development, 2018, 154, 12-23.	1.7	28
1452	Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics. Advances in Anatomic Pathology, 2018, 25, 143-171.	2.4	31

#	Article	IF	Citations
1453	Untargeted and stable isotope-assisted metabolomic analysis of MDA-MB-231 cells under hypoxia. Metabolomics, 2018, 14, 40.	1.4	14
1454	Mitochondria and Hypoxia: Metabolic Crosstalk in Cell-Fate Decisions. Trends in Endocrinology and Metabolism, 2018, 29, 249-259.	3.1	45
1455	Prediction of platinum-based chemotherapy efficacy in lung cancer based on LCâ€“MS metabolomics approach. Journal of Pharmaceutical and Biomedical Analysis, 2018, 154, 95-101.	1.4	16
1456	D-2-hydroxyglutarate interferes with HIF-1Î± stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization. OncoImmunology, 2018, 7, e1445454.	2.1	97
1457	The role of compartmentalized signaling pathways in the control of mitochondrial activities in cancer cells. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1869, 293-302.	3.3	19
1458	Rapid detection of mutation in isocitrate dehydrogenase 1 and 2 genes using mass spectrometry. Brain Tumor Pathology, 2018, 35, 90-96.	1.1	15
1459	InÂVivo Microscopy in Neurosurgical Oncology. World Neurosurgery, 2018, 115, 110-127.	0.7	19
1460	Recent advances in cancer metabolism: a technological perspective. Experimental and Molecular Medicine, 2018, 50, 1-16.	3.2	46
1461	Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nature Communications, 2018, 9, 1474.	5.8	106
1462	Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia. Experimental Hematology, 2018, 63, 1-11.	0.2	12
1463	Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting <scp>IDH</scp>2 and <scp>PIK</scp>3<scp>CA</scp>: a validation cohort. Histopathology, 2018, 73, 339-344.	1.6	44
1464	Separation and determination of the enantiomers of lactic acid and 2â€hydroxyglutaric acid by chiral derivatization combined with gas chromatography and mass spectrometry. Journal of Separation Science, 2018, 41, 2576-2584.	1.3	19
1465	Reconstructing the molecular life history of gliomas. Acta Neuropathologica, 2018, 135, 649-670.	3.9	61
1466	Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system. Neuro-Oncology, 2018, 20, 1197-1206.	0.6	27
1467	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell Reports, 2018, 23, 255-269.e4.	2.9	204
1468	Anticancer Potential of Dietary Polyphenols. , 2018, , 25-50.		3
1469	Association between mutant IDHs and tumorigenesis in gliomas. Medical Molecular Morphology, 2018, 51, 194-198.	0.4	9
1470	Functions of the sirtuin deacylase SIRT5 in normal physiology and pathobiology. Critical Reviews in Biochemistry and Molecular Biology, 2018, 53, 311-334.	2.3	162

#	Article	IF	Citations
1471	Novel Insights for Inhibiting Mutant Heterodimer IDH1wt-R132H in Cancer: An In-Silico Approach. Molecular Diagnosis and Therapy, 2018, 22, 369-380.	1.6	2
1472	Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas. Journal of Neuro-Oncology, 2018, 138, 241-250.	1.4	9
1474	IDH1 mutation is associated with a higher preoperative seizure incidence in low-grade glioma: A systematic review and meta-analysis. Seizure: the Journal of the British Epilepsy Association, 2018, 55, 76-82.	0.9	38
1475	Current state and future prospects of immunotherapy for glioma. Immunotherapy, 2018, 10, 317-339.	1.0	60
1476	PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations. EBioMedicine, 2018, 28, 97-104.	2.7	55
1477	Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas. Neuro-Oncology, 2018, 20, 1262-1271.	0.6	31
1478	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathologica, 2018, 135, 601-615.	3.9	76
1479	LncRNA IDH1-AS1 links the functions of c-Myc and HIF1Î± via IDH1 to regulate the Warburg effect. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1465-E1474.	3.3	93
1480	New aspects of glioblastoma multiforme revealed by similarities between neural and glioblastoma stem cells. Cell Biology and Toxicology, 2018, 34, 425-440.	2.4	29
1481	Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates. Trends in Cancer, 2018, 4, 151-165.	3.8	160
1482	Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 694-699.	1.0	18
1483	The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms. Laboratory Investigation, 2018, 98, 414-426.	1.7	22
1484	TOF-SIMS analysis of an isocitrate dehydrogenase 1 mutation-associated oncometabolite in cancer cells. Biointerphases, 2018, 13, 03B404.	0.6	5
1485	Current therapeutic approaches to diffuse grade II and III gliomas. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628561775203.	1.5	35
1486	IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors. Clinical Cancer Research, 2018, 24, 1705-1715.	3.2	80
1487	Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers. ACS Medicinal Chemistry Letters, 2018, 9, 300-305.	1.3	292
1488	Wild-type and mutated IDH1/2 enzymes and therapy responses. Oncogene, 2018, 37, 1949-1960.	2.6	169
1489	Exogenous Gene Transmission of Isocitrate Dehydrogenase 2 Mimics Ischemic Preconditioning Protection. Journal of the American Society of Nephrology: JASN, 2018, 29, 1154-1164.	3.0	29

#	Article	IF	Citations
1490	Temporal stability of MGMT promoter methylation in glioblastoma patients undergoing STUPP protocol. Journal of Neuro-Oncology, 2018, 137, 233-240.	1.4	10
1491	IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy. Epilepsy and Behavior, 2018, 78, 30-36.	0.9	26
1492	Consumption of NADPH for 2-HG Synthesis Increases Pentose Phosphate Pathway Flux and Sensitizes Cells to Oxidative Stress. Cell Reports, 2018, 22, 512-522.	2.9	74
1493	2-Hydroxyglutarate Detection by Short Echo Time Magnetic Resonance Spectroscopy in Routine Imaging Study of Brain Glioma at 3.0 T. Journal of Computer Assisted Tomography, 2018, 42, 469-474.	0.5	10
1494	Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis. Acta Neuropathologica, 2018, 135, 285-298.	3.9	10
1495	R132 mutations in canine isocitrate dehydrogenase 1 (IDH1) lead to functional changes. Veterinary Research Communications, 2018, 42, 49-56.	0.6	6
1496	Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 388-393.	1.0	15
1498	Optical Analysis of Glioma: Fourier-Transform Infrared Spectroscopy Reveals the IDH1 Mutation Status. Clinical Cancer Research, 2018, 24, 2530-2538.	3.2	27
1499	Eight Kinetically Stable but Thermodynamically Activated Molecules that Power Cell Metabolism. Chemical Reviews, 2018, 118, 1460-1494.	23.0	194
1500	Connections Between Metabolism and Epigenetics in Programming Cellular Differentiation. Annual Review of Immunology, 2018, 36, 221-246.	9.5	93
1501	A comparison of 2â€hydroxyglutarate detection at 3 and 7ÂT with longâ€TE semiâ€LASER. NMR in Biomedicine, 2018, 31, e3886.	1.6	25
1502	Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma. CNS Oncology, 2018, 7, 41-50.	1.2	10
1503	Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy. Neuro-Oncology, 2018, 20, 907-916.	0.6	72
1504	Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenaseâ€“mutated intrahepatic cholangiocarcinomas. European Journal of Cancer, 2018, 90, 83-91.	1.3	28
1505	Metabolomics and Isotope Tracing. Cell, 2018, 173, 822-837.	13.5	537
1506	Isocitrate dehydrogenase 1â€“snail axis dysfunction significantly correlates with breast cancer prognosis and regulates cell invasion ability. Breast Cancer Research, 2018, 20, 25.	2.2	31
1507	Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry. Acta Neuropathologica Communications, 2018, 6, 21.	2.4	28
1508	Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer. World Journal of Urology, 2018, 36, 877-882.	1.2	26

#	Article	IF	Citations
1509	Mechanism of N6-methyladenosine modification and its emerging role in cancer. , 2018, 189, 173-183.		31
1510	Steroids from Ganoderma sinense as new natural inhibitors of cancer-associated mutant IDH1. Bioorganic Chemistry, 2018, 79, 89-97.	2.0	13
1511	Mutant IDH1 Promotes Glioma Formation InÂVivo. Cell Reports, 2018, 23, 1553-1564.	2.9	91
1512	Synthesis and Evaluation of a ¹⁸F-Labeled Triazinediamine Analogue for Imaging Mutant IDH1 Expression in Gliomas by PET. ACS Medicinal Chemistry Letters, 2018, 9, 606-611.	1.3	17
1513	Applications of metabolomics to study cancer metabolism. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 2-14.	3.3	129
1514	Signaling Pathways Involved in the Regulation of mRNA Translation. Molecular and Cellular Biology, 2018, 38, .	1.1	236
1515	Insights into the Action of Inhibitor Enantiomers against Histone Lysine Demethylase 5A. Journal of Medicinal Chemistry, 2018, 61, 3193-3208.	2.9	9
1516	D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutantâ€“Induced MIR148A Promoter Methylation. Molecular Cancer Research, 2018, 16, 947-960.	1.5	8
1517	Pathologies liÃ©es aux dÃ©ficits du cycle de Krebs. Revue Francophone Des Laboratoires, 2018, 2018, 49-57.	0.0	1
1518	Mitochondria Remodeling in Cancer. , 2018, , 153-191.		0
1519	Mycoplasma infection and hypoxia initiate succinate accumulation and release in the VM-M3 cancer cells. Biochimica Et Biophysica Acta - Bioenergetics, 2018, 1859, 975-983.	0.5	24
1520	Loss of IDH2 Accelerates Age-related Hearing Loss in Male Mice. Scientific Reports, 2018, 8, 5039.	1.6	33
1521	The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer. Cell Cycle, 2018, 17, 702-711.	1.3	36
1522	The role of IDH mutations in acute myeloid leukemia. Future Oncology, 2018, 14, 979-993.	1.1	100
1523	Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1037-1047.	1.2	18
1524	Oncogenic IDH1 Mutations Promote Enhanced Proline Synthesis through PYCR1 to Support the Maintenance of Mitochondrial Redox Homeostasis. Cell Reports, 2018, 22, 3107-3114.	2.9	64
1525	Human Elongation Factor 4 Regulates Cancer Bioenergetics by Acting as a Mitochondrial Translation Switch. Cancer Research, 2018, 78, 2813-2824.	0.4	16
1526	Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma. Clinical Cancer Research, 2018, 24, 2951-2962.	3.2	25

#	Article	IF	Citations
1527	Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis. European Radiology, 2018, 28, 3779-3788.	2.3	58
1528	Radiomics, Metabolic, and Molecular MRI for Brain Tumors. Seminars in Neurology, 2018, 38, 032-040.	0.5	19
1529	Origin of Gliomas. Seminars in Neurology, 2018, 38, 005-010.	0.5	52
1530	What's New in Grade II and Grade III Gliomas?. Seminars in Neurology, 2018, 38, 041-049.	0.5	1
1531	New Directions in the Treatment of Glioblastoma. Seminars in Neurology, 2018, 38, 050-061.	0.5	33
1532	Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenaseâ€“mutant glioma. Journal of Neurosurgery, 2018, 130, 56-66.	0.9	14
1533	Validation of a routine gas chromatography mass spectrometry method for 2-hydroxyglutarate quantification in human serum as a screening tool for detection of idh mutations. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1083, 28-34.	1.2	11
1534	DNA hydroxymethylation of colorectal primary carcinoma and its association with survival. Journal of Surgical Oncology, 2018, 117, 1029-1037.	0.8	6
1535	Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer. Cancer Biology and Therapy, 2018, 19, 249-253.	1.5	18
1536	Hallmarks of Pulmonary Hypertension: Mesenchymal and Inflammatory Cell Metabolic Reprogramming. Antioxidants and Redox Signaling, 2018, 28, 230-250.	2.5	71
1537	The impact of structural biology in medicine illustrated with four case studies. Journal of Molecular Medicine, 2018, 96, 9-19.	1.7	7
1538	The emerging role and targetability of the TCA cycle in cancer metabolism. Protein and Cell, 2018, 9, 216-237.	4.8	345
1539	Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications. Neuro-Oncology, 2018, 20, 608-620.	0.6	194
1540	Regulation and Dysregulation of Chromosome Structure in Cancer. Annual Review of Cancer Biology, 2018, 2, 21-40.	2.3	26
1541	A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds. Redox Biology, 2018, 14, 316-327.	3.9	166
1542	Impact of DNA methylation programming on normal and pre-leukemic hematopoiesis. Seminars in Cancer Biology, 2018, 51, 89-100.	4.3	21
1543	Investigations on the role of a solvent tunnel in the Î±-ketoglutarate dependent oxygenase factor inhibiting HIF (FIH). Journal of Inorganic Biochemistry, 2018, 178, 63-69.	1.5	8
1544	Comparison between Short and Long Echo Time Magnetic Resonance Spectroscopic Imaging at 3T and 7T for Evaluating Brain Metabolites in Patients with Glioma. ACS Chemical Neuroscience, 2018, 9, 130-137.	1.7	17

#	Article	IF	Citations
1545	DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies. Oncogene, 2018, 37, 566-577.	2.6	65
1546	Metabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2018, 10, e1406.	6.6	70
1547	Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy. Neurosurgical Review, 2018, 41, 641-647.	1.2	18
1548	The role of TET-mediated DNA hydroxymethylation in prostate cancer. Molecular and Cellular Endocrinology, 2018, 462, 41-55.	1.6	15
1549	Echoâ€planar spectroscopic imaging with dualâ€readout alternated gradients (DRAGâ€EPSI) at 7 T: Application for 2â€hydroxyglutarate imaging in glioma patients. Magnetic Resonance in Medicine, 2018, 79, 1851-1861.	1.9	30
1550	Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas. , 2018, 182, 70-79.		25
1551	Biomarkers and therapeutic advances in glioblastoma multiforme. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 40-51.	0.7	120
1552	Neurological update: gliomas and other primary brain tumours in adults. Journal of Neurology, 2018, 265, 717-727.	1.8	24
1553	Glioma epigenetics: From subclassification to novel treatment options. Seminars in Cancer Biology, 2018, 51, 50-58.	4.3	377
1554	Enchondromatosis-associated oligodendroglioma: case report and literature review. Brain Tumor Pathology, 2018, 35, 36-40.	1.1	8
1555	R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling. Cell, 2018, 172, 90-105.e23.	13.5	794
1556	Familial Tumor Syndromes. , 2018, , 505-545.		5
1557	Contemporary management of high-grade gliomas. CNS Oncology, 2018, 7, 51-65.	1.2	32
1558	Intraventricular Glioblastoma Multiforme in A Child with L2-Hydroxyglutaric Aciduria. World Neurosurgery, 2018, 110, 288-290.	0.7	4
1559	Histone Mutations in Cancer. Annual Review of Cancer Biology, 2018, 2, 337-351.	2.3	23
1560	Chiral separation of disease biomarkers with 2â€hydroxycarboxylic acid structure. Journal of Separation Science, 2018, 41, 1224-1231.	1.3	16
1561	Reverse engineering the cancer metabolic network using flux analysis to understand drivers of human disease. Metabolic Engineering, 2018, 45, 95-108.	3.6	36
1562	Mitochondrial metabolism and cancer. Cell Research, 2018, 28, 265-280.	5.7	818

#	Article	IF	Citations
1563	Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities. Cancer Research, 2018, 78, 36-50.	0.4	35
1564	Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia. Future Oncology, 2018, 14, 23-40.	1.1	37
1565	Discovery of a novel class of pyridine derivatives that selectively inhibits mutant isocitrate dehydrogenase 2. Chemical Biology and Drug Design, 2018, 91, 1087-1093.	1.5	6
1566	Readers of DNA methylation, the MBD family as potential therapeutic targets. , 2018, 184, 98-111.		54
1567	Epigenetics in myelodysplastic syndromes. Seminars in Cancer Biology, 2018, 51, 170-179.	4.3	45
1568	The Synonymous Isocitrate Dehydrogenase 1 315C>T SNP Confers an Adverse Prognosis in Egyptian Adult Patients with NPM1-/CEBPA-Negative Acute Myeloid Leukemia. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 240-252.	0.3	3
1569	Mass Spectrometry-Based Method to Study Inhibitor-Induced Metabolic Redirection in the Central Metabolism of Cancer Cells. Mass Spectrometry, 2018, 7, A0067-A0067.	0.2	11
1571	The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas. Wspolczesna Onkologia, 2018, 22, 215-222.	0.7	23
1572	Systemic Therapies for Locally Recurrent or Metastatic Disease. , 2018, , 399-409.		0
1573	Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas. Current Opinion in Neurology, 2018, 31, 727-732.	1.8	6
1574	Mitochondrial Substrate-Level Phosphorylation as Energy Source for Glioblastoma: Review and Hypothesis. ASN Neuro, 2018, 10, 175909141881826.	1.5	80
1575	IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas. Medicine (United States), 2018, 97, e13675.	0.4	11
1576	Detection of IDH1 and IDH2 Mutation in Formalin-fixed Paraffin-embedded Gliomas Using Allele-specific COLD-PCR and Probe Melting Curve Analysis. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, e93-e100.	0.6	1
1577	Glyoxalase activity in human erythrocytes and mouse lymphoma, liver and brain probed with hyperpolarized 13C-methylglyoxal. Communications Biology, 2018, 1, 232.	2.0	8
1578	Oncogenic Metabolism Acts as a Prerequisite Step for Induction of Cancer Metastasis and Cancer Stem Cell Phenotype. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-28.	1.9	48
1579	Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas. Current Opinion in Oncology, 2018, 30, 368-374.	1.1	18
1580	A New Insight into the Development of Novel Anti-Cancer Drugs that Improve the Expression of Mitochondrial Function-Associated Genes. , 2018, , .		0
1581	Survivorship in Neuro-Oncology: Improving Care by Advancing Science. Neuro-Oncology, 2018, 20, NP-NP.	0.6	0

#	Article	IF	Citations
1582	Biological role of metabolic reprogramming of cancer cells during epithelialâ€'mesenchymal transition (Review). Oncology Reports, 2019, 41, 727-741.	1.2	15
1583	A Novel Bus Station Coding Method to Balance the Supply Ability and the Demand Attraction of Public Transit. , 2018, , .		0
1584	Updates in prognostic markers for gliomas. Neuro-Oncology, 2018, 20, vii17-vii26.	0.6	78
1585	GABA, glutamine, glutamate oxidation and succinic semialdehyde dehydrogenase expression in human gliomas. Journal of Experimental and Clinical Cancer Research, 2018, 37, 271.	3.5	22
1586	IDH1: Linking Metabolism and Epigenetics. Frontiers in Genetics, 2018, 9, 493.	1.1	53
1587	Cancer stem cell metabolism: target for cancer therapy. BMB Reports, 2018, 51, 319-326.	1.1	120
1588	Molecular landscape and targeted therapy of acute myeloid leukemia. Biomarker Research, 2018, 6, 32.	2.8	24
1589	Metabolic regulation of infection and inflammation. Cytokine, 2018, 112, 1-11.	1.4	28
1590	The 2016 World Health Organization classification of tumours of the central nervous system. Presse Medicale, 2018, 47, e187-e200.	0.8	75
1591	The clinical use of IDH1 and IDH2 mutations in gliomas. Expert Review of Molecular Diagnostics, 2018, 18, 1041-1051.	1.5	34
1592	The Influence of Metabolism on Drug Response in Cancer. Frontiers in Oncology, 2018, 8, 500.	1.3	182
1593	Cerebrospinal fluid untargeted metabolomic profiling of aneurysmal subarachnoid hemorrhage: an exploratory study. British Journal of Neurosurgery, 2018, 32, 637-641.	0.4	15
1594	Spectral Comparison of Pass-By Traffic Noise. , 2018, , .		2
1595	Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy. OncoTargets and Therapy, 2019, Volume 12, 303-308.	1.0	13
1596	The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the Î²-catenin/SIRT3 signaling pathway in cervical cancer. Journal of Hematology and Oncology, 2018, 11, 139.	6.9	65
1597	Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies. Frontiers in Oncology, 2018, 8, 556.	1.3	67
1598	Future of Enzymology: An Appraisal. , 2018, , 521-551.		0
1599	CDK7 inhibition is a novel therapeutic strategy against GBM both in vitro and in vivo. Cancer Management and Research, 2018, Volume 10, 5747-5758.	0.9	29

#	Article	IF	Citations
1601	Metabolic control of PPAR activity by aldehyde dehydrogenase regulates invasive cell behavior and predicts survival in hepatocellular and renal clear cell carcinoma. BMC Cancer, 2018, 18, 1180.	1.1	22
1602	IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme. Oncotarget, 2018, 9, 16462-16476.	0.8	17
1603	The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nature Reviews Cancer, 2018, 18, 696-705.	12.8	1,059
1604	Cyclin F-Dependent Degradation of RBPJ Inhibits IDH1R132H-Mediated Tumorigenesis. Cancer Research, 2018, 78, 6386-6398.	0.4	24
1605	Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants. Biochemical Journal, 2018, 475, 3221-3238.	1.7	10
1606	Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma. International Journal of Molecular Sciences, 2018, 19, 2903.	1.8	30
1607	Salivary metabolite profiling distinguishes patients with oral cavity squamous cell carcinoma from normal controls. PLoS ONE, 2018, 13, e0204249.	1.1	62
1608	900MHz 1H-/13C-NMR analysis of 2-hydroxyglutarate and other brain metabolites in human brain tumor tissue extracts. PLoS ONE, 2018, 13, e0203379.	1.1	8
1609	Molecular Drivers in Chondrosarcoma. , 2018, , 31-41.		0
1610	Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the <scp>BET</scp> inhibitor <scp>JQ</scp>1. Cancer Science, 2018, 109, 3602-3610.	1.7	17
1611	Protein interaction and functional data indicate MTHFD2 involvement in RNA processing and translation. Cancer & Metabolism, 2018, 6, 12.	2.4	32
1612	Application of Metabolomics in Cancer Research: As a Powerful Tool to Screen Biomarker for Diagnosis, Monitoring and Prognosis of Cancer. Biomarkers Journal, 2018, 01, .	0.2	15
1613	Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas. Cancer Genomics and Proteomics, 2018, 15, 421-436.	1.0	9
1614	An improved method for extraction of polar and charged metabolites from cyanobacteria. PLoS ONE, 2018, 13, e0204273.	1.1	31
1615	Stable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2018, 19, 3325.	1.8	46
1616	Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate. Journal of Biological Chemistry, 2018, 293, 20051-20061.	1.6	11
1617	Methylation dependent down-regulation of G0S2 leads to suppression of invasion and improved prognosis of IDH1-mutant glioma. PLoS ONE, 2018, 13, e0206552.	1.1	8
1618	Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects. Pharmacology Research and Perspectives, 2018, 6, e00436.	1.1	10

#	Article	IF	Citations
1619	Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Cells. Cell Reports, 2018, 25, 1018-1026.e4.	2.9	56
1620	Selective Usage of Isozymes for Stress Response. ACS Chemical Biology, 2018, 13, 3059-3064.	1.6	7
1621	Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. Cancer Discovery, 2018, 8, 1540-1547.	7.7	138
1622	IDH1 mutation promotes lung cancer cell proliferation through methylation of Fibulin-5. Open Biology, 2018, 8, .	1.5	10
1623	The Ins and Outs of Autophagy and Metabolism in Hematopoietic and Leukemic Stem Cells: Food for Thought. Frontiers in Cell and Developmental Biology, 2018, 6, 120.	1.8	17
1624	Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene U2af1. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10437-E10446.	3.3	59
1625	Potent immunosuppressive effects of the oncometaboliteR-2-hydroxyglutarate. OncoImmunology, 2018, 7, e1528815.	2.1	16
1626	Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets. Frontiers in Genetics, 2018, 9, 427.	1.1	88
1627	T Cellâ€“Inflamed versus Non-T Cellâ€“Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunology Research, 2018, 6, 990-1000.	1.6	297
1628	Association between IDH1/2 mutations and brain glioma grade. Oncology Letters, 2018, 16, 5405-5409.	0.8	31
1629	Using genomics to guide treatment for glioblastoma. Pharmacogenomics, 2018, 19, 1217-1229.	0.6	10
1630	Reciprocal Regulation of Metabolic Reprogramming and Epigenetic Modifications in Cancer. Frontiers in Genetics, 2018, 9, 394.	1.1	46
1631	Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell, 2018, 175, 101-116.e25.	13.5	234
1632	IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma. Journal of Cancer, 2018, 9, 998-1005.	1.2	50
1633			

#	Article	IF	Citations
1637	Increased glutarate production by blocking the glutaryl-CoA dehydrogenation pathway and a catabolic pathway involving l-2-hydroxyglutarate. Nature Communications, 2018, 9, 2114.	5.8	48
1638	Metabolic regulation of chromatin modifications and gene expression. Journal of Cell Biology, 2018, 217, 2247-2259.	2.3	163
1639	Targeting the IDH2 Pathway in Acute Myeloid Leukemia. Clinical Cancer Research, 2018, 24, 4931-4936.	3.2	28
1640	Biological Role and Therapeutic Potential of IDH Mutations in Cancer. Cancer Cell, 2018, 34, 186-195.	7.7	234
1641	IDH1 mutation in human glioma induces chemical alterations that are amenable to optical Raman spectroscopy. Journal of Neuro-Oncology, 2018, 139, 261-268.	1.4	35
1642	Cellular Metabolism and Aging. Progress in Molecular Biology and Translational Science, 2018, 155, 85-107.	0.9	33
1643	Diffuse Gliomas for Nonneuropathologists: The New Integrated Molecular Diagnostics. Archives of Pathology and Laboratory Medicine, 2018, 142, 804-814.	1.2	22
1644	Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective. Journal of Medicinal Chemistry, 2018, 61, 8981-9003.	2.9	23
1645	Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations. Endocrine, 2018, 61, 216-223.	1.1	7
1646	Durable Remissions with Ivosidenib inIDH1-Mutated Relapsed or Refractory AML. New England Journal of Medicine, 2018, 378, 2386-2398.	13.9	1,092
1647	The post-surgical era of GBM: How molecular biology has impacted on our clinical management. A review. Clinical Neurology and Neurosurgery, 2018, 170, 120-126.	0.6	26
1648	Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways. BioMed Research International, 2018, 2018, 1-15.	0.9	45
1649	Cancer-associated 2-oxoglutarate analogues modify histone methylation by inhibiting histone lysine demethylases. Journal of Molecular Biology, 2018, 430, 3081-3092.	2.0	43
1650	IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC. Journal of Surgical Research, 2018, 231, 116-125.	0.8	13
1651	Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and redox capacity. , 2018, 191, 148-161.		24
1652	Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature, 2018, 559, 125-129.	13.7	223
1653	The Heterogeneity of Cancer Metabolism. Advances in Experimental Medicine and Biology, 2018, , .	0.8	7
1654	The Multifaceted Metabolism of Glioblastoma. Advances in Experimental Medicine and Biology, 2018, 1063, 59-72.	0.8	23

#	Article	IF	Citations
1655	An Overview of Molecular Genetics of Brain Tumors. , 2018, , 249-255.		1
1656	Chemotherapy of Pediatric High-Grade Gliomas. , 2018, , 557-568.		0
1657	The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia. Therapeutic Advances in Hematology, 2018, 9, 163-173.	1.1	50
1658	Glutamine Metabolism in Cancer. Advances in Experimental Medicine and Biology, 2018, 1063, 13-32.	0.8	153
1659	The Role of Advanced Brain Tumor Imaging in the Care of Patients with Central Nervous System Malignancies. Current Treatment Options in Oncology, 2018, 19, 40.	1.3	7
1660	Predictive Value of Epigenetic Signatures. , 2018, , 275-311.		0
1661	MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status. Disease Markers, 2018, 2018, 1-8.	0.6	9
1662	IDH1â€mutant cancer cells are sensitive to cisplatin and an IDH1â€mutant inhibitor counteracts this sensitivity. FASEB Journal, 2018, 32, 6344-6352.	0.2	28
1663	Cancerâ€associated thrombosis: The search for the holy grail continues. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 622-629.	1.0	21
1664	Identification of serum biomarkers of chemoradiosensitivity in esophageal cancer via the targeted metabolomics approach. Biomarkers in Medicine, 2018, 12, 827-840.	0.6	15
1665	Computational approach to unravel the impact of missense mutations of proteins (D2HGDH and IDH2) causing D-2-hydroxyglutaric aciduria 2. Metabolic Brain Disease, 2018, 33, 1699-1710.	1.4	38
1666	The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas. Frontiers in Molecular Neuroscience, 2018, 11, 82.	1.4	61
1667	The Mitochondrial Citrate Carrier (SLC25A1) Sustains Redox Homeostasis and Mitochondrial Metabolism Supporting Radioresistance of Cancer Cells With Tolerance to Cycling Severe Hypoxia. Frontiers in Oncology, 2018, 8, 170.	1.3	54
1668	Metabolic Alterations in Cancer Cells and the Emerging Role of Oncometabolites as Drivers of Neoplastic Change. Antioxidants, 2018, 7, 16.	2.2	27
1669	Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies. Cancers, 2018, 10, 49.	1.7	31
1670	Elucidating the Metabolic Plasticity of Cancer: Mitochondrial Reprogramming and Hybrid Metabolic States. Cells, 2018, 7, 21.	1.8	167
1671	Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nature Medicine, 2018, 24, 1192-1203.	15.2	359
1672	Metabolic Regulation of Hypoxia-Inducible Transcription Factors: The Role of Small Molecule Metabolites and Iron. Biomedicines, 2018, 6, 60.	1.4	32

#	Article	IF	Citations
1673	Clinical and immunological correlates of long term survival in glioblastoma. Wspolczesna Onkologia, 2018, 2018, 81-85.	0.7	15
1674	Isocitrate dehydrogenase 1 mutations in melanoma frequently coâ€•occur with NRAS mutations. Histopathology, 2018, 73, 963-968.	1.6	15
1675	D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells. Clinical Cancer Research, 2018, 24, 5381-5391.	3.2	55
1676	The metabolic axis of macrophage and immune cell polarization. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	46
1677	Comparison of glioblastoma (GBM) molecular classification methods. Seminars in Cancer Biology, 2018, 53, 201-211.	4.3	125
1678	Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations. Cancers, 2018, 10, 187.	1.7	27
1679	Metabolic recoding of epigenetics in cancer. Cancer Communications, 2018, 38, 1-8.	3.7	74
1680	Metabolism and Transcription in Cancer: Merging Two Classic Tales. Frontiers in Cell and Developmental Biology, 2017, 5, 119.	1.8	35
1681	Metabolomics of oncogene-specific metabolic reprogramming during breast cancer. Cancer & Metabolism, 2018, 6, 5.	2.4	35
1682	Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities. Cancer & Metabolism, 2018, 6, 4.	2.4	55
1683	Pheochromocytoma/Paraganglioma: A Poster Child for Cancer Metabolism. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1779-1789.	1.8	5
1684	Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation. Cancer Letters, 2018, 429, 1-10.	3.2	14
1685	Seizures at presentation are correlated with better survival outcomes in adult diffuse glioma: A systematic review and meta-analysis. Seizure: the Journal of the British Epilepsy Association, 2018, 59, 16-23.	0.9	24
1686	IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53. Journal of Biological Chemistry, 2018, 293, 9747-9758.	1.6	20
1687	IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis. PLoS ONE, 2018, 13, e0199737.	1.1	4
1688	Gene Expression Integration into Pathway Modules Reveals a Pan-Cancer Metabolic Landscape. Cancer Research, 2018, 78, 6059-6072.	0.4	40
1689	Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2. Biochemical and Biophysical Research Communications, 2018, 503, 2912-2917.	1.0	51
1690	Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer. Clinical Cancer Research, 2018, 24, 6433-6446.	3.2	54

#	Article	IF	Citations
1691	3â€(7â€Azaindolyl)â€4â€indolylmaleimides as a novel class of mutant isocitrate dehydrogenaseâ€1 inhibitors: Design, synthesis, and biological evaluation. Archiv Der Pharmazie, 2018, 351, e1800039.	2.1	7
1692	Inhibition of a K9/K36 demethylase by an H3.3 point mutation found in paediatric glioblastoma. Nature Communications, 2018, 9, 3142.	5.8	49
1693	Cerebrospinal fluid biomarkers of malignancies located in the central nervous system. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 146, 139-169.	1.0	16
1694	Correlation of IDH1 and B7 H3 expression with prognosis of CRC patients. European Journal of Surgical Oncology, 2018, 44, 1254-1260.	0.5	26
1695	MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas. Neurologia Medico-Chirurgica, 2018, 58, 290-295.	1.0	29
1696	Metabolic changes in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 327-337.	0.8	43
1697	Isocitrate dehydrogenase 1â€“mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress. FASEB Journal, 2019, 33, 557-571.	0.2	33
1698	Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. Genetics in Medicine, 2019, 21, 705-717.	1.1	60
1699	Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical Implications. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a030445.	2.9	33
1700	Genetic and epigenetic determinants of AML pathogenesis. Seminars in Hematology, 2019, 56, 84-89.	1.8	65
1701	Epigenome modifiers and metabolic rewiring: New frontiers in therapeutics. , 2019, 193, 178-193.		13
1702	DNA methylation as a transcriptional regulator of the immune system. Translational Research, 2019, 204, 1-18.	2.2	102
1703	Reprogramming the Epigenome With Vitamin C. Frontiers in Cell and Developmental Biology, 2019, 7, 128.	1.8	86
1704	Melanomics: Comprehensive Molecular Analysis of Normal and Neoplastic Melanocytes. , 2019, , 181-224.		0
1705	Genetic and Epigenetic Profiling in Personalized Medicine: Advances in Treatment of Acute Myeloid Leukemia. Europeanization and Globalization, 2019, , 341-374.	0.1	0
1706	Mutant IDH Sensitizes Gliomas to Endoplasmic Reticulum Stress and Triggers Apoptosis via miR-183-Mediated Inhibition of Semaphorin 3E. Cancer Research, 2019, 79, 4994-5007.	0.4	28
1707	3D Chromosomal Landscapes in Hematopoiesis and Immunity. Trends in Immunology, 2019, 40, 809-824.	2.9	21
1708	Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic 18F-FET PET. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2581-2589.	3.3	34

#	Article	IF	Citations
1709	Metabolomics for Investigating Physiological and Pathophysiological Processes. Physiological Reviews, 2019, 99, 1819-1875.	13.1	516
1710	Personalized Medicine in Healthcare Systems. Europeanization and Globalization, 2019, , .	0.1	2
1711	The epigenomic impact of methylation in metabolic dysfunction and cancer. , 2019, , 67-83.		1
1712	Diffuse Astrocytoma and Oligodendroglioma: An Integrated Diagnosis and Management. , 2019, , .		0
1713	Spatial Regulation of Mitochondrial Heterogeneity by Stromal Confinement in Micropatterned Tumor Models. Scientific Reports, 2019, 9, 11187.	1.6	15
1714	IDH1 fine-tunes cap-dependent translation initiation. Journal of Molecular Cell Biology, 2019, 11, 816-828.	1.5	3
1715	Metabolomics in the Diagnosis of Pheochromocytoma and Paraganglioma. Hormone and Metabolic Research, 2019, 51, 443-450.	0.7	9
1716	Global DNA Methylation Patterns in Human Gliomas and Their Interplay with Other Epigenetic Modifications. International Journal of Molecular Sciences, 2019, 20, 3478.	1.8	35
1717	Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia. BMC Biology, 2019, 17, 57.	1.7	31
1718	Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. The Lancet Gastroenterology and Hepatology, 2019, 4, 711-720.	3.7	161
1719	Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development. Frontiers in Oncology, 2019, 9, 506.	1.3	102
1720	Comprehensive Metabolomic Analysis of IDH1R132H Clinical Glioma Samples Reveals Suppression of Î²-oxidation Due to Carnitine Deficiency. Scientific Reports, 2019, 9, 9787.	1.6	23
1721	Super-enhancers: critical roles and therapeutic targets in hematologic malignancies. Journal of Hematology and Oncology, 2019, 12, 77.	6.9	69
1722	Leukemia Stem Cells in Hematologic Malignancies. Advances in Experimental Medicine and Biology, 2019, , .	0.8	1
1723	Molecular Underpinnings Governing Genetic Complexity of ETS-Fusion-Negative Prostate Cancer. Trends in Molecular Medicine, 2019, 25, 1024-1038.	3.5	10
1724	Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions. Current Hematologic Malignancy Reports, 2019, 14, 386-394.	1.2	34
1725	Precision oncology in Latin America: current situation, challenges and perspectives. Ecancermedicalscience, 2019, 13, 920.	0.6	11
1726	Radiosensitization and a Less Aggressive Phenotype of Human Malignant Glioma Cells Expressing Isocitrate Dehydrogenase 1 (IDH1) Mutant Protein: Dissecting the Mechanisms. Cancers, 2019, 11, 889.	1.7	17

#	Article	IF	Citations
1727	Lack of B and T cell reactivity towards IDH1R132H in blood and tumor tissue from LGG patients. Journal of Neuro-Oncology, 2019, 144, 79-87.	1.4	11
1728	Molecular Therapy for Oligodendrogliomas. , 2019, , 359-366.		0
1729	Genetic investigation of childhood vascular tumor biology reveals pathways for therapeutic intervention. F1000Research, 2019, 8, 590.	0.8	6
1730	Evidence of Neutral Evolution of Mitochondrial DNA in Human Hepatocellular Carcinoma. Genome Biology and Evolution, 2019, 11, 2909-2916.	1.1	3
1731	Friend or foeâ€"IDH1 mutations in glioma 10 years on. Carcinogenesis, 2019, 40, 1299-1307.	1.3	58
1732	Isocitrate dehydrogenase inhibitors in acute myeloid leukemia. Biomarker Research, 2019, 7, 22.	2.8	73
1733	La mÃ©tabolomique : applications mÃ©dicales. Medecine Des Maladies Metaboliques, 2019, 13, 263-267.	0.1	0
1734	Metabolic dependencies and vulnerabilities in leukemia. Genes and Development, 2019, 33, 1460-1474.	2.7	63
1735	Increased 14C-acetate accumulation in IDH-mutated human glioblastoma: implications for detecting IDH-mutated glioblastoma with 11C-acetate PET imaging. Journal of Neuro-Oncology, 2019, 145, 441-447.	1.4	8
1736	The Transsulfuration Pathway Makes, the Tumor Takes. Cell Metabolism, 2019, 30, 845-846.	7.2	12
1737	Glutamine Metabolism in Brain Tumors. Cancers, 2019, 11, 1628.	1.7	53
1738	Pharmacological characterization of <scp>TQ</scp>05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants. Cancer Science, 2019, 110, 3306-3314.	1.7	13
1739	Detection Of Mutations In The Isocitrate Dehydrogenase Genes (IDH1/IDH2) Using castPCR^{TM} In Patients With AML And Their Clinical Impact In Mexico City . OncoTargets and Therapy, 2019, Volume 12, 8023-8031.	1.0	3
1740	Microenvironmental Heterogeneity in Brain Malignancies. Frontiers in Immunology, 2019, 10, 2294.	2.2	78
1741	Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma. International Journal of Molecular Sciences, 2019, 20, 200.	1.8	30
1742	Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance. Cancers, 2019, 11, 1231.	1.7	90
1743	Targeting Metabolic Reprogramming in Acute Myeloid Leukemia. Cells, 2019, 8, 967.	1.8	43
1744	Prognostic implications of IDH1rs11554137 and IDH2R140Q SNPs mutations in cytogenetically normal acute myeloid leukemia. Egyptian Journal of Medical Human Genetics, 2019, 20, .	0.5	1

#	Article	IF	Citations
1745	Rapid intraoperative molecular genetic classification of gliomas using Raman spectroscopy. Neuro-Oncology Advances, 2019, 1, vdz008.	0.4	27
1746	Tumor Metabolism as a Regulator of Tumorâ€“Host Interactions in the B-Cell Lymphoma Microenvironmentâ€”Fueling Progression and Novel Brakes for Therapy. International Journal of Molecular Sciences, 2019, 20, 4158.	1.8	14
1747	Intricacies in the cross talk between metabolic enzymes, RNA, and protein translation. Journal of Molecular Cell Biology, 2019, 11, 813-815.	1.5	6
1748	Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production. Oncotarget, 2019, 10, 2675-2692.	0.8	13
1749	Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies. Blood, 2019, 134, 1487-1497.	0.6	95
1750	Mechanisms and Implications of Metabolic Heterogeneity in Cancer. Cell Metabolism, 2019, 30, 434-446.	7.2	355
1751	Transient-State Analysis of Human Isocitrate Dehydrogenase I: Accounting for the Interconversion of Active and Non-Active Conformational States. Biochemistry, 2019, 58, 5366-5380.	1.2	10
1752	Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. Journal of Gastrointestinal Oncology, 2019, 10, 751-765.	0.6	105
1753	Understanding Cancer Through the Lens of Epigenetic Inheritance, Allele-Specific Gene Expression, and High-Throughput Technology. Frontiers in Oncology, 2019, 9, 794.	1.3	10
1754	Detection of chromosome-mediated tet(X4)-carrying Aeromonas caviae in a sewage sample from a chicken farm. Journal of Antimicrobial Chemotherapy, 2019, 74, 3628-3630.	1.3	27
1755	Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration. European Journal of Medicinal Chemistry, 2019, 183, 111694.	2.6	9
1756	Chemical toolbox for â€˜liveâ€™ biochemistry to understand enzymatic functions in living systems. Journal of Biochemistry, 2019, 167, 139-149.	0.9	2
1757	Warburg and Krebs and related effects in cancer. Expert Reviews in Molecular Medicine, 2019, 21, e4.	1.6	22
1758	Novel management of glioma by molecular therapies, a review article. European Journal of Translational Myology, 2019, 29, 8209.	0.8	12
1759	Family-wide Annotation of Enzymatic Pathways by Parallel InÂVivo Metabolomics. Cell Chemical Biology, 2019, 26, 1623-1629.e3.	2.5	15
1760	PPARÎ± agonist alleviates tumor growth and chemo-resistance associated with the inhibition of glucose metabolic pathway. European Journal of Pharmacology, 2019, 863, 172664.	1.7	9
1761	Tunable enzyme responses in amphiphilic nanoassemblies through alterations in the unimerâ€“aggregate equilibrium. Chemical Science, 2019, 10, 3018-3024.	3.7	18
1762	In-Cell NMR: Analysis of Proteinâ€“Small Molecule Interactions, Metabolic Processes, and Protein Phosphorylation. International Journal of Molecular Sciences, 2019, 20, 378.	1.8	14

#	Article	IF	Citations
1763	Detection of Metabolic Changes Induced via Drug Treatments in Live Cancer Cells and Tissue Using Raman Imaging Microscopy. Biosensors, 2019, 9, 5.	2.3	11
1764	Alternol eliminates excessive ATP production by disturbing Krebs cycle in prostate cancer. Prostate, 2019, 79, 628-639.	1.2	27
1765	Insight into novel RNA-binding activities via large-scale analysis of lncRNA-bound proteome and IDH1-bound transcriptome. Nucleic Acids Research, 2019, 47, 2244-2262.	6.5	29
1766	Rapid determination of isocitrate dehydrogenase mutation status of human gliomas by extraction nanoelectrospray using a miniature mass spectrometer. Analytical and Bioanalytical Chemistry, 2019, 411, 1503-1508.	1.9	18
1767	Control of the Antitumor Immune Response by Cancer Metabolism. Cells, 2019, 8, 104.	1.8	50
1768	Metabolic Regulation of the Epitranscriptome. ACS Chemical Biology, 2019, 14, 316-324.	1.6	19
1769	Isocitrate dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients . Cancer Management and Research, 2019, Volume 11, 3227-3236.	0.9	17
1770	Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics. Frontiers in Oncology, 2019, 9, 417.	1.3	183
1771	Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease. Science Advances, 2019, 5, eaaw4543.	4.7	98
1772	Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate. Cancer & Metabolism, 2019, 7, 4.	2.4	18
1773	Increasing consensus of context-specific metabolic models by integrating data-inferred cell functions. PLoS Computational Biology, 2019, 15, e1006867.	1.5	61
1774	Functional analysis and clinical significance of the isocitrate dehydrogenase 2 gene in papillary thyroid carcinoma . Cancer Management and Research, 2019, Volume 11, 3765-3777.	0.9	5
1775	Circulating MACC1 Transcripts in Glioblastoma Patients Predict Prognosis and Treatment Response. Cancers, 2019, 11, 825.	1.7	7
1776	Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma. Academic Pathology, 2019, 6, 2374289519848353.	0.7	21
1777	Abundance of d â€2â€hydroxyglutarate in G2/M is determined by FOXM1 in mutant IDH1â€expressing cells. FEBS Letters, 2019, 593, 2177-2193.	1.3	11
1778	The novel nonâ€immunological role and underlying mechanisms of B7â€H3 in tumorigenesis. Journal of Cellular Physiology, 2019, 234, 21785-21795.	2.0	20
1779	The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism. Experimental and Molecular Medicine, 2019, 51, 1-17.	3.2	118
1780	MET in glioma: signaling pathways and targeted therapies. Journal of Experimental and Clinical Cancer Research, 2019, 38, 270.	3.5	99

#	Article	IF	Citations
1781	Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers. Scientific Reports, 2019, 9, 8946.	1.6	44
1782	Sulfur metabolism and its contribution to malignancy. International Review of Cell and Molecular Biology, 2019, 347, 39-103.	1.6	40
1783	Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. Cancer & Metabolism, 2019, 7, 6.	2.4	51
1784	Emerging Applications of Metabolomics in Clinical Pharmacology. Clinical Pharmacology and Therapeutics, 2019, 106, 544-556.	2.3	73
1785	Imaging of Central Nervous System Tumors. , 2019, , 111-142.		0
1786	Connections between metabolism and epigenetics in cancers. Seminars in Cancer Biology, 2019, 57, 52-58.	4.3	109
1787	2-hydroxyglutarate inhibits MyoD-mediated differentiation by preventing H3K9 demethylation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 12851-12856.	3.3	28
1788	Detection of glioma by surfaceâ€enhanced Raman scattering spectra with optimized mathematical methods. Journal of Raman Spectroscopy, 2019, 50, 1130-1140.	1.2	10
1789	Prediction of IDH genotype in gliomas with dynamic susceptibility contrast perfusion MR imaging using an explainable recurrent neural network. Neuro-Oncology, 2019, 21, 1197-1209.	0.6	80
1790	Differentiation of 2â€hydroxyglutarate enantiomers and its lactones by gas chromatography/electron ionization tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2019, 33, 1401-1409.	0.7	2
1791	Metformin inhibits PPARÎ´ agonist-mediated tumor growth by reducing Glut1 and SLC1A5 expressions of cancer cells. European Journal of Pharmacology, 2019, 857, 172425.	1.7	18
1792	Kinase Networks Regulate Metabolism: I'D(H1) Never Have Guessed!. Cancer Discovery, 2019, 9, 699-701.	7.7	0
1793	IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells. International Journal of Molecular Sciences, 2019, 20, 2679.	1.8	14
1794	Tumor Biology. , 2019, , 143-152.		0
1795	Podoplanin Expression and IDH-Wildtype Status Predict Venous Thromboembolism in Patients with High-Grade Gliomas in the Early Postoperative Period. World Neurosurgery, 2019, 128, e982-e988.	0.7	20
1796	Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 6575-6596.	2.9	25
1797	Metabolic remodeling contributes towards an immune-suppressive phenotype in glioblastoma. Cancer Immunology, Immunotherapy, 2019, 68, 1107-1120.	2.0	37
1798	The landscape of cancer cell line metabolism. Nature Medicine, 2019, 25, 850-860.	15.2	350

#	Article	IF	Citations
1799	Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects. European Journal of Clinical Pharmacology, 2019, 75, 1099-1108.	0.8	28
1800	Malignant Transformation of a Rosette-Forming Glioneuronal Tumor with IDH1 Mutation: A Case Report and Literature Review. World Neurosurgery: X, 2019, 2, 100006.	0.6	10
1801	Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. Neuro-Oncology, 2019, 21, 1184-1196.	0.6	28
1802	Novel Therapeutics Affecting Metabolic Pathways. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e79-e87.	1.8	9
1803	Imaging of cancer lipid metabolism in response to therapy. NMR in Biomedicine, 2019, 32, e4070.	1.6	10
1804	Tumorigenesis and Metabolism Disorder. , 2019, , 209-250.		0
1805	Tissue Factor and Cancer: Regulation, Tumor Growth, and Metastasis. Seminars in Thrombosis and Hemostasis, 2019, 45, 385-395.	1.5	94
1806	Degradation of D-2-hydroxyglutarate in the presence of isocitrate dehydrogenase mutations. Scientific Reports, 2019, 9, 7436.	1.6	7
1807	The oncometabolite 2-hydroxyglutarate inhibits microglial activation via the AMPK/mTOR/NF-Î²B pathway. Acta Pharmacologica Sinica, 2019, 40, 1292-1302.	2.8	46
1808	Immunometabolism: A new target for improving cancer immunotherapy. Advances in Cancer Research, 2019, 143, 195-253.	1.9	30
1809	The small members of the JMJD protein family: Enzymatic jewels or jinxes?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 406-418.	3.3	36
1810	An integrated genomic and metabolomic approach for defining survival time in adult oligodendrogliomas patients. Metabolomics, 2019, 15, 69.	1.4	5
1811	Functional Assessment of Lipoyltransferase-1 Deficiency in Cells, Mice, and Humans. Cell Reports, 2019, 27, 1376-1386.e6.	2.9	55
1812	Wild-Type IDH Enzymes as Actionable Targets for Cancer Therapy. Cancers, 2019, 11, 563.	1.7	38
1813	Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. Biochemical Pharmacology, 2019, 167, 133-148.	2.0	19
1814	Glioblastoma Stem-Like Cells, Metabolic Strategy to Kill a Challenging Target. Frontiers in Oncology, 2019, 9, 118.	1.3	98
1815	Characterization of the nicotinamide adenine dinucleotides (NAD+ and NADP+) binding sites of the monomeric isocitrate dehydrogenases from Campylobacter species. Biochimie, 2019, 160, 148-155.	1.3	4
1816	Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nature Medicine, 2019, 25, 403-418.	15.2	297

#	Article	IF	Citations
1817	In Silico Modeling of FDA-Approved Drugs for Discovery of Anticancer Agents: A Drug-Repurposing Approach. , 2019, , 527-548.		0
1818	Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism. Cancers, 2019, 11, 260.	1.7	28
1819	Hypoxia/pseudohypoxiaâ€mediated activation of hypoxiaâ€inducible factorâ€1Î± in cancer. Cancer Science, 2019, 110, 1510-1517.	1.7	143
1820	The Analysis of Risk Factors and Survival Outcome for Chinese Patients with Epilepsy with High-Grade Glioma. World Neurosurgery, 2019, 125, e947-e957.	0.7	8
1821	In vivo investigation of hyperpolarized [1,3-13C2]acetoacetate as a metabolic probe in normal brain and in glioma. Scientific Reports, 2019, 9, 3402.	1.6	12
1822	Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma. Frontiers in Oncology, 2019, 8, 656.	1.3	32
1823	Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. Cancer Discovery, 2019, 9, 756-777.	7.7	18
1824	Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity. Frontiers in Genetics, 2019, 10, 133.	1.1	58
1825	New drugs creating new challenges in acute myeloid leukemia. Genes Chromosomes and Cancer, 2019, 58, 903-914.	1.5	39
1826	Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins. Molecules, 2019, 24, 968.	1.7	72
1827	Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications. Leukemia and Lymphoma, 2019, 60, 2635-2645.	0.6	6
1828	Oncometabolites in cancer aggressiveness and tumour repopulation. Biological Reviews, 2019, 94, 1530-1546.	4.7	33
1829	Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis. Technology in Cancer Research and Treatment, 2019, 18, 153303381982839.	0.8	5
1830	3D-QSAR, molecular docking and molecular dynamics simulations study of 3-pyrimidin-4-yl-oxazolidin-2-one derivatives to explore the structure requirements of mutant IDH1 inhibitors. Journal of Molecular Structure, 2019, 1189, 187-202.	1.8	7
1831	On Artemisinin, Cyclopamine, D-Isocitric acid, Hyperforin, Epigenetics, Sialic Acid, and More. Synlett, 2019, 30, 1401-1418.	1.0	5
1832	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. Neuro-Oncology, 2019, 21, 837-853.	0.6	66
1833	Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia, 2019, 33, 2575-2584.	3.3	164
1834	Prognostic Role of Chicken Ovalbumin Upstream Promoter Transcription Factor II in Isocitrate Dehydrogenase-Mutant Glioma with 1p19q Co-Deletion. Journal of Molecular Neuroscience, 2019, 68, 234-242.	1.1	4

#	Article	IF	Citations
1835	Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas. American Journal of Human Genetics, 2019, 104, 651-664.	2.6	51
1836	Ivosidenib in relapsed or refractory acute myeloid leukemia: a profile of its use in the USA. Drugs and Therapy Perspectives, 2019, 35, 160-166.	0.3	1
1837	Imaging in Neuro-Oncology. , 2019, , 53-68.		1
1838	Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway. Journal of Bone Oncology, 2019, 15, 100222.	1.0	14
1839	Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy. Neuro-Oncology, 2019, 21, 765-774.	0.6	51
1840	Generation of Highly Productive Chinese Hamster Ovary Cells by Application of Metabolic Pool Selection During Cell Line Development. Current Biotechnology, 2019, 7, 355-367.	0.2	0
1841	Metabolic Profiling of Live Cancer Tissues Using NAD(P)H Fluorescence Lifetime Imaging. Methods in Molecular Biology, 2019, 1928, 365-387.	0.4	8
1842	Exploring the molecular interface between hypoxia-inducible factor signalling and mitochondria. Cellular and Molecular Life Sciences, 2019, 76, 1759-1777.	2.4	147
1843	High-resolution metabolic mapping of gliomas via patch-based super-resolution magnetic resonance spectroscopic imaging at 7T. NeuroImage, 2019, 191, 587-595.	2.1	33
1844	DNA demethylation is associated with malignant progression of lower-grade gliomas. Scientific Reports, 2019, 9, 1903.	1.6	31
1845	Synthesis and biological evaluation of anthraquinone derivatives as allosteric phosphoglycerate mutase 1 inhibitors for cancer treatment. European Journal of Medicinal Chemistry, 2019, 168, 45-57.	2.6	25
1846	Mass Spectrometry-Based Profiling of Metabolites in Human Biofluids. Methods in Molecular Biology, 2019, 1928, 205-234.	0.4	0
1847	Metabolic signatures of cancer cells and stem cells. Nature Metabolism, 2019, 1, 177-188.	5.1	215
1848	Progress in the problem of relapsed or refractory acute myeloid leukemia. Current Opinion in Hematology, 2019, 26, 88-95.	1.2	17
1850	Tissue 2-Hydroxyglutarate as a Biomarker for Isocitrate Dehydrogenase Mutations in Gliomas. Clinical Cancer Research, 2019, 25, 3366-3373.	3.2	17
1851	Cellular Compartmentation and the Redox/Nonredox Functions of NAD⁺. Antioxidants and Redox Signaling, 2019, 31, 623-642.	2.5	40
1852	IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Science Translational Medicine, 2019, 11, .	5.8	169
1853	Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects. Cancer Chemotherapy and Pharmacology, 2019, 83, 837-848.	1.1	15

#	Article	IF	Citations
1854	Targeting IDH1-Mutated Malignancies with NRF2 Blockade. Journal of the National Cancer Institute, 2019, 111, 1033-1041.	3.0	61
1855	The DNA methylation landscape in cancer. Essays in Biochemistry, 2019, 63, 797-811.	2.1	169
1856	Molecular basis for the function of the Î±Î² heterodimer of human NAD-dependent isocitrate dehydrogenase. Journal of Biological Chemistry, 2019, 294, 16214-16227.	1.6	15
1857	Carcinoma of Unknown Primary with EML4-ALK Fusion Response to ALK Inhibitors. Oncologist, 2019, 24, 449-454.	1.9	12
1858	Clinically Actionable Insights into Initial and Matched Recurrent Glioblastomas to Inform Novel Treatment Approaches. Journal of Oncology, 2019, 2019, 1-14.	0.6	4
1859	Epigenetic therapies in acute myeloid leukemia: where to from here?. Blood, 2019, 134, 1891-1901.	0.6	36
1860	Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers. Scientific Reports, 2019, 9, 16830.	1.6	29
1861	Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin. Cancers, 2019, 11, 2028.	1.7	23
1862	Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response. Frontiers in Oncology, 2019, 9, 1289.	1.3	10
1863	Genetic Mouse Models as In Vivo Tools for Cholangiocarcinoma Research. Cancers, 2019, 11, 1868.	1.7	5
1864	Current Advances and Future Perspectives of Cerebrospinal Fluid Biopsy in Midline Brain Malignancies. Current Treatment Options in Oncology, 2019, 20, 88.	1.3	6
1865	Chemical Compounds Targeting DNA Methylation and Hydroxymethylation. Topics in Medicinal Chemistry, 2019, , 255-286.	0.4	1
1866	Reprogramming of cellular metabolic pathways by human oncogenic viruses. Current Opinion in Virology, 2019, 39, 60-69.	2.6	20
1867	Intraoperative detection of isocitrate dehydrogenase mutations in human gliomas using a miniature mass spectrometer. Analytical and Bioanalytical Chemistry, 2019, 411, 7929-7933.	1.9	19
1868	The Power of Human Cancer Genetics as Revealed by Low-Grade Gliomas. Annual Review of Genetics, 2019, 53, 483-503.	3.2	22
1869	Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma. Cancers, 2019, 11, 1895.	1.7	17
1870	Targeting the interplay between metabolism and epigenetics in cancer. Current Opinion in Oncology, 2019, 31, 92-99.	1.1	12
1871	The Translational Status of Cancer Liquid Biopsies. Regenerative Engineering and Translational Medicine, 2021, 7, 312-352.	1.6	39

#	Article	IF	Citations
1872	Bioinformatic Profiling Identifies a Fatty Acid Metabolism-Related Gene Risk Signature for Malignancy, Prognosis, and Immune Phenotype of Glioma. Disease Markers, 2019, 2019, 1-14.	0.6	22
1873	Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation. Scientific Reports, 2019, 9, 18859.	1.6	18
1874	Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature, 2019, 574, 273-277.	13.7	149
1875	New metabolic imaging tools in neuro-oncology. Current Opinion in Neurology, 2019, 32, 872-877.	1.8	5
1876	Targeting DNA repair in gliomas. Current Opinion in Neurology, 2019, 32, 878-885.	1.8	11
1877	CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP. Molecular Cancer Research, 2019, 17, 2042-2050.	1.5	15
1878	Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas. Acta Neuropathologica Communications, 2019, 7, 201.	2.4	13
1879	Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status. Cancers, 2019, 11, 1918.	1.7	24
1880	Rescue of TCA Cycle Dysfunction for Cancer Therapy. Journal of Clinical Medicine, 2019, 8, 2161.	1.0	29
1881	3D highâ€resolution imaging of 2â€hydroxyglutarate in glioma patients using DRAGâ€EPSI at 3T in vivo. Magnetic Resonance in Medicine, 2019, 81, 795-802.	1.9	9
1882	An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing. Genes Chromosomes and Cancer, 2019, 58, 88-99.	1.5	67
1883	Rapid diagnosis of IDH1-mutated gliomas by 2-HG detection with gas chromatography mass spectrometry. Laboratory Investigation, 2019, 99, 588-598.	1.7	16
1884	The Role of Standard and Advanced Imaging for the Management of Brain Malignancies From a Radiation Oncology Standpoint. Neurosurgery, 2019, 85, 165-179.	0.6	6
1885	Integrated Metabolomics and Lipidomics Analyses Reveal Metabolic Reprogramming in Human Glioma with IDH1 Mutation. Journal of Proteome Research, 2019, 18, 960-969.	1.8	56
1886	Combined texture analysis of diffusion-weighted imaging with conventional MRI for non-invasive assessment of IDH1 mutation in anaplastic gliomas. Clinical Radiology, 2019, 74, 154-160.	0.5	16
1887	In vitro inhibition of human nucleoside transporters and uptake of azacitidine by an isocitrate dehydrogenase-2 inhibitor enasidenib and its metabolite AGI-16903. Xenobiotica, 2019, 49, 1229-1236.	0.5	1
1888	Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenaseâ€“mutant Glioma. Clinical Cancer Research, 2019, 25, 1261-1271.	3.2	50
1889	Integrative cross-platform analyses identify enhanced heterotrophy as a metabolic hallmark in glioblastoma. Neuro-Oncology, 2019, 21, 337-347.	0.6	25

#	Article	IF	Citations
1890	Commentary: Radiological Characteristics and Natural History of Adult IDH-Wild-Type Astrocytomas With TERT Promoter Mutations. Neurosurgery, 2019, 85, E457-E458.	0.6	0
1891	Isocitrate dehydrogenase 1 and 2 mutations, 2â€hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer, 2019, 125, 541-549.	2.0	23
1892	The Role of Immunohistochemistry and Molecular Analysis of Succinate Dehydrogenase in the Diagnosis of Endocrine and Non-Endocrine Tumors and Related Syndromes. Endocrine Pathology, 2019, 30, 64-73.	5.2	26
1893	An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors. Carcinogenesis, 2019, 40, 27-40.	1.3	14
1894	Molecular Pathogenesis of Low-Grade Glioma. Neurosurgery Clinics of North America, 2019, 30, 17-25.	0.8	31
1895	NMR and MS-based Stable Isotope-Resolved Metabolomics and applications in cancer metabolism. TrAC - Trends in Analytical Chemistry, 2019, 120, 115322.	5.8	29
1896	Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesis. Journal of Neuro-Oncology, 2019, 141, 289-301.	1.4	11
1897	IDH3Î± regulates one-carbon metabolism in glioblastoma. Science Advances, 2019, 5, eaat0456.	4.7	59
1898	Lactate dehydrogenase C is required for the protein expression of a sperm-specific isoform of lactate dehydrogenase A. Journal of Biochemistry, 2019, 165, 323-334.	0.9	15
1899	Epilepsy Associates with Decreased HIF-1Î±/STAT5b Signaling in Glioblastoma. Cancers, 2019, 11, 41.	1.7	12
1900	Fitting algorithms and baseline correction influence the results of nonâ€invasive in vivo quantitation of 2â€hydroxyglutarate with ¹Hâ€MRS. NMR in Biomedicine, 2019, 32, e4027.	1.6	13
1901	Coupling Krebs cycle metabolites to signalling in immunity and cancer. Nature Metabolism, 2019, 1, 16-33.	5.1	260
1902	IDH1-R132 changes vary according to NPM1 and other mutations status in AML. Leukemia, 2019, 33, 1043-1047.	3.3	17
1903	Pathways to Understanding Virus-Host Metabolism Interactions. Current Clinical Microbiology Reports, 2019, 6, 34-43.	1.8	5
1904	Characterization of Squamous Cell Lung Cancers from Appalachian Kentucky. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 348-356.	1.1	5
1905	The Continuing Evolution of Molecular Functional Imaging in Clinical Oncology: The Road to Precision Medicine and Radiogenomics (PartÂII). Molecular Diagnosis and Therapy, 2019, 23, 27-51.	1.6	17
1906	Targeting metabolic vulnerabilities of cancer: Small molecule inhibitors in clinic. Cancer Reports, 2019, 2, e1131.	0.6	8
1907	Metabolic underpinnings of leukemia pathology and treatment. Cancer Reports, 2019, 2, e1139.	0.6	16

#	Article	IF	Citations
1908	Frequent Diagnostic Under-Grading in Isocitrate Dehydrogenase Wild-Type Gliomas due to Small Pathological Tissue Samples. Neurosurgery, 2019, 85, 689-694.	0.6	7
1909	Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma. Medical Oncology, 2019, 36, 11.	1.2	4
1910	Point-of-Care Tissue Analysis Using Miniature Mass Spectrometer. Analytical Chemistry, 2019, 91, 1157-1163.	3.2	44
1911	Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood, 2019, 133, 676-687.	0.6	262
1912	Management of primary refractory acute myeloid leukemia in the era of targeted therapies. Leukemia and Lymphoma, 2019, 60, 583-597.	0.6	10
1913	Establishing assay-specific 97.5th percentile upper reference limit for serum D-2-hydroxyglutarate for the management of patients with acute myeloid leukemia. Clinical Chemistry and Laboratory Medicine, 2019, 57, e57-e59.	1.4	3
1914	Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas. Clinical Cancer Research, 2019, 25, 747-759.	3.2	35
1915	RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer. Molecular Cancer Research, 2019, 17, 508-520.	1.5	17
1916	In vivo Metabolic Profiles as Determined by 31P and short TE 1H MR-Spectroscopy. Clinical Neuroradiology, 2019, 29, 27-36.	1.0	14
1917	Disruption of protein function by pathogenic mutations: common and uncommon mechanisms. Biochemistry and Cell Biology, 2019, 97, 46-57.	0.9	16
1918	Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans. Xenobiotica, 2019, 49, 200-210.	0.5	12
1919	Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease. Seminars in Cell and Developmental Biology, 2020, 98, 105-117.	2.3	33
1920	The multifaceted contribution of Î±-ketoglutarate to tumor progression: An opportunity to exploit?. Seminars in Cell and Developmental Biology, 2020, 98, 26-33.	2.3	50
1921	Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. Investigational New Drugs, 2020, 38, 433-444.	1.2	69
1922	Cancer Metabolism. , 2020, , 127-138.e4.		3
1923	Magnetic Resonance Spectroscopic Assessment of Isocitrate Dehydrogenase Status inÂGliomas: The New Frontiers of Spectrobiopsy in Neurodiagnostics. World Neurosurgery, 2020, 133, e421-e427.	0.7	16
1924	In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site. Leukemia, 2020, 34, 416-426.	3.3	13
1925	Adapt and conquer: Metabolic flexibility in cancer growth, invasion and evasion. Molecular Metabolism, 2020, 33, 83-101.	3.0	93

#	Article	IF	Citations
1926	Therapeutic potential of natural products in glioblastoma treatment: targeting key glioblastoma signaling pathways and epigenetic alterations. Clinical and Translational Oncology, 2020, 22, 963-977.	1.2	30
1927	Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma. Clinical Cancer Research, 2020, 26, 419-427.	3.2	60
1928	Myeloproliferative neoplasms. , 2020, , 555-588.		0
1929	The Mitochondrion as an Emerging Therapeutic Target in Cancer. Trends in Molecular Medicine, 2020, 26, 119-134.	3.5	121
1930	Vitamin C in combination with inhibition of mutant IDH1 synergistically activates TET enzymes and epigenetically modulates gene silencing in colon cancer cells. Epigenetics, 2020, 15, 307-322.	1.3	20
1931	To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma. Cellular and Molecular Neurobiology, 2020, 40, 53-63.	1.7	22
1932	Letter to the editor concerning â€œTumor-associated macrophage related interleukin-6 in cerebrospinal fluid as a prognostic marker for glioblastomaâ€. Journal of Clinical Neuroscience, 2020, 71, 306.	0.8	0
1933	Inborn errors of metabolite repair. Journal of Inherited Metabolic Disease, 2020, 43, 14-24.	1.7	30
1935	Polysaccharides of mushroom Pleurotus spp.: New extraction techniques, biological activities and development of new technologies. Carbohydrate Polymers, 2020, 229, 115550.	5.1	58
1936	Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the <scp>d</scp>â€2â€hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma. Histopathology, 2020, 76, 722-730.	1.6	19
1937	Oncometabolites in renal cancer. Nature Reviews Nephrology, 2020, 16, 156-172.	4.1	113
1938	Cerebral neoplasm in L-2-hydroxyglutaric aciduria: two different presentations. Child's Nervous System, 2020, 36, 1545-1548.	0.6	2
1939	Epigallocatechin-3-gallate downregulates PDHA1 interfering the metabolic pathways in human herpesvirus 8 harboring primary effusion lymphoma cells. Toxicology in Vitro, 2020, 65, 104753.	1.1	3
1940	Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity. Biochemistry, 2020, 59, 479-490.	1.2	4
1941	Bioinformatics Analysis of Metabolomics Data Unveils Association of Metabolic Signatures with Methylation in Breast Cancer. Journal of Proteome Research, 2020, 19, 2879-2889.	1.8	7
1942	2-Hydroxyglutarate in Cancer Cells. Antioxidants and Redox Signaling, 2020, 33, 903-926.	2.5	68
1943	Twenty Metabolic Genes Based Signature Predicts Survival of Glioma Patients. Journal of Cancer, 2020, 11, 441-449.	1.2	3
1944	The Tricarboxylic Acid Cycle at the Crossroad Between Cancer and Immunity. Antioxidants and Redox Signaling, 2020, 32, 834-852.	2.5	40

#	Article	IF	Citations
1945	Metabolism, Epigenetics, and Causal Inference in Heart Failure. Trends in Endocrinology and Metabolism, 2020, 31, 181-191.	3.1	26
1946	Imaging of Central Nervous System Tumors Based on the 2016 World Health Organization Classification. Neurologic Clinics, 2020, 38, 95-113.	0.8	21
1947	Targeting Cell Metabolism as Cancer Therapy. Antioxidants and Redox Signaling, 2020, 32, 285-308.	2.5	32
1948	A double surrogate approach for the quantitation of 2-Hydroxyglutarate â€“ An oncometabolite in human brain tumors via LC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2020, 179, 112916.	1.4	14
1949	Interweaving Tumor Heterogeneity into the Cancer Epigenetic/Metabolic Axis. Antioxidants and Redox Signaling, 2020, 33, 946-965.	2.5	2
1950	Mitochondrial TCA cycle metabolites control physiology and disease. Nature Communications, 2020, 11, 102.	5.8	1,213
1951	Cancer of the Central Nervous System. , 2020, , 906-967.e12.		9
1952	Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1â€“mutated Human Gliomas. Radiology, 2020, 294, 589-597.	3.6	18
1953	Measurement of 2-hydroxyglutarate enantiomers in serum by chiral gas chromatography-tandem mass spectrometry and its application as a biomarker for IDH mutant gliomas. Clinical Mass Spectrometry, 2020, 15, 16-24.	1.9	14
1954	Metabolic adaptations in spontaneously immortalized PGC-1Î± knock-out mouse embryonic fibroblasts increase their oncogenic potential. Redox Biology, 2020, 29, 101396.	3.9	12
1955	Imaging Gliomas After Treatment. , 2020, , .		0
1956	Androgen receptor reverses the oncometabolite R-2-hydroxyglutarate-induced prostate cancer cell invasion via suppressing the circRNA-51217/miRNA-646/TGFÎ²1/p-Smad2/3 signaling. Cancer Letters, 2020, 472, 151-164.	3.2	43
1957	A metabolomic data fusion approach to support gliomas grading. NMR in Biomedicine, 2020, 33, e4234.	1.6	6
1958	TGFÎ²-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer. Cellular and Molecular Life Sciences, 2020, 77, 2103-2123.	2.4	152
1959	Blockade of Glutathione Metabolism in IDH1-Mutated Glioma. Molecular Cancer Therapeutics, 2020, 19, 221-230.	1.9	55
1960	Hypomethylating agent based combinations in higher risk myelodysplastic syndrome. Leukemia and Lymphoma, 2020, 61, 1012-1027.	0.6	2
1961	New aspects of amino acid metabolism in cancer. British Journal of Cancer, 2020, 122, 150-156.	2.9	250
1962	Altered cellular metabolism in gliomas â€" an emerging landscape of actionable co-dependency targets. Nature Reviews Cancer, 2020, 20, 57-70.	12.8	187

#	Article	IF	Citations
1963	HSF1-Mediated Control of Cellular Energy Metabolism and mTORC1 Activation Drive Acute T-Cell Lymphoblastic Leukemia Progression. Molecular Cancer Research, 2020, 18, 463-476.	1.5	7
1964	Aberrant mitochondrial function in ageing and cancer. Biogerontology, 2020, 21, 445-459.	2.0	17
1965	Response Kinetics and Clinical Benefits of Nonintensive AML Therapies in the Absence of Morphologic Response. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e66-e75.	0.2	10
1966	Advances in Diagnostic Immunohistochemistry for Primary Tumors of the Central Nervous System. Advances in Anatomic Pathology, 2020, 27, 206-219.	2.4	7
1967	The Association between Wholeâ€Brain MR Spectroscopy and IDH Mutation Status in Gliomas. Journal of Neuroimaging, 2020, 30, 58-64.	1.0	13
1968	Take Advantage of Glutamine Anaplerosis, the Kernel of the Metabolic Rewiring in Malignant Gliomas. Biomolecules, 2020, 10, 1370.	1.8	12
1969	The Metabolic Heterogeneity and Flexibility of Cancer Stem Cells. Cancers, 2020, 12, 2780.	1.7	33
1970	A system-level approach identifies HIF-2Î± as a critical regulator of chondrosarcoma progression. Nature Communications, 2020, 11, 5023.	5.8	14
1971	(2R,3S)-Dihydroxybutanoic Acid Synthesis as a Novel Metabolic Function of Mutant Isocitrate Dehydrogenase 1 and 2 in Acute Myeloid Leukemia. Cancers, 2020, 12, 2842.	1.7	6
1972	The Janus-like role of proline metabolism in cancer. Cell Death Discovery, 2020, 6, 104.	2.0	65
1973	Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features. Molecules, 2020, 25, 4641.	1.7	7
1974	2-Oxoglutarate-dependent dioxygenases in cancer. Nature Reviews Cancer, 2020, 20, 710-726.	12.8	119
1975	Loss of 5-Hydroxymethylcytosine is an Epigenetic Hallmark of Thyroid Carcinomas with TERT Promoter Mutations. Endocrine Pathology, 2020, 31, 359-366.	5.2	15
1976	Quantitation of 2-hydroxyglutarate in human plasma via LCâ€“MS/MS using a surrogate analyte approach. Bioanalysis, 2020, 12, 1149-1159.	0.6	10
1977	Glioblastoma multiforme: Metabolic differences to peritumoral tissue and <scp>IDH</scp>â€mutated gliomas revealed by mass spectrometry imaging. Neuropathology, 2020, 40, 546-558.	0.7	25
1978	A Review of Radiomics and Deep Predictive Modeling in Glioma Characterization. Academic Radiology, 2021, 28, 1599-1621.	1.3	45
1979	Hematopoietic Stem Cell Metabolism during Development and Aging. Developmental Cell, 2020, 54, 239-255.	3.1	124
1980	Structure-based design, synthesis and bioactivity evaluation of macrocyclic inhibitors of mutant isocitrate dehydrogenase 2 (IDH2) displaying activity in acute myeloid leukemia cells. European Journal of Medicinal Chemistry, 2020, 203, 112491.	2.6	3

#	Article	IF	Citations
1981	The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2020, 150, 143-164.	1.4	9
1982	Discovery of Novel IDH1 Inhibitor Through Comparative Structure-Based Virtual Screening. Frontiers in Pharmacology, 2020, 11, 579768.	1.6	15
1983	Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma. Cell Death and Disease, 2020, 11, 998.	2.7	19
1984	The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma. Frontiers in Endocrinology, 2020, 11, 586857.	1.5	25
1985	Cachexia, a Systemic Disease beyond Muscle Atrophy. International Journal of Molecular Sciences, 2020, 21, 8592.	1.8	22
1986	Advances in Targeted Therapies for Pediatric Brain Tumors. Current Treatment Options in Neurology, 2020, 22, 1.	0.7	16
1987	Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation. Expert Review of Precision Medicine and Drug Development, 2020, 5, 421-428.	0.4	3
1988	Targeting the Ubiquitin System in Glioblastoma. Frontiers in Oncology, 2020, 10, 574011.	1.3	21
1989	Role of tyrosine phosphorylation in modulating cancer cell metabolism. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188442.	3.3	33
1990	Metabolic Cancer-Macrophage Crosstalk in the Tumor Microenvironment. Biology, 2020, 9, 380.	1.3	16
1991	IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting. Cancers, 2020, 12, 3310.	1.7	25
1992	Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma. Cancers, 2020, 12, 3589.	1.7	19
1993	Metabolic regulation of prostate cancer heterogeneity and plasticity. Seminars in Cancer Biology, 2022, 82, 94-119.	4.3	20
1994	Mir142 loss unlocks IDH2R140-dependent leukemogenesis through antagonistic regulation of HOX genes. Scientific Reports, 2020, 10, 19390.	1.6	10
1995	Treating acute myeloid leukemia in the modern era: A primer. Cancer, 2020, 126, 4668-4677.	2.0	18
1996	Alternative splicing and cancer: insights, opportunities, and challenges from an expanding view of the transcriptome. Genes and Development, 2020, 34, 1005-1016.	2.7	61
1997	The Significance of Mitochondrial Dysfunction in Cancer. International Journal of Molecular Sciences, 2020, 21, 5598.	1.8	141
1998	Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1. Neuro-Oncology Advances, 2020, 2, vdaa042.	0.4	12

#	Article	IF	Citations
1999	Isocitrate dehydrogenase variants in cancer â€" Cellular consequences and therapeutic opportunities. Current Opinion in Chemical Biology, 2020, 57, 122-134.	2.8	35
2000	The epigenomics of sarcoma. Nature Reviews Cancer, 2020, 20, 608-623.	12.8	121
2001	Epigenetic Therapies for Cancer. New England Journal of Medicine, 2020, 383, 650-663.	13.9	289
2002	Advances in understanding of angioimmunoblastic T-cell lymphoma. Leukemia, 2020, 34, 2592-2606.	3.3	91
2003	Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies. Journal of Biomedical Science, 2020, 27, 81.	2.6	35
2004	From Cancer to Immune-Mediated Diseases and Tolerance Induction: Lessons Learned From Immune Oncology and Classical Anti-cancer Treatment. Frontiers in Immunology, 2020, 11, 1423.	2.2	5
2005	Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment. Frontiers in Oncology, 2020, 10, 1197.	1.3	30
2006	Optimized Protocol for the In Situ Derivatization of Glutathione with N-Ethylmaleimide in Cultured Cells and the Simultaneous Determination of Glutathione/Glutathione Disulfide Ratio by HPLC-UV-QTOF-MS. Metabolites, 2020, 10, 292.	1.3	15
2007	Cutting Edge Molecular Therapy for Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2020, 21, 5114.	1.8	5
2008	Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study. CNS Oncology, 2020, 9, CNS62.	1.2	21
2009	Interplay between Cellular Metabolism and the DNA Damage Response in Cancer. Cancers, 2020, 12, 2051.	1.7	37
2010	Correlation of preoperative seizures with a wide range of tumor molecular markers in gliomas: An analysis of 442 glioma patients from China. Epilepsy Research, 2020, 166, 106430.	0.8	8
2011	Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. Leukemia, 2020, 34, 2903-2913.	3.3	38
2012	Gene of the month: IDH1. Journal of Clinical Pathology, 2020, 73, 611-615.	1.0	8
2013	Non-Conventional Treatments for Conventional Chondrosarcoma. Cancers, 2020, 12, 1962.	1.7	22
2014	Remarkable response of a patient with secondary glioblastoma to a histone deacetylase inhibitor. Oxford Medical Case Reports, 2020, 2020, omaa006.	0.2	8
2016	Metabolic regulation in HPV associated head and neck squamous cell carcinoma. Life Sciences, 2020, 258, 118236.	2.0	17
2017	Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-Î²-hydroxylase. Bioorganic and Medicinal Chemistry, 2020, 28, 115675.	1.4	8

#	Article	IF	Citations
2018	Mitochondrial metabolism and cancer metastasis. Annals of Translational Medicine, 2020, 8, 904-904.	0.7	19
2019	GSH and GABA decreases in IDH1-mutated low-grade gliomas detected by HERMES spectral editing at 3ÂT in vivo. Neurochemistry International, 2020, 141, 104889.	1.9	5
2021	FGFR3â—37â€“9 promotes tumor progression via the phosphorylation and destabilization of ten-eleven translocation-2 in human hepatocellular carcinoma. Cell Death and Disease, 2020, 11, 903.	2.7	16
2022	Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation. Expert Review of Precision Medicine and Drug Development, 2020, 5, 429-438.	0.4	2
2023	Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types. Genome Medicine, 2020, 12, 90.	3.6	29
2024	Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition. Cancer & Metabolism, 2020, 8, 23.	2.4	14
2025	An integrated RF-receive/B0-shim array coil boosts performance of whole-brain MR spectroscopic imaging at 7ÂT. Scientific Reports, 2020, 10, 15029.	1.6	12
2026	Chiral discrimination in a mutated IDH enzymatic reaction in cancer: a computational perspective. European Biophysics Journal, 2020, 49, 549-559.	1.2	4
2027	Oncogenic Mechanisms and Therapeutic Targeting of Metabolism in Leukemia and Lymphoma. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a035477.	2.9	2
2028	Overcoming the Odds: Toward a Molecular Profile of Long-Term Survival in Glioblastoma. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1031-1037.	0.9	15
2029	Prognostic and Predictive Value of an Immunoscore Signature in Glioblastoma Multiform. Frontiers in Genetics, 2020, 11, 514363.	1.1	8
2030	Epigenomic Reprogramming as a Driver of Malignant Glioma. Cancer Cell, 2020, 38, 647-660.	7.7	66
2031	Biochemical and biophysical analyses of hypoxia sensing prolyl hydroxylases from Dictyostelium discoideum and Toxoplasma gondii. Journal of Biological Chemistry, 2020, 295, 16545-16561.	1.6	10
2032	Generation of induced neural stem cells with inducible IDH1R132H for analysis of glioma development and drug testing. PLoS ONE, 2020, 15, e0239325.	1.1	5
2033	The Role of RNA Epigenetic Modification in Normal and Malignant Hematopoiesis. Current Stem Cell Reports, 2020, 6, 144-155.	0.7	12
2034	Neuro-Oncology and Radiogenomics: Time to Integrate?. American Journal of Neuroradiology, 2020, 41, 1982-1988.	1.2	18
2035	IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatmentâ€"Current State and Future Perspectives. Molecules, 2020, 25, 3754.	1.7	18
2036	Glutamine reliance in cell metabolism. Experimental and Molecular Medicine, 2020, 52, 1496-1516.	3.2	391

#	Article	IF	Citations
2037	Oncometabolites and the response to radiotherapy. Radiation Oncology, 2020, 15, 197.	1.2	17
2038	Mitochondria as a target in cancer treatment. MedComm, 2020, 1, 129-139.	3.1	57
2039	Evaluating ivosidenib for the treatment of acute myeloid leukemia. Expert Opinion on Pharmacotherapy, 2020, 21, 2205-2213.	0.9	9
2040	Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications. Biomedicines, 2020, 8, 294.	1.4	39
2041	The Crosstalk of Epigenetics and Metabolism in Herpesvirus Infection. Viruses, 2020, 12, 1377.	1.5	14
2042	Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduction and Targeted Therapy, 2020, 5, 288.	7.1	98
2043	NADPH debt drives redox bankruptcy: SLC7A11/xCT-mediated cystine uptake as a double-edged sword in cellular redox regulation. Genes and Diseases, 2021, 8, 731-745.	1.5	57
2044	Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?. Current Opinion in Neurology, 2020, 33, 707-715.	1.8	8
2045	Interrogation of IDH1 Status in Gliomas by Fourier Transform Infrared Spectroscopy. Cancers, 2020, 12, 3682.	1.7	12
2046	Kinetic and Bioinformatic Characterization of <scp>d</scp>-2-Hydroxyglutarate Dehydrogenase from Pseudomonas aeruginosa PAO1. Biochemistry, 2020, 59, 4833-4844.	1.2	5
2047	A Novel Four-Gene Signature Associated With Immune Checkpoint for Predicting Prognosis in Lower-Grade Glioma. Frontiers in Oncology, 2020, 10, 605737.	1.3	13
2049	DNA Associated with Circulating Exosomes as a Biomarker for Glioma. Genes, 2020, 11, 1276.	1.0	19
2050	â€œMitochondrial Toolboxâ€•â€“ A Review of Online Resources to Explore Mitochondrial Genomics. Frontiers in Genetics, 2020, 11, 439.	1.1	3
2051	NAD+ Controls Circadian Reprogramming through PER2 Nuclear Translocation to Counter Aging. Molecular Cell, 2020, 78, 835-849.e7.	4.5	116
2052	Quantitative analysis of amino acid metabolism in liver cancer links glutamate excretion to nucleotide synthesis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 10294-10304.	3.3	45
2053	Role of molecular biomarkers in glioma resection: a systematic review. Chinese Neurosurgical Journal, 2020, 6, 18.	0.3	9
2054	Anion-exchange chromatography mass spectrometry provides extensive coverage of primary metabolic pathways revealing altered metabolism in IDH1 mutant cells. Communications Biology, 2020, 3, 247.	2.0	51
2055	Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment. Advanced Science, 2020, 7, 1902971.	5.6	95

#	Article	IF	Citations
2056	Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Advances, 2020, 4, 1894-1905.	2.5	129
2057	Oncometabolites suppress DNA repair by disrupting local chromatin signalling. Nature, 2020, 582, 586-591.	13.7	183
2058	Warburg and Beyond: The Power of Mitochondrial Metabolism to Collaborate or Replace Fermentative Glycolysis in Cancer. Cancers, 2020, 12, 1119.	1.7	117
2059	Acute myeloid leukemia transformed to a targetable disease. Future Oncology, 2020, 16, 961-972.	1.1	12
2060	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncology, The, 2020, 21, 796-807.	5.1	620
2061	Metabolic alterations in the tumor microenvironment and their role in oncogenesis. Cancer Letters, 2020, 484, 65-71.	3.2	32
2062	Glioblastoma multiforme: novel therapeutic targets. Expert Opinion on Therapeutic Targets, 2020, 24, 605-614.	1.5	36
2063	IDH-Mutant Gliomas. , 2020, , .		4
2064	Lower Grade Gliomas. Current Neurology and Neuroscience Reports, 2020, 20, 21.	2.0	68
2065	Tumour predisposition and cancer syndromes as models to study geneâ€“environment interactions. Nature Reviews Cancer, 2020, 20, 533-549.	12.8	93
2066	Advances in targeted therapy for acute myeloid leukemia. Biomarker Research, 2020, 8, 17.	2.8	41
2067	Ivosidenib in Isocitrate Dehydrogenase 1â€“Mutated Advanced Glioma. Journal of Clinical Oncology, 2020, 38, 3398-3406.	0.8	167
2068	The DNA methylation landscape of hematological malignancies: an update. Molecular Oncology, 2020, 14, 1616-1639.	2.1	26
2069	Magnetic resonance spectroscopic imaging in gliomas: clinical diagnosis and radiotherapy planning. BJR|Open, 2020, 2, 20190026.	0.4	13
2070	The epigenetics of brain tumors and its modulation during radiation: A review. Life Sciences, 2020, 256, 117974.	2.0	8
2071	Next Generation Sequencing and Machine Learning Technologies Are Painting the Epigenetic Portrait of Glioblastoma. Frontiers in Oncology, 2020, 10, 798.	1.3	26
2072	ROS-associated immune response and metabolism: a mechanistic approach with implication of various diseases. Archives of Toxicology, 2020, 94, 2293-2317.	1.9	30
2073	Enzyme promiscuity, metabolite damage, and metabolite damage control systems of the tricarboxylic acid cycle. FEBS Journal, 2020, 287, 1343-1358.	2.2	21

#	Article	IF	Citations
2074	Role of Isocitrate Dehydrogenase 2 on DNA Hydroxymethylation in Human Airway Smooth Muscle Cells. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 36-45.	1.4	12
2075	Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives. Cells, 2020, 9, 596.	1.8	13
2076	Interaction profiling methods to map protein and pathway targets of bioactive ligands. Current Opinion in Chemical Biology, 2020, 54, 76-84.	2.8	6
2077	Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research. Frontiers in Immunology, 2020, 11, 176.	2.2	101
2078	2-Hydroxyglutarate Metabolism Is Altered in an in vivo Model of LPS Induced Endotoxemia. Frontiers in Physiology, 2020, 11, 147.	1.3	9
2079	Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma. Translational Oncology, 2020, 13, 100758.	1.7	14
2080	Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. Journal of Clinical Oncology, 2020, 38, 1693-1701.	0.8	86
2081	Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors. Molecules, 2020, 25, 1471.	1.7	33
2082	Correlation between IDH, ATRX, and TERT promoter mutations in glioma. Brain Tumor Pathology, 2020, 37, 33-40.	1.1	38
2083	The Role of D-3-Phosphoglycerate Dehydrogenase in Cancer. International Journal of Biological Sciences, 2020, 16, 1495-1506.	2.6	49
2084	Normal Hematopoiesis Is a Balancing Act of Self-Renewal and Regeneration. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a035519.	2.9	29
2085	Lighting Up Live-Cell and In Vivo Central Carbon Metabolism with Genetically Encoded Fluorescent Sensors. Annual Review of Analytical Chemistry, 2020, 13, 293-314.	2.8	41
2086	Intermediary metabolism: An intricate network at the crossroads of cell fate and function. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165887.	1.8	12
2087	Treatment of Relapsed Acute Myeloid Leukemia. Current Treatment Options in Oncology, 2020, 21, 66.	1.3	138
2088	The neural stem-cell marker CD24 is specifically upregulated in IDH-mutant glioma. Translational Oncology, 2020, 13, 100819.	1.7	9
2089	Metabolite sensing and signaling in cancer. Journal of Biological Chemistry, 2020, 295, 11938-11946.	1.6	42
2090	Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML. Blood Advances, 2020, 4, 3109-3122.	2.5	3
2091	Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas. Cancers, 2020, 12, 1817.	1.7	43

#	Article	IF	Citations
2092	Identification of a synergistic combination of dimethylaminoparthenolide and shikonin alters metabolism and inhibits proliferation of pediatric precursorâ€B cell acute lymphoblastic leukemia. Molecular Carcinogenesis, 2020, 59, 399-411.	1.3	19
2093	Biochemical and phylogenetic characterization of a monomeric isocitrate dehydrogenase from a marine methanogenic archaeon Methanococcoides methylutens. Extremophiles, 2020, 24, 319-328.	0.9	4
2094	The PHGDH enigma: Do cancer cells only need serine or also a redox modulator?. Cancer Letters, 2020, 476, 97-105.	3.2	37
2095	IDH1-dependent Î±-KG regulates brown fat differentiation and function by modulating histone methylation. Metabolism: Clinical and Experimental, 2020, 105, 154173.	1.5	15
2096	Acetate supplementation restores chromatin accessibility and promotes tumor cell differentiation under hypoxia. Cell Death and Disease, 2020, 11, 102.	2.7	39
2097	Integrative analyses identify a DNA damage repair gene signature for prognosis prediction in lower grade gliomas. Future Oncology, 2020, 16, 367-382.	1.1	11
2098	Making heads or tails â€“ the emergence of capicua (CIC) as an important multifunctional tumour suppressor. Journal of Pathology, 2020, 250, 532-540.	2.1	20
2099	Recent advances in the biology of tumour hypoxia with relevance to diagnostic practice and tissueâ€based research. Journal of Pathology, 2020, 250, 593-611.	2.1	23
2100	The Time Has Come for Targeted Therapies for AML: Lights and Shadows. Oncology and Therapy, 2020, 8, 13-32.	1.0	32
2101	Advances into understanding metabolites as signaling molecules in cancer progression. Current Opinion in Cell Biology, 2020, 63, 144-153.	2.6	22
2102	Glycine by MR spectroscopy is an imaging biomarker of glioma aggressiveness. Neuro-Oncology, 2020, 22, 1018-1029.	0.6	37
2103	Modulation of dysregulated cancer metabolism by plant secondary metabolites: A mechanistic review. Seminars in Cancer Biology, 2022, 80, 276-305.	4.3	53
2104	Vascular habitat analysis based on dynamic susceptibility contrast perfusion MRI predicts IDH mutation status and prognosis in high-grade gliomas. European Radiology, 2020, 30, 3254-3265.	2.3	25
2105	Computer-aided diagnosis of isocitrate dehydrogenase genotypes in glioblastomas from radiomic patterns. Medicine (United States), 2020, 99, e19123.	0.4	10
2106	5-(Carbamoylmethylene)-oxazolidin-2-ones as a Promising Class of Heterocycles Inducing Apoptosis Triggered by Increased ROS Levels and Mitochondrial Dysfunction in Breast and Cervical Cancer. Biomedicines, 2020, 8, 35.	1.4	22
2107	The Landscape of the Anti-Kinase Activity of the IDH1 Inhibitors. Cancers, 2020, 12, 536.	1.7	9
2108	Baicalein protects PC12 cells from AÎ²25â€“35-induced cytotoxicity via inhibition of apoptosis and metabolic disorders. Life Sciences, 2020, 248, 117471.	2.0	30
2109	Emerging Roles for Branched-Chain Amino Acid Metabolism in Cancer. Cancer Cell, 2020, 37, 147-156.	7.7	233

#	Article	IF	Citations
2110	Tumor antigens in glioma. Seminars in Immunology, 2020, 47, 101385.	2.7	34
2111	The EGFR-ZNF263 signaling axis silences SIX3 in glioblastoma epigenetically. Oncogene, 2020, 39, 3163-3178.	2.6	31
2112	Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth. Cancers, 2020, 12, 141.	1.7	17
2113	High resolution mass spectrometry for single cell analysis. International Journal of Mass Spectrometry, 2020, 450, 116302.	0.7	6
2114	Alternative Lengthening of Telomeres: Building Bridges To Connect Chromosome Ends. Trends in Cancer, 2020, 6, 247-260.	3.8	43
2115	Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor. Journal of Medicinal Chemistry, 2020, 63, 1612-1623.	2.9	76
2116	Deregulated Mitochondrial DNA in Diseases. DNA and Cell Biology, 2020, 39, 1385-1400.	0.9	19
2117	Interaction between IDH1 WT and calmodulin and its implications for glioblastoma cell growth and migration. Biochemical and Biophysical Research Communications, 2020, 524, 224-230.	1.0	8
2118	Metformin as Potential Therapy for High-Grade Glioma. Cancers, 2020, 12, 210.	1.7	52
2119	Potential implications of hydrogen peroxide in the pathogenesis and therapeutic strategies of gliomas. Archives of Pharmacal Research, 2020, 43, 187-203.	2.7	12
2120	Prospects of biological and synthetic pharmacotherapies for glioblastoma. Expert Opinion on Biological Therapy, 2020, 20, 305-317.	1.4	16
2121	ATP-responsive mitochondrial probes for monitoring metabolic processes of glioma stem cells in a 3D model. Chemical Science, 2020, 11, 2744-2749.	3.7	20
2122	Non-conventional pathways enable pennycress (Thlaspi arvense L.) embryos to achieve high efficiency of oil biosynthesis. Journal of Experimental Botany, 2020, 71, 3037-3051.	2.4	26
2123	Regulation of immune cell metabolism by cancer cell oncogenic mutations. International Journal of Cancer, 2020, 147, 307-316.	2.3	3
2124	Extracellular glutamate and IDH1R132H inhibitor promote glioma growth by boosting redox potential. Journal of Neuro-Oncology, 2020, 146, 427-437.	1.4	14
2125	Recent Trends of microRNA Significance in Pediatric Population Glioblastoma and Current Knowledge of Micro RNA Function in Glioblastoma Multiforme. International Journal of Molecular Sciences, 2020, 21, 3046.	1.8	17
2126	Understanding the Oxygen-Sensing Pathway and Its Therapeutic Implications in Diseases. American Journal of Pathology, 2020, 190, 1584-1595.	1.9	33
2127	A high-throughput SAMDI-mass spectrometry assay for isocitrate dehydrogenase 1. Analyst, The, 2020, 145, 3899-3908.	1.7	11

#	Article	IF	Citations
2128	Insights into the Regulatory Role of m6A Epitranscriptome in Glioblastoma. International Journal of Molecular Sciences, 2020, 21, 2816.	1.8	32
2129	IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution. Cancer Medicine, 2020, 9, 4386-4394.	1.3	18
2130	Cytokine-like Roles for Metabolites in Immunity. Molecular Cell, 2020, 78, 814-823.	4.5	119
2131	Toxicometabolomics of the new psychoactive substances Î±-PBP and Î±-PEP studied in HepaRG cell incubates by means of untargeted metabolomics revealed unexpected amino acid adducts. Archives of Toxicology, 2020, 94, 2047-2059.	1.9	18
2132	Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation. Cancer Chemotherapy and Pharmacology, 2020, 85, 959-968.	1.1	15
2133	Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9964-9972.	3.3	85
2134	Epigenetic Mechanisms in Leukemias and Lymphomas. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a034959.	2.9	14
2135	Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood, 2020, 135, 463-471.	0.6	266
2136	Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis. Blood, 2020, 135, 845-856.	0.6	27
2137	mTORC2/Rac1 Pathway Predisposes Cancer Aggressiveness in IDH1-Mutated Glioma. Cancers, 2020, 12, 787.	1.7	22
2138	Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer. Seminars in Cancer Biology, 2020, 67, 34-42.	4.3	12
2139	IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. British Journal of Cancer, 2020, 122, 1580-1589.	2.9	301
2140	Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia. Haematologica, 2021, 106, 565-573.	1.7	29
2141	Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes. Internal Medicine, 2021, 60, 15-23.	0.3	1
2142	Tenâ€Eleven Translocation 1 Promotes Malignant Progression of Cholangiocarcinoma With Wildâ€Type Isocitrate Dehydrogenase 1. Hepatology, 2021, 73, 1747-1763.	3.6	20
2143	Sirtuin activation targets IDH-mutant tumors. Neuro-Oncology, 2021, 23, 53-62.	0.6	15
2144	Challenges and Opportunities in Cancer Drug Resistance. Chemical Reviews, 2021, 121, 3297-3351.	23.0	203
2145	Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood, 2021, 137, 1792-1803.	0.6	123

#	Article	IF	Citations
2146	Metabolic Coordination of Cell Fate by Î±-Ketoglutarate-Dependent Dioxygenases. Trends in Cell Biology, 2021, 31, 24-36.	3.6	63
2147	Systematic Proteome and Lysine Succinylome Analysis Reveals Enhanced Cell Migration by Hyposuccinylation in Esophageal Squamous Cell Carcinoma. Molecular and Cellular Proteomics, 2021, 20, 100053.	2.5	28
2148	Early indicators of primary brain tumours: a populationâ€based study with 10Âyearsâ€™ followâ€up. European Journal of Neurology, 2021, 28, 278-285.	1.7	2
2149	Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma. Neuropathology and Applied Neurobiology, 2021, 47, 379-393.	1.8	4
2150	From anti-aging drugs to cancer therapy: is there a potential for sirtuin activators in gliomas?. Neuro-Oncology, 2021, 23, 3-5.	0.6	2
2151	Discovery of an Unnatural DNA Modification Derived from a Natural Secondary Metabolite. Cell Chemical Biology, 2021, 28, 97-104.e4.	2.5	6
2152	Otto Warburg: The journey towards the seminal discovery of tumor cell bioenergetic reprogramming. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 165965.	1.8	19
2153	Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study. Leukemia and Lymphoma, 2021, 62, 438-445.	0.6	5
2154	Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy. Expert Opinion on Investigational Drugs, 2021, 30, 365-375.	1.9	10
2155	The presence of TIMâ€3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status. Brain Pathology, 2021, 31, e12921.	2.1	5
2156	Cancer cell metabolism: Rewiring the mitochondrial hub. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166016.	1.8	33
2157	Isocitrate dehydrogenase 1 from Acinetobacter baumannii (AbIDH1) enzymatic characterization and its regulation by phosphorylation. Biochimie, 2021, 181, 77-85.	1.3	2
2158	The Bidirectional Relationship Between Cancer Epigenetics and Metabolism. Annual Review of Cancer Biology, 2021, 5, 235-257.	2.3	28
2159	NAD+ depletion radiosensitizes 2-DG-treated glioma cells by abolishing metabolic adaptation. Free Radical Biology and Medicine, 2021, 162, 514-522.	1.3	6
2160	A basic review on systemic treatment options in WHO grade II-III gliomas. Cancer Treatment Reviews, 2021, 92, 102124.	3.4	44
2161	Exploring the crosstalk of glycolysis and mitochondrial metabolism in psychiatric disorders and brain tumours. European Journal of Neuroscience, 2021, 53, 3002-3018.	1.2	4
2162	Identification of new IDH2 R140Q inhibitors by discriminatory analysisâ€based molecular docking and biological evaluation. Archiv Der Pharmazie, 2021, 354, 2000063.	2.1	4
2163	7-T Magnetic Resonance Imaging in the Management of Brain Tumors. Magnetic Resonance Imaging Clinics of North America, 2021, 29, 83-102.	0.6	6

#	Article	IF	Citations
2165	Enchondromatosis and Growth Plate Development. Current Osteoporosis Reports, 2021, 19, 40-49.	1.5	8
2166	TNFAIP8 drives metabolic reprogramming to promote prostate cancer cell proliferation. International Journal of Biochemistry and Cell Biology, 2021, 130, 105885.	1.2	5
2167	Oncometabolite <scp>Lâ€2â€hydroxyglurate</scp> directly induces vasculogenic mimicry through <scp>PHLDB2</scp> in renal cell carcinoma. International Journal of Cancer, 2021, 148, 1743-1755.	2.3	13
2168	Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology, 2021, 39, 57-65.	0.8	118
2169	Spectral editing in ¹H magnetic resonance spectroscopy: Experts' consensus recommendations. NMR in Biomedicine, 2021, 34, e4411.	1.6	74
2170	Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies. Clinical Cancer Research, 2021, 27, 383-388.	3.2	12
2171	Preoperative Determination of Isocitrate Dehydrogenase Mutation in Gliomas Using Spectral Editing MRS : A Prospective Study. Journal of Magnetic Resonance Imaging, 2021, 53, 416-426.	1.9	6
2172	Epigenetics of epithelial to mesenchymal transition (EMT) in cancer. , 2021, , 237-264.		0
2173	Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia. Bosnian Journal of Basic Medical Sciences, 2021, 21, 409-421.	0.6	7
2175	The oncometabolite R-2-hydroxyglutarate dysregulates the differentiation of human mesenchymal stromal cells via inducing DNA hypermethylation. BMC Cancer, 2021, 21, 36.	1.1	8
2176	The Multifaceted Glioblastoma: From Genomic Alterations to Metabolic Adaptations. Advances in Experimental Medicine and Biology, 2021, 1311, 59-76.	0.8	14
2177	Cystathionine-Î³-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas. Neuro-Oncology Advances, 2021, 3, vdab057.	0.4	10
2178	The Future of Chondrosarcoma Research and Treatment. , 2021, , 283-298.		0
2179	Glutamine Metabolism in Cancer. Advances in Experimental Medicine and Biology, 2021, 1311, 17-38.	0.8	43
2180	Biliary tract cancer. Lancet, The, 2021, 397, 428-444.	6.3	429
2181	Clinical utility of solid tumor epigenetics. , 2021, , 425-446.		0
2182	Reverse Engineering Glioma Radiomics to Conventional Neuroimaging. Neurologia Medico-Chirurgica, 2021, 61, 505-514.	1.0	1
2183	Nitrile-containing pharmaceuticals: target, mechanism of action, and their SAR studies. RSC Medicinal Chemistry, 2021, 12, 1650-1671.	1.7	50

#	Article	IF	Citations
2184	Hallmarks of cancerâ€"the new testament. Open Biology, 2021, 11, 200358.	1.5	104
2185	Acute Myeloid Leukemia and Allogeneic Hematopoietic Cell Transplant. , 2021, , 231-250.		0
2186	Synthesis and Evaluation of 3-(Indol-3-yl)-4-(pyrazolo[3,4- c]pyridazin-3-yl)maleimides as Potent Mutant Isocitrate Dehydrogenase-1 Inhibitors. Chinese Journal of Organic Chemistry, 2021, , 1991.	0.6	0
2187	Tumors of the Central Nervous System. , 2021, , 121-145.		0
2188	High expression of cluster of differentiation 276 indicates poor prognosis in glioma. Clinical Medicine Insights: Oncology, 2021, 15, 117955492110323.	0.6	2
2189	Personalized Genome-Scale Metabolic Models Identify Targets of Redox Metabolism in Radiation-Resistant Tumors. Cell Systems, 2021, 12, 68-81.e11.	2.9	39
2190	Targeting Cancer Metabolism and Current Anti-Cancer Drugs. Advances in Experimental Medicine and Biology, 2021, 1286, 15-48.	0.8	12
2191	Epigenetics and Metabolism. Learning Materials in Biosciences, 2021, , 179-201.	0.2	2
2192	Molecular Stratification of Adult and Pediatric High Grade Gliomas. Molecular Pathology Library, 2021, , 123-151.	0.1	0
2193	Metabolomics of Glioma. Advances in Experimental Medicine and Biology, 2021, 1280, 261-276.	0.8	9
2194	Targeting epigenetic alterations in the treatment of glioma. MGM Journal of Medical Sciences, 2021, 8, 194.	0.1	1
2195	Diffuse Glioma Heterogeneity and Its Therapeutic Implications. Cancer Discovery, 2021, 11, 575-590.	7.7	193
2196	MLK3 Is Associated With Poor Prognosis in Patients With Glioblastomas and Actin Cytoskeleton Remodeling in Glioblastoma Cells. Frontiers in Oncology, 2020, 10, 600762.	1.3	3
2197	Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview. OncoTargets and Therapy, 2021, Volume 14, 1341-1366.	1.0	12
2198	Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas. JCO Precision Oncology, 2021, 5, 466-472.	1.5	24
2199	An IDH1-vitamin C crosstalk drives human erythroid development by inhibiting pro-oxidant mitochondrial metabolism. Cell Reports, 2021, 34, 108723.	2.9	28
2200	Bibliometric analysis of the top 100 most-cited articles on astrocytoma. , 2021, 12, 62.		2
2202	Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. Clinical Cancer Research, 2021, 27, 2723-2733.	3.2	33

#	Article	IF	Citations
2203	Interaction between transforming Theileria parasites and their host bovine leukocytes. Molecular Microbiology, 2021, 115, 860-869.	1.2	6
2204	Intraoperative Mass Spectrometry Platform for IDH Mutation Status Prediction, Glioma Diagnosis, and Estimation of Tumor Cell Infiltration. journal of applied laboratory medicine, The, 2021, 6, 902-916.	0.6	16
2205	Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma. Metabolites, 2021, 11, 109.	1.3	15
2206	Cancer metabolism and intervention therapy. Molecular Biomedicine, 2021, 2, 5.	1.7	20
2208	Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML, an ALFA study. Blood, 2021, 137, 2827-2837.	0.6	36
2209	Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice. Journal of Clinical Investigation, 2021, 131, .	3.9	70
2210	Magnetic resonance spectroscopy for the study of cns malignancies. Progress in Nuclear Magnetic Resonance Spectroscopy, 2021, 122, 23-41.	3.9	19
2211	Molecular and Metabolic Mechanisms Underlying Selective 5-Aminolevulinic Acid-Induced Fluorescence in Gliomas. Cancers, 2021, 13, 580.	1.7	37
2212	IDH1 Non-Canonical Mutations and Survival in Patients with Glioma. Diagnostics, 2021, 11, 342.	1.3	15
2213	Resiliency of a perpetual optimist: neurosurgeon Dr. Linda Liau. Neurosurgical Focus, 2021, 50, E18.	1.0	0
2214	Oncometabolites in Cancer: Current Understanding and Challenges. Cancer Research, 2021, 81, 2820-2823.	0.4	36
2215	Dietary Alphaâ€Ketoglutarate Promotes Epithelial Metabolic Transition and Protects against DSSâ€Induced Colitis. Molecular Nutrition and Food Research, 2021, 65, e2000936.	1.5	20
2216	The Glioblastoma Microenvironment: Morphology, Metabolism, and Molecular Signature of Glial Dynamics to Discover Metabolic Rewiring Sequence. International Journal of Molecular Sciences, 2021, 22, 3301.	1.8	33
2217	Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy?. Cells, 2021, 10, 705.	1.8	15
2218	Recent Advancements in Nanomedicine for â€˜Coldâ€™ Tumor Immunotherapy. Nano-Micro Letters, 2021, 13, 92.	14.4	41
2219	Targeting Energy Metabolism in Cancer Stem Cells: Progress and Challenges in Leukemia and Solid Tumors. Cell Stem Cell, 2021, 28, 378-393.	5.2	67
2220	The Role of 2-Oxoglutarate Dependent Dioxygenases in Gliomas and Glioblastomas: A Review of Epigenetic Reprogramming and Hypoxic Response. Frontiers in Oncology, 2021, 11, 619300.	1.3	12
2221	Rapid estimation of tumor cell percentage in brain tissue biopsy samples using inline cartridge extraction mass spectrometry. Analytical and Bioanalytical Chemistry, 2021, 413, 2913-2922.	1.9	11

#	Article	IF	Citations
2222	Systemic Immune Bias Delineates Malignant Astrocytoma Survival Cohorts. Journal of Immunology, 2021, 206, 1483-1492.	0.4	0
2223	Characterization of the fatty acid metabolism in colorectal cancer to guide clinical therapy. Molecular Therapy - Oncolytics, 2021, 20, 532-544.	2.0	50
2224	Treatment options for older unfit patients with acute myeloid leukemia. Future Oncology, 2021, 17, 837-851.	1.1	0
2225	R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis. Molecular Cell, 2021, 81, 922-939.e9.	4.5	157
2226	Bcl2l10 induces metabolic alterations in ovarian cancer cells by regulating the TCA cycle enzymes SDHD and IDH1. Oncology Reports, 2021, 45, .	1.2	3
2227	Rational Design of Dual-Emission Lanthanide Metalâ€“Organic Framework for Visual Alkaline Phosphatase Activity Assay. ACS Applied Materials & Interfaces, 2021, 13, 11646-11656.	4.0	66
2228	Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to Immunophenotype. Cancers, 2021, 13, 1317.	1.7	6
2229	Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. Leukemia, 2021, 35, 3278-3281.	3.3	10
2230	Novel Strategy for Untargeted Chiral Metabolomics using Liquid Chromatography-High Resolution Tandem Mass Spectrometry. Analytical Chemistry, 2021, 93, 5805-5814.	3.2	17
2231	Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers. Current Opinion in Biotechnology, 2021, 68, 181-185.	3.3	16
2232	IDH Inhibitors in AMLâ€”Promise and Pitfalls. Current Hematologic Malignancy Reports, 2021, 16, 207-217.	1.2	33
2233	Lactonization of the Oncometabolite D-2-Hydroxyglutarate Produces a Novel Endogenous Metabolite. Cancers, 2021, 13, 1756.	1.7	8
2234	CanDriS: posterior profiling of cancer-driving sites based on two-component evolutionary model. Briefings in Bioinformatics, 2021, 22, .	3.2	5
2235	Deep learning can accelerate and quantify simulated localized correlated spectroscopy. Scientific Reports, 2021, 11, 8727.	1.6	13
2236	Discovery and Optimization of 2‹i›H‹/i›-1Î»‹sup›2‹/sup›-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer. Journal of Medicinal Chemistry, 2021, 64, 4913-4946.	2.9	12
2237	The metabolic adaptation mechanism of metastatic organotropism. Experimental Hematology and Oncology, 2021, 10, 30.	2.0	15
2238	The landscape of metabolic pathway dependencies in cancer cell lines. PLoS Computational Biology, 2021, 17, e1008942.	1.5	9
2239	Withanolides from dietary tomatillo suppress HT1080 cancer cell growth by targeting mutant IDH1. Bioorganic and Medicinal Chemistry, 2021, 36, 116095.	1.4	8

#	Article	IF	Citations
2240	The functional roles of TCA cycle metabolites in cancer. Oncogene, 2021, 40, 3351-3363.	2.6	98
2241	Advances in epigenetic therapeutics with focus on solid tumors. Clinical Epigenetics, 2021, 13, 83.	1.8	53
2242	R-2-HG in AMLâ€¦ friend or foe?. Blood Science, 2021, 3, 62-63.	0.4	0
2243	Normalization of metabolic data to total thymine content and its application to determination of 2-hydroxyglutarate. Analytical Biochemistry, 2021, 618, 114129.	1.1	3
2244	Targeting the Metabolic Adaptation of Metastatic Cancer. Cancers, 2021, 13, 1641.	1.7	10
2245	Metabolic adaptation in hypoxia and cancer. Cancer Letters, 2021, 502, 133-142.	3.2	86
2246	Exploring the Allosteric Territory of Protein Function. Journal of Physical Chemistry B, 2021, 125, 3763-3780.	1.2	26
2247	Control of endothelial quiescence by FOXO-regulated metabolites. Nature Cell Biology, 2021, 23, 413-423.	4.6	56
2248	Impact of MiRNA-181a2 on the Clinical Course of IDH1 Wild Type Glioblastoma. Processes, 2021, 9, 728.	1.3	1
2249	Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors. NAR Cancer, 2021, 3, zcab018.	1.6	17
2250	Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma. Cancer Research and Treatment, 2021, 53, 367-377.	1.3	13
2251	Mitochondrial metabolism as a target for acute myeloid leukemia treatment. Cancer & Metabolism, 2021, 9, 17.	2.4	31
2252	Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM. Journal of Personalized Medicine, 2021, 11, 290.	1.1	30
2253	Rediscovering Potential Molecular Targets for Glioma Therapy Through the Analysis of the Cell of Origin, Microenvironment and Metabolism. Current Cancer Drug Targets, 2021, 21, 558-574.	0.8	7
2254	The language of chromatin modification in human cancers. Nature Reviews Cancer, 2021, 21, 413-430.	12.8	179
2255	Ketogenic Metabolic Therapy, Without Chemo or Radiation, for the Long-Term Management of IDH1-Mutant Glioblastoma: An 80-Month Follow-Up Case Report. Frontiers in Nutrition, 2021, 8, 682243.	1.6	13
2256	Chondrosarcoma-from Molecular Pathology to Novel Therapies. Cancers, 2021, 13, 2390.	1.7	31
2257	Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nature Communications, 2021, 12, 2607.	5.8	61

#	Article	IF	Citations
2258	Hypoxia-Driven Oncometabolite L-2HG Maintains Stemness-Differentiation Balance and Facilitates Immune Evasion in Pancreatic Cancer. Cancer Research, 2021, 81, 4001-4013.	0.4	39
2259	The metabolite Î±-KG induces GSDMC-dependent pyroptosis through death receptor 6-activated caspase-8. Cell Research, 2021, 31, 980-997.	5.7	148
2260	From Metabolism to Genetics and Vice Versa: The Rising Role of Oncometabolites in Cancer Development and Therapy. International Journal of Molecular Sciences, 2021, 22, 5574.	1.8	6
2261	QSAR analysis of 3-pyrimidin-4-yl-oxazolidin-2-one derivatives isocitrate dehydrogenase inhibitors using Topomer CoMFA and HQSAR methods. Molecular Diversity, 2022, 26, 1017-1037.	2.1	6
2262	Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma. Expert Review of Gastroenterology and Hepatology, 2021, 15, 475-481.	1.4	2
2263	From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas. Cells, 2021, 10, 1225.	1.8	17
2264	Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. Nature Cancer, 2021, 2, 723-740.	5.7	110
2265	Metabolic regulation on the immune environment of glioma through gut microbiota. Seminars in Cancer Biology, 2022, 86, 990-997.	4.3	20
2266	Metabolomics in cancer research and emerging applications in clinical oncology. Ca-A Cancer Journal for Clinicians, 2021, 71, 333-358.	157.7	267
2267	Adverse Impact of DNA Methylation Regulatory Gene Mutations on the Prognosis of AML Patients in the 2017 ELN Favorable Risk Group, Particularly Those Defined by NPM1 Mutation. Diagnostics, 2021, 11, 986.	1.3	2
2268	How metabolism bridles cytotoxic CD8+ T cells through epigenetic modifications. Trends in Immunology, 2021, 42, 401-417.	2.9	18
2269	Evaluating Mechanisms of IDH1 Regulation through Site-Specific Acetylation Mimics. Biomolecules, 2021, 11, 740.	1.8	3
2270	Emerging Roles of Wild-type and Mutant IDH1 in Growth, Metabolism and Therapeutics of Glioma. , 0, , 61-78.		5
2271	Mitochondrial DNA variation and cancer. Nature Reviews Cancer, 2021, 21, 431-445.	12.8	98
2272	Glutamatergic Mechanisms in Glioblastoma and Tumor-Associated Epilepsy. Cells, 2021, 10, 1226.	1.8	40
2273	A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors. Cancers, 2021, 13, 2474.	1.7	13
2274	Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities. Mini-Reviews in Medicinal Chemistry, 2021, 21, 1113-1122.	1.1	0
2275	Spectral fitting strategy to overcome the overlap between 2â€hydroxyglutarate and lipid resonances at 2.25 ppm. Magnetic Resonance in Medicine, 2021, 86, 1818-1828.	1.9	7

#	Article	IF	Citations
2276	Integration of machine learning and genome-scale metabolic modeling identifies multi-omics biomarkers for radiation resistance. Nature Communications, 2021, 12, 2700.	5.8	95
2277	The Inhibition of B7H3 by 2-HG Accumulation Is Associated With Downregulation of VEGFA in IDH Mutated Gliomas. Frontiers in Cell and Developmental Biology, 2021, 9, 670145.	1.8	4
2278	The Acidic Brainâ€"Glycolytic Switch in the Microenvironment of Malignant Glioma. International Journal of Molecular Sciences, 2021, 22, 5518.	1.8	24
2279	Metabolic reprogramming and epigenetic modifications on the path to cancer. Protein and Cell, 2022, 13, 877-919.	4.8	179
2280	Imaging Findings of New Entities and Patterns in Brain Tumor. Radiologic Clinics of North America, 2021, 59, 305-322.	0.9	2
2281	Molecular and Metabolic Reprogramming: Pulling the Strings Toward Tumor Metastasis. Frontiers in Oncology, 2021, 11, 656851.	1.3	9
2282	Metabolic regulation in the immune response to cancer. Cancer Communications, 2021, 41, 661-694.	3.7	23
2283	Mitochondria and the permeability transition pore in cancer metabolic reprogramming. Biochemical Pharmacology, 2021, 188, 114537.	2.0	12
2284	The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ). Cancer Biology and Therapy, 2021, 22, 392-403.	1.5	4
2285	Quantitation of ivosidenib in human plasma via LCâ€"MS/MS and its application in clinical trials. Bioanalysis, 2021, 13, 875-889.	0.6	7
2286	RNA modifications in hematopoietic malignancies: a new research frontier. Blood, 2021, 138, 637-648.	0.6	24
2287	Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm. Blood Cancer Journal, 2021, 11, 107.	2.8	73
2288	Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate. Biochemistry, 2021, 60, 1983-1994.	1.2	2
2289	Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies. Frontiers in Oncology, 2021, 11, 631037.	1.3	10
2290	Metabolomics Monitoring of Treatment Response to Brain Tumor Immunotherapy. Frontiers in Oncology, 2021, 11, 691246.	1.3	13
2291	DNA Repair Mechanisms and Therapeutic Targets in Glioma. Current Oncology Reports, 2021, 23, 87.	1.8	16
2292	Altered Spontaneous Glutamatergic and GABAergic Activity in the Peritumoral Cortex of Low-Grade Gliomas Presenting With History of Seizures. Frontiers in Neuroscience, 2021, 15, 689769.	1.4	4
2293	Exploiting Electrode Nanoconfinement to Investigate the Catalytic Properties of Isocitrate Dehydrogenase (IDH1) and a Cancer-Associated Variant. Journal of Physical Chemistry Letters, 2021, 12, 6095-6101.	2.1	10

#	Article	IF	Citations
2294	Tumor Microenvironment-Derived Metabolites: A Guide to Find New Metabolic Therapeutic Targets and Biomarkers. Cancers, 2021, 13, 3230.	1.7	17
2295	Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. Oncologist, 2021, 26, 865-878.	1.9	39
2296	An l-2-hydroxyglutarate biosensor based on specific transcriptional regulator LhgR. Nature Communications, 2021, 12, 3619.	5.8	21
2297	Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. Clinical Cancer Research, 2021, 27, 4491-4499.	3.2	112
2298	Metabolic Rewiring and the Characterization of Oncometabolites. Cancers, 2021, 13, 2900.	1.7	32
2299	The implications of IDH mutations for cancer development and therapy. Nature Reviews Clinical Oncology, 2021, 18, 645-661.	12.5	155
2300	Cancer cell metabolism connects epigenetic modifications to transcriptional regulation. FEBS Journal, 2022, 289, 1302-1314.	2.2	23
2301	Urinary 2-Hydroxyglutarate Enantiomers Are Markedly Elevated in a Murine Model of Type 2 Diabetic Kidney Disease. Metabolites, 2021, 11, 469.	1.3	5
2302	2-HG modulates glioma macrophages via Trp metabolism. Nature Cancer, 2021, 2, 677-679.	5.7	2
2303	Rapid chiral discrimination of oncometabolite dl â€2â€hydroxyglutaric acid using derivatization and field asymmetric waveform ion mobility spectrometry/mass spectrometry. Journal of Separation Science, 2021, 44, 3489-3496.	1.3	7
2304	SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone. Cancers, 2021, 13, 3823.	1.7	7
2305	Complementary Nuclear Magnetic Resonance-Based Metabolomics Approaches for Glioma Biomarker Identification in a Drosophila melanogaster Model. Journal of Proteome Research, 2021, 20, 3977-3991.	1.8	4
2306	Metformin Decreases 2-HG Production through the MYC-PHGDH Pathway in Suppressing Breast Cancer Cell Proliferation. Metabolites, 2021, 11, 480.	1.3	6
2307	Therapeutic targeting of the hypoxic tumour microenvironment. Nature Reviews Clinical Oncology, 2021, 18, 751-772.	12.5	185
2308	Cancer metabolism: looking forward. Nature Reviews Cancer, 2021, 21, 669-680.	12.8	676
2309	Sensitive Detection of Molecular Targets in Cancer by Minisequencing. Acibadem Universitesi Saglik Bilimleri Dergisi, 2021, 12, .	0.0	0
2310	Molecular characterization of fast-growing melanomas. Journal of the American Academy of Dermatology, 2022, 86, 312-321.	0.6	11
2311	Cytosolic GDH1 degradation restricts protein synthesis to sustain tumor cell survival following amino acid deprivation. EMBO Journal, 2021, 40, e107480.	3.5	11

#	Article	IF	Citations
2312	Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant IDH1 for Treatment of IDH1-Mutant Malignancies. Drug Metabolism and Disposition, 2021, 49, DMD-AR-2020-000234.	1.7	4
2313	Chromatin insulation dynamics in glioblastoma: challenges and future perspectives of precision oncology. Clinical Epigenetics, 2021, 13, 150.	1.8	9
2314	IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma. Advanced Science, 2021, 8, e2101230.	5.6	26
2315	Harnessing Lactate Metabolism for Radiosensitization. Frontiers in Oncology, 2021, 11, 672339.	1.3	11
2316	Synthesis of [1â€¹³Câ€5â€¹²C]â€alphaâ€ketoglutarate enables noninvasive detection of 2â€hydroxyglutarate. NMR in Biomedicine, 2021, 34, e4588.	1.6	6
2317	Chance Favors the Perplexed Mind: The Critical Role of Mechanistic Biochemistry in Drug Discovery. Biochemistry, 2021, 60, 2275-2284.	1.2	2
2318	Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma. Frontiers in Cellular Neuroscience, 2021, 15, 704344.	1.8	15
2319	Immunometabolism: A â€˜Hotâ€™ Switch for â€˜Coldâ€™ Pediatric Solid Tumors. Trends in Cancer, 2021, 7, 751-778.	3.8	8
2320	Monoallelic IDH1 R132H Mutation Mediates Glioma Cell Response to Anticancer Therapies via Induction of Senescence. Molecular Cancer Research, 2021, 19, 1878-1888.	1.5	2
2321	The Crucial Roles of Intermediate Metabolites in Cancer. Cancer Management and Research, 2021, Volume 13, 6291-6307.	0.9	5
2322	Joint application of biochemical markers and imaging techniques in the accurate and early detection of glioblastoma. Pathology Research and Practice, 2021, 224, 153528.	1.0	1
2324	TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas. Clinical Cancer Research, 2021, 27, 5669-5680.	3.2	4
2325	Prolyl-4-hydroxylase 3 maintains Î² cell glucose metabolism during fatty acid excess in mice. JCI Insight, 2021, 6, .	2.3	5
2326	IDH-Mutant Brain Tumors Hit the Achillesâ€™ Heel of Macrophages with R-2-Hydroxyglutarate. Trends in Cancer, 2021, 7, 666-667.	3.8	6
2328	TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	29
2329	Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer. Oncogene, 2021, 40, 5880-5892.	2.6	15
2330	Influence of scalp block on oncological outcomes of high-grade glioma in adult patients with and without isocitrate dehydrogenase-1 mutation. Scientific Reports, 2021, 11, 16489.	1.6	1
2331	Metabolomics, metabolic flux analysis and cancer pharmacology. , 2021, 224, 107827.		44

#	Article	IF	Citations
2332	Current human brain applications and challenges of dynamic hyperpolarized carbon-13 labeled pyruvate MR metabolic imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4225-4235.	3.3	10
2333	Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma. Cells, 2021, 10, 2116.	1.8	8
2334	Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications. Frontiers in Oncology, 2021, 11, 703764.	1.3	27
2335	A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer Database. Cancers, 2021, 13, 4299.	1.7	20
2336	Metabolomics in oncology â€“ A fascinating travel into the mechanisms of metabolic disturbances during carcinogenesis. Forum of Clinical Oncology, 2021, 12, 1-2.	0.1	0
2337	IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat. Journal of Neuro-Oncology, 2021, 154, 159-170.	1.4	8
2338	Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. Molecular Cell, 2021, 81, 3833-3847.e11.	4.5	10
2339	D-2-Hydroxyglutarate in Glioma Biology. Cells, 2021, 10, 2345.	1.8	26
2340	Guaiazulene derivative 1,2,3,4â€tetrahydroazuleno[1,2â€•b] tropone reduces the production of ATP by inhibiting electron transfer complex II. FEBS Open Bio, 2021, 11, 2921-2932.	1.0	1
2341	Interplay between Epigenetics and Cellular Metabolism in Colorectal Cancer. Biomolecules, 2021, 11, 1406.	1.8	4
2342	The Interplay Between Prostate Cancer Genomics, Metabolism, and the Epigenome: Perspectives and Future Prospects. Frontiers in Oncology, 2021, 11, 704353.	1.3	8
2343	Biological evaluation of mitochondria targeting small molecules as potent anticancer drugs. Bioorganic Chemistry, 2021, 114, 105055.	2.0	6
2344	Metabolic Reprogramming and Immune Evasion in Nasopharyngeal Carcinoma. Frontiers in Immunology, 2021, 12, 680955.	2.2	16
2346	Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma. Frontiers in Endocrinology, 2021, 12, 731096.	1.5	5
2347	Simple Esterification of [1-¹³C]-Alpha-Ketoglutarate Enhances Membrane Permeability and Allows for Noninvasive Tracing of Glutamate and Glutamine Production. ACS Chemical Biology, 2021, 16, 2144-2150.	1.6	6
2348	The Big Picture of Glioblastoma Malignancy: A Meta-Analysis of Glioblastoma Proteomics to Identify Altered Biological Pathways. ACS Omega, 2021, 6, 24535-24544.	1.6	6
2349	Prognostic and Predictive Biomarkers in Gliomas. International Journal of Molecular Sciences, 2021, 22, 10373.	1.8	110
2350	Single-cell multimodal glioma analyses identify epigenetic regulators of cellular plasticity and environmental stress response. Nature Genetics, 2021, 53, 1456-1468.	9.4	111

#	Article	IF	Citations
2351	Absolute quantification of 2â€hydroxyglutarate on tissue by matrixâ€assisted laser desorption/ionization mass spectrometry imaging for rapid and precise identification of isocitrate dehydrogenase mutations in human glioma. International Journal of Cancer, 2021, 149, 2091-2098.	2.3	2
2352	A map of the altered glioma metabolism. Trends in Molecular Medicine, 2021, 27, 1045-1059.	3.5	18
2353	HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells. Cells, 2021, 10, 2371.	1.8	41
2354	Clinical Targeting of Altered Metabolism in High-Grade Glioma. Cancer Journal (Sudbury, Mass), 2021, 27, 386-394.	1.0	6
2355	Current emerging MRI tools for radionecrosis and pseudoprogression diagnosis. Current Opinion in Oncology, 2021, 33, 597-607.	1.1	17
2356	The Evolving Molecular Landscape of High-Grade Gliomas. Cancer Journal (Sudbury, Mass), 2021, 27, 337-343.	1.0	5
2357	Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments. Cancers, 2021, 13, 4544.	1.7	11
2358	Cancer-associated IDH mutations induce Glut1 expression and glucose metabolic disorders through a PI3K/Akt/mTORC1-Hif1Î± axis. PLoS ONE, 2021, 16, e0257090.	1.1	5
2360	Chromatographic methods coupled to mass spectrometry for the determination of oncometabolites in biological samples-A review. Analytica Chimica Acta, 2021, 1177, 338646.	2.6	5
2361	SOHO State of the Art Updates and Next Questions: IDH Inhibition. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 567-572.	0.2	0
2362	Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development. Frontiers in Immunology, 2021, 12, 738435.	2.2	13
2363	Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair. Molecular Cancer Research, 2021, 19, 2057-2067.	1.5	10
2364	Crystal structures of NAD+-linked isocitrate dehydrogenase from the green alga Ostreococcus tauri and its evolutionary relationship with eukaryotic NADP+-linked homologs. Archives of Biochemistry and Biophysics, 2021, 708, 108898.	1.4	2
2365	Atomic Force Microscope Nanoindentation Analysis of Diffuse Astrocytic Tumor Elasticity: Relation with Tumor Histopathology. Cancers, 2021, 13, 4539.	1.7	6
2367	Comparison of 2-Hydroxyglutarate Detection With sLASER and MEGA-sLASER at 7T. Frontiers in Neurology, 2021, 12, 718423.	1.1	9
2368	Growth Inhibition and Induction of Innate Immune Signaling of Chondrosarcomas with Epigenetic Inhibitors. Molecular Cancer Therapeutics, 2021, 20, 2362-2371.	1.9	4
2369	Mutant IDH1 inhibitors activate pSTAT3-Y705 leading to an increase in BCAT1 and YKL-40 levels in mutant IDH1-expressing cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 119114.	1.9	9
2370	Targeting the replication stress response through synthetic lethal strategies in cancer medicine. Trends in Cancer, 2021, 7, 930-957.	3.8	48

#	Article	IF	Citations
2371	Single-cell profiling of D-2-hydroxyglutarate using surface-immobilized resazurin analogs. Biosensors and Bioelectronics, 2021, 190, 113368.	5.3	5
2372	Antioxidant responses related to temozolomide resistance in glioblastoma. Neurochemistry International, 2021, 149, 105136.	1.9	17
2373	Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1. Cancer Letters, 2021, 517, 35-45.	3.2	15
2374	Determination of intracellular 2-hydroxyglutarate enantiomers using two-dimensional liquid chromatography. Journal of Chromatography Open, 2021, 1, 100005.	0.8	3
2375	R-2HG downregulates ERÎ± to inhibit cholangiocarcinoma via the FTO/m6A-methylated ERÎ±/miR16-5p/YAP1 signal pathway. Molecular Therapy - Oncolytics, 2021, 23, 65-81.	2.0	14
2376	Clotrimazole presents anticancer properties against a mouse melanoma model acting as a PI3K inhibitor and inducing repolarization of tumor-associated macrophages. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166263.	1.8	8
2377	Biology of cartilage tumor family. , 2022, , 649-662.		1
2378	Markers for bone sarcomas. , 2022, , 543-577.		0
2379	Mitochondrial dysfunction in kidney diseases. , 2021, , 119-154.		0
2380	ToPP: Tumor online Prognostic Analysis Platform for Prognostic Feature Selection and Clinical Patient Subgroup Selection. SSRN Electronic Journal, 0, , .	0.4	1
2381	Oxygen regulation of TET enzymes. FEBS Journal, 2021, 288, 7143-7161.	2.2	20
2382	Tricarboxylic Acid (TCA) Cycle Intermediates: Regulators of Immune Responses. Life, 2021, 11, 69.	1.1	66
2383	The metabolic reprogramming in acute myeloid leukemia patients depends on their genotype and is a prognostic marker. Blood Advances, 2021, 5, 156-166.	2.5	26
2384	Characterization of primary glioma cell lines derived from the patients according to 2016 CNS tumour WHO classification and comparison with their parental tumours. Journal of Neuro-Oncology, 2021, 151, 123-133.	1.4	9
2385	Novel Magnetic Resonance Imaging and Positron Emission Tomography in the RT Planning and Assessment of Response of Malignant Gliomas. , 2021, , 1031-1048.		2
2386	Significance of Research Career for Neurosurgeons : Development of Brain Tumor Biology through Translational Research. Japanese Journal of Neurosurgery, 2021, 30, 280-286.	0.0	0
2387	Proteins moonlighting in tumor metabolism and epigenetics. Frontiers of Medicine, 2021, 15, 383-403.	1.5	12
2388	Metabolic Control of m6A RNA Modification. Metabolites, 2021, 11, 80.	1.3	24

#	Article	IF	Citations
2389	Bioinformatics Approaches for Interpreting Metabolomics Datasets. , 2021, , 370-384.		0
2390	Structure, substrate specificity, and catalytic mechanism of human D-2-HGDH and insights into pathogenicity of disease-associated mutations. Cell Discovery, 2021, 7, 3.	3.1	12
2391	The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia. Seminars in Hematology, 2021, 58, 56-65.	1.8	8
2392	Diagnosis of Glioma Molecular Markers by Terahertz Technologies. Photonics, 2021, 8, 22.	0.9	21
2393	Synthesis of 2-oxoglutarate derivatives and their evaluation as cosubstrates and inhibitors of human aspartate/asparagine-Î²-hydroxylase. Chemical Science, 2021, 12, 1327-1342.	3.7	8
2394	Population pharmacokinetic and exposureâ€response analyses of ivosidenib in patients with IDH1â€mutant advanced hematologic malignancies. Clinical and Translational Science, 2021, 14, 942-953.	1.5	8
2396	Advances in Research of Adult Gliomas. International Journal of Molecular Sciences, 2021, 22, 924.	1.8	27
2397	Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate. Advances in Experimental Medicine and Biology, 2021, 1280, 161-172.	0.8	3
2398	IDH1 mutations induce organelle defects via dysregulated phospholipids. Nature Communications, 2021, 12, 614.	5.8	44
2399	In vivo MRS measurement of 2â€hydroxyglutarate in patientâ€derived IDHâ€mutant xenograft mouse models versus glioma patients. Magnetic Resonance in Medicine, 2020, 84, 1152-1160.	1.9	11
2400	Deuterium Tracing to Interrogate Compartment-Specific NAD(P)H Metabolism in Cultured Mammalian Cells. Methods in Molecular Biology, 2020, 2088, 51-71.	0.4	5
2401	Understanding Cancer Metabolism Through Global Metabolomics. , 2012, , 177-190.		6
2402	Histone Methylation in Chromatin Signaling. , 2014, , 213-256.		4
2403	Inhibition of Glycolysis as a Therapeutic Strategy in Acute Myeloid Leukemias. , 2015, , 709-723.		1
2404	Adult High-Grade (Diffuse) Glioma. Molecular Pathology Library, 2015, , 77-93.	0.1	2
2405	Regulation of 5-Hydroxymethylcytosine Distribution by the TET Enzymes. RNA Technologies, 2019, , 229-263.	0.2	3
2406	Origin and Mechanisms of DNA Methylation Dynamics in Cancers. RNA Technologies, 2019, , 27-52.	0.2	2
2407	MRS for D-2HG Detection in IDH-Mutant Glioma. , 2020, , 173-189.		1

#	Article	IF	Citations
2408	C-13 Hyperpolarized MR Spectroscopy for Metabolic Imaging of Brain Tumors. , 2020, , 191-209.		7
2409	Exploring Cancer Metabolism: Applications of Metabolomics and Metabolic Phenotyping in Cancer Research and Diagnostics. Advances in Experimental Medicine and Biology, 2020, 1219, 367-385.	0.8	7
2410	Novel Chemotherapeutic Approaches in Adult High-Grade Gliomas. Cancer Treatment and Research, 2015, 163, 117-142.	0.2	5
2411	Molecular-Genetic Classification of Gliomas and Its Practical Application to Diagnostic Neuropathology. , 2017, , 73-100.		2
2412	Cerebral Organic Acid Disorders and Other Disorders of Lysine Catabolism. , 2012, , 333-347.		3
2413	Metabolic Fluxes in Cancer Metabolism. , 2015, , 315-348.		5
2414	Gliomatosis Cerebri: Implications of Genetic Findings. Tumors of the Central Nervous System, 2014, , 85-92.	0.1	1
2416	Liver Transplantation Biomarkers in the Metabolomics Era. Biomarkers in Disease, 2017, , 99-128.	0.0	2
2417	Mitophagy and Reverse Warburg Effect: Metabolic Compartmentalization of Tumor Microenvironment. , 2020, , 117-140.		1
2418	Reduced expression of DNA repair genes and chemosensitivity in 1p19q codeleted lower-grade gliomas. Journal of Neuro-Oncology, 2018, 139, 563-571.	1.4	17
2419	Differential expression of the BCAT isoforms between breast cancer subtypes. Breast Cancer, 2021, 28, 592-607.	1.3	7
2420	Cancer and the Nervous System. , 2008, , 1313-1333.		1
2421	Cancer of the Central Nervous System. , 2014, , 938-1001.e16.		1
2422	Epigenetic regulation of cancer stem cell and tumorigenesis. Advances in Cancer Research, 2020, 148, 1-26.	1.9	12
2423	Reprogramming of serine, glycine and one-carbon metabolism in cancer. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165841.	1.8	53
2424	Glioblastoma Utilizes Fatty Acids and Ketone Bodies for Growth Allowing Progression during Ketogenic Diet Therapy. IScience, 2020, 23, 101453.	1.9	47
2425	Metabonomic study of the intervention effects of Parthenolide on anti-thyroid cancer activity. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1150, 122179.	1.2	8
2426	Cancer metabolism. , 0, , 295-308.		1

#	Article	IF	Citations
2427	Mechanistic enzymology in drug discovery: a fresh perspective. Nature Reviews Drug Discovery, 2018, 17, 115-132.	21.5	124
2428	Structure and allosteric regulation of human NAD-dependent isocitrate dehydrogenase. Cell Discovery, 2020, 6, 94.	3.1	14
2429	Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. Nature Genetics, 2018, 50, 62-72.	9.4	137
2430	Introduction to Structural Studies on 2-Oxoglutarate-Dependent Oxygenases and Related Enzymes. 2-Oxoglutarate-Dependent Oxygenases, 2015, , 59-94.	0.8	30
2431	Mass spectrometry-based metabolomics in health and medical science: a systematic review. RSC Advances, 2020, 10, 3092-3104.	1.7	117
2432	An acidic residue buried in the dimer interface of isocitrate dehydrogenase 1 (IDH1) helps regulate catalysis and pH sensitivity. Biochemical Journal, 2020, 477, 2999-3018.	1.7	8
2433	In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma. Bioscience Reports, 2020, 40, .	1.1	12
2435	Clinicopathologic Characterization of Hypocellular Acute Myeloid Leukemia (AML) Showed Fewer Genetic Abnormalities Involving Cell Proliferation and NPM1 When Compared With Nonhypocellular AML. American Journal of Clinical Pathology, 2021, 155, 446-454.	0.4	2
2436	Adult precision medicine: learning from the past to enhance the future. Neuro-Oncology Advances, 2021, 3, vdaa145.	0.4	11
2437	Glycolytic expression in lower-grade glioma reveals an epigenetic association between IDH mutation status and PDL1/2 expression. Neuro-Oncology Advances, 2021, 3, vdaa162.	0.4	3
2448	Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of nonâ€smallâ€cell lung cancer: A multicenter in vitro diagnostic clinical trial. Cancer Science, 2020, 111, 1739-1749.	1.7	11
2449	Mitochondrial Alteration: A Major Player in Carcinogenesis. Cell Biology, 2015, 3, 8.	0.2	3
2450	Nicotinamide metabolism regulates glioblastoma stem cell maintenance. JCI Insight, 2017, 2, .	2.3	93
2451	Emerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy. Journal of Clinical Investigation, 2018, 128, 3682-3691.	3.9	59
2452	Isocitrate dehydrogenase mutations in leukemia. Journal of Clinical Investigation, 2013, 123, 3672-3677.	3.9	59
2453	Resisting fatal attraction: a glioma oncometabolite prevents CD8+ T cell recruitment. Journal of Clinical Investigation, 2017, 127, 1218-1220.	3.9	15
2454	JAK2/IDH-mutantâ€“driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. Journal of Clinical Investigation, 2018, 128, 789-804.	3.9	66
2455	How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?. Hematology American Society of Hematology Education Program, 2012, 2012, 28-34.	0.9	30

#	Article	IF	Citations
2456	Interpreting new molecular genetics in myelodysplastic syndromes. Hematology American Society of Hematology Education Program, 2012, 2012, 56-64.	0.9	26
2457	Single-agent and combination biologics in acute myeloid leukemia. Hematology American Society of Hematology Education Program, 2019, 2019, 548-556.	0.9	22
2458	Low-grade Gliomas. CONTINUUM Lifelong Learning in Neurology, 2017, 23, 1564-1579.	0.4	17
2459	IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma. Medical Science Monitor, 2014, 20, 247-254.	0.5	10
2460	Chondrosarcoma: biology, genetics, and epigenetics. F1000Research, 2018, 7, 1826.	0.8	90
2461	Advances in treating acute myeloid leukemia. F1000prime Reports, 2014, 6, 96.	5.9	28
2462	Chicken or the egg: Warburg effect and mitochondrial dysfunction. F1000prime Reports, 2015, 7, 41.	5.9	64
2463	MicroRNA and Target Protein Patterns Reveal Physiopathological Features of Glioma Subtypes. PLoS ONE, 2011, 6, e20600.	1.1	121
2464	Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis. PLoS ONE, 2012, 7, e43090.	1.1	97
2465	Cancer Missense Mutations Alter Binding Properties of Proteins and Their Interaction Networks. PLoS ONE, 2013, 8, e66273.	1.1	102
2466	Mutation Analysis of IDH1 in Paired Gliomas Revealed IDH1 Mutation Was Not Associated with Malignant Progression but Predicted Longer Survival. PLoS ONE, 2013, 8, e67421.	1.1	25
2467	IDH1/IDH2 Mutations Define the Prognosis and Molecular Profiles of Patients with Gliomas: A Meta-Analysis. PLoS ONE, 2013, 8, e68782.	1.1	96
2468	A New Specific Succinate-Glutamate Metabolomic Hallmark in Sdhx-Related Paragangliomas. PLoS ONE, 2013, 8, e80539.	1.1	39
2469	Molecular Subtypes of Glioblastoma Are Relevant to Lower Grade Glioma. PLoS ONE, 2014, 9, e91216.	1.1	76
2470	Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis. PLoS ONE, 2014, 9, e100206.	1.1	47
2471	Single Arginine Mutation in Two Yeast Isocitrate Dehydrogenases: Biochemical Characterization and Functional Implication. PLoS ONE, 2014, 9, e115025.	1.1	7
2472	A Novel Type II NAD+-Specific Isocitrate Dehydrogenase from the Marine Bacterium Congregibacter litoralis KT71. PLoS ONE, 2015, 10, e0125229.	1.1	10
2473	On the Utility of Short Echo Time (TE) Single Voxel 1Hâ€“MRS in Nonâ€“Invasive Detection of 2â€“Hydroxyglutarate (2HG); Challenges and Potential Improvement Illustrated with Animal Models Using MRUI and LCModel. PLoS ONE, 2016, 11, e0147794.	1.1	10

#	Article	IF	Citations
2474	Loss of 5-Hydroxymethylcytosine Is an Independent Unfavorable Prognostic Factor for Esophageal Squamous Cell Carcinoma. PLoS ONE, 2016, 11, e0153100.	1.1	22
2475	Assessment of FBA Based Gene Essentiality Analysis in Cancer with a Fast Context-Specific Network Reconstruction Method. PLoS ONE, 2016, 11, e0154583.	1.1	13
2476	Diagnostic markers for glioblastoma. Histology and Histopathology, 2011, 26, 1327-41.	0.5	16
2477	The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis. Journal of Clinical Medicine Research, 2016, 8, 29-39.	0.6	13
2478	Identification of a New Selective Chemical Inhibitor of Mutant Isocitrate Dehydrogenase-1. Journal of Cancer Prevention, 2015, 20, 78-83.	0.8	6
2479	Glioblastoma Genomics: A Very Complicated Story. , 0, , 3-25.		18
2480	Molecular Genetics of Secondary Glioblastoma. , 0, , 27-42.		13
2481	mIDH-associated DNA hypermethylation in acute myeloid leukemia reflects differentiation blockage rather than inhibition of TET-mediated demethylation. Cell Stress, 2017, 1, 55-67.	1.4	3
2483	In vitro visualization and characterization of wild type and mutant IDH homo- and heterodimers using Bimolecular Fluorescence Complementation. Cancer Research Frontiers, 2016, 2, 311-329.	0.2	7
2484	Improved Localization for 2-Hydroxyglutarate Detection at 3 T Using Long-TE Semi-LASER. Tomography, 2016, 2, 94-105.	0.8	22
2485	The Immunobiology of Cancer: An Update Review. Indonesian Biomedical Journal, 2017, 9, 53.	0.2	2
2486	IDH mutation-specific radiomic signature in lower-grade gliomas. Aging, 2019, 11, 673-696.	1.4	51
2487	Another small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancer. Oncoscience, 2015, 2, 483-486.	0.9	16
2488	Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma. Oncotarget, 2016, 7, 69518-69535.	0.8	51
2489	IGFBP2 expression predicts IDH-mutant glioma patient survival. Oncotarget, 2017, 8, 191-202.	0.8	30
2490	Prognostic and diagnostic potential of isocitrate dehydrogenase 1 in esophageal squamous cell carcinoma. Oncotarget, 2016, 7, 86148-86160.	0.8	9
2491	Decreased 5-hydroxymethylcytosine levels correlate with cancer progression and poor survival: a systematic review and meta-analysis. Oncotarget, 2017, 8, 1944-1952.	0.8	32
2492	5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget, 2013, 4, 1737-1747.	0.8	141

#	Article	IF	Citations
2493	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget, 2013, 4, 1729-1736.	0.8	213
2494	PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas. Oncotarget, 2017, 8, 15827-15837.	0.8	14
2495	In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma. Oncotarget, 2017, 8, 49165-49177.	0.8	61
2496	Radiomic model for predicting mutations in the isocitrate dehydrogenase gene in glioblastomas. Oncotarget, 2017, 8, 45888-45897.	0.8	43
2497	Targeting Metabolic Remodeling in Glioblastoma Multiforme. Oncotarget, 2010, 1, 552-562.	0.8	178
2498	Pyrimidine metabolic rate limiting enzymes in poorly-differentiated hepatocellular carcinoma are signature genes of cancer stemness and associated with poor prognosis. Oncotarget, 2017, 8, 77734-77751.	0.8	38
2499	Identification of SPOP related metabolic pathways in prostate cancer. Oncotarget, 2017, 8, 103032-103046.	0.8	16
2500	Targeted inhibition of glutaminase as a potential new approach for the treatment of NF1 associated soft tissue malignancies. Oncotarget, 2017, 8, 94054-94068.	0.8	26
2501	WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression. Oncotarget, 2017, 8, 106352-106368.	0.8	4
2502	Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity. Oncotarget, 2014, 5, 7960-7979.	0.8	35
2503	Deep sequencing of a recurrent oligodendroglioma and the derived xenografts reveals new insights into the evolution of human oligodendroglioma and candidate driver genes. Oncotarget, 2019, 10, 3641-3653.	0.8	1
2504	High expression of N-myc (and STAT) interactor predicts poor prognosis and promotes tumor growth in human glioblastoma. Oncotarget, 2015, 6, 4901-4919.	0.8	29
2505	D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth. Oncotarget, 2015, 6, 8606-8620.	0.8	46
2506	Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget, 2015, 6, 12279-12296.	0.8	53
2507	Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies. Oncotarget, 2015, 6, 17354-17365.	0.8	51
2508	The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo. Oncotarget, 2015, 6, 14832-14842.	0.8	33
2509	Capturing the Molecular and Biological Diversity of High-Grade Astrocytoma in Genetically Engineered Mouse Models. Oncotarget, 2012, 3, 67-77.	0.8	16
2510	IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma. Oncotarget, 2015, 6, 30232-30238.	0.8	77

#	Article	IF	Citations
2511	Co-expression of mitosis-regulating genes contributes to malignant progression and prognosis in oligodendrogliomas. Oncotarget, 2015, 6, 38257-38269.	0.8	11
2512	IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. Oncotarget, 2015, 6, 40896-40906.	0.8	116
2513	Mutant IDH1 is required for IDH1 mutated tumor cell growth. Oncotarget, 2012, 3, 774-782.	0.8	37
2514	Decrease of 5hmC in gastric cancers is associated withTET1silencing due to with DNA methylation and bivalent histone marks atTET1CpG island 3â€²-shore. Oncotarget, 2015, 6, 37647-37662.	0.8	27
2515	Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget, 2012, 3, 1194-1203.	0.8	241
2516	Hypotaurine evokes a malignant phenotype in glioma through aberrant hypoxic signaling. Oncotarget, 2016, 7, 15200-15214.	0.8	30
2517	Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters. Oncotarget, 2016, 7, 34942-34955.	0.8	32
2518	Validation of a multi-omics strategy for prioritizing personalized candidate driver genes. Oncotarget, 2016, 7, 38440-38450.	0.8	6
2519	(R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas. Translational Cancer Research, 2019, 8, S167-S170.	0.4	22
2520	Epigenetic Metalloenzymes. Current Medicinal Chemistry, 2019, 26, 2748-2785.	1.2	12
2521	The Role of Mitochondria in Cancer Induction, Progression and Changes in Metabolism. Mini-Reviews in Medicinal Chemistry, 2016, 16, 524-530.	1.1	14
2522	Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation. Current Cancer Drug Targets, 2020, 20, 490-500.	0.8	14
2523	Untangling the Metabolic Reprogramming in Brain Cancer: Discovering Key Molecular Players Using Mass Spectrometry. Current Topics in Medicinal Chemistry, 2019, 19, 1521-1534.	1.0	20
2524	Identification of New Inhibitors of Mutant Isocitrate Dehydrogenase 2 through Molecular Similarity-based Virtual Screening. Letters in Drug Design and Discovery, 2019, 16, 861-867.	0.4	2
2525	Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer. Medicinal Chemistry, 2018, 14, 715-724.	0.7	5
2526	Molecular Markers of Glioblastoma and the Potential for Integration with Imaging: the Future for Assigning Prognosis and Best Treatment Strategy. Current Molecular Imaging, 2013, 2, 107-116.	0.7	1
2527	Quantification of 2-Hydroxyglutarate Enantiomers by Liquid Chromatography-mass Spectrometry. Bio-protocol, 2016, 6, .	0.2	17
2528	Transplantation in oncology: the future of a multidisciplinary approach. TransplantologiÃ¢, 2019, 11, 218-233.	0.1	7

#	Article	IF	Citations
2529	Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells. Radiology and Oncology, 2018, 52, 392-398.	0.6	3
2530	Advances in New Targets for Differentiation Therapy of Acute Myeloid Leukemia. Journal of Cancer Research Updates, 0, 9, 88-95.	0.3	1
2531	Maffucci syndrome complicated by three different central nervous system tumors sharing an IDH1 R132C mutation: case report. Journal of Neurosurgery, 2019, 131, 1829-1834.	0.9	6
2532	Molecular Biomarkers of Brain and Spinal Cord Astrocytomas. Acta Naturae, 2019, 11, 17-27.	1.7	9
2533	Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them?. Frontiers in Neurology, 2012, 3, 188.	1.1	17
2534	Regulating Methylation at H3K27: A Trick or Treat for Cancer Cell Plasticity. Cancers, 2020, 12, 2792.	1.7	26
2535	Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice. World Journal of Gastroenterology, 2016, 22, 2071.	1.4	11
2536	Role of succinate dehydrogenase deficiency and oncometabolites in gastrointestinal stromal tumors. World Journal of Gastroenterology, 2020, 26, 5074-5089.	1.4	15
2537	IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1â€‘mutant tumor cells. Molecular Medicine Reports, 2019, 20, 1893-1900.	1.1	4
2538	Wildâ€‘type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells. Molecular Medicine Reports, 2020, 22, 1949-1957.	1.1	13
2539	EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma. Oncology Letters, 2020, 20, 1-1.	0.8	3
2540	Increased RLIP76 expression in IDH1 wildâ€‘type glioblastoma multiforme is associated with worse prognosis. Oncology Reports, 2020, 43, 188-200.	1.2	9
2541	Reactive oxygen species in eradicating acute myeloid leukemic stem cells. Stem Cell Investigation, 2014, 1, 13.	1.3	20
2542	Arteriovenous malformation within an isocitrate dehydrogenase 1 mutated anaplastic oligodendroglioma. , 2015, 6, 295.		1
2543	Role of natural killer cells in isocitrate dehydrogenase 1/2 mutant glioma pathogenesis and emerging therapies. Glioma (Mumbai, India), 2019, 2, 133.	0.0	2
2544	Impact of the revised WHO classification of diffuse low-grade glioma on clinical decision making: A case report. , 2017, 8, 223.		5
2545	Therapeutic Targeting of Cancer Cell Metabolism: Role of Metabolic Enzymes, Oncogenes and Tumor Suppressor Genes. Journal of Cancer Science & Therapy, 2012, 04, .	1.7	14
2546	Cancer Metabolism and Its Therapeutic Implications. Journal of Cell Science & Therapy, 2013, 04, .	0.3	3

#	Article	IF	Citations
2547	Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models. BMB Reports, 2011, 44, 158-164.	1.1	53
2548	Molecular biology of Philadelphia-negative myeloproliferative neoplasms. Revista Brasileira De Hematologia E Hemoterapia, 2012, 34, 150-155.	0.7	14
2549	Molecular Diagnostics of Gliomas. Archives of Pathology and Laboratory Medicine, 2011, 135, 558-568.	1.2	67
2550	IDH1 Overexpression Induced Chemotherapy Resistance and IDH1 Mutation Enhanced Chemotherapy Sensitivity in Glioma Cells in Vitro and in Vivo. Asian Pacific Journal of Cancer Prevention, 2014, 15, 427-432.	0.5	38
2551	Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. ELife, 2016, 5, .	2.8	17
2552	Metabolic network rewiring of propionate flux compensates vitamin B12 deficiency in C. elegans. ELife, 2016, 5, .	2.8	96
2553	Oncometabolite D-2-Hydroxyglutarate enhances gene silencing through inhibition of specific H3K36 histone demethylases. ELife, 2017, 6, .	2.8	25
2554	Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. ELife, 2017, 6, .	2.8	17
2555	Mutation profile of acute myeloid leukaemia in a Chinese cohort by targeted nextâ€generation sequencing. Cancer Reports, 2022, 5, e1573.	0.6	2
2556	From a dimer to a monomer: Construction of a chimeric monomeric isocitrate dehydrogenase. Protein Science, 2021, 30, 2396-2407.	3.1	2
2557	Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives. International Journal of Molecular Sciences, 2021, 22, 10931.	1.8	22
2558	Potential Diagnostic Value of the Differential Expression of Histone H3 Variants between Low- and High-Grade Gliomas. Cancers, 2021, 13, 5261.	1.7	4
2559	Pharmacoresistant seizures and IDH mutation in low-grade gliomas. Neuro-Oncology Advances, 2021, 3, vdab146.	0.4	5
2560	Tissue 2-Hydroxyglutarate and Preoperative Seizures in Patients With Diffuse Gliomas. Neurology, 2021, 97, e2114-e2123.	1.5	3
2561	Synthesis and Evaluation of 3-(Indol-3-yl)-4-(Pyrazolo[3,4-c]Pyridazin-3-yl)-Maleimides as Potent Mutant Isocitrate Dehydrogenase-1 Inhibitors. Pharmaceutical Chemistry Journal, 2021, 55, 655-664.	0.3	0
2562	Improving Dâ€2â€hydroxyglutarate MR spectroscopic imaging in mutant isocitrate dehydrogenase glioma patients with multiplexed RFâ€receive/B₀â€shim array coils at 3â€‰T. NMR in Biomedicine, 2022, 35, e4621.	1.6	2
2563	YAP1-mediated regulation of mitochondrial dynamics in IDH1 mutant gliomas. Journal of Cell Science, 2021, 134, .	1.2	7
2564	One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies. Epigenomes, 2021, 5, 22.	0.8	3

#	Article	IF	Citations
2565	Oligodendroglioma: A Review of Management and Pathways. Frontiers in Molecular Neuroscience, 2021, 14, 722396.	1.4	11
2566	Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms. Hematology/Oncology Clinics of North America, 2021, 36, 95-111.	0.9	6
2567	Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. Cancer, 2022, 128, 47-58.	2.0	132
2568	Aberrant Metabolism as Inductor of Epigenetic Changes in Breast Cancer: Therapeutic Opportunities. Frontiers in Oncology, 2021, 11, 676562.	1.3	10
2569	Tyrosine phosphorylation of DEPTOR functions as a molecular switch to activate mTOR signaling. Journal of Biological Chemistry, 2021, 297, 101291.	1.6	8
2570	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Yearbook of Neurology and Neurosurgery, 2010, 2010, 111-112.	0.0	0
2572	Gliomagenesis: Advantages and Limitations of Biomarkers. , 2011, , 11-24.		1
2573	ProgrÃ¨s rÃ©cents dans la gÃ©nomique et dans le traitement mÃ©dical des gliomes cÃ©rÃ©braux. Bulletin De L'Academie Nationale De Medecine, 2011, 195, 11-21.	0.0	0
2574	Global Molecular and Cellular Measurement Technologies. , 2011, , 97-126.		0
2575	Biomarker Discovery, Validation and Clinical Application for Patients Diagnosed with Glioma. , 0, , .		0
2576	Molecular Etiology of Glioblastomas: Implication of Genomic Profiling From the Cancer Genome Atlas Project. , 0, , .		0
2577	Diagnostic Evaluation of Diffuse Gliomas. , 0, , .		1
2578	IDH mutations in Primary Myelofibrosis Predict Leukemic Transformation and Shortened Survival: Clinical Evidence for Leukemogenic Collaboration with JAK2V617F. Blood, 2011, 118, 1751-1751.	0.6	5
2579	Genomic Abnormalities in Gliomas. , 0, , .		0
2580	Analysis of Leukemogenic Gene Products in Hematopoietic Progenitor Cells. , 0, , .		0
2581	Blastic Transformation of BCR-ABL-Negative Myeloproliferative Neoplasms. , 2012, , 131-145.		0
2582	Cancer and the Nervous System. , 2012, , 1116-1136.		0
2583	Genetic Analysis and Direction of Basic Research in Glioma(<Special Issue>Current Status and) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.0	1

#	Article	IF	Citations
2586	Genetic Alterations Involving the Progression of Human Gliomas. Japanese Journal of Neurosurgery, 2013, 22, 582-589.	0.0	0
2587	Animal Models for Low-Grade Gliomas. , 2013, , 165-175.		0
2588	Abstract A144: Inhibition of 2-HG production in IDH mutant xenograft models.. , 2013, , .		0
2589	Genetic Basis for the Development of Adult Gliomas. Japanese Journal of Neurosurgery, 2014, 23, 532-540.	0.0	2
2590	Metabolic Adaptation in Reprogrammed Cancer Cells. Cancer Drug Discovery and Development, 2014, , 157-180.	0.2	0
2591	Emerging Anti-cancer Targets in Mitochondria. , 2014, , 265-290.		0
2593	Regulation of Renal Glutamine Metabolism During Metabolic Acidosis. , 2014, , 101-121.		0
2594	Expression of IDH1 Mutant Protein R132H and SDHB in Adult and Pediatric Gliomas. International Journal of Neuropathology, 0, , .	0.0	0
2595	Novel Strategies in Chemotherapy for Gliomas. Japanese Journal of Neurosurgery, 2015, 24, 386-398.	0.0	0
2596	Fighting Fire with Fire in Cancer. , 2015, , 39-49.		1
2597	CIC Mutation as Signature Alteration in Oligodendroglioma. , 2015, , 423-440.		0
2598	Pathogenesis and Mutations of Myeloproliferative Neoplasms: An Overview. British Journal of Medicine and Medical Research, 2015, 9, 1-24.	0.2	0
2599	Refined Glioma Classification based on Molecular Pathology. Japanese Journal of Neurosurgery, 2015, 24, 366-377.	0.0	0
2600	Mutation Analysis of IDH1/2 Genes in Unselected De novo Acute Myeloid Leukaemia Patients in India - Identification of A Novel IDH2 Mutation. Asian Pacific Journal of Cancer Prevention, 2015, 16, 4095-4101.	0.5	5
2601	Liver Transplantation Biomarkers in the Metabolomics Era. Biomarkers in Disease, 2016, , 1-29.	0.0	0
2602	Cancer Biology of Molecular Imaging. , 2016, , 1-31.		0
2603	Translating Molecular Biomarkers of Gliomas to Clinical Practice. , 2016, , 33-53.		0
2605	Synthesis and Application of Cell-Permeable Metabolites for Modulating Chromatin Modifications Regulated by Î±-Ketoglutarate-Dependent Enzymes. Methods in Pharmacology and Toxicology, 2017, , 63-79.	0.1	0

#	Article	IF	Citations
2606	Molecular Pathogenesis of Bone Tumours. , 2017, , 41-63.		0
2607	An Update on the Genome, Epigenome, and Transcriptome in Gliomas. Japanese Journal of Neurosurgery, 2017, 26, 798-805.	0.0	0
2608	Molecular genetic markers of gliomas. Molekuliarnaia Genetika, Mikrobiologiia I Virusologiia, 2017, 35, 132.	0.1	1
2609	Molecular Imaging of Diffuse Low Grade Glioma. , 2017, , 173-195.		0
2610	Malignant Tumors Arising in Inflammatory Bowel Disease. , 2017, , 669-683.		0
2612	Cancer Metabolism. , 2018, , 129-154.		0
2613	Metabolic Dysregulation in Environmental Carcinogenesis and Toxicology. , 0, , 511-606.		0
2614	Melanomics: Comprehensive Molecular Analysis of Normal and Neoplastic Melanocytes. , 2018, , 1-44.		0
2615	In Vitro Versus In Vivo: Concepts and Consequences. , 2018, , 493-519.		2
2616	IDH1 Mutation Enhances Catabolic Flexibility and Mitochondrial Dependencies to Favor Drug Resistance in Acute Myeloid Leukemia. SSRN Electronic Journal, 0, , .	0.4	0
2620	5-Methylcytosine and Its Oxidized Derivatives. , 2019, , 65-86.		0
2621	Immunometabolic Regulation of Anti-Tumor T-Cell Responses by the Oncometabolite D-2-Hydroxyglutarate. , 2019, , .		1
2622	Metabolic Plasticity of IDH1- Mutant Glioma Cell Lines Is Responsible for Low Sensitivity to Glutaminase Inhibition. SSRN Electronic Journal, 0, , .	0.4	1
2624	Aberrant Epigenomic Regulatory Networks in Multiple Myeloma and Strategies for Their Targeted Reversal. RNA Technologies, 2019, , 543-572.	0.2	0
2625	Metabolic Deregulations Affecting Chromatin Architecture: One-Carbon Metabolism and Krebs Cycle Impact Histone Methylation. RNA Technologies, 2019, , 573-606.	0.2	1
2626	Epigenetic Abnormalities in Acute Myeloid Leukemia and Leukemia Stem Cells. Advances in Experimental Medicine and Biology, 2019, 1143, 173-189.	0.8	2
2628	Imaging Markers of Lower-Grade Diffuse Glioma. , 2020, , 139-159.		0
2629	Chemotherapy and Future Developments. , 2020, , 29-37.		0

#	Article	IF	Citations
2636	New era with the genetic assessment for biliary tree cancers beyond the anatomical assessment alone. Annals of Translational Medicine, 2020, 8, 732-732.	0.7	0
2638	Mouse Models of Diffuse Lower-Grade Gliomas of the Adult. Neuromethods, 2021, , 3-38.	0.2	0
2639	Metabolite discovery through global annotation of untargeted metabolomics data. Nature Methods, 2021, 18, 1377-1385.	9.0	107
2640	Roles of metal ions in the selective inhibition of oncogenic variants of isocitrate dehydrogenase 1. Communications Biology, 2021, 4, 1243.	2.0	12
2641	Metabolic Changes and Their Characterization. , 2020, , 35-70.		1
2642	Attaining Epigenetic Rejuvenation: Challenges Ahead. , 2020, , 159-179.		0
2643	Carbonic anhydrase IX as a marker of hypoxia in gliomas: A narrative review. Glioma (Mumbai, India), 2020, 3, 97.	0.0	1
2644	Molecular Genetics in the Multidisciplinary Management of Sarcoma. , 2021, , 135-152.		0
2645	Transcriptional and epigenetic regulatory mechanisms in glioblastoma stem cells. , 2020, , 231-255.		1
2646	Withaferin A suppresses skin tumor promotion by inhibiting proteasome-dependent isocitrate dehydrogenase 1 degradation. Translational Cancer Research, 2019, 8, 2449-2460.	0.4	2
2647	Molecular Landscape of MDS. , 2020, , 73-90.		0
2648	Tumors of Glial Origin. , 2020, , 159-167.		0
2650	Glioblastoma. , 2020, , 173-182.		0
2651	Metabolic Pathways of Eukaryotes and Connection to Cell Mechanics. Biological and Medical Physics Series, 2020, , 825-891.	0.3	1
2653	Loss of FBXW7 Correlates with Increased IDH1 Expression in Glioma and Enhances IDH1-Mutant Cancer Cell Sensitivity to Radiation. Cancer Research, 2022, 82, 497-509.	0.4	13
2655	A Specific Peptide Vaccine Against IDH1(R132H) Glioma. Neuroscience Bulletin, 2021, , 1.	1.5	2
2656	Novel Ion Channel Targets and Drug Delivery Tools for Controlling Glioblastoma Cell Invasiveness. International Journal of Molecular Sciences, 2021, 22, 11909.	1.8	7
2657	Development of simultaneous quantitative analysis of tricarboxylic acid cycle metabolites to identify specific metabolites in cancer cells by targeted metabolomic approach. Biochemical and Biophysical Research Communications, 2021, 584, 53-59.	1.0	5

#	Article	IF	Citations
2658	Effect of sodium (S)-2-hydroxyglutarate in male, and succinic acid in female Wistar rats against renal ischemia-reperfusion injury, suggesting a role of the HIF-1 pathway. PeerJ, 2020, 8, e9438.	0.9	7
2660	Nanophotonic Techniques for Single-Cell Analysis. , 2021, , 79-109.		0
2661	Glioblastoma genetics: in rapid flux. Discovery Medicine, 2010, 9, 125-31.	0.5	11
2662	Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis. American Journal of Blood Research, 2012, 2, 254-64.	0.6	39
2663	Gene mutations and molecularly targeted therapies in acute myeloid leukemia. American Journal of Blood Research, 2013, 3, 29-51.	0.6	36
2664	Molecular biology of gliomas: present and future challenges. Translational Medicine @ UniSa, 2014, 10, 29-37.	0.8	33
2665	Gene mutation profiling of primary glioblastoma through multiple tumor biopsy guided by 1H-magnetic resonance spectroscopy. International Journal of Clinical and Experimental Pathology, 2015, 8, 5327-35.	0.5	13
2666	IDH1 Mutations in Glioma: Considerations for Radiotracer Development. , 2016, 2, .		1
2667	Mutation Analysis of Isocitrate Dehydrogenase (IDH1/2) and DNA Methyltransferase 3A (DNMT3A) in Thai Patients with Newly Diagnosed Acute Myeloid Leukemia. Asian Pacific Journal of Cancer Prevention, 2017, 18, 413-420.	0.5	3
2668	Vascular-endothelial response to IDH1 mutant fibrosarcoma secretome and metabolite: implications on cancer microenvironment. American Journal of Cancer Research, 2019, 9, 122-133.	1.4	3
2669	Advances in Brain Cancer: Creating Monoallelic Single Point Mutation in IDH1 by Single Base Editing. Journal of Oncology Research and Therapy, 2019, 5, .	0.0	2
2670	LKB1 deficiency promotes proliferation and invasion of glioblastoma through activation of mTOR and focal adhesion kinase signaling pathways. American Journal of Cancer Research, 2019, 9, 1650-1663.	1.4	6
2672	Novel canine isocitrate dehydrogenase 1 mutation Y208C attenuates dimerization ability. Oncology Letters, 2020, 20, 351.	0.8	0
2674	Oxidative Stress Targeted Therapies for the Treatment of Acute Myeloid Leukemia. , 2021, , 1-10.		0
2675	Oncometabolites as Regulators of DNA Damage Response and Repair. Seminars in Radiation Oncology, 2022, 32, 82-94.	1.0	3
2676	Glioma invasion along white matter tracts: A dilemma for neurosurgeons. Cancer Letters, 2022, 526, 103-111.	3.2	12
2677	Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma. Oncogene, 2022, 41, 613-621.	2.6	29
2678	Cancer metabolism and tumor microenvironment: fostering each other?. Science China Life Sciences, 2022, 65, 236-279.	2.3	68

#	Article	IF	Citations
2679	Establishment of patient-derived organoid models of lower-grade glioma. Neuro-Oncology, 2022, 24, 612-623.	0.6	36
2680	Emerging methods and applications of ultra-high field MR spectroscopic imaging in the human brain. Analytical Biochemistry, 2022, 638, 114479.	1.1	11
2681	Treatment with sodium (S)-2-hydroxyglutarate prevents liver injury in an ischemia-reperfusion model in female Wistar rats. PeerJ, 2021, 9, e12426.	0.9	1
2682	Dualâ€purpose coils in MRSI of brain tumours. NMR in Biomedicine, 2022, 35, e4660.	1.6	0
2684	Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches. Cancers, 2021, 13, 5847.	1.7	16
2685	Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives. Cancers, 2021, 13, 5722.	1.7	17
2686	The isocitrate dehydrogenase 1 is a potential prognostic indicator for non-small cell lung cancer patients. International Journal of Biological Markers, 2021, 36, 27-35.	0.7	2
2687	Subtyping non-small cell lung cancer by histology-guided spatial metabolomics. Journal of Cancer Research and Clinical Oncology, 2022, 148, 351-360.	1.2	20
2688	Current development and future perspective of IDH1 inhibitors in cholangiocarcinoma. Liver Cancer International, 2022, 3, 17-31.	0.2	6
2689	The Importance of Cellular Metabolic Pathways in Pathogenesis and Selective Treatments of Hematological Malignancies. Frontiers in Oncology, 2021, 11, 767026.	1.3	26
2690	Mutant IDH Inhibits IFNÎ³â€“TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma. Cancer Discovery, 2022, 12, 812-835.	7.7	55
2692	Integration into cancer studies. Advances in Magnetic Resonance Technology and Applications, 2021, 3, 157-185.	0.0	0
2693	IDH-mutated gliomas promote epileptogenesis through <scp>d</scp>-2-hydroxyglutarate-dependent mTOR hyperactivation. Neuro-Oncology, 2022, 24, 1423-1435.	0.6	27
2694	D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment. Molecular Therapy, 2022, 30, 1188-1200.	3.7	19
2695	Comprehensive omics analyses profile genesets related with tumor heterogeneity of multifocal glioblastomas and reveal LIF/CCL2 as biomarkers for mesenchymal subtype. Theranostics, 2022, 12, 459-473.	4.6	5
2696	Synthesis and biological evaluation of novel PET tracers [18F]AG120 & [18F]AG135 for imaging mutant isocitrate dehydrogenase 1 expression. Bioorganic and Medicinal Chemistry, 2022, 53, 116525.	1.4	4
2697	Post-translational modifications on mitochondrial metabolic enzymes in cancer. Free Radical Biology and Medicine, 2022, 179, 11-23.	1.3	20
2698	Alpha-Ketoglutarate dietary supplementation to improve health in humans. Trends in Endocrinology and Metabolism, 2022, 33, 136-146.	3.1	41

#	Article	IF	Citations
2699	Discovery of linear unnatural peptides as potent mutant isocitrate dehydrogenase 1 inhibitors by Ugi reaction. Bioorganic Chemistry, 2022, 119, 105569.	2.0	1
2700	Clinical development of IDH1 inhibitors for cancer therapy. Cancer Treatment Reviews, 2022, 103, 102334.	3.4	18
2701	Novel canine isocitrate dehydrogenase 1 mutation Y208C attenuates dimerization ability. Oncology Letters, 2020, 20, 1-1.	0.8	2
2702	Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia. Cancer Journal (Sudbury, Mass), 2022, 28, 21-28.	1.0	3
2703	Evolution of Therapy for Older Patients With Acute Myeloid Leukemia. Cancer Journal (Sudbury, Mass) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.0	2
2704	Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond. Expert Opinion on Investigational Drugs, 2022, 31, 125-131.	1.9	12
2705	2-Hydroxyglutarate destabilizes chromatin regulatory landscape and lineage fidelity to promote cellular heterogeneity. Cell Reports, 2022, 38, 110220.	2.9	8
2706	Beyond Isocitrate Dehydrogenase Mutations: Emerging Mechanisms for the Accumulation of the Oncometabolite 2-Hydroxyglutarate. Chemical Research in Toxicology, 2022, 35, 115-124.	1.7	3
2707	Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review. Cureus, 2022, 14, e21018.	0.2	0
2708	Metabolomic Phenotyping of Gliomas: What Can We Get with Simplified Protocol for Intact Tissue Analysis?. Cancers, 2022, 14, 312.	1.7	11
2709	Oncogenesis induced by combined Phf6 and Idh2 mutations through increased oncometabolites and impaired DNA repair. Oncogene, 2022, 41, 1576-1588.	2.6	3
2710	Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets. Cancers, 2022, 14, 664.	1.7	7
2711	Highlighting the mechanistic role of Olutasidenib (FT-2102) in the selective inhibition of mutated isocitrate dehydrogenase 1 (mIDH1) in cancer therapy. Informatics in Medicine Unlocked, 2022, 28, 100829.	1.9	8
2712	A preliminary model of football-related neural stress that integrates metabolomics with transcriptomics and virtual reality. IScience, 2022, 25, 103483.	1.9	2
2713	CNS High Grade Glioma. , 0, , .		0
2714	Analysis of Factors Affecting 5-ALA Fluorescence Intensity in Visualizing Glial Tumor Cellsâ€"Literature Review. International Journal of Molecular Sciences, 2022, 23, 926.	1.8	16
2715	Integrative Multiomics Evaluation of IIDH1 Metabolic Enzyme as a Candidate Oncogene That is Correlated with Poor Prognosis and Immune Infiltration in Prostate Adenocarcinoma. Journal of Oncology, 2022, 2022, 1-13.	0.6	0
2717	Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma. International Journal of Molecular Sciences, 2022, 23, 1096.	1.8	17

#	Article	IF	Citations
2718	Effects of the IDH1 R132H Mutation on the Energy Metabolism: A Comparison between Tissue and Corresponding Primary Glioma Cell Cultures. ACS Omega, 2022, 7, 3568-3578.	1.6	5
2719	Spectroscopic and inâ€...vitro Investigations of Fe²⁺/Îąâ€Ketoglutarateâ€Dependent Enzymes Involved in Nucleic Acid Repair and Modification. ChemBioChem, 2022, 23, .	1.3	5
2720	Distribution of copy number variations and rearrangement endpoints in human cancers with a review of literature. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2022, 824, 111773.	0.4	6
2721	Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genetics in Medicine, 2022, 24, 986-998.	1.1	55
2722	Oxidative Stress-Targeted Therapies for the Treatment of Acute Myeloid Leukemia. , 2022, , 1845-1854.		0
2723	Clinical development of metabolic inhibitors for oncology. Journal of Clinical Investigation, 2022, 132, .	3.9	59
2724	The Distribution and Significance of IDH Mutations in Gliomas. , 0, , .		1
2725	New Approaches with Precision Medicine in Adult Brain Tumors. Cancers, 2022, 14, 712.	1.7	2
2727	Probing altered enzyme activity in the biochemical characterization of cancer. Bioscience Reports, 2022, 42, .	1.1	1
2728	Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas. , 0, 79, .		11
2729	An Innovation 10 Years in the Making: The Stories in the Pages of ACS Medicinal Chemistry Letters. ACS Medicinal Chemistry Letters, 2022, 13, 540-545.	1.3	0
2730	Immune Dysfunction, Cytokine Disruption, and Stromal Changes in Myelodysplastic Syndrome: A Review. Cells, 2022, 11, 580.	1.8	7
2731	The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma. PLoS ONE, 2022, 17, e0257725.	1.1	2
2732	Metabolomics and the Multi-Omics View of Cancer. Metabolites, 2022, 12, 154.	1.3	17
2733	Put in a â€œCa2+llâ€•to Acute Myeloid Leukemia. Cells, 2022, 11, 543.	1.8	3
2734	Histone modifiers at the crossroads of oncolytic and oncogenic viruses. Molecular Therapy, 2022, 30, 2153-2162.	3.7	4
2735	Tissue metabolites in diffuse glioma and their modulations by IDH1 mutation, histology, and treatment. JCI Insight, 2022, 7, .	2.3	8
2736	The epigenetic dysfunction underlying malignant glioma pathogenesis. Laboratory Investigation, 2022, 102, 682-690.	1.7	4

#	Article	IF	Citations
2737	Connections between metabolism and epigenetic modifications in cancer. Medical Review, 2021, 1, 199-221.	0.3	7
2738	Targeting fuel pocket of cancer cell metabolism: A focus on glutaminolysis. Biochemical Pharmacology, 2022, 198, 114943.	2.0	15
2739	Oncometabolite Fingerprinting Using Fluorescent Singleâ€Walled Carbon Nanotubes. Advanced Materials Interfaces, 2022, 9, .	1.9	14
2740	A d-2-hydroxyglutarate biosensor based on specific transcriptional regulator DhdR. Nature Communications, 2021, 12, 7108.	5.8	14
2741	Interplay Among Metabolism, Epigenetic Modifications, and Gene Expression in Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 793428.	1.8	30
2742	YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma. Advances in Cancer Research, 2022, , 283-317.	1.9	4
2743	Enantiomeric Separation of 2-Hydroxyglutarate Using Chiral Mobile Phase Additives. Chromatography, 2022, 43, 43-46.	0.8	1
2744	Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2 â€Mutant Acute Myeloid Leukemia. Clinical Pharmacology in Drug Development, 2022, 11, 429-441.	0.8	3
2745	Overcoming Radiation Resistance in Gliomas by Targeting Metabolism and DNA Repair Pathways. International Journal of Molecular Sciences, 2022, 23, 2246.	1.8	8
2746	DNA Hydroxymethylation in Smoking-Associated Cancers. International Journal of Molecular Sciences, 2022, 23, 2657.	1.8	7
2747	Systemic Therapy for Chondrosarcoma. Current Treatment Options in Oncology, 2022, 23, 199-209.	1.3	6
2748	Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations. Cancers, 2022, 14, 1125.	1.7	10
2749	Innovating Strategies and Tailored Approaches in Neuro-Oncology. Cancers, 2022, 14, 1124.	1.7	3
2750	Malic enzyme 2 maintains protein stability of mutant p53 through 2-hydroxyglutarate. Nature Metabolism, 2022, 4, 225-238.	5.1	15
2751	IDH1 Mutation Induces HIF-1Î± and Confers Angiogenic Properties in Chondrosarcoma JJ012 Cells. Disease Markers, 2022, 2022, 1-11.	0.6	4
2752	YAP/TAZ drives cell proliferation and tumour growth via a polyamineâ€“eIF5A hypusinationâ€“LSD1 axis. Nature Cell Biology, 2022, 24, 373-383.	4.6	26
2754	Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma. BMC Cancer, 2022, 22, 215.	1.1	15
2756	PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications. Neuro-Oncology, 2022, 24, 1471-1481.	0.6	14

#	Article	IF	Citations
2757	Distinct Roles of Glutamine Metabolism in Benign and Malignant Cartilage Tumors With IDH Mutations. Journal of Bone and Mineral Research, 2020, 37, 983-996.	3.1	4
2758	Combinatorial Effects of the Natural Products Arctigenin, Chlorogenic Acid, and Cinnamaldehyde Commit Oxidation Assassination on Breast Cancer Cells. Antioxidants, 2022, 11, 591.	2.2	11
2759	Increased Ascorbate Content of Glioblastoma Is Associated With a Suppressed Hypoxic Response and Improved Patient Survival. Frontiers in Oncology, 2022, 12, 829524.	1.3	4
2760	Biology of IDH mutant cholangiocarcinoma. Hepatology, 2022, 75, 1322-1337.	3.6	20
2761	Multi-tracer and multiparametric PET imaging to detect the IDH mutation in glioma: a preclinical translational in vitro, in vivo, and ex vivo study. Cancer Imaging, 2022, 22, 16.	1.2	5
2762	Diminishing GSH-Adduct Formation of Tricyclic Diazepine-based Mutant IDH1 Inhibitors. ACS Medicinal Chemistry Letters, 2022, 13, 734-741.	1.3	1
2763	IDH1/2 mutations in acute myeloid leukemia. Blood Research, 2022, 57, 13-19.	0.5	6
2764	The Role of Ten-Eleven Translocation Proteins in Inflammation. Frontiers in Immunology, 2022, 13, 861351.	2.2	9
2765	Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents. Cancers, 2022, 14, 1689.	1.7	6
2766	Emerging MR Imaging and Spectroscopic Methods to Study Brain Tumor Metabolism. Frontiers in Neurology, 2022, 13, 789355.	1.1	8
2767	Metabolomic Pathway Activity with Genomic Single-Nucleotide Polymorphisms Associated with Colorectal Cancer Recurrence and 5-Year Overall Survival. Journal of Gastrointestinal Cancer, 2022, , 1.	0.6	1
2768	Relapsing Highâ€"Grade Glioma from Peritumoral Zone: Critical Review of Radiotherapy Treatment Options. Brain Sciences, 2022, 12, 416.	1.1	5
2769	Metabolomics analysis reveals Oct4 overexpression drives metabolic reprogramming and enhanced glycolysis and pentose phosphate pathway in lung adenocarcinoma cells. Biomedical Chromatography, 2022, , e5367.	0.8	1
2770	Systematic Review of Epigenetic Therapies for Treatment of IDH-mutant Glioma. World Neurosurgery, 2022, 162, 47-56.	0.7	8
2771	Classification of adultâ€type diffuse gliomas: Impact of the World Health Organization 2021 update. Brain Pathology, 2022, 32, e13062.	2.1	53
2772	Metabolic Regulation of CD8⁺T Cells: From Mechanism to Therapy. Antioxidants and Redox Signaling, 2022, 37, 1234-1253.	2.5	5
2773	SDHB knockout and succinate accumulation are insufficient for tumorigenesis but dual SDHB/NF1 loss yields SDHx-like pheochromocytomas. Cell Reports, 2022, 38, 110453.	2.9	16
2774	Acute aerobic exercise reveals that FAHFAs distinguish the metabolomes of overweight and normal-weight runners. JCI Insight, 2022, 7, .	2.3	11

#	Article	IF	Citations
2775	Uncovering the interference from lipid fragments on the qualification and quantification of serum metabolites in matrixâ€assisted laser desorption/ionization timeâ€ofâ€flight mass spectrometric analysis. Rapid Communications in Mass Spectrometry, 2022, 36, e9293.	0.7	1
2776	Drp1 Regulated Mitochondrial Hypofission Promotes the Invasion and Proliferation of Growth Hormone-Secreting Pituitary Adenomas via Activating STAT3. Frontiers in Oncology, 2022, 12, 739631.	1.3	3
2777	In-Depth Matrisome and Glycoproteomic Analysis of Human Brain Glioblastoma Versus Control Tissue. Molecular and Cellular Proteomics, 2022, 21, 100216.	2.5	22
2778	Epigenomic alterations in cancer: mechanisms and therapeutic potential. Clinical Science, 2022, 136, 473-492.	1.8	4
2779	The influence of cystathionine on neurochemical quantification in brain tumor in vivo MR spectroscopy. Magnetic Resonance in Medicine, 2022, 88, 537-545.	1.9	2
2780	Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma. Translational Oncology, 2022, 18, 101368.	1.7	2
2781	The epigeneticâ€“metabolic interplay in gliomagenesis. Open Biology, 2022, 12, 210350.	1.5	2
2782	Methylation classifiers: Brain tumors, sarcomas, and what's next. Genes Chromosomes and Cancer, 2022, 61, 346-355.	1.5	16
2784	Discovery of two novel ALKBH5 selective inhibitors that exhibit uncompetitive or competitive type and suppress the growth activity of glioblastoma multiforme. Chemical Biology and Drug Design, 2022, 100, 1-12.	1.5	19
2785	Mitochondrial complex IV defects induce metabolic and signaling perturbations that expose potential vulnerabilities in HCT116 cells. FEBS Open Bio, 2022, 12, 959-982.	1.0	2
2786	Metaboloepigenetics in cancer, immunity, and cardiovascular disease. Cardiovascular Research, 2023, 119, 357-370.	1.8	5
2787	Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells. Neoplasia, 2022, 28, 100790.	2.3	5
2788	Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations. Cell Reports Medicine, 2021, 2, 100469.	3.3	21
2789	An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas. Journal of Oncology, 2021, 2021, 1-19.	0.6	2
2790	Primal-dual for classification with rejection (PD-CR): a novel method for classification and feature selectionâ€an application in metabolomics studies. BMC Bioinformatics, 2021, 22, 594.	1.2	1
2791	Cancer metabolism and dietary interventions. Cancer Biology and Medicine, 2021, , .	1.4	9
2793	Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia. Genes, 2021, 12, 1963.	1.0	1
2794	IDH1/2 Mutations in Patients With Diffuse Gliomas: A Single Centre Retrospective Massively Parallel Sequencing Analysis. Applied Immunohistochemistry and Molecular Morphology, 2022, 30, 178-183.	0.6	6

#	Article	IF	Citations
2795	In Vivo Absolute Metabolite Quantification Using a Multiplexed <scp>ERETICâ€RX</scp> Array Coil for Wholeâ€Brain <scp>MR</scp> Spectroscopic Imaging. Journal of Magnetic Resonance Imaging, 2022, 56, 121-133.	1.9	2
2796	Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis. Expert Opinion on Therapeutic Targets, 2021, 25, 1045-1060.	1.5	7
2797	Glioblastoma: Relationship between Metabolism and Immunosuppressive Microenvironment. Cells, 2021, 10, 3529.	1.8	16
2798	Isocitrate dehydrogenase gene variants in cancer and their clinical significance. Biochemical Society Transactions, 2021, 49, 2561-2572.	1.6	10
2799	IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy. Journal of Histochemistry and Cytochemistry, 2022, 70, 83-97.	1.3	10
2801	Effects of Exogenous ATP on Melanoma Growth and Tumor Metabolism in C57BL/6 Mice. Comparative Medicine, 2022, , .	0.4	0
2802	The role of epigenetic modifications in Colorectal Cancer Metastasis. Clinical and Experimental Metastasis, 2022, 39, 521-539.	1.7	6
2803	Targeting oncometabolism to maximize immunotherapy in malignant brain tumors. Oncogene, 2022, 41, 2663-2671.	2.6	5
2804	Ivosidenib and Azacitidine inIDH1-Mutated Acute Myeloid Leukemia. New England Journal of Medicine, 2022, 386, 1519-1531.	13.9	186
2805	Deciphering of Adult Glioma Vulnerabilities through Expression Pattern Analysis of GABA, Glutamate and Calcium Neurotransmitter Genes. Journal of Personalized Medicine, 2022, 12, 633.	1.1	0
2806	Targeting mutations in cancer. Journal of Clinical Investigation, 2022, 132, .	3.9	56
2807	Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer. Nature Reviews Cardiology, 2022, 19, 414-425.	6.1	23
2808	Mitochondrial and metabolic alterations in cancer cells. European Journal of Cell Biology, 2022, 101, 151225.	1.6	19
2826	SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors. Cell Research, 2022, 32, 638-658.	5.7	19
2827	Interpreting new molecular genetics in myelodysplastic syndromes. Hematology American Society of Hematology Education Program, 2012, 2012, 56-64.	0.9	14
2832	New Insights into TETs in Psychiatric Disorders. International Journal of Molecular Sciences, 2022, 23, 4909.	1.8	3
2833	Epigenetic Aberrations and Targets in Peripheral T-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 659-665.	0.2	2
2834	Identification of Novel Mutant (R132H) Isocitrate Dehydrogenase 1 Inhibitors for Glioma Therapy. Journal of Computational Biophysics and Chemistry, 2022, 21, 647-661.	1.0	1

#	Article	IF	Citations
2835	The immune regulation of BCL3 in glioblastoma with mutated IDH1. Aging, 2022, 14, 3856-3873.	1.4	3
2836	Targeting IDH-Mutant Glioma. Neurotherapeutics, 2022, 19, 1724-1732.	2.1	13
2837	Molecular and clinical characteristics of <scp>IDH</scp> mutations in Chinese <scp>NSCLC</scp> patients and potential treatment strategies. Cancer Medicine, 2022, , .	1.3	1
2838	Chirality in Lightâ€“Matter Interaction. Advanced Materials, 2023, 35, e2107325.	11.1	43
2839	Liquid biopsies to occult brain metastasis. Molecular Cancer, 2022, 21, 113.	7.9	23
2840	A Novel Multi-Omics Analysis Model for Diagnosis and Survival Prediction of Lower-Grade Glioma Patients. Frontiers in Oncology, 2022, 12, .	1.3	3
2841	Regulation of Transactivation at C-TAD Domain of HIF-1Î± by Factor-Inhibiting HIF-1Î± (FIH-1): A Potential Target for Therapeutic Intervention in Cancer. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-21.	1.9	19
2842	What can metabolites tell us about gliomas?. Neuro-Oncology, 2022, , .	0.6	1
2843	Metabolism in the progression and metastasis of brain tumors. Cancer Letters, 2022, 539, 215713.	3.2	14
2844	Targeting allosteric regulation of cancer metabolism. Nature Chemical Biology, 2022, 18, 441-450.	3.9	14
2845	Targeting 2-oxoglutarate dehydrogenase for cancer treatment.. American Journal of Cancer Research, 2022, 12, 1436-1455.	1.4	0
2849	IDH mutation and cancer stem cell. Essays in Biochemistry, 2022, 66, 413-422.	2.1	6
2850	Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma. , 2022, 10, e004644.		14
2851	AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas. Neurological Research and Practice, 2022, 4, .	1.0	13
2852	A Comparative Study Between Tumor Blood Vessels and Dynamic Contrast-enhanced MRI for Identifying Isocitrate Dehydrogenase Gene 1 (IDH1) Mutation Status in Glioma. Current Medical Science, 2022, 42, 650-657.	0.7	3
2853	Lack of Major Genome-Wide DNA Methylation Changes in Succinate-Treated Human Epithelial Cells. International Journal of Molecular Sciences, 2022, 23, 5663.	1.8	0
2854	Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma. Cancers, 2022, 14, 2641.	1.7	11
2856	Deep Learning Super-resolution MR Spectroscopic Imaging of Brain Metabolism and Mutant IDH Glioma. Neuro-Oncology Advances, 0, , .	0.4	2

#	Article	IF	Citations
2857	Different Effects of RNAi-Mediated Downregulation or Chemical Inhibition of NAMPT in an Isogenic IDH Mutant and Wild-Type Glioma Cell Model. International Journal of Molecular Sciences, 2022, 23, 5787.	1.8	3
2858	Atypical cartilage in type II germ cell tumors of the mediastinum show significantly different patterns of IDH1/2 mutations from conventional chondrosarcoma. Modern Pathology, 2022, 35, 1636-1643.	2.9	1
2859	Periosteal chondrosarcoma: A case series in a referral center with survivorship analysis. European Journal of Surgical Oncology, 2022, 48, 1730-1738.	0.5	2
2860	Cancer metabolism regulation by phytonutrients. , 2022, , 237-290.		0
2861	Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial. Neuro-Oncology, 2023, 25, 146-156.	0.6	23
2863	Advances in the systemic treatment of therapeutic approaches in biliary tract cancer. ESMO Open, 2022, 7, 100503.	2.0	8
2864	Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma. Frontiers in Immunology, 0, 13, .	2.2	9
2865	Silybin suppresses ovarian cancer cell proliferation by inhibiting isocitrate dehydrogenase 1 activity. Cancer Science, 2022, 113, 3032-3043.	1.7	5
2866	2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies. Biomedicines, 2022, 10, 1359.	1.4	8
2867	Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma. Neuroscience Bulletin, 2022, 38, 1069-1084.	1.5	6
2868	Development and Validation of an Individualized Metabolism-Related Prognostic Model for Adult Acute Myeloid Leukemia Patients. Frontiers in Oncology, 0, 12, .	1.3	2
2869	Targeting Tumour-Associated Fibroblasts in Cancers. Frontiers in Oncology, 0, 12, .	1.3	9
2870	Metabolism-Associated DNA Methylation Signature Stratifies Lower-Grade Glioma Patients and Predicts Response to Immunotherapy. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	1
2871	Profiling the Effect of Targeting Wild Isocitrate Dehydrogenase 1 (IDH1) on the Cellular Metabolome of Leukemic Cells. International Journal of Molecular Sciences, 2022, 23, 6653.	1.8	2
2872	The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas. Neuro-Oncology, 2023, 25, 326-336.	0.6	23
2873	Novel Radioiodinated and Radiofluorinated Analogues of FT-2102 for SPECT or PET Imaging of mIDH1 Mutant Tumours. Molecules, 2022, 27, 3766.	1.7	2
2874	SMAD4 Controls Cancer Cell Metabolism by Regulating Methylmalonic Aciduria Cobalamin Deficiency (cbl) B Type. Molecules and Cells, 2022, 45, 413-424.	1.0	2
2877	Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas. Journal of Neuro-Oncology, 2022, 159, 43-52.	1.4	6

#	Article	IF	Citations
2878	The DNA Double-Strand Break Repair in Glioma: Molecular Players and Therapeutic Strategies. Molecular Neurobiology, 2022, 59, 5326-5365.	1.9	13
2879	Pattern of Recurrence of Glioblastoma Versus Grade 4 IDH-Mutant Astrocytoma Following Chemoradiation: A Retrospective Matched-Cohort Analysis. Technology in Cancer Research and Treatment, 2022, 21, 153303382211096.	0.8	9
2880	Oncometabolites and their role in cancer. , 2022, , 393-408.		0
2882	MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma. Nature Communications, 2022, 13, .	5.8	18
2883	Cardio-Onco-Metabolism â€“ Metabolic vulnerabilities in cancer and the heart. Journal of Molecular and Cellular Cardiology, 2022, 171, 71-80.	0.9	2
2884	Glutamine Is Required for M1-like Polarization of Macrophages in Response to Mycobacterium tuberculosis Infection. MBio, 2022, 13, .	1.8	17
2885	Obstacles to Glioblastoma Treatment Two Decades after Temozolomide. Cancers, 2022, 14, 3203.	1.7	23
2886	Maffucci syndrome complicated by giant chondrosarcoma in the left ankle with an IDH1 R132C mutation: a case report. World Journal of Surgical Oncology, 2022, 20, .	0.8	1
2887	A Novel Signature of Necroptosis-Associated Genes as a Potential Prognostic Tool for Head and Neck Squamous Cell Carcinoma. Frontiers in Genetics, 0, 13, .	1.1	2
2888	Metabolic Regulation of Hematopoietic Stem Cells. HemaSphere, 2022, 6, e740.	1.2	15
2889	Computational study on novel natural compound inhibitor targeting IDH1_R132H. Aging, 2022, 14, 5478-5492.	1.4	2
2890	Therapeutic Potential and Activity Modulation of the Protein Lysine Deacylase Sirtuin 5. Journal of Medicinal Chemistry, 2022, 65, 9580-9606.	2.9	21
2891	Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia. Journal of Internal Medicine, 2022, 292, 262-277.	2.7	7
2892	Mitochondrial <scp>DNA</scp> mutations in ageing and cancer. Molecular Oncology, 2022, 16, 3276-3294.	2.1	18
2893	Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies. Cancers, 2022, 14, 3456.	1.7	18
2894	Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development. Frontiers in Pharmacology, 0, 13, .	1.6	6
2895	Noncanonical (Non-R132H) IDH-Mutated Gliomas. , 0, , .		0
2896	IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas. Journal of Neuro-Oncology, 2022, 159, 261-270.	1.4	6

#	Article	IF	Citations
2897	Single-Cell Metabolomics in Hematopoiesis and Hematological Malignancies. Frontiers in Oncology, 0, 12, .	1.3	4
2898	Indirect Enantioseparations: Recent Advances in Chiral Metabolomics for Biomedical Research. International Journal of Molecular Sciences, 2022, 23, 7428.	1.8	4
2899	Using AI-Based Evolutionary Algorithms to Elucidate Adult Brain Tumor (Glioma) Etiology Associated with IDH1 for Therapeutic Target Identification. Current Issues in Molecular Biology, 2022, 44, 2982-3000.	1.0	1
2901	Metabolic analysis as a driver for discovery, diagnosis, and therapy. Cell, 2022, 185, 2678-2689.	13.5	51
2902	Glioblastomas: Molecular Diagnosis and Pathology. , 0, , .		0
2903	Metabolic Rewiring in Glioblastoma Cancer: EGFR, IDH and Beyond. Frontiers in Oncology, 0, 12, .	1.3	14
2904	REGLIV: Molecular regulation data of diverse living systems facilitating current multiomics research. Computers in Biology and Medicine, 2022, 148, 105825.	3.9	10
2905	Comparing DESI-MSI and MALDI-MSI Mediated Spatial Metabolomics and Their Applications in Cancer Studies. Frontiers in Oncology, 0, 12, .	1.3	25
2906	The role of branched chain amino acids metabolic disorders in tumorigenesis and progression. Biomedicine and Pharmacotherapy, 2022, 153, 113390.	2.5	9
2907	Accumulation of oncometabolite D-2-Hydroxyglutarate by SLC25A1 inhibition: A metabolic strategy for induction of HR-ness and radiosensitivity. Cell Death and Disease, 2022, 13, .	2.7	2
2908	Precision Medicine in Therapy of Non-solid Cancer. Handbook of Experimental Pharmacology, 2022, , .	0.9	0
2910	Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas. Journal of Neuropathology and Experimental Neurology, 2022, 81, 707-716.	0.9	0
2912	Immunometabolic and potential tumor-promoting changes in 3D cervical cell models infected with bacterial vaginosis-associated bacteria. Communications Biology, 2022, 5, .	2.0	7
2913	Connections between metabolism and epigenetics: mechanisms and novel anti-cancer strategy. Frontiers in Pharmacology, 0, 13, .	1.6	12
2915	Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases. Current Opinion in Structural Biology, 2022, 75, 102433.	2.6	3
2916	An Epigenetic Role of Mitochondria in Cancer. Cells, 2022, 11, 2518.	1.8	57
2917	Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds. International Reviews of Immunology, 2022, 41, 582-605.	1.5	12
2918	Current understanding of the human microbiome in glioma. Frontiers in Oncology, 0, 12, .	1.3	5

#	Article	IF	Citations
2919	Correlation of Matrisome-Associatted Gene Expressions with LOX Family Members in Astrocytomas Stratified by IDH Mutation Status. International Journal of Molecular Sciences, 2022, 23, 9507.	1.8	1
2920	Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma. Neuro-Oncology, 2023, 25, 28-36.	0.6	7
2921	R-2-HG assists IDH1-mutant solid tumors by promoting angiogenesis. Cell Research, 2022, 32, 795-796.	5.7	1
2922	The elevated D-2-hydroxyglutarate level found as a characteristic metabolic change of colon cancer in both inÂvitro and inÂvivo models. Biochemical and Biophysical Research Communications, 2022, 627, 191-199.	1.0	3
2923	Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells. Cell Reports, 2022, 40, 111182.	2.9	5
2924	Advances in the pharmacological management of acute myeloid leukemia in adults. Expert Opinion on Pharmacotherapy, 2022, 23, 1535-1543.	0.9	1
2925	Genetic, metabolic and immunological features of cancers with <scp>NRF2</scp> addiction. FEBS Letters, 2022, 596, 1981-1993.	1.3	5
2926	De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma. Cancer Cell, 2022, 40, 939-956.e16.	7.7	43
2927	Entner-Doudoroff pathway in Synechocystis PCC 6803: Proposed regulatory roles and enzyme multifunctionalities. Frontiers in Microbiology, 0, 13, .	1.5	2
2928	Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors. Nature Communications, 2022, 13, .	5.8	18
2929	Reprogramming of central carbon metabolism in hepatocellular carcinoma. Biomedicine and Pharmacotherapy, 2022, 153, 113485.	2.5	8
2930	Gankyrin and <scp>TIGAR</scp> cooperatively accelerate glucose metabolism toward the <scp>PPP</scp> and <scp>TCA</scp> cycle in hepatocellular carcinoma. Cancer Science, 2022, 113, 4151-4164.	1.7	3
2931	The metabolic genomic atlas reveals potential drivers and clinically relevant insights into the etiology of esophageal squamous cell carcinoma. Theranostics, 2022, 12, 6160-6178.	4.6	2
2932	Cancer Biology of Molecular Imaging. , 2022, , 3-39.		0
2933	Targeting Natural Compounds to Mitochondria as a Novel Strategy for Cancer Therapy. , 2022, , 465-487.		0
2934	Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas. Neuro-Oncology Advances, 2022, 4, .	0.4	2
2935	Signaling Metabolite Succinylacetone Activates HIF-1Î± and Promotes Angiogenesis in <i>GSTZ1</i>-Deficient Hepatocellular Carcinoma. SSRN Electronic Journal, 0, , .	0.4	0
2936	Metabolomics in High Grade Gliomas. RAS Oncology & Therapy, 2022, 3, .	0.1	0

#	Article	IF	Citations
2937	Oncometabolites, epigenetic marks, and DNA repair. , 2022, , 191-202.		0
2938	Application of 7T MRS to High-Grade Gliomas. American Journal of Neuroradiology, 2022, 43, 1378-1395.	1.2	7
2939	Terahertz technology in diagnosis of glioma molecular markers. Journal of Physics: Conference Series, 2022, 2316, 012016.	0.3	1
2940	Resolving Enantiomers of 2-Hydroxy Acids by Nuclear Magnetic Resonance. Analytical Chemistry, 2022, 94, 12286-12291.	3.2	3
2941	Advances in research on glioma microenvironment and immunotherapeutic targets. , 0, , 14-29.		0
2942	Insight into the interplay between mitochondria-regulated cell death and energetic metabolism in osteosarcoma. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	8
2943	Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line. Clinical Epigenetics, 2022, 14, .	1.8	4
2944	Low expression of isocitrate dehydrogenase 1 (IDH1) R132H is associated with advanced pathological features in laryngeal squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2023, 149, 4253-4267.	1.2	3
2945	Genomic and Epigenomic Features of Glioblastoma Multiforme and its Biomarkers. Journal of Oncology, 2022, 2022, 1-16.	0.6	0
2946	In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of IDH -Mutant Diffuse Gliomas. Neurology, 2023, 100, .	1.5	7
2947	CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies. Frontiers in Immunology, 0, 13, .	2.2	10
2948	Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide. Frontiers in Oncology, 0, 12, .	1.3	1
2949	Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment. Frontiers in Medicine, 0, 9, .	1.2	10
2950	Brain tumor related epilepsy: pathophysiological approaches and rational management of antiseizure medication. Neurological Research and Practice, 2022, 4, .	1.0	10
2951	Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness. Cancer Research, 2022, 82, 4325-4339.	0.4	7
2952	Oncometabolite <scp>d</scp> -2HG alters T cell metabolism to impair CD8 ⁺ T cell function. Science, 2022, 377, 1519-1529.	6.0	85
2953	Understanding emerging bioactive metabolites with putative roles in cancer biology. Frontiers in Oncology, 0, 12, .	1.3	1
2954	Rewired Metabolism of Amino Acids and Its Roles in Glioma Pathology. Metabolites, 2022, 12, 918.	1.3	2

#	Article	IF	Citations
2955	Metabolite-driven antitumor immunity. Science, 2022, 377, 1488-1489.	6.0	4
2956	Metabolomics: Going Deeper, Going Broader, Going Further. Methods in Molecular Biology, 2023, , 155-178.	0.4	8
2957	Proteinâ€“Metabolite Interactions Shape Cellular Metabolism and Physiology. Methods in Molecular Biology, 2023, , 1-10.	0.4	1
2958	A noncoding single-nucleotide polymorphism at 8q24 drives IDH1 -mutant glioma formation. Science, 2022, 378, 68-78.	6.0	20
2959	The complex interactions between the cellular and non-cellular components of the brain tumor microenvironmental landscape and their therapeutic implications. Frontiers in Oncology, 0, 12, .	1.3	12
2960	Mitochondrial biogenesis alteration in arsenic-induced carcinogenesis and its therapeutic interventions. Toxin Reviews, 2023, 42, 447-459.	1.5	0
2961	Prognostic value of cuproptosis-related genes signature and its impact on the reshaped immune microenvironment of glioma. Frontiers in Pharmacology, 0, 13, .	1.6	2
2962	Understanding the Crosstalk Between Epigenetics and Immunometabolism to Combat Cancer. Sub-Cellular Biochemistry, 2022, , 581-616.	1.0	0
2963	Epigenetic Small-Molecule Modulators Targeting Metabolic Pathways in Cancer. Sub-Cellular Biochemistry, 2022, , 523-555.	1.0	0
2964	Modulation of DNA/RNA Methylation Signaling Mediating Metabolic Homeostasis in Cancer. Sub-Cellular Biochemistry, 2022, , 201-237.	1.0	1
2965	Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities. Cancer Communications, 2022, 42, 1049-1082.	3.7	28
2966	Hypoxia-Inducible Factor 2 Alpha (HIF2Î±) Inhibitors: Targeting Genetically Driven Tumor Hypoxia. Endocrine Reviews, 2023, 44, 312-322.	8.9	16
2967	Implications of Concurrent IDH1 and IDH2 Mutations on Survival in Gliomaâ€”A Case Report and Systematic Review. Current Issues in Molecular Biology, 2022, 44, 5117-5125.	1.0	4
2968	Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro-Oncology, 2023, 25, 4-25.	0.6	45
2969	The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors. Current Treatment Options in Oncology, 2022, 23, 1566-1589.	1.3	1
2970	New insights into the Immune TME of adult-type diffuse gliomas. Current Opinion in Neurology, 2022, 35, 794-802.	1.8	8
2971	Roles of Chromatin Remodelling and Molecular Heterogeneity in Therapy Resistance in Glioblastoma. Cancers, 2022, 14, 4942.	1.7	2
2972	Chromatin as a sensor of metabolic changes during early development. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	1

#	Article	IF	Citations
2973	Tracing the electron flow in redox metabolism: The appropriate distribution of electrons is essential to maintain redox balance in cancer cells. Seminars in Cancer Biology, 2022, 87, 32-47.	4.3	3
2975	The genetics of myelodysplastic syndromes and the opportunities for tailored treatments. Frontiers in Oncology, 0, 12, .	1.3	4
2976	Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance. Cancer Discovery, 2023, 13, 170-193.	7.7	6
2977	Tumor glycolysis, an essential sweet tooth of tumor cells. Seminars in Cancer Biology, 2022, 86, 1216-1230.	4.3	43
2978	Genetics and epigenetics in conventional chondrosarcoma with focus on non-coding RNAs. Pathology Research and Practice, 2022, 239, 154172.	1.0	2
2979	Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Research, 2023, 83, 181-194.	0.4	11
2980	Shuffle-ResNet: Deep learning for predicting LGG IDH1 mutation from multicenter anatomical MRI sequences. Biomedical Physics and Engineering Express, 2022, 8, 065036.	0.6	2
2981	A functional analysis of 180 cancer cell lines reveals conserved intrinsic metabolic programs. Molecular Systems Biology, 2022, 18, .	3.2	13
2982	Resistance to targeted therapies in acute myeloid leukemia. Clinical and Experimental Metastasis, 2023, 40, 33-44.	1.7	3
2983	The Role of DNA Methylation and DNA Methyltransferases in Cancer. Advances in Experimental Medicine and Biology, 2022, , 317-348.	0.8	7
2984	Role of DNMTs in the Brain. Advances in Experimental Medicine and Biology, 2022, , 363-394.	0.8	5
2985	Targeting IDH1/IDH2 mutations in gliomas. Current Opinion in Neurology, 2022, 35, 787-793.	1.8	8
2986	High-throughput analysis of tissue microarrays using automated desorption electrospray ionization mass spectrometry. Scientific Reports, 2022, 12, .	1.6	11
2988	Application of Metabolomics in Childhood Leukemia Diagnostics. Archivum Immunologiae Et Therapiae Experimentalis, 2022, 70, .	1.0	3
2989	SomaticIDH1Hotspot Variants in Chinese Patients With Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 1215-1223.	1.8	1
2991	IDH Mutations Are Potentially the Intrinsic Genetic Link among the Multiple Neoplastic Lesions in Ollier Disease and Maffucci Syndrome: A Clinicopathologic Analysis from a Single Institute in Shanghai, China. Diagnostics, 2022, 12, 2764.	1.3	1
2992	Mutations of FH and IDH may induce gliomagenesis by similar mechanisms. Journal of Neuropathology and Experimental Neurology, 2023, 82, 99-100.	0.9	0
2993	Mutant IDH1 attenuates hepatic lipogenesis through PTEN dependent pathway. Biochemical and Biophysical Research Communications, 2022, 637, 254-258.	1.0	0

#	Article	IF	Citations
2994	DNA damage in IDH-mutant gliomas: mechanisms and clinical implications. Journal of Neuro-Oncology, 2023, 162, 515-523.	1.4	6
2995	Targeting intraâ€tumoral heterogeneity of human brain tumors with in vivo imaging: A roadmap for imaging genomics from multiparametric MR signals. Medical Physics, 2023, 50, 2590-2606.	1.6	0
2996	Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability. Cancer Discovery, 2023, 13, 496-515.	7.7	14
2997	Glutamine-dependent effects of nitric oxide on cancer cells subjected to hypoxia-reoxygenation. Nitric Oxide - Biology and Chemistry, 2022, , .	1.2	0
2998	Mitochondrial function and immune response-regulating factor-encoding gene promoters. , 2023, , 15-31.		0
2999	Intertwined regulation between RNA m6A modification and cancer metabolism. , 2023, 2, 100075.		1
3000	The magic bullet: Niclosamide. Frontiers in Oncology, 0, 12, .	1.3	14
3001	Targeting TET2 as a Therapeutic Approach for Angioimmunoblastic T Cell Lymphoma. Cancers, 2022, 14, 5699.	1.7	2
3002	The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors. Cell Communication and Signaling, 2022, 20, .	2.7	18
3003	Antitumor pharmacological research in the era of personalized medicine. Acta Pharmacologica Sinica, 2022, 43, 3015-3020.	2.8	4
3004	Metabolic regulation of cholestatic liver injury by D-2-hydroxyglutarate with the modulation of hepatic microenvironment and the mammalian target of rapamycin signaling. Cell Death and Disease, 2022, 13, .	2.7	1
3005	SDHx mutation and pituitary adenoma: can in vivo 1H-MR spectroscopy unravel the link?. Endocrine-Related Cancer, 2023, 30, .	1.6	2
3006	DNA methylation-based classification of sinonasal tumors. Nature Communications, 2022, 13, .	5.8	22
3007	Metabolic determinants of tumour initiation. Nature Reviews Endocrinology, 2023, 19, 134-150.	4.3	16
3008	Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia. Biomedicines, 2022, 10, 3008.	1.4	0
3009	Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology. International Journal of Molecular Sciences, 2022, 23, 15124.	1.8	6
3010	Cancer epigenetics in clinical practice. Ca-A Cancer Journal for Clinicians, 2023, 73, 376-424.	157.7	43
3011	Molecular targeted therapy: A new avenue in glioblastoma treatment (Review). Oncology Letters, 2022, 25, .	0.8	7

#	Article	IF	Citations
3012	Stromal protein CCN family contributes to the poor prognosis in lower-grade gioma by modulating immunity, matrix, stemness, and metabolism. Frontiers in Molecular Biosciences, 0, 9, .	1.6	2
3013	Prognostic Value of Choline and Other Metabolites Measured Using 1H-Magnetic Resonance Spectroscopy in Gliomas: A Meta-Analysis and Systemic Review. Metabolites, 2022, 12, 1219.	1.3	0
3014	Rational combinations of targeted cancer therapies: background, advances and challenges. Nature Reviews Drug Discovery, 2023, 22, 213-234.	21.5	69
3016	Is induction of Hypomethylation with Ivosidenib and 5-Azacitidine curative regimen against IDH1-mutated Acute Myeloid Leukemia?. Anti-Cancer Agents in Medicinal Chemistry, 2022, 23, .	0.9	0
3017	The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome. Frontiers in Immunology, 0, 13, .	2.2	6
3019	Regulation and function of the mammalian tricarboxylic acidÂcycle. Journal of Biological Chemistry, 2023, 299, 102838.	1.6	53
3020	Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets. Blood, 2023, 141, 1119-1135.	0.6	7
3021	Natural and Synthetic 2-Oxogluturate Derivatives are Substrates for Oncogenic Variants of Human Isocitrate Dehydrogenase 1 and 2. Journal of Biological Chemistry, 2023, , 102873.	1.6	3
3022	Recent advances in epigenetic anticancer therapeutics and future perspectives. Frontiers in Genetics, 0, 13, .	1.1	3
3023	Impact of epigenetic reprogramming on antitumor immune responses in glioma. Journal of Clinical Investigation, 2023, 133, .	3.9	15
3024	Wild-type IDH1 Knockout Leads to G0/G1 Arrest, Impairs Cancer Cell Proliferation, Altering Glycolysis, and the TCA Cycle in Colon Cancer. Biochemical Genetics, 2023, 61, 1470-1486.	0.8	1
3025	Gut microbiota in brain tumors: An emerging crucial player. CNS Neuroscience and Therapeutics, 2023, 29, 84-97.	1.9	4
3026	The impact of glucose on mitochondria and lifespan is determined by the integrity of proline catabolism in C. elegans. Journal of Biological Chemistry, 2023, , 102881.	1.6	1
3027	Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2. Clinical Cancer Research, 2023, 29, 1305-1316.	3.2	4
3028	Cancer plasticity: Investigating the causes for this agility. Seminars in Cancer Biology, 2023, 88, 138-156.	4.3	8
3029	Apparent Diffusion Coefficient as Imaging Biomarker for Identifying <scp>IDH</scp> Mutation, 1p19q Codeletion, and <scp>MGMT</scp> Promoter Methylation Status in Patients With Glioma. Journal of Magnetic Resonance Imaging, 2023, 58, 732-738.	1.9	4
3030	D-2-Hydroxyglutarate Inhibits Calcineurin Phosphatase Activity to Abolish NF-AT Activation and IL-2 Induction in Stimulated Lymphocytes. Journal of Immunology, 2023, 210, 504-514.	0.4	2
3031	Metabolomics of small extracellular vesicles derived from isocitrate dehydrogenase 1-mutant HCT116 cells collected by semi-automated size exclusion chromatography. Frontiers in Molecular Biosciences, 0, 9, .	1.6	3

#	Article	IF	Citations
3032	Genetic mutations affecting mitochondrial function in cancer drug resistance. Genes and Genomics, 2023, 45, 261-270.	0.5	2
3033	Upstaging and Downstaging in Gliomasâ€"Clinical Implications for the Fifth Edition of the World Health Organization Classification of Tumors of the Central Nervous System. Diagnostics, 2023, 13, 197.	1.3	1
3034	Early immune pressure makes tumors metabolically stronger. Cell Metabolism, 2023, 35, 3-5.	7.2	1
3035	An intermediate phenotype in IDH related enchondromatosis spectrum. European Journal of Medical Genetics, 2023, 66, 104697.	0.7	0
3036	The roles of IDH1 in tumor metabolism and immunity. Future Oncology, 2022, 18, 3941-3953.	1.1	1
3037	From Protein Film Electrochemistry to Nanoconfined Enzyme Cascades and the Electrochemical Leaf. Chemical Reviews, 2023, 123, 5421-5458.	23.0	13
3039	NADP(H)-dependent biocatalysis without adding NADP(H). Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	5
3040	Oxazolidinones as versatile scaffolds in medicinal chemistry. RSC Medicinal Chemistry, 2023, 14, 823-847.	1.7	6
3041	Hypoxia signaling in cancer: Implications for therapeutic interventions. MedComm, 2023, 4, .	3.1	16
3042	Preclinical Models of Low-Grade Gliomas. Cancers, 2023, 15, 596.	1.7	4
3043	Epigeneticâ€"Metabolic Interplay in the DNA Damage Response and Therapeutic Resistance of Breast Cancer. Cancer Research, 2023, 83, 657-666.	0.4	4
3044	An Overview: The Diversified Role of Mitochondria in Cancer Metabolism. International Journal of Biological Sciences, 2023, 19, 897-915.	2.6	29
3045	Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	7
3046	Anti-Vascular Endothelial Growth Factor Therapy Abolishes Glioma-Associated Endothelial Cell-Induced Tumor Invasion. Journal of Molecular Neuroscience, 0, , .	1.1	0
3047	Practice-Changing Evidence in Surgical Oncology 2021: Hepatobiliary Articles. Annals of Surgical Oncology, 2023, 30, 1960-1965.	0.7	2
3048	Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective. Targeted Oncology, 2023, 18, 51-76.	1.7	2
3049	Colitis-Associated Cancers. , 2023, , 773-788.		0
3050	Metabolomic Profiles of Human Glioma Inform Patient Survival. Antioxidants and Redox Signaling, 2023, 39, 942-956.	2.5	2

#	Article	IF	Citations
3051	Case report: Sustained complete remission with ivosidenib in a patient with relapsed, IDH1-mutated acute leukemia. , 0, 2, .		0
3052	Using radiomics based on multicenter magnetic resonance images to predict isocitrate dehydrogenase mutation status of gliomas. Quantitative Imaging in Medicine and Surgery, 2023, 13, 2143-2155.	1.1	1
3053	A FÃ¶rster resonance energy transfer-based d-2-hydroxyglutarate biosensor. Sensors and Actuators B: Chemical, 2023, 385, 133681.	4.0	1
3054	Epigenomic machinery regulating pediatric AML: Clonal expansion mechanisms, therapies, and future perspectives. Seminars in Cancer Biology, 2023, 92, 84-101.	4.3	2
3056	Multicenter Phase II Trial of the PARP Inhibitor Olaparib in RecurrentIDH1-andIDH2-mutant Glioma. Cancer Research Communications, 2023, 3, 192-201.	0.7	2
3057	Vitamin Chemistry Drives Human Metabolic Logic. , 2018, , 414-431.		0
3058	Human Vitamins: Discovery and Characterization. , 2018, , 5-39.		0
3059	D-2-hydroxyglutarate dehydrogenase governs adult neural stem cell activation and promotes histone acetylation via ATP-citrate lyase. Cell Reports, 2023, 42, 112067.	2.9	3
3060	Endocannabinoids are potential inhibitors of glioblastoma multiforme proliferation. Journal of Integrative Medicine, 2023, 21, 120-129.	1.4	1
3061	The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer. Acta Pharmaceutica Sinica B, 2023, 13, 1438-1466.	5.7	3
3062	MRI-Based Radiomics Combined with Deep Learning for Distinguishing IDH-Mutant WHO Grade 4 Astrocytomas from IDH-Wild-Type Glioblastomas. Cancers, 2023, 15, 951.	1.7	8
3063	Transgenic IDH2R172K and IDH2R140Q zebrafish models recapitulated features of human acute myeloid leukemia. Oncogene, 2023, 42, 1272-1281.	2.6	1
3064	Quantitative multiple fragment monitoring with enhanced in-source fragmentation/annotation mass spectrometry. Nature Protocols, 2023, 18, 1296-1315.	5.5	2
3065	Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation. Cell Reports Medicine, 2023, 4, 100940.	3.3	4
3066	Long non-coding RNA in glioma: novel genetic players in temozolomide resistance. Animal Cells and Systems, 2023, 27, 19-28.	0.8	5
3067	Advances in the study of aerobic glycolytic effects in resistance to radiotherapy in malignant tumors. PeerJ, 0, 11, e14930.	0.9	0
3068	Imaging 2-hydroxyglutarate and other brain oncometabolites pertinent to critical genomic alterations in brain tumors. BJR|Open, 2023, 5, .	0.4	1
3069	The â€œSuperoncogeneâ€•Myc at the Crossroad between Metabolism and Gene Expression in Glioblastoma Multiforme. International Journal of Molecular Sciences, 2023, 24, 4217.	1.8	4

#	Article	IF	Citations
3070	Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nature Medicine, 2023, 29, 615-622.	15.2	46
3071	Update for astrocytomas: medical and surgical management considerations. , 0, , 1-26.		2
3072	What clinical metabolomics will bring to the medicine of tomorrow. Frontiers in Analytical Science, 0, 3, .	1.1	3
3073	Comparative survey of mitochondrial ultrastructure in IDH1-mutant astrocytoma and IDH1-wildtype glioblastoma (GBM). Ultrastructural Pathology, 2023, 47, 116-121.	0.4	2
3074	(R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation inIDH-Mutant Cancers. Cancer Discovery, 2023, 13, 1478-1497.	7.7	3
3075	Epigenetic Abnormalities in Chondrosarcoma. International Journal of Molecular Sciences, 2023, 24, 4539.	1.8	1
3076	Kynureninase Promotes Immunosuppression and Predicts Survival in Glioma Patients: In Silico Data Analyses of the Chinese Glioma Genome Atlas (CGGA) and of the Cancer Genome Atlas (TCGA). Pharmaceuticals, 2023, 16, 369.	1.7	1
3078	Capturing the Dynamic Conformational Changes of Human Isocitrate Dehydrogenase 1 (IDH1) upon Ligand and Metal Binding Using Hydrogenâ€“Deuterium Exchange Mass Spectrometry. Biochemistry, 2023, 62, 1145-1159.	1.2	3
3079	Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer. Frontiers in Oncology, 0, 13, .	1.3	9
3080	L-2hydroxyglutaric acid rewires amino acid metabolism in colorectal cancer via the mTOR-ATF4 axis. Oncogene, 2023, 42, 1294-1307.	2.6	4
3081	Emerging Roles of SIRT5 in Metabolism, Cancer, and SARS-CoV-2 Infection. Cells, 2023, 12, 852.	1.8	5
3082	Current and future applications of liquid biopsy in non-small-cell lung cancerâ€”a narrative review. Translational Lung Cancer Research, 2023, 12, 594-614.	1.3	6
3083	Cutaneous Melanoma and Glioblastoma Multiforme Associationâ€”Case Presentation and Literature Review. Diagnostics, 2023, 13, 1046.	1.3	0
3084	Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma. International Journal of Molecular Sciences, 2023, 24, 5493.	1.8	2
3085	Metabolic sensing and control in mitochondria. Molecular Cell, 2023, 83, 877-889.	4.5	8
3087	Detection and analysis of chiral molecules as disease biomarkers. Nature Reviews Chemistry, 2023, 7, 355-373.	13.8	27
3088	Supratentorial multifocal gliomas associated with Ollier disease harboring <scp> IDH1 R132H </scp> mutation: A case report. Neuropathology, 0, , .	0.7	0
3089	To metabolomics and beyond: a technological portfolio to investigate cancer metabolism. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	26

#	Article	IF	Citations
3090	An Updated Overview of the Role of CYP450 during Xenobiotic Metabolization in Regulating the Acute Myeloid Leukemia Microenvironment. International Journal of Molecular Sciences, 2023, 24, 6031.	1.8	1
3091	Differentiating Inhibition Selectivity and Binding Affinity of Isocitrate Dehydrogenase 1 Variant Inhibitors. Journal of Medicinal Chemistry, 2023, 66, 5279-5288.	2.9	2
3092	Characterization of purinergic signaling in tumor-infiltrating lymphocytes from lower- and high-grade gliomas. Purinergic Signalling, 2024, 20, 47-64.	1.1	0
3093	Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas. Molecules, 2023, 28, 2890.	1.7	3
3094	Cytosolic and mitochondrial NADPH fluxes are independently regulated. Nature Chemical Biology, 2023, 19, 837-845.	3.9	6
3095	Preclinical modeling of lower-grade gliomas. Frontiers in Oncology, 0, 13, .	1.3	1
3096	Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions. Cancers, 2023, 15, 1962.	1.7	7
3097	A Toolbox for Glutamine Use in Dissolution Dynamic Nuclear Polarization: from Enzymatic Reaction Monitoring to the Study of Cellular Metabolic Pathways and Imaging. ChemPhysChem, 2023, 24, .	1.0	0
3098	N7-methylguanosin regulators-mediated methylation modification patterns and characterization of the immune microenvironment in lower-grade glioma. European Journal of Medical Research, 2023, 28, .	0.9	3
3099	PrognosticÂAnalysis of a Hypoxia-Associated lncRNA SignatureÂin Glioblastoma and its Pan-Cancer Landscape.. Journal of Neurological Surgery, Part A: Central European Neurosurgery, 0, , .	0.4	2
3100	Dissecting the brain with spatially resolved multi-omics. Journal of Pharmaceutical Analysis, 2023, 13, 694-710.	2.4	3
3101	Regulative Roles of Metabolic Plasticity Caused by Mitochondrial Oxidative Phosphorylation and Glycolysis on the Initiation and Progression of Tumorigenesis. International Journal of Molecular Sciences, 2023, 24, 7076.	1.8	3
3102	A D-2-hydroxyglutarate dehydrogenase mutant reveals a critical role for ketone body metabolism in Caenorhabditis elegans development. PLoS Biology, 2023, 21, e3002057.	2.6	2
3103	Metabolic dependencies and targets in ovarian cancer. , 2023, 245, 108413.		8
3104	Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials. JCO Precision Oncology, 2023, , .	1.5	1
3105	Gemistocytic Differentiation in Isocitrate Dehydrogenase Mutant Astrocytomas: A Histopathological and Survival Analysis. Cureus, 2023, , .	0.2	0
3106	Metabolic Rewiring in Adult-Type Diffuse Gliomas. International Journal of Molecular Sciences, 2023, 24, 7348.	1.8	2
3107	Paracatalytic induction: Subverting specificity in hedgehog protein autoprocessing with small molecules. Methods in Enzymology, 2023, , 1-41.	0.4	0

#	Article	IF	Citations
3108	Crosstalk between Metabolite Production and Signaling Activity in Breast Cancer. International Journal of Molecular Sciences, 2023, 24, 7450.	1.8	2
3109	Biology of Cancer. , 2023, , 86-186.		0
3118	Epigenetic profiling in cancer: triage, prognosis, and precision oncology. , 2023, , 651-674.		0
3120	Methylation and hydroxymethylation in cancer. , 2023, , 11-37.		0
3126	Magnetic Resonance Spectroscopy: Clinical Applications. , 2023, , 241-292.		0
3131	Metabolite signaling in the heart. , 2023, 2, 504-516.		2
3155	Quantitative and Physiological Magnetic Resonance Imaging in Glioma. , 2023, , 433-457.		0
3163	Recent advances in understanding brain cancer metabolomics: a review. , 2023, 40, .		0
3164	History, Evolution, Milestones in Cancer Research and Treatment. , 2023, , 1-29.		0
3167	A new era for glioma therapy â€" targeting mutant IDH. Nature Reviews Clinical Oncology, 0, , .	12.5	0
3169	Pathology of the Tumors of the Central Nervous System. , 2023, , 71-110.		0
3174	Cyanopyridine as a privileged scaffold in drug discovery. , 2023, , 163-198.		0
3187	TET (Ten-eleven translocation) family proteins: structure, biological functions and applications. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	11
3188	Liquid biopsy: creating opportunities in brain space. British Journal of Cancer, 2023, 129, 1727-1746.	2.9	1
3202	An Update on Potential Molecular Biomarkers of Dietary Phytochemicals Targeting Lung Cancer Interception and Prevention. Pharmaceutical Research, 2023, 40, 2699-2714.	1.7	1
3211	Epigenetic Targeting of Cancer. , 2023, , 181-198.		2
3217	Molecular genetics of soft tissue tumors. , 2016, , 115-180.		0
3221	Genomic Landscape and Risk Stratification of Acute Myeloid Leukemia. , 2023, , 61-89.		0

#	Article	IF	Citations
3224	Commentary: Why have different key biomarkers been reported in the same types of samples from patients with identical diseases?. Urine, 2023, 5, 53-56.	4.0	0
3238	Molecular mechanisms in colitis-associated colorectal cancer. Oncogenesis, 2023, 12, .	2.1	3
3257	15 years after a giant leap for cancer genomics. Nature, 2023, 623, 920-921.	13.7	0
3277	Glioma. , 2024, , 184-192.		0
3287	Epigenetic dysregulation in brain tumors. , 2024, , 269-285.		0
3289	Metabolic alterations in hereditary and sporadic renal cell carcinoma. Nature Reviews Nephrology, 2024, 20, 233-250.	4.1	0